Word	Tag	Begin-End
Somatic	O	0-7
-	O	7-8
cell	O	8-12
selection	O	13-22
is	O	23-25
a	O	26-27
major	O	28-33
determinant	O	34-45
of	O	46-48
the	O	49-52
blood	O	53-58
-	O	58-59
cell	O	59-63
phenotype	O	64-73
in	O	74-76
heterozygotes	O	77-90
for	O	91-94
glucose	O	95-102
-	O	102-103
6	O	103-104
-	O	102-103
phosphate	O	105-114
dehydrogenase	O	115-128
mutations	O	129-138
causing	O	139-146
severe	O	147-153
enzyme	B	154-160
deficiency	I	161-171
.	O	171-172

X	O	173-174
-	O	174-175
chromosome	O	175-185
inactivation	O	186-198
in	O	199-201
mammals	O	202-209
is	O	210-212
regarded	O	213-221
as	O	222-224
an	O	225-227
essentially	O	228-239
random	O	240-246
process	O	247-254
,	O	254-255
but	O	256-259
the	O	260-263
resulting	O	264-273
somatic	O	274-281
-	O	281-282
cell	O	282-286
mosaicism	O	287-296
creates	O	297-304
the	O	305-308
opportunity	O	309-320
for	O	321-324
cell	O	325-329
selection	O	330-339
.	O	339-340

In	O	341-343
most	O	344-348
people	O	349-355
with	O	356-360
red	O	361-364
-	O	364-365
blood	O	365-370
-	O	364-365
cell	O	371-375
glucose	B	376-383
-	I	383-384
6	I	384-385
-	I	383-384
phosphate	I	386-395
dehydrogenase	I	396-409
(	I	410-411
G6PD	I	411-415
)	I	415-416
deficiency	I	417-427
,	O	427-428
the	O	429-432
enzyme	O	433-439
-	O	439-440
deficient	O	440-449
phenotype	O	450-459
is	O	460-462
only	O	463-467
moderately	O	468-478
expressed	O	479-488
in	O	489-491
nucleated	O	492-501
cells	O	502-507
.	O	507-508

However	O	509-516
,	O	516-517
in	O	518-520
a	O	521-522
small	O	523-528
subset	O	529-535
of	O	536-538
hemizygous	O	539-549
males	O	550-555
who	O	556-559
suffer	O	560-566
from	O	567-571
chronic	B	572-579
nonspherocytic	I	580-594
hemolytic	I	595-604
anemia	I	605-611
,	O	611-612
the	O	613-616
underlying	O	617-627
mutations	O	628-637
(	O	638-639
designated	O	639-649
class	O	650-655
I	O	656-657
)	O	657-658
cause	O	659-664
more	O	665-669
-	O	669-670
severe	O	670-676
G6PD	B	677-681
deficiency	I	682-692
,	O	692-693
and	O	694-697
this	O	698-702
might	O	703-708
provide	O	709-716
an	O	717-719
opportunity	O	720-731
for	O	732-735
selection	O	736-745
in	O	746-748
heterozygous	O	749-761
females	O	762-769
during	O	770-776
development	O	777-788
.	O	788-789

In	O	790-792
order	O	793-798
to	O	799-801
test	O	802-806
this	O	807-811
possibility	O	812-823
we	O	824-826
have	O	827-831
analyzed	O	832-840
four	O	841-845
heterozygotes	O	846-859
for	O	860-863
class	O	864-869
I	O	870-871
G6PD	O	872-876
mutations	O	877-886
two	O	888-891
with	O	892-896
G6PD	O	897-901
Portici	O	902-909
(	O	910-911
1178G	O	911-916
-	O	916-917
-	O	916-917
>	O	919-920
A	O	921-922
)	O	922-923
and	O	924-927
two	O	928-931
with	O	932-936
G6PD	O	937-941
Bari	O	942-946
(	O	947-948
1187C	O	948-953
-	O	953-954
-	O	953-954
>	O	956-957
T	O	958-959
)	O	959-960
.	O	960-961

We	O	962-964
found	O	965-970
that	O	971-975
in	O	976-978
fractionated	O	979-991
blood	O	992-997
cell	O	998-1002
types	O	1003-1008
(	O	1009-1010
including	O	1010-1019
erythroid	O	1020-1029
,	O	1029-1030
myeloid	O	1031-1038
,	O	1038-1039
and	O	1040-1043
lymphoid	O	1044-1052
cell	O	1053-1057
lineages	O	1058-1066
)	O	1066-1067
there	O	1068-1073
was	O	1074-1077
a	O	1078-1079
significant	O	1080-1091
excess	O	1092-1098
of	O	1099-1101
G6PD	O	1102-1106
-	O	1106-1107
normal	O	1107-1113
cells	O	1114-1119
.	O	1119-1120

The	O	1121-1124
significant	O	1125-1136
concordance	O	1137-1148
that	O	1149-1153
we	O	1154-1156
have	O	1157-1161
observed	O	1162-1170
in	O	1171-1173
the	O	1174-1177
degree	O	1178-1184
of	O	1185-1187
imbalance	O	1188-1197
in	O	1198-1200
the	O	1201-1204
different	O	1205-1214
blood	O	1215-1220
-	O	1220-1221
cell	O	1221-1225
lineages	O	1226-1234
indicates	O	1235-1244
that	O	1245-1249
a	O	1250-1251
selective	O	1252-1261
mechanism	O	1262-1271
is	O	1272-1274
likely	O	1275-1281
to	O	1282-1284
operate	O	1285-1292
at	O	1293-1295
the	O	1296-1299
level	O	1300-1305
of	O	1306-1308
pluripotent	O	1309-1320
blood	O	1321-1326
stem	O	1327-1331
cells	O	1332-1337
.	O	1337-1338

Thus	O	1339-1343
,	O	1343-1344
it	O	1345-1347
appears	O	1348-1355
that	O	1356-1360
severe	O	1361-1367
G6PD	B	1368-1372
deficiency	I	1373-1383
affects	O	1384-1391
adversely	O	1392-1401
the	O	1402-1405
proliferation	O	1406-1419
or	O	1420-1422
the	O	1423-1426
survival	O	1427-1435
of	O	1436-1438
nucleated	O	1439-1448
blood	O	1449-1454
cells	O	1455-1460
and	O	1461-1464
that	O	1465-1469
this	O	1470-1474
phenotypic	O	1475-1485
characteristic	O	1486-1500
is	O	1501-1503
critical	O	1504-1512
during	O	1513-1519
hematopoiesis	O	1520-1533
.	O	1533-1534
.	O	1533-1534

The	O	0-3
ataxia	B	4-10
-	I	10-11
telangiectasia	I	11-25
gene	O	26-30
product	O	31-38
,	O	38-39
a	O	40-41
constitutively	O	42-56
expressed	O	57-66
nuclear	O	67-74
protein	O	75-82
that	O	83-87
is	O	88-90
not	O	91-94
up	O	95-97
-	O	97-98
regulated	O	98-107
following	O	108-117
genome	O	118-124
damage	O	125-131
.	O	131-132

The	O	133-136
product	O	137-144
of	O	145-147
the	O	148-151
ataxia	B	152-158
-	I	158-159
telangiectasia	I	159-173
gene	O	174-178
(	O	179-180
ATM	O	180-183
)	O	183-184
was	O	185-188
identified	O	189-199
by	O	200-202
using	O	203-208
an	O	209-211
antiserum	O	212-221
developed	O	222-231
to	O	232-234
a	O	235-236
peptide	O	237-244
corresponding	O	245-258
to	O	259-261
the	O	262-265
deduced	O	266-273
amino	O	274-279
acid	O	280-284
sequence	O	285-293
.	O	293-294

The	O	295-298
ATM	O	299-302
protein	O	303-310
is	O	311-313
a	O	314-315
single	O	316-322
,	O	322-323
high	O	324-328
-	O	328-329
molecular	O	329-338
weight	O	339-345
protein	O	346-353
predominantly	O	354-367
confined	O	368-376
to	O	377-379
the	O	380-383
nucleus	O	384-391
of	O	392-394
human	O	395-400
fibroblasts	O	401-412
,	O	412-413
but	O	414-417
is	O	418-420
present	O	421-428
in	O	429-431
both	O	432-436
nuclear	O	437-444
and	O	445-448
microsomal	O	449-459
fractions	O	460-469
from	O	470-474
human	O	475-480
lymphoblast	O	481-492
cells	O	493-498
and	O	499-502
peripheral	O	503-513
blood	O	514-519
lymphocytes	O	520-531
.	O	531-532

ATM	O	533-536
protein	O	537-544
levels	O	545-551
and	O	552-555
localization	O	556-568
remain	O	569-575
constant	O	576-584
throughout	O	585-595
all	O	596-599
stages	O	600-606
of	O	607-609
the	O	610-613
cell	O	614-618
cycle	O	619-624
.	O	624-625

Truncated	O	626-635
ATM	O	636-639
protein	O	640-647
was	O	648-651
not	O	652-655
detected	O	656-664
in	O	665-667
lymphoblasts	O	668-680
from	O	681-685
ataxia	B	686-692
-	I	692-693
telangiectasia	I	693-707
patients	O	708-716
homozygous	O	717-727
for	O	728-731
mutations	O	732-741
leading	O	742-749
to	O	750-752
premature	O	753-762
protein	O	763-770
termination	O	771-782
.	O	782-783

Exposure	O	784-792
of	O	793-795
normal	O	796-802
human	O	803-808
cells	O	809-814
to	O	815-817
gamma	O	818-823
-	O	823-824
irradiation	O	824-835
and	O	836-839
the	O	840-843
radiomimetic	O	844-856
drug	O	857-861
neocarzinostatin	O	862-878
had	O	879-882
no	O	883-885
effect	O	886-892
on	O	893-895
ATM	O	896-899
protein	O	900-907
levels	O	908-914
,	O	914-915
in	O	916-918
contrast	O	919-927
to	O	928-930
a	O	931-932
noted	O	933-938
rise	O	939-943
in	O	944-946
p53	O	947-950
levels	O	951-957
over	O	958-962
the	O	963-966
same	O	967-971
time	O	972-976
interval	O	977-985
.	O	985-986

These	O	987-992
findings	O	993-1001
are	O	1002-1005
consistent	O	1006-1016
with	O	1017-1021
a	O	1022-1023
role	O	1024-1028
for	O	1029-1032
the	O	1033-1036
ATM	O	1037-1040
protein	O	1041-1048
in	O	1049-1051
ensuring	O	1052-1060
the	O	1061-1064
fidelity	O	1065-1073
of	O	1074-1076
DNA	O	1077-1080
repair	O	1081-1087
and	O	1088-1091
cell	O	1092-1096
cycle	O	1097-1102
regulation	O	1103-1113
following	O	1114-1123
genome	O	1124-1130
damage	O	1131-1137
.	O	1137-1138
.	O	1137-1138

Molecular	O	0-9
basis	O	10-15
for	O	16-19
Duarte	B	20-26
and	I	27-30
Los	I	31-34
Angeles	I	35-42
variant	I	43-50
galactosemia	I	51-63
.	O	63-64

Human	O	65-70
orythrocytes	O	71-83
that	O	84-88
are	O	89-92
homozygous	O	93-103
for	O	104-107
the	O	108-111
Duarte	B	112-118
enzyme	I	119-125
variant	I	126-133
of	I	134-136
galactosemia	I	137-149
(	O	150-151
D	O	151-152
/	O	152-153
D	O	151-152
)	O	154-155
have	O	156-160
a	O	161-162
characteristic	O	163-177
isoform	O	178-185
on	O	186-188
isoelectric	O	189-200
focusing	O	201-209
and	O	210-213
50	O	214-216
%	O	216-217
reduction	O	218-227
in	O	228-230
galactose	O	231-240
-	O	240-241
1	O	241-242
-	O	240-241
phosphate	O	243-252
uridyltransferase	O	253-270
(	O	271-272
GALT	O	272-276
)	O	276-277
enzyme	O	278-284
activity	O	285-293
.	O	293-294

The	O	295-298
Duarte	O	299-305
biochemical	O	306-317
phenotype	O	318-327
has	O	328-331
a	O	332-333
molecular	O	334-343
genotype	O	344-352
of	O	353-355
N314D	O	356-361
/	O	361-362
N314D	O	356-361
.	O	367-368

The	O	369-372
characteristic	O	373-387
Duarte	O	388-394
isoform	O	395-402
is	O	403-405
also	O	406-410
associated	O	411-421
with	O	422-426
a	O	427-428
variant	O	429-436
called	O	437-443
the	O	444-447
"	O	448-449
Los	O	450-453
Angeles	O	454-461
(	O	462-463
LA	O	463-465
)	O	465-466
phenotype	O	467-476
,	O	476-477
"	O	478-479
which	O	480-485
has	O	486-489
increased	O	490-499
GALT	O	500-504
enzyme	O	505-511
activity	O	512-520
.	O	520-521

We	O	522-524
evaluated	O	525-534
GALT	O	535-539
enzyme	O	540-546
activity	O	547-555
and	O	556-559
screened	O	560-568
the	O	569-572
GALT	O	573-577
genes	O	578-583
of	O	584-586
145	O	587-590
patients	O	591-599
with	O	600-604
one	O	605-608
or	O	609-611
more	O	612-616
N314D	O	617-622
-	O	622-623
containing	O	623-633
alleles	O	634-641
.	O	641-642

We	O	643-645
found	O	646-651
seven	O	652-657
with	O	658-662
the	O	663-666
LA	O	667-669
biochemical	O	670-681
phenotype	O	682-691
,	O	691-692
and	O	693-696
all	O	697-700
had	O	701-704
a	O	705-706
1721C	O	707-712
-	O	712-713
-	O	712-713
>	O	715-716
T	O	717-718
transition	O	719-729
in	O	730-732
exon	O	733-737
7	O	738-739
in	O	740-742
cis	O	743-746
with	O	747-751
the	O	752-755
N314D	O	756-761
missense	O	762-770
mutation	O	771-779
.	O	779-780

The	O	781-784
1721C	O	785-790
-	O	790-791
-	O	790-791
>	O	793-794
T	O	795-796
transition	O	797-807
is	O	808-810
a	O	811-812
neutral	O	813-820
polymorphism	O	821-833
for	O	834-837
leucine	O	838-845
at	O	846-848
amino	O	849-854
acid	O	855-859
218	O	860-863
(	O	864-865
L218L	O	865-870
)	O	870-871
.	O	871-872

In	O	873-875
pedigree	O	876-884
analyses	O	885-893
,	O	893-894
this	O	895-899
1721C	O	900-905
-	O	905-906
-	O	905-906
>	O	908-909
T	O	910-911
transition	O	912-922
segregated	O	923-933
with	O	934-938
the	O	939-942
LA	O	943-945
phenotype	O	946-955
of	O	956-958
increased	O	959-968
GALT	O	969-973
activity	O	974-982
in	O	983-985
three	O	986-991
different	O	992-1001
biochemical	O	1002-1013
phenotypes	O	1014-1024
(	O	1025-1026
LA	O	1026-1028
/	O	1028-1029
N	O	1029-1030
,	O	1030-1031
LA	O	1032-1034
/	O	1034-1035
G	O	1035-1036
,	O	1036-1037
and	O	1038-1041
LA	O	1042-1044
/	O	1044-1045
D	O	1045-1046
)	O	1046-1047
.	O	1047-1048

To	O	1049-1051
determine	O	1052-1061
the	O	1062-1065
mechanism	O	1066-1075
for	O	1076-1079
increased	O	1080-1089
activity	O	1090-1098
of	O	1099-1101
the	O	1102-1105
LA	O	1106-1108
variant	O	1109-1116
,	O	1116-1117
we	O	1118-1120
compared	O	1121-1129
GALT	O	1130-1134
mRNA	O	1135-1139
,	O	1139-1140
protein	O	1141-1148
abundance	O	1149-1158
,	O	1158-1159
and	O	1160-1163
enzyme	O	1164-1170
thermal	O	1171-1178
stability	O	1179-1188
in	O	1189-1191
lymphoblast	O	1192-1203
cell	O	1204-1208
lines	O	1209-1214
of	O	1215-1217
D	O	1218-1219
and	O	1220-1223
LA	O	1224-1226
phenotypes	O	1227-1237
with	O	1238-1242
comparable	O	1243-1253
genotypes	O	1254-1263
.	O	1263-1264

GALT	O	1265-1269
protein	O	1270-1277
abundance	O	1278-1287
was	O	1288-1291
increased	O	1292-1301
in	O	1302-1304
LA	O	1305-1307
compared	O	1308-1316
to	O	1317-1319
D	O	1320-1321
alleles	O	1322-1329
,	O	1329-1330
but	O	1331-1334
mRNA	O	1335-1339
was	O	1340-1343
similar	O	1344-1351
among	O	1352-1357
all	O	1358-1361
genotypes	O	1362-1371
.	O	1371-1372

When	O	1373-1377
LA	O	1378-1380
/	O	1380-1381
D	O	1381-1382
and	O	1383-1386
D	O	1387-1388
/	O	1388-1389
D	O	1387-1388
GALT	O	1391-1395
biochemical	O	1396-1407
phenotypes	O	1408-1418
were	O	1419-1423
compared	O	1424-1432
to	O	1433-1435
N	O	1436-1437
/	O	1437-1438
N	O	1436-1437
GALT	O	1440-1444
phenotypes	O	1445-1455
,	O	1455-1456
both	O	1457-1461
had	O	1462-1465
50	O	1466-1468
%	O	1468-1469
,	O	1469-1470
as	O	1471-1473
compared	O	1474-1482
to	O	1483-1485
21	O	1486-1488
%	O	1488-1489
,	O	1489-1490
reduction	O	1491-1500
in	O	1501-1503
GALT	O	1504-1508
activity	O	1509-1517
in	O	1518-1520
the	O	1521-1524
wild	O	1525-1529
type	O	1530-1534
(	O	1535-1536
N	O	1536-1537
/	O	1537-1538
N	O	1536-1537
)	O	1539-1540
after	O	1541-1546
exposure	O	1547-1555
at	O	1556-1558
identical	O	1559-1568
initial	O	1569-1576
enzyme	O	1577-1583
activity	O	1584-1592
to	O	1593-1595
50	O	1596-1598
degrees	O	1599-1606
C	O	1607-1608
for	O	1609-1612
15	O	1613-1615
min	O	1616-1619
.	O	1619-1620

We	O	1621-1623
conclude	O	1624-1632
that	O	1633-1637
the	O	1638-1641
codon	O	1642-1647
change	O	1648-1654
N314D	O	1655-1660
in	O	1661-1663
cis	O	1664-1667
with	O	1668-1672
the	O	1673-1676
base	O	1677-1681
-	O	1681-1682
pair	O	1682-1686
transition	O	1687-1697
1721C	O	1698-1703
-	O	1703-1704
-	O	1703-1704
>	O	1706-1707
T	O	1708-1709
produces	O	1710-1718
the	O	1719-1722
LA	B	1723-1725
variant	I	1726-1733
of	I	1734-1736
galactosemia	I	1737-1749
and	O	1750-1753
that	O	1754-1758
this	O	1759-1763
nucleotide	O	1764-1774
change	O	1775-1781
increases	O	1782-1791
GALT	O	1792-1796
activity	O	1797-1805
by	O	1806-1808
increasing	O	1809-1819
GALT	O	1820-1824
protein	O	1825-1832
abundance	O	1833-1842
without	O	1843-1850
increasing	O	1851-1861
transcription	O	1862-1875
or	O	1876-1878
decreasing	O	1879-1889
thermal	O	1890-1897
lability	O	1898-1906
.	O	1906-1907

A	O	1908-1909
favorable	O	1910-1919
codon	O	1920-1925
bias	O	1926-1930
for	O	1931-1934
the	O	1935-1938
mutated	O	1939-1946
codon	O	1947-1952
with	O	1953-1957
consequently	O	1958-1970
increased	O	1971-1980
translation	O	1981-1992
rates	O	1993-1998
is	O	1999-2001
postulated	O	2002-2012
as	O	2013-2015
the	O	2016-2019
mechanism	O	2020-2029
.	O	2029-2030
.	O	2029-2030

An	O	0-2
intronic	O	3-11
mutation	O	12-20
in	O	21-23
a	O	24-25
lariat	O	26-32
branchpoint	O	33-44
sequence	O	45-53
is	O	54-56
a	O	57-58
direct	O	59-65
cause	O	66-71
of	O	72-74
an	O	75-77
inherited	B	78-87
human	I	88-93
disorder	I	94-102
(	O	103-104
fish	B	104-108
-	I	108-109
eye	I	109-112
disease	I	113-120
)	O	120-121
.	O	121-122

The	O	123-126
first	O	127-132
step	O	133-137
in	O	138-140
the	O	141-144
splicing	O	145-153
of	O	154-156
an	O	157-159
intron	O	160-166
from	O	167-171
nuclear	O	172-179
precursors	O	180-190
of	O	191-193
mRNA	O	194-198
results	O	199-206
in	O	207-209
the	O	210-213
formation	O	214-223
of	O	224-226
a	O	227-228
lariat	O	229-235
structure	O	236-245
.	O	245-246

A	O	247-248
distinct	O	249-257
intronic	O	258-266
nucleotide	O	267-277
sequence	O	278-286
,	O	286-287
known	O	288-293
as	O	294-296
the	O	297-300
branchpoint	O	301-312
region	O	313-319
,	O	319-320
plays	O	321-326
a	O	327-328
central	O	329-336
role	O	337-341
in	O	342-344
this	O	345-349
process	O	350-357
.	O	357-358

We	O	359-361
here	O	362-366
describe	O	367-375
a	O	376-377
point	O	378-383
mutation	O	384-392
in	O	393-395
such	O	396-400
a	O	401-402
sequence	O	403-411
.	O	411-412

Three	O	413-418
sisters	O	419-426
were	O	427-431
shown	O	432-437
to	O	438-440
suffer	O	441-447
from	O	448-452
fish	B	453-457
-	I	457-458
eye	I	458-461
disease	I	462-469
(	O	470-471
FED	B	471-474
)	O	474-475
,	O	475-476
a	O	477-478
disorder	O	479-487
which	O	488-493
is	O	494-496
caused	O	497-503
by	O	504-506
mutations	O	507-516
in	O	517-519
the	O	520-523
gene	O	524-528
coding	O	529-535
for	O	536-539
lecithin	O	540-548
cholesterol	O	550-561
acyltransferase	O	562-577
(	O	578-579
LCAT	O	579-583
)	O	583-584
.	O	584-585

Sequencing	O	586-596
of	O	597-599
the	O	600-603
LCAT	O	604-608
gene	O	609-613
of	O	614-616
all	O	617-620
three	O	621-626
probands	O	627-635
revealed	O	636-644
compound	O	645-653
heterozygosity	O	654-668
for	O	669-672
a	O	673-674
missense	O	675-683
mutation	O	684-692
in	O	693-695
exon	O	696-700
4	O	701-702
which	O	703-708
is	O	709-711
reported	O	712-720
to	O	721-723
underlie	O	724-732
the	O	733-736
FED	B	737-740
phenotype	O	741-750
,	O	750-751
and	O	752-755
a	O	756-757
point	O	758-763
mutation	O	764-772
located	O	773-780
in	O	781-783
intron	O	784-790
4	O	791-792
(	O	793-794
IVS4	O	794-798
T	O	800-801
-	O	801-802
22C	O	802-805
)	O	805-806
.	O	806-807

By	O	808-810
performing	O	811-821
in	O	822-824
vitro	O	825-830
expression	O	831-841
of	O	842-844
LCAT	O	845-849
minigenes	O	850-859
and	O	860-863
reverse	O	864-871
transcriptase	O	872-885
PCR	O	886-889
on	O	890-892
mRNA	O	893-897
isolated	O	898-906
from	O	907-911
leukocytes	O	912-922
of	O	923-925
the	O	926-929
patient	O	930-937
,	O	937-938
this	O	939-943
gene	O	944-948
defect	O	949-955
was	O	956-959
shown	O	960-965
to	O	966-968
cause	O	969-974
a	O	975-976
null	O	977-981
allele	O	982-988
as	O	989-991
the	O	992-995
result	O	996-1002
of	O	1003-1005
complete	O	1006-1014
intron	O	1015-1021
retention	O	1022-1031
.	O	1031-1032

In	O	1033-1035
conclusion	O	1036-1046
,	O	1046-1047
we	O	1048-1050
demonstrated	O	1051-1063
that	O	1064-1068
a	O	1069-1070
point	O	1071-1076
mutation	O	1077-1085
in	O	1086-1088
a	O	1089-1090
lariat	O	1091-1097
branchpoint	O	1098-1109
consensus	O	1110-1119
sequence	O	1120-1128
causes	O	1129-1135
a	O	1136-1137
null	O	1138-1142
allele	O	1143-1149
in	O	1150-1152
a	O	1153-1154
patient	O	1155-1162
with	O	1163-1167
FED	B	1168-1171
.	O	1171-1172

In	O	1173-1175
addition	O	1176-1184
,	O	1184-1185
our	O	1186-1189
finding	O	1190-1197
illustrates	O	1198-1209
the	O	1210-1213
importance	O	1214-1224
of	O	1225-1227
this	O	1228-1232
sequence	O	1233-1241
for	O	1242-1245
normal	O	1246-1252
human	O	1253-1258
mRNA	O	1259-1263
processing	O	1264-1274
.	O	1274-1275

Finally	O	1276-1283
,	O	1283-1284
this	O	1285-1289
report	O	1290-1296
provides	O	1297-1305
a	O	1306-1307
widely	O	1308-1314
applicable	O	1315-1325
strategy	O	1326-1334
which	O	1335-1340
ensures	O	1341-1348
fast	O	1349-1353
and	O	1354-1357
effective	O	1358-1367
screening	O	1368-1377
for	O	1378-1381
intronic	O	1382-1390
defects	O	1391-1398
that	O	1399-1403
underlie	O	1404-1412
differential	O	1413-1425
gene	O	1426-1430
expression	O	1431-1441
.	O	1441-1442
.	O	1441-1442

Genetic	O	0-7
heterogeneity	O	8-21
in	O	22-24
hereditary	B	25-35
breast	I	36-42
cancer	I	43-49
:	O	49-50
role	O	51-55
of	O	56-58
BRCA1	O	59-64
and	O	65-68
BRCA2	O	69-74
.	O	74-75

The	O	76-79
common	O	80-86
hereditary	O	87-97
forms	O	98-103
of	O	104-106
breast	B	107-113
cancer	I	114-120
have	O	121-125
been	O	126-130
largely	O	131-138
attributed	O	139-149
to	O	150-152
the	O	153-156
inheritance	O	157-168
of	O	169-171
mutations	O	172-181
in	O	182-184
the	O	185-188
BRCA1	O	189-194
or	O	195-197
BRCA2	O	198-203
genes	O	204-209
.	O	209-210

However	O	211-218
,	O	218-219
it	O	220-222
is	O	223-225
not	O	226-229
yet	O	230-233
clear	O	234-239
what	O	240-244
proportion	O	245-255
of	O	256-258
hereditary	B	259-269
breast	I	270-276
cancer	I	277-283
is	O	284-286
explained	O	287-296
by	O	297-299
BRCA1	O	300-305
and	O	306-309
BRCA2	O	310-315
or	O	316-318
by	O	319-321
some	O	322-326
other	O	327-332
unidentified	O	333-345
susceptibility	O	346-360
gene	O	361-365
(	O	366-367
s	O	367-368
)	O	368-369
.	O	369-370

We	O	371-373
describe	O	374-382
the	O	383-386
proportion	O	387-397
of	O	398-400
hereditary	B	401-411
breast	I	412-418
cancer	I	419-425
explained	O	426-435
by	O	436-438
BRCA1	O	439-444
or	O	445-447
BRCA2	O	448-453
in	O	454-456
a	O	457-458
sample	O	459-465
of	O	466-468
North	O	469-474
American	O	475-483
hereditary	B	484-494
breast	I	495-501
cancers	I	502-509
and	O	510-513
assess	O	514-520
the	O	521-524
evidence	O	525-533
for	O	534-537
additional	O	538-548
susceptibility	O	549-563
genes	O	564-569
that	O	570-574
may	O	575-578
confer	O	579-585
hereditary	B	586-596
breast	I	597-603
or	I	604-606
ovarian	I	607-614
cancer	I	615-621
risk	O	622-626
.	O	626-627

Twenty	O	628-634
-	O	634-635
three	O	635-640
families	O	641-649
were	O	650-654
identified	O	655-665
through	O	666-673
two	O	674-677
high	O	678-682
-	O	682-683
risk	O	683-687
breast	B	688-694
cancer	I	695-701
research	O	702-710
programs	O	711-719
.	O	719-720

Genetic	O	721-728
analysis	O	729-737
was	O	738-741
undertaken	O	742-752
to	O	753-755
establish	O	756-765
linkage	O	766-773
between	O	774-781
the	O	782-785
breast	B	786-792
or	I	793-795
ovarian	I	796-803
cancer	I	804-810
cases	O	811-816
and	O	817-820
markers	O	821-828
on	O	829-831
chromosomes	O	832-843
17q	O	844-847
(	O	848-849
BRCA1	O	849-854
)	O	854-855
and	O	856-859
13q	O	860-863
(	O	864-865
BRCA2	O	865-870
)	O	870-871
.	O	871-872

Mutation	O	873-881
analysis	O	882-890
in	O	891-893
the	O	894-897
BRCA1	O	898-903
and	O	904-907
BRCA2	O	908-913
genes	O	914-919
was	O	920-923
also	O	924-928
undertaken	O	929-939
in	O	940-942
all	O	943-946
families	O	947-955
.	O	955-956

The	O	957-960
pattern	O	961-968
of	O	969-971
hereditary	B	972-982
cancer	I	983-989
in	O	990-992
14	O	993-995
(	O	996-997
61	O	997-999
%	O	999-1000
)	O	1000-1001
of	O	1002-1004
the	O	1005-1008
23	O	1009-1011
families	O	1012-1020
studied	O	1021-1028
was	O	1029-1032
attributed	O	1033-1043
to	O	1044-1046
BRCA1	O	1047-1052
by	O	1053-1055
a	O	1056-1057
combination	O	1058-1069
of	O	1070-1072
linkage	O	1073-1080
and	O	1081-1084
mutation	O	1085-1093
analyses	O	1094-1102
.	O	1102-1103

No	O	1104-1106
families	O	1107-1115
were	O	1116-1120
attributed	O	1121-1131
to	O	1132-1134
BRCA2	O	1135-1140
.	O	1140-1141

Five	O	1142-1146
families	O	1147-1155
(	O	1156-1157
22	O	1157-1159
%	O	1159-1160
)	O	1160-1161
provided	O	1162-1170
evidence	O	1171-1179
against	O	1180-1187
linkage	O	1188-1195
to	O	1196-1198
both	O	1199-1203
BRCA1	O	1204-1209
and	O	1210-1213
BRCA2	O	1214-1219
.	O	1219-1220

No	O	1221-1223
BRCA1	O	1224-1229
or	O	1230-1232
BRCA2	O	1233-1238
mutations	O	1239-1248
were	O	1249-1253
detected	O	1254-1262
in	O	1263-1265
these	O	1266-1271
five	O	1272-1276
families	O	1277-1285
.	O	1285-1286

The	O	1287-1290
BRCA1	O	1291-1296
or	O	1297-1299
BRCA2	O	1300-1305
status	O	1306-1312
of	O	1313-1315
four	O	1316-1320
families	O	1321-1329
(	O	1330-1331
17	O	1331-1333
%	O	1333-1334
)	O	1334-1335
could	O	1336-1341
not	O	1342-1345
be	O	1346-1348
determined	O	1349-1359
.	O	1359-1360

BRCA1	O	1361-1366
and	O	1367-1370
BRCA2	O	1371-1376
probably	O	1377-1385
explain	O	1386-1393
the	O	1394-1397
majority	O	1398-1406
of	O	1407-1409
hereditary	B	1410-1420
breast	I	1421-1427
cancer	I	1428-1434
that	O	1435-1439
exists	O	1440-1446
in	O	1447-1449
the	O	1450-1453
North	O	1454-1459
American	O	1460-1468
population	O	1469-1479
.	O	1479-1480

However	O	1481-1488
,	O	1488-1489
one	O	1490-1493
or	O	1494-1496
more	O	1497-1501
additional	O	1502-1512
genes	O	1513-1518
may	O	1519-1522
yet	O	1523-1526
be	O	1527-1529
found	O	1530-1535
that	O	1536-1540
explain	O	1541-1548
some	O	1549-1553
proportion	O	1554-1564
of	O	1565-1567
hereditary	B	1568-1578
breast	I	1579-1585
cancer	I	1586-1592
.	O	1592-1593
.	O	1592-1593

The	O	0-3
tumor	B	4-9
suppressor	O	10-20
gene	O	21-25
Brca1	O	26-31
is	O	32-34
required	O	35-43
for	O	44-47
embryonic	O	48-57
cellular	O	58-66
proliferation	O	67-80
in	O	81-83
the	O	84-87
mouse	O	88-93
.	O	93-94

Mutations	O	95-104
of	O	105-107
the	O	108-111
BRCA1	O	112-117
gone	O	118-122
in	O	123-125
humans	O	126-132
are	O	133-136
associated	O	137-147
with	O	148-152
predisposition	O	153-167
to	O	168-170
breast	B	171-177
and	I	178-181
ovarian	I	182-189
cancers	I	190-197
.	O	197-198

We	O	199-201
show	O	202-206
here	O	207-211
that	O	212-216
Brca1	O	217-222
+	O	223-224
/	O	224-225
-	O	225-226
mice	O	227-231
are	O	232-235
normal	O	236-242
and	O	243-246
fertile	O	247-254
and	O	255-258
lack	O	259-263
tumors	B	264-270
by	O	271-273
age	O	274-277
eleven	O	278-284
months	O	285-291
.	O	291-292

Homozygous	O	293-303
Brca1	O	304-309
(	O	310-311
5	O	311-312
-	O	312-313
6	O	313-314
)	O	314-315
mutant	O	316-322
mice	O	323-327
die	O	328-331
before	O	332-338
day	O	339-342
7	O	343-344
.	O	344-345
5	O	346-347
of	O	348-350
embryogenesis	O	351-364
.	O	364-365

Mutant	O	366-372
embryos	O	373-380
are	O	381-384
poorly	O	385-391
developed	O	392-401
,	O	401-402
with	O	403-407
no	O	408-410
evidence	O	411-419
of	O	420-422
mesoderm	O	423-431
formation	O	432-441
.	O	441-442

The	O	443-446
extraembryonic	O	447-461
region	O	462-468
is	O	469-471
abnormal	O	472-480
,	O	480-481
but	O	482-485
aggregation	O	486-497
with	O	498-502
wild	O	503-507
-	O	507-508
type	O	508-512
tetraploid	O	513-523
embryos	O	524-531
does	O	532-536
not	O	537-540
rescue	O	541-547
the	O	548-551
lethality	O	552-561
.	O	561-562

In	O	563-565
vivo	O	566-570
,	O	570-571
mutant	O	572-578
embryos	O	579-586
do	O	587-589
not	O	590-593
exhibit	O	594-601
increased	O	602-611
apoptosis	O	612-621
but	O	622-625
show	O	626-630
reduced	O	631-638
cell	O	639-643
proliferation	O	644-657
accompanied	O	658-669
by	O	670-672
decreased	O	673-682
expression	O	683-693
of	O	694-696
cyclin	O	697-703
E	O	704-705
and	O	706-709
mdm	O	710-713
-	O	713-714
2	O	714-715
,	O	715-716
a	O	717-718
regulator	O	719-728
of	O	729-731
p53	O	732-735
activity	O	736-744
.	O	744-745

The	O	746-749
expression	O	750-760
of	O	761-763
cyclin	O	764-770
-	O	770-771
dependent	O	771-780
kinase	O	781-787
inhibitor	O	788-797
p21	O	798-801
is	O	802-804
dramatically	O	805-817
increased	O	818-827
in	O	828-830
the	O	831-834
mutant	O	835-841
embryos	O	842-849
.	O	849-850

Buttressing	O	851-862
these	O	863-868
in	O	869-871
vivo	O	872-876
observations	O	877-889
is	O	890-892
the	O	893-896
fact	O	897-901
that	O	902-906
mutant	O	907-913
blastocyst	O	914-924
growth	O	925-931
is	O	932-934
grossly	O	935-942
impaired	O	943-951
in	O	952-954
vitro	O	955-960
.	O	960-961

Thus	O	962-966
,	O	966-967
the	O	968-971
death	O	972-977
of	O	978-980
Brca1	O	981-986
(	O	987-988
5	O	988-989
-	O	989-990
6	O	990-991
)	O	991-992
mutant	O	993-999
embryos	O	1000-1007
prior	O	1008-1013
to	O	1014-1016
gastrulation	O	1017-1029
may	O	1030-1033
be	O	1034-1036
due	O	1037-1040
to	O	1041-1043
a	O	1044-1045
failure	O	1046-1053
of	O	1054-1056
the	O	1057-1060
proliferative	O	1061-1074
burst	O	1075-1080
required	O	1081-1089
for	O	1090-1093
the	O	1094-1097
development	O	1098-1109
of	O	1110-1112
the	O	1113-1116
different	O	1117-1126
germ	O	1127-1131
layers	O	1132-1138
.	O	1138-1139

Fusion	O	0-6
genes	O	7-12
resulting	O	13-22
from	O	23-27
alternative	O	28-39
chromosomal	O	40-51
translocations	O	52-66
are	O	67-70
overexpressed	O	71-84
by	O	85-87
gene	O	88-92
-	O	92-93
specific	O	93-101
mechanisms	O	102-112
in	O	113-115
alveolar	B	116-124
rhabdomyosarcoma	I	125-141
.	O	141-142

Chromosomal	O	143-154
translocations	O	155-169
identified	O	170-180
in	O	181-183
hematopoietic	B	184-197
and	I	198-201
solid	I	202-207
tumors	I	208-214
result	O	215-221
in	O	222-224
deregulated	O	225-236
expression	O	237-247
of	O	248-250
protooncogenes	O	251-265
or	O	266-268
creation	O	269-277
of	O	278-280
chimeric	O	281-289
proteins	O	290-298
with	O	299-303
tumorigenic	O	304-315
potential	O	316-325
.	O	325-326

In	O	327-329
the	O	330-333
pediatric	O	334-343
solid	B	344-349
tumor	I	350-355
alveolar	B	356-364
rhabdomyosarcoma	I	365-381
,	O	381-382
a	O	383-384
consistent	O	385-395
t	O	396-397
(	O	398-399
2	O	399-400
;	O	400-401
13	O	402-404
)	O	404-405
(	O	406-407
q35	O	407-410
;	O	410-411
q14	O	412-415
)	O	415-416
or	O	417-419
variant	O	420-427
t	O	428-429
(	O	430-431
1	O	431-432
;	O	432-433
13	O	434-436
)	O	436-437
(	O	438-439
p36	O	439-442
;	O	442-443
q14	O	444-447
)	O	447-448
translocation	O	449-462
generates	O	463-472
PAX3	O	473-477
-	O	477-478
FKHR	O	478-482
or	O	483-485
PAX7	O	486-490
-	O	490-491
FKHR	O	491-495
fusion	O	496-502
proteins	O	503-511
,	O	511-512
respectively	O	513-525
.	O	525-526

In	O	527-529
this	O	530-534
report	O	535-541
,	O	541-542
we	O	543-545
demonstrate	O	546-557
that	O	558-562
in	O	563-565
addition	O	566-574
to	O	575-577
functional	O	578-588
alterations	O	589-600
these	O	601-606
translocations	O	607-621
are	O	622-625
associated	O	626-636
with	O	637-641
fusion	O	642-648
product	O	649-656
overexpression	O	657-671
.	O	671-672

Furthermore	O	673-684
,	O	684-685
PAX3	O	686-690
-	O	690-691
FKHR	O	691-695
and	O	696-699
PAX7	O	700-704
-	O	704-705
FKHR	O	705-709
overexpression	O	710-724
occurs	O	725-731
by	O	732-734
distinct	O	735-743
mechanisms	O	744-754
.	O	754-755

Transcription	O	756-769
of	O	770-772
PAX3	O	773-777
-	O	777-778
FKHR	O	778-782
is	O	783-785
increased	O	786-795
relative	O	796-804
to	O	805-807
wild	O	808-812
-	O	812-813
type	O	813-817
PAX3	O	818-822
by	O	823-825
a	O	826-827
copy	O	828-832
number	O	833-839
-	O	839-840
independent	O	840-851
process	O	852-859
.	O	859-860

In	O	861-863
contrast	O	864-872
,	O	872-873
PAX7	O	874-878
-	O	878-879
FKHR	O	879-883
overexpression	O	884-898
results	O	899-906
from	O	907-911
fusion	O	912-918
gene	O	919-923
amplification	O	924-937
.	O	937-938

Thus	O	939-943
,	O	943-944
gene	O	945-949
-	O	949-950
specific	O	950-958
mechanisms	O	959-969
were	O	970-974
selected	O	975-983
to	O	984-986
overexpress	O	987-998
PAX3	O	999-1003
-	O	1003-1004
FKHR	O	1004-1008
and	O	1009-1012
PAX7	O	1013-1017
-	O	1017-1018
FKHR	O	1018-1022
in	O	1023-1025
alveolar	B	1026-1034
rhabdomyosarcoma	I	1035-1051
,	O	1051-1052
presumably	O	1053-1063
due	O	1064-1067
to	O	1068-1070
differences	O	1071-1082
in	O	1083-1085
regulation	O	1086-1096
between	O	1097-1104
the	O	1105-1108
wild	O	1109-1113
-	O	1113-1114
type	O	1114-1118
loci	O	1119-1123
.	O	1123-1124

We	O	1125-1127
postulate	O	1128-1137
that	O	1138-1142
these	O	1143-1148
overexpression	O	1149-1163
mechanisms	O	1164-1174
ensure	O	1175-1181
a	O	1182-1183
critical	O	1184-1192
level	O	1193-1198
of	O	1199-1201
gene	O	1202-1206
product	O	1207-1214
for	O	1215-1218
the	O	1219-1222
oncogenic	O	1223-1232
effects	O	1233-1240
of	O	1241-1243
these	O	1244-1249
fusions	O	1250-1257
.	O	1257-1258
.	O	1257-1258

Pleiotropic	O	0-11
defects	O	12-19
in	O	20-22
ataxia	B	23-29
-	I	29-30
telangiectasia	I	30-44
protein	O	45-52
-	O	52-53
deficient	O	53-62
mice	O	63-67
.	O	67-68

We	O	69-71
have	O	72-76
generated	O	77-86
a	O	87-88
mouse	O	89-94
model	O	95-100
for	O	101-104
ataxia	B	105-111
-	I	111-112
telangiectasia	I	112-126
by	O	127-129
using	O	130-135
gene	O	136-140
targeting	O	141-150
to	O	151-153
generate	O	154-162
mice	O	163-167
that	O	168-172
do	O	173-175
not	O	176-179
express	O	180-187
the	O	188-191
Atm	O	192-195
protein	O	196-203
.	O	203-204

Atm	O	205-208
-	O	208-209
deficient	O	209-218
mice	O	219-223
are	O	224-227
retarded	O	228-236
in	O	237-239
growth	O	240-246
,	O	246-247
do	O	248-250
not	O	251-254
produce	O	255-262
mature	O	263-269
sperm	O	270-275
,	O	275-276
and	O	277-280
exhibit	O	281-288
severe	O	289-295
defects	O	296-303
in	O	304-306
T	O	307-308
cell	O	309-313
maturation	O	314-324
while	O	325-330
going	O	331-336
on	O	337-339
to	O	340-342
develop	O	343-350
thymomas	B	351-359
.	O	359-360

Atm	O	361-364
-	O	364-365
deficient	O	365-374
fibroblasts	O	375-386
grow	O	387-391
poorly	O	392-398
in	O	399-401
culture	O	402-409
and	O	410-413
display	O	414-421
a	O	422-423
high	O	424-428
level	O	429-434
of	O	435-437
double	O	438-444
-	O	444-445
stranded	O	445-453
chromosome	O	454-464
breaks	O	465-471
.	O	471-472

Atm	O	473-476
-	O	476-477
deficient	O	477-486
thymocytes	O	487-497
undergo	O	498-505
spontaneous	O	506-517
apoptosis	O	518-527
in	O	528-530
vitro	O	531-536
significantly	O	537-550
more	O	551-555
than	O	556-560
controls	O	561-569
.	O	569-570

Atm	O	571-574
-	O	574-575
deficient	O	575-584
mice	O	585-589
then	O	590-594
exhibit	O	595-602
many	O	603-607
of	O	608-610
the	O	611-614
same	O	615-619
symptoms	O	620-628
found	O	629-634
in	O	635-637
ataxia	B	638-644
-	I	644-645
telangiectasia	I	645-659
patients	O	660-668
and	O	669-672
in	O	673-675
cells	O	676-681
derived	O	682-689
from	O	690-694
them	O	695-699
.	O	699-700

Furthermore	O	701-712
,	O	712-713
we	O	714-716
demonstrate	O	717-728
that	O	729-733
the	O	734-737
Atm	O	738-741
protein	O	742-749
exists	O	750-756
as	O	757-759
two	O	760-763
discrete	O	764-772
molecular	O	773-782
species	O	783-790
,	O	790-791
and	O	792-795
that	O	796-800
loss	O	801-805
of	O	806-808
one	O	809-812
or	O	813-815
of	O	816-818
both	O	819-823
of	O	824-826
these	O	827-832
can	O	833-836
lead	O	837-841
to	O	842-844
the	O	845-848
development	O	849-860
of	O	861-863
the	O	864-867
disease	O	868-875
.	O	875-876
.	O	875-876

Muscle	O	0-6
expression	O	7-17
of	O	18-20
glucose	B	21-28
-	I	28-29
6	I	29-30
-	I	28-29
phosphate	I	31-40
dehydrogenase	I	41-54
deficiency	I	55-65
in	O	66-68
different	O	69-78
variants	O	79-87
.	O	87-88

Muscle	O	89-95
expression	O	96-106
of	O	107-109
G6PD	B	110-114
deficiency	I	115-125
has	O	126-129
been	O	130-134
investigated	O	135-147
in	O	148-150
Mediterranean	O	151-164
,	O	164-165
Seattle	O	166-173
-	O	173-174
like	O	174-178
and	O	179-182
A	O	183-184
-	O	184-185
variants	O	185-193
.	O	193-194

G6PD	O	195-199
activity	O	200-208
was	O	209-212
detected	O	213-221
in	O	222-224
samples	O	225-232
obtained	O	233-241
from	O	242-246
biopsies	O	247-255
on	O	256-258
the	O	259-262
quadriceps	O	263-273
muscle	O	274-280
of	O	281-283
seven	O	284-289
males	O	290-295
and	O	296-299
one	O	300-303
female	O	304-310
.	O	310-311

The	O	312-315
type	O	316-320
of	O	321-323
genetic	O	324-331
variant	O	332-339
was	O	340-343
determined	O	344-354
by	O	355-357
molecular	O	358-367
analysis	O	368-376
of	O	377-379
DNA	O	380-383
,	O	383-384
extracted	O	385-394
from	O	395-399
blood	O	400-405
samples	O	406-413
.	O	413-414

All	O	415-418
variants	O	419-427
showed	O	428-434
the	O	435-438
enzyme	O	439-445
defect	O	446-452
in	O	453-455
muscle	O	456-462
.	O	462-463

A	O	464-465
statistically	O	466-479
significant	O	480-491
relationship	O	492-504
was	O	505-508
found	O	509-514
in	O	515-517
the	O	518-521
activity	O	522-530
of	O	531-533
G6PD	O	534-538
between	O	539-546
erythrocytes	O	547-559
and	O	560-563
muscle	O	564-570
of	O	571-573
the	O	574-577
male	O	578-582
subjects	O	583-591
(	O	592-593
r	O	593-594
=	O	595-596
0	O	597-598
.	O	598-599
968	O	600-603
;	O	603-604
p	O	605-606
=	O	607-608
0	O	609-610
.	O	610-611
00008	O	612-617
)	O	617-618
.	O	618-619

The	O	620-623
equation	O	624-632
for	O	633-636
the	O	637-640
best	O	641-645
fit	O	646-649
line	O	650-654
was	O	655-658
Y	O	660-661
=	O	662-663
0	O	664-665
.	O	665-666
390X	O	667-671
+	O	672-673
0	O	674-675
.	O	675-676
198	O	677-680
198	O	681-684
.	O	684-685

The	O	686-689
results	O	690-697
suggest	O	698-705
that	O	706-710
,	O	710-711
for	O	712-715
a	O	716-717
given	O	718-723
variant	O	724-731
,	O	731-732
the	O	733-736
extent	O	737-743
of	O	744-746
the	O	747-750
enzyme	O	751-757
defect	O	758-764
in	O	765-767
muscle	O	768-774
may	O	775-778
be	O	779-781
determined	O	782-792
,	O	792-793
using	O	794-799
this	O	800-804
equation	O	805-813
,	O	813-814
from	O	815-819
the	O	820-823
G6PD	O	824-828
activity	O	829-837
of	O	838-840
erythrocytes	O	841-853

PTEN	O	0-4
,	O	4-5
a	O	6-7
putative	O	8-16
protein	O	17-24
tyrosine	O	25-33
phosphatase	O	34-45
gene	O	46-50
mutated	O	51-58
in	O	59-61
human	O	62-67
brain	B	68-73
,	I	73-74
breast	I	75-81
,	I	81-82
and	I	83-86
prostate	I	87-95
cancer	I	96-102
.	O	102-103

Mapping	O	104-111
of	O	112-114
homozygous	O	115-125
deletions	O	126-135
on	O	136-138
human	O	139-144
chromosome	O	145-155
10q23	O	156-161
has	O	162-165
led	O	166-169
to	O	170-172
the	O	173-176
isolation	O	177-186
of	O	187-189
a	O	190-191
candidate	O	192-201
tumor	B	202-207
suppressor	O	208-218
gene	O	219-223
,	O	223-224
PTEN	O	225-229
,	O	229-230
that	O	231-235
appears	O	236-243
to	O	244-246
be	O	247-249
mutated	O	250-257
at	O	258-260
considerable	O	261-273
frequency	O	274-283
in	O	284-286
human	O	287-292
cancers	B	293-300
.	O	300-301

In	O	302-304
preliminary	O	305-316
screens	O	317-324
,	O	324-325
mutations	O	326-335
of	O	336-338
PTEN	O	339-343
were	O	344-348
detected	O	349-357
in	O	358-360
31	O	361-363
%	O	363-364
(	O	365-366
13	O	366-368
/	O	368-369
42	O	369-371
)	O	371-372
of	O	373-375
glioblastoma	B	376-388
cell	O	389-393
lines	O	394-399
and	O	400-403
xenografts	O	404-414
,	O	414-415
100	O	416-419
%	O	419-420
(	O	421-422
4	O	422-423
/	O	423-424
4	O	422-423
)	O	425-426
of	O	427-429
prostate	B	430-438
cancer	I	439-445
cell	O	446-450
lines	O	451-456
,	O	456-457
6	O	458-459
%	O	459-460
(	O	461-462
4	O	462-463
/	O	463-464
65	O	464-466
)	O	466-467
of	O	468-470
breast	B	471-477
cancer	I	478-484
cell	O	485-489
lines	O	490-495
and	O	496-499
xenografts	O	500-510
,	O	510-511
and	O	512-515
17	O	516-518
%	O	518-519
(	O	520-521
3	O	521-522
/	O	522-523
18	O	523-525
)	O	525-526
of	O	527-529
primary	B	530-537
glioblastomas	I	538-551
.	O	551-552

The	O	553-556
predicted	O	557-566
PTEN	O	567-571
product	O	572-579
has	O	580-583
a	O	584-585
protein	O	586-593
tyrosine	O	594-602
phosphatase	O	603-614
domain	O	615-621
and	O	622-625
extensive	O	626-635
homology	O	636-644
to	O	645-647
tensin	O	648-654
,	O	654-655
a	O	656-657
protein	O	658-665
that	O	666-670
interacts	O	671-680
with	O	681-685
actin	O	686-691
filaments	O	692-701
at	O	702-704
focal	O	705-710
adhesions	O	711-720
.	O	720-721

These	O	722-727
homologies	O	728-738
suggest	O	739-746
that	O	747-751
PTEN	O	752-756
may	O	757-760
suppress	O	761-769
tumor	B	770-775
cell	O	776-780
growth	O	781-787
by	O	788-790
antagonizing	O	791-803
protein	O	804-811
tyrosine	O	812-820
kinases	O	821-828
and	O	829-832
may	O	833-836
regulate	O	837-845
tumor	B	846-851
cell	O	852-856
invasion	O	857-865
and	O	866-869
metastasis	B	870-880
through	O	881-888
interactions	O	889-901
at	O	902-904
focal	O	905-910
adhesions	O	911-920
.	O	920-921
.	O	920-921

Somatic	O	0-7
alterations	O	8-19
of	O	20-22
the	O	23-26
DPC4	O	27-31
gene	O	32-36
in	O	37-39
human	O	40-45
colorectal	B	46-56
cancers	I	57-64
in	O	65-67
vivo	O	68-72
.	O	72-73

BACKGROUND	O	74-84
&	O	85-86
AIMS	O	87-91
The	O	93-96
chromosome	O	97-107
region	O	108-114
18q21	O	115-120
has	O	121-124
been	O	125-129
shown	O	130-135
to	O	136-138
be	O	139-141
frequently	O	142-152
deleted	O	153-160
in	O	161-163
colorectal	B	164-174
cancers	I	175-182
,	O	182-183
and	O	184-187
such	O	188-192
frequent	O	193-201
allelic	O	202-209
loss	O	210-214
is	O	215-217
a	O	218-219
hallmark	O	220-228
of	O	229-231
the	O	232-235
presence	O	236-244
of	O	245-247
a	O	248-249
tumor	O	250-255
-	O	255-256
suppressor	O	256-266
gene	O	267-271
.	O	271-272

The	O	273-276
DPC4	O	277-281
gene	O	282-286
,	O	286-287
which	O	288-293
is	O	294-296
located	O	297-304
at	O	305-307
18q21	O	308-313
,	O	313-314
has	O	315-318
been	O	319-323
identified	O	324-334
as	O	335-337
a	O	338-339
tumor	O	340-345
-	O	345-346
suppressor	O	346-356
gene	O	357-361
from	O	362-366
examination	O	367-378
of	O	379-381
pancreatic	B	382-392
cancers	I	393-400
.	O	400-401

The	O	402-405
aim	O	406-409
of	O	410-412
the	O	413-416
present	O	417-424
study	O	425-430
was	O	431-434
to	O	435-437
determine	O	438-447
if	O	448-450
it	O	451-453
might	O	454-459
also	O	460-464
be	O	465-467
altered	O	468-475
in	O	476-478
colorectal	B	479-489
cancers	I	490-497
.	O	497-498

METHODS	O	499-506
Mutation	O	508-516
analyses	O	517-525
of	O	526-528
the	O	529-532
DPC4	O	533-537
gene	O	538-542
were	O	543-547
performed	O	548-557
on	O	558-560
complementary	O	561-574
DNA	O	575-578
samples	O	579-586
from	O	587-591
31	O	592-594
primary	O	595-602
colorectal	B	603-613
cancer	I	614-620
specimens	O	621-630
using	O	631-636
a	O	637-638
combination	O	639-650
of	O	651-653
polymerase	O	654-664
chain	O	665-670
reaction	O	671-679
,	O	679-680
single	O	681-687
-	O	687-688
strand	O	688-694
conformation	O	695-707
polymorphism	O	708-720
,	O	720-721
and	O	722-725
DNA	O	726-729
sequencing	O	730-740
.	O	740-741

RESULTS	O	742-749
Four	O	751-755
missense	O	756-764
mutations	O	765-774
producing	O	775-784
amino	O	785-790
acid	O	791-795
substitutions	O	796-809
and	O	810-813
a	O	814-815
somatic	O	816-823
12	O	824-826
-	O	826-827
base	O	827-831
pair	O	832-836
deletion	O	837-845
in	O	846-848
the	O	849-852
coding	O	853-859
region	O	860-866
of	O	867-869
the	O	870-873
DPC4	O	874-878
gene	O	879-883
were	O	884-888
detected	O	889-897
in	O	898-900
the	O	901-904
31	O	905-907
cancers	B	908-915
(	O	916-917
16	O	917-919
%	O	919-920
;	O	920-921
5	O	922-923
of	O	924-926
31	O	927-929
)	O	929-930
.	O	930-931

CONCLUSIONS	O	932-943
The	O	945-948
DPC4	O	949-953
gene	O	954-958
may	O	959-962
play	O	963-967
a	O	968-969
role	O	970-974
as	O	975-977
a	O	978-979
tumor	O	980-985
-	O	985-986
suppressor	O	986-996
gene	O	997-1001
in	O	1002-1004
a	O	1005-1006
fraction	O	1007-1015
of	O	1016-1018
colorectal	B	1019-1029
cancers	I	1030-1037
;	O	1037-1038
however	O	1039-1046
,	O	1046-1047
while	O	1048-1053
allelic	O	1054-1061
loss	O	1062-1066
at	O	1067-1069
18q21	O	1070-1075
is	O	1076-1078
very	O	1079-1083
often	O	1084-1089
seen	O	1090-1094
in	O	1095-1097
colorectal	B	1098-1108
cancers	I	1109-1116
,	O	1116-1117
only	O	1118-1122
a	O	1123-1124
minority	O	1125-1133
show	O	1134-1138
DPC4	O	1139-1143
mutations	O	1144-1153
,	O	1153-1154
suggesting	O	1155-1165
that	O	1166-1170
there	O	1171-1176
might	O	1177-1182
be	O	1183-1185
another	O	1186-1193
tumor	O	1194-1199
-	O	1199-1200
suppressor	O	1200-1210
gene	O	1211-1215
in	O	1216-1218
this	O	1219-1223
chromosome	O	1224-1234
region	O	1235-1241
.	O	1241-1242
.	O	1241-1242

Complete	O	0-8
genomic	O	9-16
sequence	O	17-25
and	O	26-29
analysis	O	30-38
of	O	39-41
117	O	42-45
kb	O	46-48
of	O	49-51
human	O	52-57
DNA	O	58-61
containing	O	62-72
the	O	73-76
gene	O	77-81
BRCA1	O	82-87
.	O	87-88

Over	O	89-93
100	O	94-97
distinct	O	98-106
disease	O	107-114
-	O	114-115
associated	O	115-125
mutations	O	126-135
have	O	136-140
been	O	141-145
identified	O	146-156
in	O	157-159
the	O	160-163
breast	B	164-170
-	I	170-171
ovarian	I	171-178
cancer	I	179-185
susceptibility	O	186-200
gene	O	201-205
BRCA1	O	206-211
.	O	211-212

Loss	O	213-217
of	O	218-220
the	O	221-224
wild	O	225-229
-	O	229-230
type	O	230-234
allele	O	235-241
in	O	242-244
>	O	245-246
90	O	247-249
%	O	249-250
of	O	251-253
tumors	B	254-260
from	O	261-265
patients	O	266-274
with	O	275-279
inherited	O	280-289
BRCA1	O	290-295
mutations	O	296-305
indicates	O	306-315
tumor	B	316-321
suppressive	O	322-333
function	O	334-342
.	O	342-343

The	O	344-347
low	O	348-351
incidence	O	352-361
of	O	362-364
somatic	O	365-372
mutations	O	373-382
suggests	O	383-391
that	O	392-396
BRCA1	O	397-402
inactivation	O	403-415
in	O	416-418
sporadic	O	419-427
tumors	B	428-434
occurs	O	435-441
by	O	442-444
alternative	O	445-456
mechanisms	O	457-467
,	O	467-468
such	O	469-473
as	O	474-476
interstitial	O	477-489
chromosomal	O	490-501
deletion	O	502-510
or	O	511-513
reduced	O	514-521
transcription	O	522-535
.	O	535-536

To	O	537-539
identify	O	540-548
possible	O	549-557
features	O	558-566
of	O	567-569
the	O	570-573
BRCA1	O	574-579
genomic	O	580-587
region	O	588-594
that	O	595-599
may	O	600-603
contribute	O	604-614
to	O	615-617
chromosomal	O	618-629
instability	O	630-641
as	O	642-644
well	O	645-649
as	O	650-652
potential	O	653-662
transcriptional	O	663-678
regulatory	O	679-689
elements	O	690-698
,	O	698-699
a	O	700-701
117	O	702-705
,	O	705-706
143	O	707-710
-	O	710-711
bp	O	711-713
DNA	O	714-717
sequence	O	718-726
encompassing	O	727-739
BRCA1	O	740-745
was	O	746-749
obtained	O	750-758
by	O	759-761
random	O	762-768
sequencing	O	769-779
of	O	780-782
four	O	783-787
cosmids	O	788-795
identified	O	796-806
from	O	807-811
a	O	812-813
human	O	814-819
chromosome	O	820-830
17	O	831-833
specific	O	834-842
library	O	843-850
.	O	850-851

The	O	852-855
24	O	856-858
exons	O	859-864
of	O	865-867
BRCA1	O	868-873
span	O	874-878
an	O	879-881
81	O	882-884
-	O	884-885
kb	O	885-887
region	O	888-894
that	O	895-899
has	O	900-903
an	O	904-906
unusually	O	907-916
high	O	917-921
density	O	922-929
of	O	930-932
Alu	O	933-936
repetitive	O	937-947
DNA	O	948-951
(	O	952-953
41	O	953-955
.	O	955-956

5	O	957-958
%	O	958-959
)	O	959-960
,	O	960-961
but	O	962-965
relatively	O	966-976
low	O	977-980
density	O	981-988
(	O	989-990
4	O	990-991
.	O	991-992

8	O	993-994
%	O	994-995
)	O	995-996
of	O	997-999
other	O	1000-1005
repetitive	O	1006-1016
sequences	O	1017-1026
.	O	1026-1027

BRCA1	O	1028-1033
intron	O	1034-1040
lengths	O	1041-1048
range	O	1049-1054
in	O	1055-1057
size	O	1058-1062
from	O	1063-1067
403	O	1068-1071
bp	O	1072-1074
to	O	1075-1077
9	O	1078-1079
.	O	1079-1080
2	O	1081-1082
kb	O	1083-1085
and	O	1086-1089
contain	O	1090-1097
the	O	1098-1101
intragenic	O	1102-1112
microsatellite	O	1113-1127
markers	O	1128-1135
D17S1323	O	1136-1144
,	O	1144-1145
D17S1322	O	1146-1154
,	O	1154-1155
and	O	1156-1159
D17S855	O	1160-1167
,	O	1167-1168
which	O	1169-1174
localize	O	1175-1183
to	O	1184-1186
introns	O	1187-1194
12	O	1195-1197
,	O	1197-1198
19	O	1199-1201
,	O	1201-1202
and	O	1203-1206
20	O	1207-1209
,	O	1209-1210
respectively	O	1211-1223
.	O	1223-1224

In	O	1225-1227
addition	O	1228-1236
to	O	1237-1239
BRCA1	O	1240-1245
,	O	1245-1246
the	O	1247-1250
contig	O	1251-1257
contains	O	1258-1266
two	O	1267-1270
complete	O	1271-1279
genes	O	1280-1285
Rho7	O	1287-1291
,	O	1291-1292
a	O	1293-1294
member	O	1295-1301
of	O	1302-1304
the	O	1305-1308
rho	O	1309-1312
family	O	1313-1319
of	O	1320-1322
GTP	O	1323-1326
binding	O	1327-1334
proteins	O	1335-1343
,	O	1343-1344
and	O	1345-1348
VAT1	O	1349-1353
,	O	1353-1354
an	O	1355-1357
abundant	O	1358-1366
membrane	O	1367-1375
protein	O	1376-1383
of	O	1384-1386
cholinergic	O	1387-1398
synaptic	O	1399-1407
vesicles	O	1408-1416
.	O	1416-1417

Partial	O	1418-1425
sequences	O	1426-1435
of	O	1436-1438
the	O	1439-1442
1A1	O	1443-1446
-	O	1446-1447
3B	O	1447-1449
B	O	1450-1451
-	O	1451-1452
box	O	1452-1455
protein	O	1456-1463
pseudogene	O	1464-1474
and	O	1475-1478
IFP	O	1479-1482
35	O	1483-1485
,	O	1485-1486
an	O	1487-1489
interferon	O	1490-1500
induced	O	1501-1508
leucine	O	1509-1516
zipper	O	1517-1523
protein	O	1524-1531
,	O	1531-1532
reside	O	1533-1539
within	O	1540-1546
the	O	1547-1550
contig	O	1551-1557
.	O	1557-1558

An	O	1559-1561
L21	O	1562-1565
ribosomal	O	1566-1575
protein	O	1576-1583
pseudogene	O	1584-1594
is	O	1595-1597
embedded	O	1598-1606
in	O	1607-1609
BRCA1	O	1610-1615
intron	O	1616-1622
13	O	1623-1625
.	O	1625-1626

The	O	1627-1630
order	O	1631-1636
of	O	1637-1639
genes	O	1640-1645
on	O	1646-1648
the	O	1649-1652
chromosome	O	1653-1663
is	O	1664-1666
centromere	O	1668-1678
-	O	1678-1679
1FP	O	1679-1682
35	O	1683-1685
-	O	1685-1686
VAT1	O	1686-1690
-	O	1685-1686
Rho7	O	1691-1695
-	O	1685-1686
BRCA1	O	1696-1701
-	O	1685-1686
1A1	O	1702-1705
-	O	1685-1686
3B	O	1706-1708
-	O	1685-1686
telomere	O	1709-1717

Type	B	0-4
II	I	5-7
human	I	8-13
complement	I	14-24
C2	I	25-27
deficiency	I	28-38
.	O	38-39

Allele	O	40-46
-	O	46-47
specific	O	47-55
amino	O	56-61
acid	O	62-66
substitutions	O	67-80
(	O	81-82
Ser189	O	82-88
-	O	89-90
-	O	89-90
>	O	91-92
Phe	O	93-96
;	O	96-97
Gly444	O	98-104
-	O	105-106
-	O	105-106
>	O	107-108
Arg	O	109-112
)	O	112-113
cause	O	114-119
impaired	O	120-128
C2	O	129-131
secretion	O	132-141
.	O	141-142

Type	B	143-147
II	I	148-150
complement	I	151-161
protein	I	162-169
C2	I	170-172
deficiency	I	173-183
is	O	184-186
characterized	O	187-200
by	O	201-203
a	O	204-205
selective	O	206-215
block	O	216-221
in	O	222-224
C2	O	225-227
secretion	O	228-237
.	O	237-238

The	O	239-242
Type	O	243-247
II	O	248-250
C2	O	251-253
null	O	254-258
allele	O	259-265
(	O	266-267
C2Q0	O	267-271
)	O	271-272
is	O	273-275
linked	O	276-282
to	O	283-285
two	O	286-289
major	O	290-295
histocompatibility	O	296-314
haplotypes	O	315-325
(	O	326-327
MHC	O	327-330
)	O	330-331
that	O	332-336
differ	O	337-343
from	O	344-348
the	O	349-352
MHC	O	353-356
of	O	357-359
the	O	360-363
more	O	364-368
common	O	369-375
Type	B	376-380
I	I	381-382
C2	I	383-385
deficiency	I	386-396
.	O	396-397

To	O	398-400
determine	O	401-410
the	O	411-414
molecular	O	415-424
basis	O	425-430
of	O	431-433
Type	B	434-438
II	I	439-441
deficiency	I	442-452
the	O	453-456
two	O	457-460
Type	O	461-465
II	O	466-468
C2Q0	O	469-473
genes	O	474-479
were	O	480-484
isolated	O	485-493
and	O	494-497
transfected	O	498-509
separately	O	510-520
into	O	521-525
L	O	526-527
-	O	527-528
cells	O	528-533
.	O	533-534

Subsequent	O	535-545
molecular	O	546-555
biology	O	556-563
,	O	563-564
biosynthetic	O	565-577
,	O	577-578
and	O	579-582
immunofluorescence	O	583-601
studies	O	602-609
demonstrated	O	610-622
that	O	623-627
C2	O	628-630
secretion	O	631-640
is	O	641-643
impaired	O	644-652
in	O	653-655
Type	B	656-660
II	I	661-663
C2	I	664-666
deficiency	I	667-677
because	O	678-685
of	O	686-688
different	O	689-698
missense	O	699-707
mutations	O	708-717
at	O	718-720
highly	O	721-727
conserved	O	728-737
residues	O	738-746
in	O	747-749
each	O	750-754
of	O	755-757
the	O	758-761
C2Q0	O	762-766
alleles	O	767-774
.	O	774-775

One	O	776-779
is	O	780-782
in	O	783-785
exon	O	786-790
5	O	791-792
(	O	793-794
nucleotide	O	794-804
C566	O	805-809
-	O	810-811
-	O	810-811
>	O	813-814
T	O	815-816
;	O	816-817
Ser189	O	818-824
-	O	825-826
-	O	825-826
>	O	828-829
Phe	O	830-833
)	O	833-834
of	O	835-837
the	O	838-841
C2Q0	O	842-846
gene	O	847-851
linked	O	852-858
to	O	859-861
the	O	862-865
MHC	O	866-869
haplotype	O	870-879
A11	O	880-883
,	O	883-884
B35	O	885-888
,	O	888-889
DRw1	O	890-894
,	O	894-895
BFS	O	896-899
,	O	899-900
C4A0B1	O	901-907
.	O	907-908

The	O	909-912
other	O	913-918
is	O	919-921
in	O	922-924
exon	O	925-929
11	O	930-932
(	O	933-934
G1930	O	934-939
-	O	940-941
-	O	940-941
>	O	943-944
A	O	945-946
;	O	946-947
Gly444	O	948-954
-	O	955-956
-	O	955-956
>	O	958-959
Arg	O	960-963
)	O	963-964
of	O	965-967
the	O	968-971
C2Q0	O	972-976
gene	O	977-981
linked	O	982-988
to	O	989-991
the	O	992-995
MHC	O	996-999
haplotype	O	1000-1009
A2	O	1010-1012
,	O	1012-1013
B5	O	1014-1016
,	O	1016-1017
DRw4	O	1018-1022
,	O	1022-1023
BFS	O	1024-1027
,	O	1027-1028
C4A3B1	O	1029-1035
.	O	1035-1036

Each	O	1037-1041
mutant	O	1042-1048
C2	O	1049-1051
gene	O	1052-1056
product	O	1057-1064
is	O	1065-1067
retained	O	1068-1076
early	O	1077-1082
in	O	1083-1085
the	O	1086-1089
secretory	O	1090-1099
pathway	O	1100-1107
.	O	1107-1108

These	O	1109-1114
mutants	O	1115-1122
provide	O	1123-1130
models	O	1131-1137
for	O	1138-1141
elucidating	O	1142-1153
the	O	1154-1157
C2	O	1158-1160
secretory	O	1161-1170
pathway	O	1171-1178
.	O	1178-1179
.	O	1178-1179

Targeted	O	0-8
disruption	O	9-19
of	O	20-22
ATM	O	23-26
leads	O	27-32
to	O	33-35
growth	B	36-42
retardation	I	43-54
,	O	54-55
chromosomal	B	56-67
fragmentation	I	68-81
during	I	82-88
meiosis	I	89-96
,	O	96-97
immune	B	98-104
defects	I	105-112
,	O	112-113
and	O	114-117
thymic	B	118-124
lymphoma	I	125-133
.	O	133-134

ATM	O	135-138
,	O	138-139
the	O	140-143
gene	O	144-148
mutated	O	149-156
in	O	157-159
the	O	160-163
inherited	B	164-173
human	I	174-179
disease	I	180-187
ataxia	B	188-194
-	I	194-195
telangiectasia	I	195-209
,	O	209-210
is	O	211-213
a	O	214-215
member	O	216-222
of	O	223-225
a	O	226-227
family	O	228-234
of	O	235-237
kinases	O	238-245
involved	O	246-254
in	O	255-257
DNA	O	258-261
metabolism	O	262-272
and	O	273-276
cell	O	277-281
-	O	281-282
cycle	O	282-287
checkpoint	O	288-298
control	O	299-306
.	O	306-307

To	O	308-310
help	O	311-315
clarify	O	316-323
the	O	324-327
physiological	O	328-341
roles	O	342-347
of	O	348-350
the	O	351-354
ATM	O	355-358
protein	O	359-366
,	O	366-367
we	O	368-370
disrupted	O	371-380
the	O	381-384
ATM	O	385-388
gene	O	389-393
in	O	394-396
mice	O	397-401
through	O	402-409
homologous	O	410-420
recombination	O	421-434
.	O	434-435

Initial	O	436-443
evaluation	O	444-454
of	O	455-457
the	O	458-461
ATM	O	462-465
knockout	O	466-474
animals	O	475-482
indicates	O	483-492
that	O	493-497
inactivation	O	498-510
of	O	511-513
the	O	514-517
mouse	O	518-523
ATM	O	524-527
gene	O	528-532
recreates	O	533-542
much	O	543-547
of	O	548-550
the	O	551-554
phenotype	O	555-564
of	O	565-567
ataxia	B	568-574
-	I	574-575
telangiectasia	I	575-589
.	O	589-590

The	O	591-594
homozygous	O	595-605
mutant	O	606-612
(	O	613-614
ATM	O	614-617
-	O	617-618
/	O	618-619
-	O	617-618
)	O	620-621
mice	O	622-626
are	O	627-630
viable	O	631-637
,	O	637-638
growth	O	639-645
-	O	645-646
retarded	O	646-654
,	O	654-655
and	O	656-659
infertile	O	660-669
.	O	669-670

The	O	671-674
infertility	B	675-686
of	O	687-689
ATM	O	690-693
-	O	693-694
/	O	694-695
-	O	693-694
mice	O	697-701
results	O	702-709
from	O	710-714
meiotic	O	715-722
failure	O	723-730
.	O	730-731

Meiosis	O	732-739
is	O	740-742
arrested	O	743-751
at	O	752-754
the	O	755-758
zygotene	O	759-767
/	O	767-768
pachytene	O	768-777
stage	O	778-783
of	O	784-786
prophase	O	787-795
I	O	796-797
as	O	798-800
a	O	801-802
result	O	803-809
of	O	810-812
abnormal	O	813-821
chromosomal	O	822-833
synapsis	O	834-842
and	O	843-846
subsequent	O	847-857
chromosome	O	858-868
fragmentation	O	869-882
.	O	882-883

Immune	B	884-890
defects	I	891-898
also	O	899-903
are	O	904-907
evident	O	908-915
in	O	916-918
ATM	O	919-922
-	O	922-923
/	O	923-924
-	O	922-923
mice	O	926-930
,	O	930-931
including	O	932-941
reduced	O	942-949
numbers	O	950-957
of	O	958-960
B220	O	961-965
+	O	966-967
CD43	O	968-972
-	O	972-973
pre	O	974-977
-	O	977-978
B	O	978-979
cells	O	980-985
,	O	985-986
thymocytes	O	987-997
,	O	997-998
and	O	999-1002
peripheral	O	1003-1013
T	O	1014-1015
cells	O	1016-1021
,	O	1021-1022
as	O	1023-1025
well	O	1026-1030
as	O	1031-1033
functional	O	1034-1044
impairment	O	1045-1055
of	O	1056-1058
T	O	1059-1060
-	O	1060-1061
cell	O	1061-1065
-	O	1060-1061
dependent	O	1066-1075
immune	O	1076-1082
responses	O	1083-1092
.	O	1092-1093

The	O	1094-1097
cerebella	O	1098-1107
of	O	1108-1110
ATM	O	1111-1114
-	O	1114-1115
/	O	1115-1116
-	O	1114-1115
mice	O	1118-1122
appear	O	1123-1129
normal	O	1130-1136
by	O	1137-1139
histologic	O	1140-1150
examination	O	1151-1162
at	O	1163-1165
3	O	1166-1167
to	O	1168-1170
4	O	1171-1172
months	O	1173-1179
and	O	1180-1183
the	O	1184-1187
mice	O	1188-1192
have	O	1193-1197
no	O	1198-1200
gross	O	1201-1206
behavioral	B	1207-1217
abnormalities	I	1218-1231
.	O	1231-1232

The	O	1233-1236
majority	O	1237-1245
of	O	1246-1248
mutant	O	1249-1255
mice	O	1256-1260
rapidly	O	1261-1268
develop	O	1269-1276
thymic	B	1277-1283
lymphomas	I	1284-1293
and	O	1294-1297
die	O	1298-1301
before	O	1302-1308
4	O	1309-1310
months	O	1311-1317
of	O	1318-1320
age	O	1321-1324
.	O	1324-1325

These	O	1326-1331
findings	O	1332-1340
indicate	O	1341-1349
that	O	1350-1354
the	O	1355-1358
ATM	O	1359-1362
gene	O	1363-1367
product	O	1368-1375
plays	O	1376-1381
an	O	1382-1384
essential	O	1385-1394
role	O	1395-1399
in	O	1400-1402
a	O	1403-1404
diverse	O	1405-1412
group	O	1413-1418
of	O	1419-1421
cellular	O	1422-1430
processes	O	1431-1440
,	O	1440-1441
including	O	1442-1451
meiosis	O	1452-1459
,	O	1459-1460
the	O	1461-1464
normal	O	1465-1471
growth	O	1472-1478
of	O	1479-1481
somatic	O	1482-1489
tissues	O	1490-1497
,	O	1497-1498
immune	O	1499-1505
development	O	1506-1517
,	O	1517-1518
and	O	1519-1522
tumor	B	1523-1528
suppression	O	1529-1540
.	O	1540-1541
.	O	1540-1541

The	O	0-3
5	O	4-5
'	O	5-6
end	O	7-10
of	O	11-13
the	O	14-17
BRCA1	O	18-23
gene	O	24-28
lies	O	29-33
within	O	34-40
a	O	41-42
duplicated	O	43-53
region	O	54-60
of	O	61-63
human	O	64-69
chromosome	O	70-80
17q21	O	81-86
.	O	86-87

To	O	88-90
begin	O	91-96
to	O	97-99
address	O	100-107
the	O	108-111
hypothesis	O	112-122
that	O	123-127
abnormal	O	128-136
regulation	O	137-147
of	O	148-150
the	O	151-154
breast	B	155-161
/	I	161-162
ovarian	I	162-169
cancer	I	170-176
susceptibility	O	177-191
gene	O	192-196
BRCA1	O	197-202
is	O	203-205
a	O	206-207
critical	O	208-216
step	O	217-221
in	O	222-224
sporadic	O	225-233
breast	O	234-240
/	O	240-241
ovarian	O	241-248
tumorigenesis	O	249-262
,	O	262-263
we	O	264-266
have	O	267-271
determined	O	272-282
the	O	283-286
detailed	O	287-295
structure	O	296-305
of	O	306-308
the	O	309-312
BRCA1	O	313-318
genomic	O	319-326
region	O	327-333
.	O	333-334

We	O	335-337
show	O	338-342
that	O	343-347
this	O	348-352
region	O	353-359
of	O	360-362
the	O	363-366
genome	O	367-373
contains	O	374-382
a	O	383-384
tandem	O	385-391
duplication	O	392-403
of	O	404-406
approximately	O	407-420
30	O	421-423
kilobases	O	424-433
,	O	433-434
which	O	435-440
results	O	441-448
in	O	449-451
two	O	452-455
copies	O	456-462
of	O	463-465
BRCA1	O	466-471
exons	O	472-477
1	O	478-479
and	O	480-483
2	O	484-485
,	O	485-486
of	O	487-489
exons	O	490-495
1	O	496-497
and	O	498-501
3	O	502-503
of	O	504-506
the	O	507-510
adjacent	O	511-519
1A1	O	520-523
-	O	523-524
3B	O	524-526
gene	O	527-531
and	O	532-535
of	O	536-538
the	O	539-542
previously	O	543-553
reported	O	554-562
295	O	563-566
base	O	567-571
pair	O	572-576
intergenic	O	577-587
region	O	588-594
.	O	594-595

Sequence	O	596-604
analysis	O	605-613
of	O	614-616
the	O	617-620
duplicated	O	621-631
exons	O	632-637
of	O	638-640
BRCA1	O	641-646
and	O	647-650
1A1	O	651-654
-	O	654-655
3B	O	655-657
and	O	658-661
flanking	O	662-670
genomic	O	671-678
DNA	O	679-682
reveals	O	683-690
maintenance	O	691-702
of	O	703-705
the	O	706-709
intron	O	710-716
-	O	716-717
exon	O	717-721
structure	O	722-731
and	O	732-735
a	O	736-737
high	O	738-742
degree	O	743-749
of	O	750-752
nucleotide	O	753-763
sequence	O	764-772
identity	O	773-781
,	O	781-782
suggesting	O	783-793
that	O	794-798
these	O	799-804
are	O	805-808
non	O	809-812
-	O	812-813
processed	O	813-822
pseudogenes	O	823-834
and	O	835-838
that	O	839-843
the	O	844-847
duplication	O	848-859
is	O	860-862
a	O	863-864
recent	O	865-871
event	O	872-877
in	O	878-880
evolutionary	O	881-893
terms	O	894-899
.	O	899-900

We	O	901-903
also	O	904-908
show	O	909-913
that	O	914-918
a	O	919-920
processed	O	921-930
pseudogene	O	931-941
of	O	942-944
the	O	945-948
acidic	O	949-955
ribosomal	O	956-965
phosphoprotein	O	966-980
P1	O	981-983
(	O	984-985
ARPP1	O	985-990
)	O	990-991
is	O	992-994
inserted	O	995-1003
directly	O	1004-1012
upstream	O	1013-1021
of	O	1022-1024
pseudo	O	1025-1031
-	O	1031-1032
BRCA1	O	1032-1037
exon	O	1038-1042
1A	O	1043-1045
.	O	1045-1046

We	O	1047-1049
believe	O	1050-1057
that	O	1058-1062
these	O	1063-1068
findings	O	1069-1077
could	O	1078-1083
not	O	1084-1087
only	O	1088-1092
confound	O	1093-1101
BRCA1	O	1102-1107
mutation	O	1108-1116
analysis	O	1117-1125
,	O	1125-1126
but	O	1127-1130
could	O	1131-1136
have	O	1137-1141
implications	O	1142-1154
for	O	1155-1158
the	O	1159-1162
normal	O	1163-1169
and	O	1170-1173
abnormal	O	1174-1182
regulation	O	1183-1193
of	O	1194-1196
BRCA1	O	1197-1202
transcription	O	1203-1216
,	O	1216-1217
translation	O	1218-1229
and	O	1230-1233
function	O	1234-1242
.	O	1242-1243
.	O	1242-1243

atm	O	0-3
and	O	4-7
p53	O	8-11
cooperate	O	12-21
in	O	22-24
apoptosis	O	25-34
and	O	35-38
suppression	O	39-50
of	O	51-53
tumorigenesis	O	54-67
,	O	67-68
but	O	69-72
not	O	73-76
in	O	77-79
resistance	O	80-90
to	O	91-93
acute	B	94-99
radiation	I	100-109
toxicity	I	110-118
.	O	118-119

Mutations	O	120-129
in	O	130-132
atm	O	133-136
and	O	137-140
p53	O	141-144
cause	O	145-150
the	O	151-154
human	O	155-160
cancer	B	161-167
-	I	167-168
associated	I	168-178
diseases	I	179-187
ataxia	B	188-194
-	I	194-195
telangiectasia	I	195-209
and	O	210-213
Li	B	214-216
-	I	216-217
Fraumeni	I	217-225
syndrome	I	226-234
,	O	234-235
respectively	O	236-248
.	O	248-249

The	O	250-253
two	O	254-257
genes	O	258-263
are	O	264-267
believed	O	268-276
to	O	277-279
interact	O	280-288
in	O	289-291
a	O	292-293
number	O	294-300
of	O	301-303
pathways	O	304-312
,	O	312-313
including	O	314-323
regulation	O	324-334
of	O	335-337
DNA	O	338-341
damage	O	342-348
-	O	348-349
induced	O	349-356
cell	O	357-361
-	O	361-362
cycle	O	362-367
checkpoints	O	368-379
,	O	379-380
apoptosis	O	381-390
and	O	391-394
radiation	O	395-404
sensitivity	O	405-416
,	O	416-417
and	O	418-421
cellular	O	422-430
proliferation	O	431-444
.	O	444-445

Atm	O	446-449
-	O	449-450
null	O	450-454
mice	O	455-459
,	O	459-460
as	O	461-463
well	O	464-468
as	O	469-471
those	O	472-477
null	O	478-482
for	O	483-486
p53	O	487-490
,	O	490-491
develop	O	492-499
mainly	O	500-506
T	B	507-508
-	I	508-509
cell	I	509-513
lymphomas	I	514-523
,	O	523-524
supporting	O	525-535
the	O	536-539
view	O	540-544
that	O	545-549
these	O	550-555
genes	O	556-561
have	O	562-566
similar	O	567-574
roles	O	575-580
in	O	581-583
thymocyte	O	584-593
development	O	594-605
.	O	605-606

To	O	607-609
study	O	610-615
the	O	616-619
interactions	O	620-632
of	O	633-635
these	O	636-641
two	O	642-645
genes	O	646-651
on	O	652-654
an	O	655-657
organismal	O	658-668
level	O	669-674
,	O	674-675
we	O	676-678
bred	O	679-683
mice	O	684-688
heterozygous	O	689-701
for	O	702-705
null	O	706-710
alleles	O	711-718
of	O	719-721
both	O	722-726
atm	O	727-730
and	O	731-734
p53	O	735-738
to	O	739-741
produce	O	742-749
all	O	750-753
genotypic	O	754-763
combinations	O	764-776
.	O	776-777

Mice	O	778-782
doubly	O	783-789
null	O	790-794
for	O	795-798
atm	O	799-802
and	O	803-806
p53	O	807-810
exhibited	O	811-820
a	O	821-822
dramatic	O	823-831
acceleration	O	832-844
of	O	845-847
tumour	B	848-854
formation	O	855-864
relative	O	865-873
to	O	874-876
singly	O	877-883
null	O	884-888
mice	O	889-893
,	O	893-894
indicating	O	895-905
that	O	906-910
both	O	911-915
genes	O	916-921
collaborate	O	922-933
in	O	934-936
a	O	937-938
significant	O	939-950
manner	O	951-957
to	O	958-960
prevent	O	961-968
tumorigenesis	O	969-982
.	O	982-983

With	O	984-988
respect	O	989-996
to	O	997-999
their	O	1000-1005
roles	O	1006-1011
in	O	1012-1014
apoptosis	O	1015-1024
,	O	1024-1025
loss	O	1026-1030
of	O	1031-1033
atm	O	1034-1037
rendered	O	1038-1046
thymocytes	O	1047-1057
only	O	1058-1062
partly	O	1063-1069
resistant	O	1070-1079
to	O	1080-1082
irradiation	O	1083-1094
-	O	1094-1095
induced	O	1095-1102
apoptosis	O	1103-1112
,	O	1112-1113
whereas	O	1114-1121
additional	O	1122-1132
loss	O	1133-1137
of	O	1138-1140
p53	O	1141-1144
engendered	O	1145-1155
complete	O	1156-1164
resistance	O	1165-1175
.	O	1175-1176

This	O	1177-1181
implies	O	1182-1189
that	O	1190-1194
the	O	1195-1198
irradiation	O	1199-1210
-	O	1210-1211
induced	O	1211-1218
atm	O	1219-1222
and	O	1223-1226
p53	O	1227-1230
apoptotic	O	1231-1240
pathways	O	1241-1249
are	O	1250-1253
not	O	1254-1257
completely	O	1258-1268
congruent	O	1269-1278
.	O	1278-1279

Finally	O	1280-1287
-	O	1287-1288
and	O	1288-1291
in	O	1292-1294
contrast	O	1295-1303
to	O	1304-1306
prior	O	1307-1312
predictions	O	1313-1324
-	O	1324-1325
atm	O	1325-1328
and	O	1329-1332
p53	O	1333-1336
do	O	1337-1339
not	O	1340-1343
appear	O	1344-1350
to	O	1351-1353
interact	O	1354-1362
in	O	1363-1365
acute	B	1366-1371
radiation	I	1372-1381
toxicity	I	1382-1390
,	O	1390-1391
suggesting	O	1392-1402
a	O	1403-1404
separate	O	1405-1413
atm	O	1414-1417
effector	O	1418-1426
pathway	O	1427-1434
for	O	1435-1438
this	O	1439-1443
DNA	O	1444-1447
damage	O	1448-1454
response	O	1455-1463
and	O	1464-1467
having	O	1468-1474
implications	O	1475-1487
for	O	1488-1491
the	O	1492-1495
prognosis	O	1496-1505
and	O	1506-1509
treatment	O	1510-1519
of	O	1520-1522
human	O	1523-1528
tumours	B	1529-1536
.	O	1536-1537
.	O	1536-1537

Molecular	O	0-9
bases	O	10-15
of	O	16-18
C7	B	19-21
deficiency	I	22-32
:	O	32-33
three	O	34-39
different	O	40-49
defects	O	50-57
.	O	57-58

The	O	59-62
molecular	O	63-72
basis	O	73-78
of	O	79-81
C7	B	82-84
deficiency	I	85-95
has	O	96-99
been	O	100-104
investigated	O	105-117
in	O	118-120
two	O	121-124
Irish	O	125-130
families	O	131-139
and	O	140-143
a	O	144-145
number	O	146-152
of	O	153-155
Israeli	O	156-163
families	O	164-172
of	O	173-175
Moroccan	O	176-184
Sephardic	O	185-194
Jewish	O	195-201
origin	O	202-208
.	O	208-209

Exon	O	210-214
PCR	O	215-218
and	O	219-222
sequencing	O	223-233
revealed	O	234-242
a	O	243-244
heterozygous	O	245-257
point	O	258-263
mutation	O	264-272
at	O	273-275
the	O	276-279
3	O	280-281
splice	O	282-288
acceptor	O	289-297
site	O	298-302
of	O	303-305
intron	O	306-312
1	O	313-314
in	O	315-317
one	O	318-321
Irish	O	322-327
family	O	328-334
.	O	334-335

In	O	336-338
the	O	339-342
other	O	343-348
Irish	O	349-354
family	O	355-361
,	O	361-362
exons	O	363-368
7	O	369-370
and	O	371-374
8	O	375-376
failed	O	377-383
to	O	384-386
amplify	O	387-394
and	O	395-398
they	O	399-403
were	O	404-408
shown	O	409-414
to	O	415-417
be	O	418-420
deleted	O	421-428
.	O	428-429

Marker	O	430-436
haplotype	O	437-446
studies	O	447-454
of	O	455-457
the	O	458-461
C6	O	462-464
and	O	465-468
C7	O	469-471
gene	O	472-476
region	O	477-483
and	O	484-487
Southern	O	488-496
blots	O	497-502
show	O	503-507
that	O	508-512
the	O	513-516
Irish	O	517-522
family	O	523-529
with	O	530-534
the	O	535-538
splice	O	539-545
defect	O	546-552
also	O	553-557
segregate	O	558-567
for	O	568-571
the	O	572-575
deletion	O	576-584
,	O	584-585
which	O	586-591
is	O	592-594
not	O	595-598
easily	O	599-605
detected	O	606-614
in	O	615-617
heterozygotes	O	618-631
.	O	631-632

The	O	633-636
Israeli	O	637-644
C7	B	645-647
-	I	647-648
deficient	I	648-657
cases	O	658-663
all	O	664-667
share	O	668-673
a	O	674-675
C7	O	676-678
haplotype	O	679-688
and	O	689-692
are	O	693-696
homozygous	O	697-707
for	O	708-711
a	O	712-713
mis	O	714-717
-	O	717-718
sense	O	718-723
mutation	O	724-732
in	O	733-735
exon	O	736-740
9	O	741-742
.	O	742-743

However	O	744-751
,	O	751-752
one	O	753-756
individual	O	757-767
is	O	768-770
heterozygous	O	771-783
for	O	784-787
markers	O	788-795
at	O	796-798
adjacent	O	799-807
C6	O	808-810
loci	O	811-815
,	O	815-816
showing	O	817-824
that	O	825-829
there	O	830-835
has	O	836-839
been	O	840-844
an	O	845-847
intergenic	O	848-858
recombination	O	859-872
and	O	873-876
suggesting	O	877-887
that	O	888-892
the	O	893-896
deficiency	O	897-907
mutation	O	908-916
is	O	917-919
of	O	920-922
appreciable	O	923-934
antiquity	O	935-944
.	O	944-945
.	O	944-945

Identification	O	0-14
of	O	15-17
WASP	O	18-22
mutations	O	23-32
,	O	32-33
mutation	O	34-42
hotspots	O	43-51
and	O	52-55
genotype	O	56-64
-	O	64-65
phenotype	O	65-74
disparities	O	75-86
in	O	87-89
24	O	90-92
patients	O	93-101
with	O	102-106
the	O	107-110
Wiskott	B	111-118
-	I	118-119
Aldrich	I	119-126
syndrome	I	127-135
.	O	135-136

The	O	137-140
Wiskott	B	141-148
-	I	148-149
Aldrich	I	149-156
syndrome	I	157-165
(	O	166-167
WAS	B	167-170
)	O	170-171
,	O	171-172
an	O	173-175
X	B	176-177
-	I	177-178
linked	I	178-184
immunodeficiency	I	185-201
disease	I	202-209
caused	O	210-216
by	O	217-219
mutation	O	220-228
in	O	229-231
the	O	232-235
recently	O	236-244
isolated	O	245-253
gene	O	254-258
encoding	O	259-267
WAS	B	268-271
protein	O	272-279
(	O	280-281
WASP	O	281-285
)	O	285-286
,	O	286-287
is	O	288-290
known	O	291-296
to	O	297-299
be	O	300-302
associated	O	303-313
with	O	314-318
extensive	O	319-328
clinical	O	329-337
heterogeneity	O	338-351
.	O	351-352

Cumulative	O	353-363
mutation	O	364-372
data	O	373-377
have	O	378-382
revealed	O	383-391
that	O	392-396
WASP	O	397-401
genotypes	O	402-411
are	O	412-415
also	O	416-420
highly	O	421-427
variable	O	428-436
among	O	437-442
WAS	B	443-446
patients	O	447-455
,	O	455-456
but	O	457-460
the	O	461-464
relationship	O	465-477
of	O	478-480
phenotype	O	481-490
with	O	491-495
genotype	O	496-504
in	O	505-507
this	O	508-512
disease	O	513-520
remains	O	521-528
unclear	O	529-536
.	O	536-537

To	O	538-540
address	O	541-548
this	O	549-553
issue	O	554-559
we	O	560-562
characterized	O	563-576
WASP	O	577-581
mutations	O	582-591
in	O	592-594
24	O	595-597
unrelated	O	598-607
WAS	B	608-611
patients	O	612-620
,	O	620-621
including	O	622-631
18	O	632-634
boys	O	635-639
with	O	640-644
severe	O	645-651
classical	O	652-661
WAS	B	662-665
and	O	666-669
6	O	670-671
boys	O	672-676
expressing	O	677-687
mild	O	688-692
forms	O	693-698
of	O	699-701
the	O	702-705
disease	O	706-713
,	O	713-714
and	O	715-718
then	O	719-723
examined	O	724-732
the	O	733-736
degree	O	737-743
of	O	744-746
correlation	O	747-758
of	O	759-761
these	O	762-767
as	O	768-770
well	O	771-775
as	O	776-778
all	O	779-782
previously	O	783-793
published	O	794-803
WASP	O	804-808
mutations	O	809-818
with	O	819-823
disease	O	824-831
severity	O	832-840
.	O	840-841

By	O	842-844
analysis	O	845-853
of	O	854-856
these	O	857-862
compiled	O	863-871
mutation	O	872-880
data	O	881-885
,	O	885-886
we	O	887-889
demonstrated	O	890-902
clustering	O	903-913
of	O	914-916
WASP	O	917-921
mutations	O	922-931
within	O	932-938
the	O	939-942
four	O	943-947
most	O	948-952
N	O	953-954
-	O	954-955
terminal	O	955-963
exons	O	964-969
of	O	970-972
the	O	973-976
gene	O	977-981
and	O	982-985
also	O	986-990
identified	O	991-1001
several	O	1002-1009
sites	O	1010-1015
within	O	1016-1022
this	O	1023-1027
region	O	1028-1034
as	O	1035-1037
hotspots	O	1038-1046
for	O	1047-1050
WASP	O	1051-1055
mutation	O	1056-1064
.	O	1064-1065

These	O	1066-1071
characteristics	O	1072-1087
were	O	1088-1092
observed	O	1093-1101
,	O	1101-1102
however	O	1103-1110
,	O	1110-1111
in	O	1112-1114
both	O	1115-1119
severe	O	1120-1126
and	O	1127-1130
mild	O	1131-1135
cases	O	1136-1141
of	O	1142-1144
the	O	1145-1148
disease	O	1149-1156
.	O	1156-1157

Similarly	O	1158-1167
,	O	1167-1168
while	O	1169-1174
the	O	1175-1178
cumulative	O	1179-1189
data	O	1190-1194
revealed	O	1195-1203
a	O	1204-1205
predominance	O	1206-1218
of	O	1219-1221
missense	O	1222-1230
mutations	O	1231-1240
among	O	1241-1246
the	O	1247-1250
WASP	O	1251-1255
gene	O	1256-1260
lesions	O	1261-1268
observed	O	1269-1277
in	O	1278-1280
boys	O	1281-1285
with	O	1286-1290
isolated	B	1291-1299
thrombocytopenia	I	1300-1316
,	O	1316-1317
missense	O	1318-1326
mutations	O	1327-1336
were	O	1337-1341
not	O	1342-1345
exclusively	O	1346-1357
associated	O	1358-1368
with	O	1369-1373
milder	O	1374-1380
WAS	B	1381-1384
phenotypes	O	1385-1395
,	O	1395-1396
but	O	1397-1400
also	O	1401-1405
comprised	O	1406-1415
a	O	1416-1417
substantial	O	1418-1429
portion	O	1430-1437
(	O	1438-1439
38	O	1439-1441
%	O	1441-1442
)	O	1442-1443
of	O	1444-1446
the	O	1447-1450
WASP	O	1451-1455
gene	O	1456-1460
defects	O	1461-1468
found	O	1469-1474
in	O	1475-1477
patients	O	1478-1486
with	O	1487-1491
severe	O	1492-1498
disease	O	1499-1506
.	O	1506-1507

These	O	1508-1513
findings	O	1514-1522
,	O	1522-1523
as	O	1524-1526
well	O	1527-1531
as	O	1532-1534
the	O	1535-1538
detection	O	1539-1548
of	O	1549-1551
identical	O	1552-1561
WASP	O	1562-1566
mutations	O	1567-1576
in	O	1577-1579
patients	O	1580-1588
with	O	1589-1593
disparate	O	1594-1603
phenotypes	O	1604-1614
,	O	1614-1615
reveal	O	1616-1622
a	O	1623-1624
lack	O	1625-1629
of	O	1630-1632
phenotype	O	1633-1642
concordance	O	1643-1654
with	O	1655-1659
genotype	O	1660-1668
in	O	1669-1671
WAS	B	1672-1675
and	O	1676-1679
thus	O	1680-1684
imply	O	1685-1690
that	O	1691-1695
phenotypic	O	1696-1706
outcome	O	1707-1714
in	O	1715-1717
this	O	1718-1722
disease	O	1723-1730
cannot	O	1731-1737
be	O	1738-1740
reliably	O	1741-1749
predicted	O	1750-1759
solely	O	1760-1766
on	O	1767-1769
the	O	1770-1773
basis	O	1774-1779
of	O	1780-1782
WASP	O	1783-1787
genotypes	O	1788-1797
.	O	1797-1798
.	O	1797-1798

Identification	O	0-14
and	O	15-18
chromosomal	O	19-30
localization	O	31-43
of	O	44-46
Atm	O	47-50
,	O	50-51
the	O	52-55
mouse	O	56-61
homolog	O	62-69
of	O	70-72
the	O	73-76
ataxia	B	77-83
-	I	83-84
telangiectasia	I	84-98
gene	O	99-103
.	O	103-104

Atm	O	105-108
,	O	108-109
the	O	110-113
mouse	O	114-119
homolog	O	120-127
of	O	128-130
the	O	131-134
human	O	135-140
ATM	O	141-144
gene	O	145-149
defective	O	150-159
in	O	160-162
ataxia	B	163-169
-	I	169-170
telangiectasia	I	170-184
(	O	185-186
A	B	186-187
-	I	187-188
T	I	188-189
)	O	189-190
,	O	190-191
has	O	192-195
been	O	196-200
identified	O	201-211
.	O	211-212

The	O	213-216
entire	O	217-223
coding	O	224-230
sequence	O	231-239
of	O	240-242
the	O	243-246
Atm	O	247-250
transcript	O	251-261
was	O	262-265
cloned	O	266-272
and	O	273-276
found	O	277-282
to	O	283-285
contain	O	286-293
an	O	294-296
open	O	297-301
reading	O	302-309
frame	O	310-315
encoding	O	316-324
a	O	325-326
protein	O	327-334
of	O	335-337
3066	O	338-342
amino	O	343-348
acids	O	349-354
with	O	355-359
84	O	360-362
%	O	362-363
overall	O	364-371
identity	O	372-380
and	O	381-384
91	O	385-387
%	O	387-388
similarity	O	389-399
to	O	400-402
the	O	403-406
human	O	407-412
ATM	O	413-416
protein	O	417-424
.	O	424-425

Variable	O	426-434
levels	O	435-441
of	O	442-444
expression	O	445-455
of	O	456-458
Atm	O	459-462
were	O	463-467
observed	O	468-476
in	O	477-479
different	O	480-489
tissues	O	490-497
.	O	497-498

Fluorescence	O	499-511
in	O	512-514
situ	O	515-519
hybridization	O	520-533
and	O	534-537
linkage	O	538-545
analysis	O	546-554
located	O	555-562
the	O	563-566
Atm	O	567-570
gene	O	571-575
on	O	576-578
mouse	O	579-584
chromosome	O	585-595
9	O	596-597
,	O	597-598
band	O	599-603
9C	O	604-606
,	O	606-607
in	O	608-610
a	O	611-612
region	O	613-619
homologous	O	620-630
to	O	631-633
the	O	634-637
ATM	O	638-641
region	O	642-648
on	O	649-651
human	O	652-657
chromosome	O	658-668
11q22	O	669-674
-	O	674-675
q23	O	675-678
.	O	678-679
.	O	678-679

Mutation	O	0-8
of	O	9-11
MSH3	O	12-16
in	O	17-19
endometrial	B	20-31
cancer	I	32-38
and	O	39-42
evidence	O	43-51
for	O	52-55
its	O	56-59
functional	O	60-70
role	O	71-75
in	O	76-78
heteroduplex	O	79-91
repair	O	92-98
.	O	98-99

Many	O	100-104
human	O	105-110
tumours	B	111-118
have	O	119-123
length	O	124-130
alterations	O	131-142
in	O	143-145
repetitive	O	146-156
sequence	O	157-165
elements	O	166-174
.	O	174-175

Although	O	176-184
this	O	185-189
microsatellite	B	190-204
instability	I	205-216
has	O	217-220
been	O	221-225
attributed	O	226-236
to	O	237-239
mutations	O	240-249
in	O	250-252
four	O	253-257
DNA	O	258-261
mismatch	O	262-270
repair	O	271-277
genes	O	278-283
in	O	284-286
hereditary	B	287-297
nonpolyposis	I	298-310
colorectal	I	311-321
cancer	I	322-328
(	O	329-330
HNPCC	B	330-335
)	O	335-336
kindreds	O	337-345
,	O	345-346
many	O	347-351
sporadic	B	352-360
tumours	I	361-368
exhibit	O	369-376
instability	O	377-388
but	O	389-392
no	O	393-395
detectable	O	396-406
mutations	O	407-416
in	O	417-419
these	O	420-425
genes	O	426-431
.	O	431-432

It	O	433-435
is	O	436-438
therefore	O	439-448
of	O	449-451
interest	O	452-460
to	O	461-463
identify	O	464-472
other	O	473-478
genes	O	479-484
that	O	485-489
contribute	O	490-500
to	O	501-503
this	O	504-508
instability	O	509-520
.	O	520-521

In	O	522-524
yeast	O	525-530
,	O	530-531
mutations	O	532-541
in	O	542-544
several	O	545-552
genes	O	553-558
,	O	558-559
including	O	560-569
RTH	O	570-573
and	O	574-577
MSH3	O	578-582
,	O	582-583
cause	O	584-589
microsatellite	O	590-604
instability	O	605-616
.	O	616-617

Thus	O	618-622
,	O	622-623
we	O	624-626
screened	O	627-635
16	O	636-638
endometrial	B	639-650
carcinomas	I	651-661
with	O	662-666
microsatellite	O	667-681
instability	O	682-693
for	O	694-697
alterations	O	698-709
in	O	710-712
FEN1	O	713-717
(	O	718-719
the	O	719-722
human	O	723-728
homolog	O	729-736
of	O	737-739
RTH	O	740-743
)	O	743-744
and	O	745-748
in	O	749-751
MSH3	O	752-756
(	O	757-758
refs	O	758-762
12	O	763-765
-	O	765-766
14	O	766-768
)	O	768-769
.	O	769-770

Although	O	771-779
we	O	780-782
found	O	783-788
no	O	789-791
FEN1	O	792-796
mutations	O	797-806
,	O	806-807
a	O	808-809
frameshift	O	810-820
mutation	O	821-829
in	O	830-832
MSH3	O	833-837
was	O	838-841
observed	O	842-850
in	O	851-853
an	O	854-856
endometrial	B	857-868
carcinoma	I	869-878
and	O	879-882
in	O	883-885
an	O	886-888
endometrial	B	889-900
carcinoma	I	901-910
cell	O	911-915
line	O	916-920
.	O	920-921

Extracts	O	922-930
of	O	931-933
the	O	934-937
cell	O	938-942
line	O	943-947
were	O	948-952
deficient	O	953-962
in	O	963-965
repair	O	966-972
of	O	973-975
DNA	O	976-979
substrates	O	980-990
containing	O	991-1001
mismatches	O	1002-1012
or	O	1013-1015
extra	O	1016-1021
nucleotides	O	1022-1033
.	O	1033-1034

Introducing	O	1035-1046
chromosome	O	1047-1057
5	O	1058-1059
,	O	1059-1060
encoding	O	1061-1069
the	O	1070-1073
MSH3	O	1074-1078
gene	O	1079-1083
,	O	1083-1084
into	O	1085-1089
the	O	1090-1093
mutant	O	1094-1100
cell	O	1101-1105
line	O	1106-1110
increased	O	1111-1120
the	O	1121-1124
stability	O	1125-1134
of	O	1135-1137
some	O	1138-1142
but	O	1143-1146
not	O	1147-1150
all	O	1151-1154
microsatellites	O	1155-1170
.	O	1170-1171

Extracts	O	1172-1180
of	O	1181-1183
these	O	1184-1189
cells	O	1190-1195
repaired	O	1196-1204
certain	O	1205-1212
substrates	O	1213-1223
containing	O	1224-1234
extra	O	1235-1240
nucleotides	O	1241-1252
,	O	1252-1253
but	O	1254-1257
were	O	1258-1262
deficient	O	1263-1272
in	O	1273-1275
repair	O	1276-1282
of	O	1283-1285
those	O	1286-1291
containing	O	1292-1302
mismatches	O	1303-1313
or	O	1314-1316
other	O	1317-1322
extra	O	1323-1328
nucleotides	O	1329-1340
.	O	1340-1341

A	O	1342-1343
subsequent	O	1344-1354
search	O	1355-1361
revealed	O	1362-1370
a	O	1371-1372
second	O	1373-1379
gene	O	1380-1384
mutation	O	1385-1393
in	O	1394-1396
HHUA	O	1397-1401
cells	O	1402-1407
,	O	1407-1408
a	O	1409-1410
missense	O	1411-1419
mutation	O	1420-1428
in	O	1429-1431
the	O	1432-1435
MSH6	O	1436-1440
gene	O	1441-1445
.	O	1445-1446

Together	O	1447-1455
the	O	1456-1459
data	O	1460-1464
suggest	O	1465-1472
that	O	1473-1477
the	O	1478-1481
MSH3	O	1482-1486
gene	O	1487-1491
encodes	O	1492-1499
a	O	1500-1501
product	O	1502-1509
that	O	1510-1514
functions	O	1515-1524
in	O	1525-1527
repair	O	1528-1534
of	O	1535-1537
some	O	1538-1542
but	O	1543-1546
not	O	1547-1550
all	O	1551-1554
pre	O	1555-1558
-	O	1558-1559
mutational	O	1559-1569
intermediates	O	1570-1583
,	O	1583-1584
its	O	1585-1588
mutation	O	1589-1597
in	O	1598-1600
tumours	B	1601-1608
can	O	1609-1612
result	O	1613-1619
in	O	1620-1622
genomic	O	1623-1630
instability	O	1631-1642
and	O	1643-1646
,	O	1646-1647
as	O	1648-1650
in	O	1651-1653
yeast	O	1654-1659
,	O	1659-1660
MSH3	O	1661-1665
and	O	1666-1669
MSH6	O	1670-1674
are	O	1675-1678
partially	O	1679-1688
redundant	O	1689-1698
for	O	1699-1702
mismatch	O	1703-1711
repair	O	1712-1718
.	O	1718-1719
.	O	1718-1719

Kniest	B	0-6
dysplasia	I	7-16
:	O	16-17
Dr	O	18-20
.	O	20-21
W	O	22-23
.	O	23-24
Kniest	O	25-31
,	O	31-32
his	O	33-36
patient	O	37-44
,	O	44-45
the	O	46-49
molecular	O	50-59
defect	O	60-66
.	O	66-67

Kniest	B	68-74
dysplasia	I	75-84
is	O	85-87
a	O	88-89
severe	O	90-96
chondrodysplasia	B	97-113
caused	O	114-120
by	O	121-123
the	O	124-127
defective	B	128-137
formation	I	138-147
of	I	148-150
type	I	151-155
II	I	156-158
collagen	I	159-167
.	O	167-168

We	O	169-171
report	O	172-178
about	O	179-184
Dr	O	185-187
.	O	187-188
Kniest	O	189-195
,	O	195-196
who	O	197-200
first	O	201-206
described	O	207-216
the	O	217-220
condition	O	221-230
in	O	231-233
1952	O	234-238
,	O	238-239
and	O	240-243
his	O	244-247
patient	O	248-255
,	O	255-256
who	O	257-260
,	O	260-261
at	O	262-264
the	O	265-268
age	O	269-272
of	O	273-275
50	O	276-278
years	O	279-284
is	O	285-287
severely	B	288-296
handicapped	I	297-308
with	O	309-313
short	B	314-319
stature	I	320-327
,	O	327-328
restricted	B	329-339
joint	I	340-345
mobility	I	346-354
,	O	354-355
and	O	356-359
blindness	B	360-369
but	O	370-373
is	O	374-376
mentally	O	377-385
alert	O	386-391
and	O	392-395
leads	O	396-401
an	O	402-404
active	O	405-411
life	O	412-416
.	O	416-417

Molecular	O	418-427
analysis	O	428-436
of	O	437-439
the	O	440-443
patients	O	444-452
DNA	O	453-456
showed	O	457-463
a	O	464-465
single	O	466-472
base	O	473-477
(	O	478-479
G	O	479-480
)	O	480-481
deletion	O	482-490
involving	O	491-500
the	O	501-504
GT	O	505-507
dinucleotide	O	508-520
at	O	521-523
the	O	524-527
start	O	528-533
of	O	534-536
intron	O	537-543
18	O	544-546
destroying	O	547-557
a	O	558-559
splice	O	560-566
site	O	567-571
of	O	572-574
the	O	575-578
COL2A1	O	579-585
gene	O	586-590
.	O	590-591

This	O	592-596
is	O	597-599
in	O	600-602
accordance	O	603-613
with	O	614-618
molecular	O	619-628
findings	O	629-637
in	O	638-640
other	O	641-646
patients	O	647-655
with	O	656-660
Kniest	B	661-667
dysplasia	I	668-677
and	O	678-681
confirms	O	682-690
,	O	690-691
in	O	692-694
the	O	695-698
original	O	699-707
patient	O	708-715
,	O	715-716
that	O	717-721
the	O	722-725
disorder	O	726-734
is	O	735-737
caused	O	738-744
by	O	745-747
small	O	748-753
inframe	O	754-761
deletions	O	762-771
often	O	772-777
due	O	778-781
to	O	782-784
exon	O	785-789
skipping	O	790-798
as	O	799-801
a	O	802-803
result	O	804-810
of	O	811-813
COL2A1	O	814-820
splice	O	821-827
site	O	828-832
mutations	O	833-842
.	O	842-843
.	O	842-843

Ashkenazi	O	0-9
Jewish	O	10-16
population	O	17-27
frequencies	O	28-39
for	O	40-43
common	O	44-50
mutations	O	51-60
in	O	61-63
BRCA1	O	64-69
and	O	70-73
BRCA2	O	74-79
.	O	79-80

BRCA1	O	81-86
and	O	87-90
BRCA2	O	91-96
are	O	97-100
the	O	101-104
two	O	105-108
major	O	109-114
identified	O	115-125
causes	O	126-132
of	O	133-135
inherited	B	136-145
breast	I	146-152
cancer	I	153-159
,	O	159-160
with	O	161-165
mutations	O	166-175
in	O	176-178
either	O	179-185
gene	O	186-190
conferring	O	191-201
up	O	202-204
to	O	205-207
80	O	208-210
-	O	210-211
90	O	211-213
%	O	213-214
lifetime	O	215-223
risk	O	224-228
of	O	229-231
breast	B	232-238
cancer	I	239-245
in	O	246-248
carrier	O	249-256
females	O	257-264
.	O	264-265

Mutations	O	266-275
in	O	276-278
BRCA1	O	279-284
account	O	285-292
for	O	293-296
approximately	O	297-310
45	O	311-313
%	O	313-314
of	O	315-317
familial	B	318-326
breast	I	327-333
cancer	I	334-340
and	O	341-344
90	O	345-347
%	O	347-348
of	O	349-351
inherited	B	352-361
breast	I	362-368
/	I	368-369
ovarian	I	369-376
cancer	I	377-383
,	O	383-384
whereas	O	385-392
mutations	O	393-402
in	O	403-405
BRCA2	O	406-411
account	O	412-419
for	O	420-423
a	O	424-425
comparable	O	426-436
percentage	O	437-447
of	O	448-450
inherited	B	451-460
breast	I	461-467
cancer	I	468-474
cases	O	475-480
.	O	480-481

Over	O	482-486
85	O	487-489
distinct	O	490-498
BRCA1	O	499-504
mutations	O	505-514
and	O	515-518
a	O	519-520
growing	O	521-528
list	O	529-533
of	O	534-536
BRCA2	O	537-542
mutations	O	543-552
have	O	553-557
been	O	558-562
identified	O	563-573
,	O	573-574
with	O	575-579
the	O	580-583
majority	O	584-592
resulting	O	593-602
in	O	603-605
protein	O	606-613
truncation	O	614-624
.	O	624-625

A	O	626-627
specific	O	628-636
BRCA1	O	637-642
mutation	O	643-651
,	O	651-652
185delAG	O	653-661
,	O	661-662
has	O	663-666
a	O	667-668
reported	O	669-677
increased	O	678-687
carrier	O	688-695
frequency	O	696-705
of	O	706-708
approximately	O	709-722
0	O	723-724
.	O	724-725
9	O	726-727
%	O	727-728
in	O	729-731
the	O	732-735
Ashkenazi	O	736-745
Jewish	O	746-752
population	O	753-763
,	O	763-764
but	O	765-768
is	O	769-771
also	O	772-776
found	O	777-782
in	O	783-785
rare	O	786-790
non	O	791-794
-	O	794-795
Jewish	O	795-801
patients	O	802-810
with	O	811-815
a	O	816-817
different	O	818-827
haplotype	O	828-837
.	O	837-838

The	O	839-842
6174delT	O	843-851
mutation	O	852-860
in	O	861-863
BRCA2	O	864-869
was	O	870-873
recently	O	874-882
identified	O	883-893
as	O	894-896
a	O	897-898
frequent	O	899-907
mutation	O	908-916
in	O	917-919
8	O	920-921
out	O	922-925
of	O	926-928
107	O	929-932
Ashkenazi	O	933-942
Jewish	O	943-949
women	O	950-955
diagnosed	O	956-965
with	O	966-970
breast	B	971-977
cancer	I	978-984
by	O	985-987
age	O	988-991
50	O	992-994
(	O	995-996
ref	O	996-999
.	O	999-1000

8	O	1001-1002
)	O	1002-1003
,	O	1003-1004
as	O	1005-1007
well	O	1008-1012
as	O	1013-1015
in	O	1016-1018
three	O	1019-1024
Ashkenazi	O	1025-1034
male	B	1035-1039
breast	I	1040-1046
cancer	I	1047-1053
patients	O	1054-1062
.	O	1062-1063

We	O	1064-1066
have	O	1067-1071
conducted	O	1072-1081
a	O	1082-1083
large	O	1084-1089
-	O	1089-1090
scale	O	1090-1095
population	O	1096-1106
study	O	1107-1112
to	O	1113-1115
investigate	O	1116-1127
the	O	1128-1131
prevalence	O	1132-1142
of	O	1143-1145
specific	O	1146-1154
BRCA1	O	1155-1160
and	O	1161-1164
BRCA2	O	1165-1170
mutations	O	1171-1180
in	O	1181-1183
Ashkenazi	O	1184-1193
Jewish	O	1194-1200
individuals	O	1201-1212
who	O	1213-1216
were	O	1217-1221
unselected	O	1222-1232
for	O	1233-1236
breast	B	1237-1243
cancer	I	1244-1250
.	O	1250-1251

BRCA1	O	1252-1257
mutation	O	1258-1266
screening	O	1267-1276
on	O	1277-1279
approximately	O	1280-1293
3	O	1294-1295
,	O	1295-1296
000	O	1297-1300
Ashkenazi	O	1301-1310
Jewish	O	1311-1317
samples	O	1318-1325
determined	O	1326-1336
a	O	1337-1338
carrier	O	1339-1346
frequency	O	1347-1356
of	O	1357-1359
1	O	1360-1361
.	O	1361-1362
09	O	1363-1365
%	O	1365-1366
for	O	1367-1370
the	O	1371-1374
185delAG	O	1375-1383
mutation	O	1384-1392
and	O	1393-1396
0	O	1397-1398
.	O	1398-1399
13	O	1400-1402
%	O	1402-1403
for	O	1404-1407
the	O	1408-1411
5382insC	O	1412-1420
mutation	O	1421-1429
.	O	1429-1430

BRCA2	O	1431-1436
analysis	O	1437-1445
on	O	1446-1448
3	O	1449-1450
,	O	1450-1451
085	O	1452-1455
individuals	O	1456-1467
from	O	1468-1472
the	O	1473-1476
same	O	1477-1481
population	O	1482-1492
showed	O	1493-1499
a	O	1500-1501
carrier	O	1502-1509
frequency	O	1510-1519
of	O	1520-1522
1	O	1523-1524
.	O	1524-1525
52	O	1526-1528
%	O	1528-1529
for	O	1530-1533
the	O	1534-1537
6174delT	O	1538-1546
mutation	O	1547-1555
.	O	1555-1556

This	O	1557-1561
expanded	O	1562-1570
population	O	1571-1581
-	O	1581-1582
based	O	1582-1587
study	O	1588-1593
confirms	O	1594-1602
that	O	1603-1607
the	O	1608-1611
BRCA1	O	1612-1617
185delAG	O	1618-1626
mutation	O	1627-1635
and	O	1636-1639
the	O	1640-1643
BRCA2	O	1644-1649
6174delT	O	1650-1658
mutation	O	1659-1667
constitute	O	1668-1678
the	O	1679-1682
two	O	1683-1686
most	O	1687-1691
frequent	O	1692-1700
mutation	O	1701-1709
alleles	O	1710-1717
predisposing	O	1718-1730
to	O	1731-1733
hereditary	B	1734-1744
breast	I	1745-1751
cancer	I	1752-1758
among	O	1759-1764
the	O	1765-1768
Ashkenazim	O	1769-1779
,	O	1779-1780
and	O	1781-1784
suggests	O	1785-1793
a	O	1794-1795
relatively	O	1796-1806
lower	O	1807-1812
penetrance	O	1813-1823
for	O	1824-1827
the	O	1828-1831
6174delT	O	1832-1840
mutation	O	1841-1849
in	O	1850-1852
BRCA2	O	1853-1858

Mapping	O	0-7
the	O	8-11
homolog	O	12-19
of	O	20-22
the	O	23-26
human	O	27-32
Rb1	O	33-36
gene	O	37-41
to	O	42-44
chromosome	O	45-55
14	O	56-58
of	O	59-61
higher	O	62-68
primates	O	69-77
.	O	77-78

The	O	79-82
Rb1	O	83-86
gene	O	87-91
has	O	92-95
been	O	96-100
implicated	O	101-111
with	O	112-116
retinoblastoma	B	117-131
and	O	132-135
is	O	136-138
located	O	139-146
on	O	147-149
human	O	150-155
Chromosome	O	156-166
(	O	167-168
Chr	O	168-171
)	O	171-172
13q14	O	173-178
.	O	178-179
2	O	180-181
2	O	182-183
.	O	183-184
A	O	185-186
unique	O	187-193
sequence	O	194-202
human	O	203-208
Rb1	O	209-212
cosmid	O	213-219
DNA	O	220-223
probe	O	224-229
has	O	230-233
been	O	234-238
used	O	239-243
to	O	244-246
localize	O	247-255
this	O	256-260
region	O	261-267
on	O	268-270
apes	O	271-275
Chr	O	276-279
14	O	280-282
by	O	283-285
the	O	286-289
FISH	O	290-294
technique	O	295-304
.	O	304-305

The	O	306-309
conservation	O	310-322
of	O	323-325
the	O	326-329
Rb1	O	330-333
gene	O	334-338
in	O	339-341
higher	O	342-348
primates	O	349-357
at	O	358-360
the	O	361-364
corresponding	O	365-378
equivalent	O	379-389
chromosome	O	390-400
locus	O	401-406
(	O	407-408
14q14	O	408-413
)	O	413-414
of	O	415-417
the	O	418-421
human	O	422-427
may	O	428-431
serve	O	432-437
as	O	438-440
a	O	441-442
phylogenetic	O	443-455
marker	O	456-462
to	O	463-465
further	O	466-473
trace	O	474-479
the	O	480-483
evolutionary	O	484-496
pathway	O	497-504
of	O	505-507
human	O	508-513
descent	O	514-521
.	O	521-522

Difficulties	O	0-12
in	O	13-15
the	O	16-19
ascertainment	O	20-33
of	O	34-36
C9	B	37-39
deficiency	I	40-50
:	O	50-51
lessons	O	52-59
to	O	60-62
be	O	63-65
drawn	O	66-71
from	O	72-76
a	O	77-78
compound	O	79-87
heterozygote	O	88-100
C9	B	101-103
-	I	103-104
deficient	I	104-113
subject	O	114-121
.	O	121-122

A	O	123-124
group	O	125-130
of	O	131-133
patients	O	134-142
with	O	143-147
long	O	148-152
-	O	152-153
surviving	O	153-162
mismatched	O	163-173
kidney	O	174-180
allografts	O	181-191
were	O	192-196
investigated	O	197-209
for	O	210-213
complement	O	214-224
function	O	225-233
using	O	234-239
haemolytic	O	240-250
assays	O	251-257
in	O	258-260
agarose	O	261-268
gels	O	269-273
.	O	273-274

One	O	275-278
patient	O	279-286
was	O	287-290
found	O	291-296
to	O	297-299
have	O	300-304
no	O	305-307
alternative	O	308-319
pathway	O	320-327
activity	O	328-336
but	O	337-340
a	O	341-342
low	O	343-346
normal	O	347-353
classical	O	354-363
pathway	O	364-371
.	O	371-372

Surprisingly	O	373-385
,	O	385-386
investigation	O	387-400
revealed	O	401-409
that	O	410-414
the	O	415-418
patients	O	419-427
complement	O	428-438
was	O	439-442
normal	O	443-449
for	O	450-453
all	O	454-457
components	O	458-468
except	O	469-475
C9	O	476-478
,	O	478-479
which	O	480-485
was	O	486-489
functionally	O	490-502
absent	O	503-509
.	O	509-510

The	O	511-514
patient	O	515-522
was	O	523-526
shown	O	527-532
to	O	533-535
be	O	536-538
heterozygous	O	539-551
for	O	552-555
DNA	O	556-559
markers	O	560-567
in	O	568-570
the	O	571-574
C6	O	575-577
,	O	577-578
C7	O	579-581
and	O	582-585
C9	O	586-588
region	O	589-595
of	O	596-598
chromosome	O	599-609
5	O	610-611
and	O	612-615
therefore	O	616-625
appears	O	626-633
to	O	634-636
be	O	637-639
a	O	640-641
compound	O	642-650
heterozygote	O	651-663
for	O	664-667
two	O	668-671
uncharacterized	O	672-687
C9	B	688-690
deficiency	I	691-701
genes	O	702-707
.	O	707-708

Serological	O	709-720
analysis	O	721-729
by	O	730-732
ELISA	O	733-738
revealed	O	739-747
that	O	748-752
he	O	753-755
has	O	756-759
trace	O	760-765
concentrations	O	766-780
of	O	781-783
a	O	784-785
non	O	786-789
-	O	789-790
functional	O	790-800
C9	O	801-803
molecule	O	804-812
.	O	812-813

Western	O	814-821
blot	O	822-826
analysis	O	827-835
was	O	836-839
not	O	840-843
sufficiently	O	844-856
sensitive	O	857-866
to	O	867-869
permit	O	870-876
detection	O	877-886
of	O	887-889
this	O	890-894
molecule	O	895-903
.	O	903-904

We	O	905-907
hypothesize	O	908-919
that	O	920-924
the	O	925-928
patient	O	929-936
is	O	937-939
heterozygous	O	940-952
for	O	953-956
a	O	957-958
complete	B	959-967
deficiency	I	968-978
of	I	979-981
C9	I	982-984
and	O	985-988
for	O	989-992
a	O	993-994
gene	O	995-999
directing	O	1000-1009
hyposynthesis	O	1010-1023
of	O	1024-1026
a	O	1027-1028
defective	O	1029-1038
C9	O	1039-1041
.	O	1041-1042

We	O	1043-1045
also	O	1046-1050
suggest	O	1051-1058
that	O	1059-1063
C9	B	1064-1066
deficiency	I	1067-1077
may	O	1078-1081
be	O	1082-1084
more	O	1085-1089
common	O	1090-1096
among	O	1097-1102
Caucasians	O	1103-1113
than	O	1114-1118
has	O	1119-1122
been	O	1123-1127
reported	O	1128-1136
.	O	1136-1137
.	O	1136-1137

Moderate	O	0-8
intergenerational	O	9-26
and	O	27-30
somatic	O	31-38
instability	O	39-50
of	O	51-53
a	O	54-55
55	O	56-58
-	O	58-59
CTG	O	59-62
repeat	O	63-69
in	O	70-72
transgenic	O	73-83
mice	O	84-88
.	O	88-89

Myotonic	B	90-98
dystrophy	I	99-108
(	O	109-110
DM	B	110-112
)	O	112-113
is	O	114-116
associated	O	117-127
with	O	128-132
the	O	133-136
expansion	O	137-146
of	O	147-149
a	O	150-151
(	O	152-153
CTG	O	153-156
)	O	156-157
n	O	158-159
trinucleotide	O	160-173
repeat	O	174-180
in	O	181-183
the	O	184-187
3	O	188-189
untranslated	O	190-202
region	O	203-209
(	O	210-211
UTR	O	211-214
)	O	214-215
of	O	216-218
the	O	219-222
DM	B	223-225
protein	O	226-233
kinase	O	234-240
gene	O	241-245
(	O	246-247
DMPK	O	247-251
)	O	251-252
.	O	252-253

The	O	254-257
(	O	258-259
CTG	O	259-262
)	O	262-263
n	O	264-265
repeat	O	266-272
is	O	273-275
polymorphic	O	276-287
and	O	288-291
varies	O	292-298
in	O	299-301
size	O	302-306
between	O	307-314
5	O	315-316
and	O	317-320
37	O	321-323
repeats	O	324-331
in	O	332-334
unaffected	O	335-345
individuals	O	346-357
whereas	O	358-365
in	O	366-368
affected	O	369-377
patients	O	378-386
there	O	387-392
are	O	393-396
between	O	397-404
50	O	405-407
and	O	408-411
4	O	412-413
,	O	413-414
000	O	415-418
CTGs	O	419-423
.	O	423-424

The	O	425-428
size	O	429-433
of	O	434-436
the	O	437-440
(	O	441-442
CTG	O	442-445
)	O	445-446
n	O	447-448
repeat	O	449-455
,	O	455-456
which	O	457-462
increases	O	463-472
through	O	473-480
generations	O	481-492
,	O	492-493
generally	O	494-503
correlates	O	504-514
with	O	515-519
clinical	O	520-528
severity	O	529-537
and	O	538-541
age	O	542-545
of	O	546-548
onset	O	549-554
.	O	554-555

The	O	556-559
instability	O	560-571
of	O	572-574
the	O	575-578
CTG	O	579-582
repeat	O	583-589
appears	O	590-597
to	O	598-600
depend	O	601-607
on	O	608-610
its	O	611-614
size	O	615-619
as	O	620-622
well	O	623-627
as	O	628-630
on	O	631-633
the	O	634-637
sex	O	638-641
of	O	642-644
the	O	645-648
transmitting	O	649-661
parent	O	662-668
.	O	668-669

Moreover	O	670-678
,	O	678-679
mitotic	O	680-687
instability	O	688-699
analysis	O	700-708
of	O	709-711
different	O	712-721
human	O	722-727
DM	B	728-730
tissues	O	731-738
shows	O	739-744
length	O	745-751
mosaicism	O	752-761
between	O	762-769
different	O	770-779
cell	O	780-784
lineages	O	785-793
.	O	793-794

The	O	795-798
molecular	O	799-808
mechanisms	O	809-819
of	O	820-822
triplet	O	823-830
instability	O	831-842
remain	O	843-849
elusive	O	850-857
.	O	857-858

To	O	859-861
investigate	O	862-873
the	O	874-877
role	O	878-882
of	O	883-885
genomic	O	886-893
sequences	O	894-903
in	O	904-906
instability	O	907-918
,	O	918-919
we	O	920-922
produced	O	923-931
transgenic	O	932-942
mice	O	943-947
containing	O	948-958
a	O	959-960
45	O	961-963
-	O	963-964
kb	O	964-966
genomic	O	967-974
segment	O	975-982
with	O	983-987
a	O	988-989
55	O	990-992
-	O	992-993
CTG	O	993-996
repeat	O	997-1003
cloned	O	1004-1010
from	O	1011-1015
a	O	1016-1017
mildly	O	1018-1024
affected	O	1025-1033
patient	O	1034-1041
.	O	1041-1042

In	O	1043-1045
contrast	O	1046-1054
to	O	1055-1057
other	O	1058-1063
mouse	O	1064-1069
models	O	1070-1076
containing	O	1077-1087
CAG	O	1088-1091
repeats	O	1092-1099
within	O	1100-1106
cDNAs	O	1107-1112
,	O	1112-1113
these	O	1114-1119
mice	O	1120-1124
showed	O	1125-1131
both	O	1132-1136
intergenerational	O	1137-1154
and	O	1155-1158
somatic	O	1159-1166
repeat	O	1167-1173
instability	O	1174-1185
.	O	1185-1186
.	O	1185-1186

Mutations	O	0-9
in	O	10-12
the	O	13-16
arginine	O	17-25
-	O	25-26
rich	O	26-30
protein	O	31-38
gene	O	39-43
(	O	44-45
ARP	O	45-48
)	O	48-49
in	O	50-52
pancreatic	B	53-63
cancer	I	64-70
.	O	70-71

The	O	72-75
ARP	O	76-79
gene	O	80-84
encodes	O	85-92
a	O	93-94
highly	O	95-101
conserved	O	102-111
arginine	O	112-120
-	O	120-121
rich	O	121-125
protein	O	126-133
from	O	134-138
chromosomal	O	139-150
band	O	151-155
3p21	O	156-160
.	O	160-161
1	O	162-163
1	O	164-165
.	O	165-166

At	O	167-169
the	O	170-173
cytogenetic	O	174-185
level	O	186-191
this	O	192-196
region	O	197-203
is	O	204-206
frequently	O	207-217
deleted	O	218-225
in	O	226-228
a	O	229-230
variety	O	231-238
of	O	239-241
different	O	242-251
solid	B	252-257
tumors	I	258-264
,	O	264-265
although	O	266-274
not	O	275-278
in	O	279-281
pancreatic	B	282-292
cancer	I	293-299
.	O	299-300

We	O	301-303
have	O	304-308
reported	O	309-317
the	O	318-321
presence	O	322-330
of	O	331-333
a	O	334-335
specific	O	336-344
mutation	O	345-353
(	O	354-355
ATG50	O	355-360
-	O	360-361
-	O	360-361
>	O	363-364
AGG	O	365-368
)	O	368-369
or	O	370-372
deletion	O	373-381
of	O	382-384
codon	O	385-390
50	O	391-393
of	O	394-396
the	O	397-400
ARP	O	401-404
gene	O	405-409
in	O	410-412
different	O	413-422
tumor	B	423-428
types	I	429-434
(	O	435-436
Shridhar	O	436-444
et	O	445-447
al	O	448-450
.	O	450-451
,	O	451-452
1996	O	453-457
,	O	457-458
1996a	O	459-464
)	O	464-465
.	O	465-466

In	O	467-469
the	O	470-473
present	O	474-481
study	O	482-487
,	O	487-488
we	O	489-491
have	O	492-496
observed	O	497-505
mutations	O	506-515
involving	O	516-525
codon	O	526-531
50	O	532-534
in	O	535-537
11	O	538-540
of	O	541-543
37	O	544-546
pancreatic	B	547-557
tumors	I	558-564
.	O	564-565

The	O	566-569
frequency	O	570-579
of	O	580-582
codon	O	583-588
50	O	589-591
mutation	O	592-600
is	O	601-603
roughly	O	604-611
the	O	612-615
same	O	616-620
in	O	621-623
pancreatic	B	624-634
tumors	I	635-641
as	O	642-644
in	O	645-647
the	O	648-651
other	O	652-657
types	O	658-663
of	O	664-666
tumors	B	667-673
previously	O	674-684
examined	O	685-693
.	O	693-694

In	O	695-697
addition	O	698-706
,	O	706-707
we	O	708-710
have	O	711-715
detected	O	716-724
mutations	O	725-734
at	O	735-737
codon	O	738-743
51	O	744-746
in	O	747-749
multiple	O	750-758
PCR	O	759-762
subclones	O	763-772
in	O	773-775
two	O	776-779
other	O	780-785
pancreatic	B	786-796
tumors	I	797-803
.	O	803-804

Mutations	O	805-814
in	O	815-817
the	O	818-821
ARP	O	822-825
gene	O	826-830
are	O	831-834
thus	O	835-839
commonly	O	840-848
observed	O	849-857
in	O	858-860
pancreatic	B	861-871
cancer	I	872-878
,	O	878-879
as	O	880-882
well	O	883-887
as	O	888-890
many	O	891-895
other	O	896-901
cancers	B	902-909
.	O	909-910

Heterogeneity	O	0-13
in	O	14-16
Schwartz	B	17-25
-	I	25-26
Jampel	I	26-32
chondrodystrophic	I	33-50
myotonia	I	51-59
.	O	59-60

The	O	61-64
Schwartz	B	65-73
-	I	73-74
Jampel	I	74-80
syndrome	I	81-89
(	O	90-91
SJS	B	91-94
;	O	94-95
chondrodystrophic	B	96-113
myotonia	I	114-122
;	O	122-123
McK	O	124-127
255	O	128-131
,	O	131-132
800	O	133-136
)	O	136-137
is	O	138-140
a	O	141-142
recessively	B	143-154
inherited	I	155-164
condition	I	165-174
defined	O	175-182
by	O	183-185
myotonia	B	186-194
,	O	194-195
short	B	196-201
stature	I	202-209
,	O	209-210
and	O	211-214
bone	B	215-219
dysplasia	I	220-229
.	O	229-230

Genetic	O	231-238
linkage	O	239-246
between	O	247-254
SJS	B	255-258
and	O	259-262
chromosomal	O	263-274
region	O	275-281
1q36	O	282-286
-	O	286-287
34	O	287-289
has	O	290-293
been	O	294-298
observed	O	299-307
in	O	308-310
several	O	311-318
families	O	319-327
,	O	327-328
but	O	329-332
the	O	333-336
gene	O	337-341
has	O	342-345
not	O	346-349
yet	O	350-353
been	O	354-358
identified	O	359-369
.	O	369-370

We	O	371-373
studied	O	374-381
the	O	382-385
clinical	O	386-394
and	O	395-398
radiological	O	399-411
features	O	412-420
in	O	421-423
81	O	424-426
patients	O	427-435
from	O	436-440
the	O	441-444
literature	O	445-455
and	O	456-459
5	O	460-461
own	O	462-465
patients	O	466-474
trying	O	475-481
to	O	482-484
identify	O	485-493
distinct	O	494-502
subgroups	O	503-512
.	O	512-513

In	O	514-516
addition	O	517-525
,	O	525-526
we	O	527-529
tested	O	530-536
genetic	O	537-544
linkage	O	545-552
to	O	553-555
the	O	556-559
SJS	B	560-563
locus	O	564-569
on	O	570-572
chromosome	O	573-583
1	O	584-585
in	O	586-588
one	O	589-592
family	O	593-599
with	O	600-604
two	O	605-608
affected	O	609-617
sibs	O	618-622
.	O	622-623

We	O	624-626
found	O	627-632
that	O	633-637
a	O	638-639
group	O	640-645
of	O	646-648
patients	O	649-657
have	O	658-662
mild	O	663-667
skeletal	O	668-676
changes	O	677-684
which	O	685-690
may	O	691-694
be	O	695-697
secondary	O	698-707
consequences	O	708-720
of	O	721-723
myotonia	B	724-732
,	O	732-733
while	O	734-739
another	O	740-747
group	O	748-753
of	O	754-756
patients	O	757-765
appear	O	766-772
to	O	773-775
have	O	776-780
primary	O	781-788
bone	B	789-793
dysplasia	I	794-803
with	O	804-808
myotonia	B	809-817
.	O	817-818

Within	O	819-825
this	O	826-830
latter	O	831-837
group	O	838-843
,	O	843-844
there	O	845-850
are	O	851-854
differences	O	855-866
in	O	867-869
age	O	870-873
of	O	874-876
manifestation	O	877-890
,	O	890-891
clinical	O	892-900
course	O	901-907
and	O	908-911
pattern	O	912-919
of	O	920-922
bone	O	923-927
changes	O	928-935
.	O	935-936

We	O	937-939
tentatively	O	940-951
isolate	O	952-959
three	O	960-965
different	O	966-975
types	O	976-981
of	O	982-984
SJS	B	985-988
type	I	990-994
1A	I	995-997
,	O	997-998
usually	O	999-1006
recognized	O	1007-1017
in	O	1018-1020
childhood	O	1021-1030
,	O	1030-1031
with	O	1032-1036
moderate	O	1037-1045
bone	B	1046-1050
dysplasia	I	1051-1060
,	O	1060-1061
corresponding	O	1062-1075
to	O	1076-1078
the	O	1079-1082
original	O	1083-1091
descriptions	O	1092-1104
of	O	1105-1107
Schwartz	O	1108-1116
,	O	1116-1117
Jampel	O	1118-1124
and	O	1125-1128
Aberfeld	O	1129-1137
;	O	1137-1138
type	O	1139-1143
1B	O	1144-1146
,	O	1146-1147
similar	O	1148-1155
to	O	1156-1158
type	O	1159-1163
1A	O	1164-1166
but	O	1167-1170
recognizable	O	1171-1183
at	O	1184-1186
birth	O	1187-1192
,	O	1192-1193
with	O	1194-1198
more	O	1199-1203
pronounced	O	1204-1214
bone	B	1215-1219
dysplasia	I	1220-1229
resembling	O	1230-1240
Kniest	B	1241-1247
dysplasia	I	1248-1257
;	O	1257-1258
and	O	1259-1262
type	O	1263-1267
2	O	1268-1269
,	O	1269-1270
manifest	O	1271-1279
at	O	1280-1282
birth	O	1283-1288
,	O	1288-1289
with	O	1290-1294
increased	O	1295-1304
mortality	O	1305-1314
and	O	1315-1318
bone	B	1319-1323
dysplasia	I	1324-1333
resembling	O	1334-1344
Pyle	B	1345-1349
disease	I	1350-1357
.	O	1357-1358

Genetic	O	1359-1366
analysis	O	1367-1375
of	O	1376-1378
the	O	1379-1382
family	O	1383-1389
with	O	1390-1394
two	O	1395-1398
sibs	O	1399-1403
affected	O	1404-1412
by	O	1413-1415
SJS	B	1416-1419
type	I	1420-1424
2	I	1425-1426
showed	O	1427-1433
evidence	O	1434-1442
against	O	1443-1450
linkage	O	1451-1458
to	O	1459-1461
chromosome	O	1462-1472
1p36	O	1473-1477
-	O	1477-1478
34	O	1478-1480
.	O	1480-1481

CONCLUSIONS	O	1482-1493
SJS	B	1495-1498
is	O	1499-1501
clinically	O	1502-1512
and	O	1513-1516
radiologically	O	1517-1531
heterogeneous	O	1532-1545
.	O	1545-1546

The	O	1547-1550
causes	O	1551-1557
of	O	1558-1560
heterogeneity	O	1561-1574
are	O	1575-1578
not	O	1579-1582
known	O	1583-1588
yet	O	1589-1592
but	O	1593-1596
are	O	1597-1600
likely	O	1601-1607
to	O	1608-1610
include	O	1611-1618
both	O	1619-1623
different	O	1624-1633
mutations	O	1634-1643
at	O	1644-1646
the	O	1647-1650
SJS	B	1651-1654
locus	O	1655-1660
on	O	1661-1663
chromosome	O	1664-1674
1	O	1675-1676
and	O	1677-1680
the	O	1681-1684
presence	O	1685-1693
of	O	1694-1696
a	O	1697-1698
second	O	1699-1705
SJS	B	1706-1709
locus	O	1710-1715
.	O	1715-1716

A	O	1717-1718
tentative	O	1719-1728
clinico	O	1729-1736
-	O	1736-1737
radiological	O	1737-1749
classification	O	1750-1764
can	O	1765-1768
be	O	1769-1771
useful	O	1772-1778
for	O	1779-1782
the	O	1783-1786
characterization	O	1787-1803
of	O	1804-1806
patients	O	1807-1815
and	O	1816-1819
the	O	1820-1823
development	O	1824-1835
of	O	1836-1838
genotype	O	1839-1847
-	O	1847-1848
phenotype	O	1848-1857
correlations	O	1858-1870
.	O	1870-1871
.	O	1870-1871

X	B	0-1
-	I	1-2
linked	I	2-8
adrenoleukodystrophy	I	9-29
is	O	30-32
a	O	33-34
frequent	O	35-43
cause	O	44-49
of	O	50-52
idiopathic	O	53-63
Addison	B	64-71
'	I	71-72
s	I	68-69
disease	I	74-81
in	O	82-84
young	O	85-90
adult	O	91-96
male	O	97-101
patients	O	102-110
.	O	110-111

X	B	112-113
-	I	113-114
Linked	I	114-120
adrenoleukodystrophy	I	121-141
(	O	142-143
ALD	B	143-146
)	O	146-147
is	O	148-150
a	O	151-152
genetic	B	153-160
disease	I	161-168
associated	O	169-179
with	O	180-184
demyelination	B	185-198
of	I	199-201
the	I	202-205
central	I	206-213
nervous	I	214-221
system	I	222-228
,	O	228-229
adrenal	B	230-237
insufficiency	I	238-251
,	O	251-252
and	O	253-256
accumulation	O	257-269
of	O	270-272
very	O	273-277
long	O	278-282
chain	O	283-288
fatty	O	289-294
acids	O	295-300
in	O	301-303
tissue	O	304-310
and	O	311-314
body	O	315-319
fluids	O	320-326
.	O	326-327

ALD	B	328-331
is	O	332-334
due	O	335-338
to	O	339-341
mutation	O	342-350
of	O	351-353
a	O	354-355
gene	O	356-360
located	O	361-368
in	O	369-371
Xq28	O	372-376
that	O	377-381
encodes	O	382-389
a	O	390-391
peroxisomal	O	392-403
transporter	O	404-415
protein	O	416-423
of	O	424-426
unknown	O	427-434
function	O	435-443
.	O	443-444

The	O	445-448
most	O	449-453
common	O	454-460
phenotype	O	461-470
of	O	471-473
ALD	B	474-477
is	O	478-480
the	O	481-484
cerebral	O	485-493
form	O	494-498
(	O	499-500
45	O	500-502
%	O	502-503
)	O	503-504
that	O	505-509
develops	O	510-518
in	O	519-521
boys	O	522-526
between	O	527-534
5	O	535-536
-	O	536-537
12	O	537-539
yr	O	540-542
.	O	542-543

Adrenomyeloneuropathy	B	544-565
(	O	566-567
AMN	B	567-570
)	O	570-571
involves	O	572-580
the	O	581-584
spinal	O	585-591
cord	O	592-596
and	O	597-600
peripheral	O	601-611
nerves	O	612-618
in	O	619-621
young	O	622-627
adults	O	628-634
(	O	635-636
35	O	636-638
%	O	638-639
)	O	639-640
.	O	640-641

Adrenal	B	642-649
insufficiency	I	650-663
(	O	664-665
Addisons	B	665-673
disease	I	674-681
)	O	681-682
is	O	683-685
frequently	O	686-696
associated	O	697-707
with	O	708-712
AMN	B	713-716
or	O	717-719
cerebral	B	720-728
ALD	I	729-732
and	O	733-736
may	O	737-740
remain	O	741-747
the	O	748-751
only	O	752-756
clinical	O	757-765
expression	O	766-776
of	O	777-779
ALD	B	780-783
(	O	784-785
8	O	785-786
%	O	786-787
of	O	788-790
cases	O	791-796
)	O	796-797
.	O	797-798

The	O	799-802
prevalence	O	803-813
of	O	814-816
ALD	B	817-820
among	O	821-826
adults	O	827-833
with	O	834-838
Addisons	B	839-847
disease	I	848-855
remains	O	856-863
unknown	O	864-871
.	O	871-872

To	O	873-875
evaluate	O	876-884
this	O	885-889
prevalence	O	890-900
,	O	900-901
we	O	902-904
performed	O	905-914
biochemical	O	915-926
analysis	O	927-935
of	O	936-938
very	O	939-943
long	O	944-948
chain	O	949-954
fatty	O	955-960
acids	O	961-966
in	O	967-969
14	O	970-972
male	O	973-977
patients	O	978-986
(	O	987-988
age	O	988-991
ranging	O	992-999
from	O	1000-1004
12	O	1005-1007
-	O	1007-1008
45	O	1008-1010
yr	O	1011-1013
at	O	1014-1016
diagnosis	O	1017-1026
)	O	1026-1027
previously	O	1028-1038
diagnosed	O	1039-1048
as	O	1049-1051
having	O	1052-1058
primary	O	1059-1066
idiopathic	O	1067-1077
adrenocortical	B	1078-1092
insufficiency	I	1093-1106
.	O	1106-1107

In	O	1108-1110
5	O	1111-1112
of	O	1113-1115
14	O	1116-1118
patients	O	1119-1127
(	O	1128-1129
35	O	1129-1131
%	O	1131-1132
)	O	1132-1133
,	O	1133-1134
elevated	O	1135-1143
plasma	O	1144-1150
concentrations	O	1151-1165
of	O	1166-1168
very	O	1169-1173
long	O	1174-1178
chain	O	1179-1184
fatty	O	1185-1190
acids	O	1191-1196
were	O	1197-1201
detected	O	1202-1210
.	O	1210-1211

None	O	1212-1216
of	O	1217-1219
these	O	1220-1225
patients	O	1226-1234
had	O	1235-1238
adrenocortical	O	1239-1253
antibodies	O	1254-1264
.	O	1264-1265

By	O	1266-1268
electrophysiological	O	1269-1289
tests	O	1290-1295
and	O	1296-1299
magnetic	O	1300-1308
resonance	O	1309-1318
imaging	O	1319-1326
it	O	1327-1329
was	O	1330-1333
determined	O	1334-1344
that	O	1345-1349
two	O	1350-1353
patients	O	1354-1362
had	O	1363-1366
cerebral	B	1367-1375
ALD	I	1376-1379
,	O	1379-1380
one	O	1381-1384
had	O	1385-1388
adrenomyeloneuropathy	B	1389-1410
with	O	1411-1415
cerebral	O	1416-1424
involvement	O	1425-1436
,	O	1436-1437
and	O	1438-1441
two	O	1442-1445
had	O	1446-1449
preclinical	O	1450-1461
AMN	B	1462-1465
.	O	1465-1466

Our	O	1467-1470
data	O	1471-1475
support	O	1476-1483
the	O	1484-1487
hypothesis	O	1488-1498
that	O	1499-1503
ALD	B	1504-1507
is	O	1508-1510
a	O	1511-1512
frequent	O	1513-1521
cause	O	1522-1527
of	O	1528-1530
idiopathic	O	1531-1541
Addisons	B	1542-1550
disease	I	1551-1558
in	O	1559-1561
children	O	1562-1570
and	O	1571-1574
adults	O	1575-1581
.	O	1581-1582
.	O	1581-1582

Low	O	0-3
incidence	O	4-13
of	O	14-16
BRCA2	O	17-22
mutations	O	23-32
in	O	33-35
breast	B	36-42
carcinoma	I	43-52
and	O	53-56
other	O	57-62
cancers	B	63-70
.	O	70-71

Inherited	O	72-81
mutant	O	82-88
alleles	O	89-96
of	O	97-99
familial	O	100-108
tumour	B	109-115
suppressor	O	116-126
genes	O	127-132
predispose	O	133-143
individuals	O	144-155
to	O	156-158
particular	O	159-169
types	O	170-175
of	O	176-178
cancer	B	179-185
.	O	185-186

In	O	187-189
addition	O	190-198
to	O	199-201
an	O	202-204
involvement	O	205-216
in	O	217-219
inherited	O	220-229
susceptibility	O	230-244
to	O	245-247
cancer	B	248-254
,	O	254-255
these	O	256-261
tumour	B	262-268
suppressor	O	269-279
genes	O	280-285
are	O	286-289
targets	O	290-297
for	O	298-301
somatic	O	302-309
mutations	O	310-319
in	O	320-322
sporadic	B	323-331
cancers	I	332-339
of	O	340-342
the	O	343-346
same	O	347-351
type	O	352-356
found	O	357-362
in	O	363-365
the	O	366-369
familial	O	370-378
forms	O	379-384
.	O	384-385

An	O	386-388
exception	O	389-398
is	O	399-401
BRCA1	O	402-407
,	O	407-408
which	O	409-414
contributes	O	415-426
to	O	427-429
a	O	430-431
significant	O	432-443
fraction	O	444-452
of	O	453-455
familial	B	456-464
breast	I	465-471
and	I	472-475
ovarian	I	476-483
cancer	I	484-490
,	O	490-491
but	O	492-495
undergoes	O	496-505
mutation	O	506-514
at	O	515-517
very	O	518-522
low	O	523-526
rates	O	527-532
in	O	533-535
sporadic	B	536-544
breast	I	545-551
and	I	552-555
ovarian	I	556-563
cancers	I	564-571
.	O	571-572

This	O	573-577
finding	O	578-585
suggests	O	586-594
that	O	595-599
other	O	600-605
genes	O	606-611
may	O	612-615
be	O	616-618
the	O	619-622
principal	O	623-632
targets	O	633-640
for	O	641-644
somatic	O	645-652
mutation	O	653-661
in	O	662-664
breast	B	665-671
carcinoma	I	672-681
.	O	681-682

A	O	683-684
second	O	685-691
,	O	691-692
recently	O	693-701
identified	O	702-712
familial	B	713-721
breast	I	722-728
cancer	I	729-735
gene	O	736-740
,	O	740-741
BRCA2	O	742-747
(	O	748-749
refs	O	749-753
5	O	754-755
-	O	755-756
8	O	756-757
)	O	757-758
,	O	758-759
accounts	O	760-768
for	O	769-772
a	O	773-774
proportion	O	775-785
of	O	786-788
breast	B	789-795
cancer	I	796-802
roughly	O	803-810
equal	O	811-816
to	O	817-819
BRCA1	O	820-825
.	O	825-826

Like	O	827-831
BRCA1	O	832-837
,	O	837-838
BRCA2	O	839-844
behaves	O	845-852
as	O	853-855
a	O	856-857
dominantly	O	858-868
inherited	O	869-878
tumour	B	879-885
suppressor	O	886-896
gene	O	897-901
.	O	901-902

Individuals	O	903-914
who	O	915-918
inherit	O	919-926
one	O	927-930
mutant	O	931-937
allele	O	938-944
are	O	945-948
at	O	949-951
increased	O	952-961
risk	O	962-966
for	O	967-970
breast	B	971-977
cancer	I	978-984
,	O	984-985
and	O	986-989
the	O	990-993
tumours	B	994-1001
they	O	1002-1006
develop	O	1007-1014
lose	O	1015-1019
the	O	1020-1023
wild	O	1024-1028
-	O	1028-1029
type	O	1029-1033
allele	O	1034-1040
by	O	1041-1043
heterozygous	O	1044-1056
deletion	O	1057-1065
.	O	1065-1066

The	O	1067-1070
BRCA2	O	1071-1076
coding	O	1077-1083
sequence	O	1084-1092
is	O	1093-1095
huge	O	1096-1100
,	O	1100-1101
composed	O	1102-1110
of	O	1111-1113
26	O	1114-1116
exons	O	1117-1122
that	O	1123-1127
span	O	1128-1132
10	O	1133-1135
,	O	1135-1136
443	O	1137-1140
bp	O	1141-1143
.	O	1143-1144

Here	O	1145-1149
we	O	1150-1152
investigate	O	1153-1164
the	O	1165-1168
rate	O	1169-1173
of	O	1174-1176
BRCA2	O	1177-1182
mutation	O	1183-1191
in	O	1192-1194
sporadic	B	1195-1203
breast	I	1204-1210
cancers	I	1211-1218
and	O	1219-1222
in	O	1223-1225
a	O	1226-1227
set	O	1228-1231
of	O	1232-1234
cell	O	1235-1239
lines	O	1240-1245
that	O	1246-1250
represent	O	1251-1260
twelve	O	1261-1267
other	O	1268-1273
tumour	B	1274-1280
types	O	1281-1286
.	O	1286-1287

Surprisingly	O	1288-1300
,	O	1300-1301
mutations	O	1302-1311
in	O	1312-1314
BRCA2	O	1315-1320
are	O	1321-1324
infrequent	O	1325-1335
in	O	1336-1338
cancers	B	1339-1346
including	O	1347-1356
breast	B	1357-1363
carcinoma	I	1364-1373
.	O	1373-1374

However	O	1375-1382
,	O	1382-1383
a	O	1384-1385
probable	O	1386-1394
germline	O	1395-1403
mutation	O	1404-1412
in	O	1413-1415
a	O	1416-1417
pancreatic	B	1418-1428
tumour	I	1429-1435
cell	O	1436-1440
line	O	1441-1445
suggests	O	1446-1454
a	O	1455-1456
role	O	1457-1461
for	O	1462-1465
BRCA2	O	1466-1471
in	O	1472-1474
susceptibility	O	1475-1489
to	O	1490-1492
pancreatic	B	1493-1503
cancer	I	1504-1510
.	O	1510-1511
.	O	1510-1511

Type	O	0-4
III	O	5-8
collagen	O	9-17
is	O	18-20
crucial	O	21-28
for	O	29-32
collagen	O	33-41
I	O	42-43
fibrillogenesis	O	44-59
and	O	60-63
for	O	64-67
normal	O	68-74
cardiovascular	O	75-89
development	O	90-101
.	O	101-102

Type	O	103-107
III	O	108-111
collagen	O	112-120
is	O	121-123
a	O	124-125
fibrillar	O	126-135
forming	O	136-143
collagen	O	144-152
comprising	O	153-163
three	O	164-169
alpha1	O	170-176
(	O	177-178
III	O	178-181
)	O	181-182
chains	O	183-189
and	O	190-193
is	O	194-196
expressed	O	197-206
in	O	207-209
early	O	210-215
embryos	O	216-223
and	O	224-227
throughout	O	228-238
embryogenesis	O	239-252
.	O	252-253

In	O	254-256
the	O	257-260
adult	O	261-266
,	O	266-267
type	O	268-272
III	O	273-276
collagen	O	277-285
is	O	286-288
a	O	289-290
major	O	291-296
component	O	297-306
of	O	307-309
the	O	310-313
extracellular	O	314-327
matrix	O	328-334
in	O	335-337
a	O	338-339
variety	O	340-347
of	O	348-350
internal	O	351-359
organs	O	360-366
and	O	367-370
skin	O	371-375
.	O	375-376

Mutations	O	377-386
in	O	387-389
the	O	390-393
COL3A1	O	394-400
gene	O	401-405
have	O	406-410
been	O	411-415
implicated	O	416-426
as	O	427-429
a	O	430-431
cause	O	432-437
of	O	438-440
type	B	441-445
IV	I	446-448
Ehlers	I	449-455
-	I	455-456
Danlos	I	456-462
syndrome	I	463-471
,	O	471-472
a	O	473-474
disease	O	475-482
leading	O	483-490
to	O	491-493
aortic	B	494-500
rupture	I	501-508
in	O	509-511
early	O	512-517
adult	O	518-523
life	O	524-528
.	O	528-529

To	O	530-532
directly	O	533-541
study	O	542-547
the	O	548-551
role	O	552-556
of	O	557-559
Col3a1	O	560-566
in	O	567-569
development	O	570-581
and	O	582-585
disease	O	586-593
,	O	593-594
we	O	595-597
have	O	598-602
inactivated	O	603-614
the	O	615-618
Col3a1	O	619-625
gene	O	626-630
in	O	631-633
embryonic	O	634-643
stem	O	644-648
cells	O	649-654
by	O	655-657
homologous	O	658-668
recombination	O	669-682
.	O	682-683

The	O	684-687
mutated	O	688-695
allele	O	696-702
was	O	703-706
transmitted	O	707-718
through	O	719-726
the	O	727-730
mouse	O	731-736
germ	O	737-741
line	O	742-746
and	O	747-750
homozygous	O	751-761
mutant	O	762-768
animals	O	769-776
were	O	777-781
derived	O	782-789
from	O	790-794
heterozygous	O	795-807
intercrosses	O	808-820
.	O	820-821

About	O	822-827
10	O	828-830
%	O	830-831
of	O	832-834
the	O	835-838
homozygous	O	839-849
mutant	O	850-856
animals	O	857-864
survived	O	865-873
to	O	874-876
adulthood	O	877-886
but	O	887-890
have	O	891-895
a	O	896-897
much	O	898-902
shorter	O	903-910
life	O	911-915
span	O	916-920
compared	O	921-929
with	O	930-934
wild	O	935-939
-	O	939-940
type	O	940-944
mice	O	945-949
.	O	949-950

The	O	951-954
major	O	955-960
cause	O	961-966
of	O	967-969
death	O	970-975
of	O	976-978
mutant	O	979-985
mice	O	986-990
was	O	991-994
rupture	O	995-1002
of	O	1003-1005
the	O	1006-1009
major	O	1010-1015
blood	O	1016-1021
vessels	O	1022-1029
,	O	1029-1030
similar	O	1031-1038
to	O	1039-1041
patients	O	1042-1050
with	O	1051-1055
type	B	1056-1060
IV	I	1061-1063
Ehlers	I	1064-1070
-	I	1070-1071
Danlos	I	1071-1077
syndrome	I	1078-1086
.	O	1086-1087

Ultrastructural	O	1088-1103
analysis	O	1104-1112
of	O	1113-1115
tissues	O	1116-1123
from	O	1124-1128
mutant	O	1129-1135
mice	O	1136-1140
revealed	O	1141-1149
that	O	1150-1154
type	O	1155-1159
III	O	1160-1163
collagen	O	1164-1172
is	O	1173-1175
essential	O	1176-1185
for	O	1186-1189
normal	O	1190-1196
collagen	O	1197-1205
I	O	1206-1207
fibrillogenesis	O	1208-1223
in	O	1224-1226
the	O	1227-1230
cardiovascular	O	1231-1245
system	O	1246-1252
and	O	1253-1256
other	O	1257-1262
organs	O	1263-1269
.	O	1269-1270
.	O	1269-1270

The	O	0-3
incidence	O	4-13
of	O	14-16
PAX6	O	17-21
mutation	O	22-30
in	O	31-33
patients	O	34-42
with	O	43-47
simple	O	48-54
aniridia	B	55-63
:	O	63-64
an	O	65-67
evaluation	O	68-78
of	O	79-81
mutation	O	82-90
detection	O	91-100
in	O	101-103
12	O	104-106
cases	O	107-112
.	O	112-113

Twelve	O	114-120
aniridia	B	121-129
patients	O	130-138
,	O	138-139
five	O	140-144
with	O	145-149
a	O	150-151
family	O	152-158
history	O	159-166
and	O	167-170
seven	O	171-176
presumed	O	177-185
to	O	186-188
be	O	189-191
sporadic	O	192-200
,	O	200-201
were	O	202-206
exhaustively	O	207-219
screened	O	220-228
in	O	229-231
order	O	232-237
to	O	238-240
test	O	241-245
what	O	246-250
proportion	O	251-261
of	O	262-264
people	O	265-271
with	O	272-276
aniridia	B	277-285
,	O	285-286
uncomplicated	O	287-300
by	O	301-303
associated	O	304-314
anomalies	O	315-324
,	O	324-325
carry	O	326-331
mutations	O	332-341
in	O	342-344
the	O	345-348
human	O	349-354
PAX6	O	355-359
gene	O	360-364
.	O	364-365

Mutations	O	366-375
were	O	376-380
detected	O	381-389
in	O	390-392
90	O	393-395
%	O	395-396
of	O	397-399
the	O	400-403
cases	O	404-409
.	O	409-410

Three	O	411-416
mutation	O	417-425
detection	O	426-435
techniques	O	436-446
were	O	447-451
used	O	452-456
to	O	457-459
determine	O	460-469
if	O	470-472
one	O	473-476
method	O	477-483
was	O	484-487
superior	O	488-496
for	O	497-500
this	O	501-505
gene	O	506-510
.	O	510-511

The	O	512-515
protein	O	516-523
truncation	O	524-534
test	O	535-539
(	O	540-541
PTT	O	541-544
)	O	544-545
was	O	546-549
used	O	550-554
on	O	555-557
RT	O	558-560
-	O	560-561
PCR	O	561-564
products	O	565-573
,	O	573-574
SSCP	O	575-579
on	O	580-582
genomic	O	583-590
PCR	O	591-594
amplifications	O	595-609
,	O	609-610
and	O	611-614
chemical	O	615-623
cleavage	O	624-632
of	O	633-635
mismatch	O	636-644
on	O	645-647
both	O	648-652
RT	O	653-655
-	O	655-656
PCR	O	656-659
and	O	660-663
genomic	O	664-671
amplifications	O	672-686
.	O	686-687

For	O	688-691
RT	O	692-694
-	O	694-695
PCR	O	695-698
products	O	699-707
,	O	707-708
only	O	709-713
the	O	714-717
translated	O	718-728
portion	O	729-736
of	O	737-739
the	O	740-743
gene	O	744-748
was	O	749-752
screened	O	753-761
.	O	761-762

On	O	763-765
genomic	O	766-773
products	O	774-782
exons	O	783-788
1	O	789-790
to	O	791-793
13	O	794-796
(	O	797-798
including	O	798-807
740	O	808-811
bp	O	812-814
of	O	815-817
the	O	818-821
3	O	822-823
untranslated	O	824-836
sequence	O	837-845
and	O	846-849
all	O	850-853
intron	O	854-860
/	O	860-861
exon	O	861-865
boundaries	O	866-876
)	O	876-877
were	O	878-882
screened	O	883-891
,	O	891-892
as	O	893-895
was	O	896-899
a	O	900-901
neuroretina	O	902-913
specific	O	914-922
enhancer	O	923-931
in	O	932-934
intron	O	935-941
4	O	942-943
.	O	943-944
Ten	O	945-948
of	O	949-951
the	O	952-955
possible	O	956-964
12	O	965-967
mutations	O	968-977
in	O	978-980
the	O	981-984
five	O	985-989
familial	O	990-998
cases	O	999-1004
and	O	1005-1008
five	O	1009-1013
of	O	1014-1016
the	O	1017-1020
sporadic	O	1021-1029
patients	O	1030-1038
were	O	1039-1043
found	O	1044-1049
,	O	1049-1050
all	O	1051-1054
of	O	1055-1057
which	O	1058-1063
conformed	O	1064-1073
to	O	1074-1076
a	O	1077-1078
functional	O	1079-1089
outcome	O	1090-1097
of	O	1098-1100
haploinsufficiency	O	1101-1119
.	O	1119-1120

Five	O	1121-1125
were	O	1126-1130
splice	O	1131-1137
site	O	1138-1142
mutations	O	1143-1152
(	O	1153-1154
one	O	1154-1157
in	O	1158-1160
the	O	1161-1164
donor	O	1165-1170
site	O	1171-1175
of	O	1176-1178
intron	O	1179-1185
4	O	1186-1187
,	O	1187-1188
two	O	1189-1192
in	O	1193-1195
the	O	1196-1199
donor	O	1200-1205
site	O	1206-1210
of	O	1211-1213
intron	O	1214-1220
6	O	1221-1222
,	O	1222-1223
one	O	1224-1227
in	O	1228-1230
each	O	1231-1235
of	O	1236-1238
the	O	1239-1242
acceptor	O	1243-1251
sites	O	1252-1257
of	O	1258-1260
introns	O	1261-1268
8	O	1269-1270
and	O	1271-1274
9	O	1275-1276
)	O	1276-1277
and	O	1278-1281
five	O	1282-1286
were	O	1287-1291
nonsense	O	1292-1300
mutations	O	1301-1310
in	O	1311-1313
exons	O	1314-1319
8	O	1320-1321
,	O	1321-1322
9	O	1323-1324
,	O	1324-1325
10	O	1326-1328
,	O	1328-1329
11	O	1330-1332
,	O	1332-1333
and	O	1334-1337
12	O	1338-1340
.	O	1340-1341
SSCP	O	1342-1346
analysis	O	1347-1355
of	O	1356-1358
individually	O	1359-1371
amplified	O	1372-1381
exons	O	1382-1387
,	O	1387-1388
with	O	1389-1393
which	O	1394-1399
nine	O	1400-1404
of	O	1405-1407
the	O	1408-1411
10	O	1412-1414
mutations	O	1415-1424
were	O	1425-1429
seen	O	1430-1434
,	O	1434-1435
was	O	1436-1439
the	O	1440-1443
most	O	1444-1448
useful	O	1449-1455
detection	O	1456-1465
method	O	1466-1472
for	O	1473-1476
PAX6	O	1477-1481
.	O	1481-1482
.	O	1481-1482

Germline	O	0-8
mutations	O	9-18
in	O	19-21
the	O	22-25
3	O	26-27
'	O	27-28
part	O	29-33
of	O	34-36
APC	B	37-40
exon	O	41-45
15	O	46-48
do	O	49-51
not	O	52-55
result	O	56-62
in	O	63-65
truncated	O	66-75
proteins	O	76-84
and	O	85-88
are	O	89-92
associated	O	93-103
with	O	104-108
attenuated	O	109-119
adenomatous	B	120-131
polyposis	I	132-141
coli	I	142-146
.	O	146-147

Familial	B	148-156
adenomatous	I	157-168
polyposis	I	169-178
(	O	179-180
FAP	B	180-183
)	O	183-184
is	O	185-187
an	O	188-190
inherited	O	191-200
predisposition	O	201-215
to	O	216-218
colorectal	B	219-229
cancer	I	230-236
characterized	O	237-250
by	O	251-253
the	O	254-257
development	O	258-269
of	O	270-272
numerous	O	273-281
adenomatous	B	282-293
polyps	I	294-300
predominantly	O	301-314
in	O	315-317
the	O	318-321
colorectal	O	322-332
region	O	333-339
.	O	339-340

Germline	O	341-349
mutations	O	350-359
in	O	360-362
the	O	363-366
adenomatous	B	367-378
polyposis	I	379-388
coli	I	389-393
(	O	394-395
APC	B	395-398
)	O	398-399
gene	O	400-404
are	O	405-408
responsible	O	409-420
for	O	421-424
most	O	425-429
cases	O	430-435
of	O	436-438
FAP	B	439-442
.	O	442-443

Mutations	O	444-453
at	O	454-456
the	O	457-460
5	O	461-462
end	O	463-466
of	O	467-469
APC	B	470-473
are	O	474-477
known	O	478-483
to	O	484-486
be	O	487-489
associated	O	490-500
with	O	501-505
a	O	506-507
relatively	O	508-518
mild	O	519-523
form	O	524-528
of	O	529-531
the	O	532-535
disease	O	536-543
,	O	543-544
called	O	545-551
attenuated	B	552-562
adenomatous	I	563-574
polyposis	I	575-584
coli	I	585-589
(	O	590-591
AAPC	B	591-595
)	O	595-596
.	O	596-597

We	O	598-600
identified	O	601-611
a	O	612-613
frameshift	O	614-624
mutation	O	625-633
in	O	634-636
the	O	637-640
3	O	641-642
part	O	643-647
of	O	648-650
exon	O	651-655
15	O	656-658
,	O	658-659
resulting	O	660-669
in	O	670-672
a	O	673-674
stop	O	675-679
codon	O	680-685
at	O	686-688
1862	O	689-693
,	O	693-694
in	O	695-697
a	O	698-699
large	O	700-705
Dutch	O	706-711
kindred	O	712-719
with	O	720-724
AAPC	B	725-729
.	O	729-730

Western	O	731-738
blot	O	739-743
analysis	O	744-752
of	O	753-755
lymphoblastoid	O	756-770
cell	O	771-775
lines	O	776-781
derived	O	782-789
from	O	790-794
affected	O	795-803
family	O	804-810
members	O	811-818
from	O	819-823
this	O	824-828
kindred	O	829-836
,	O	836-837
as	O	838-840
well	O	841-845
as	O	846-848
from	O	849-853
a	O	854-855
previously	O	856-866
reported	O	867-875
Swiss	O	876-881
family	O	882-888
carrying	O	889-897
a	O	898-899
frameshift	O	900-910
mutation	O	911-919
at	O	920-922
codon	O	923-928
1987	O	929-933
and	O	934-937
displaying	O	938-948
a	O	949-950
similar	O	951-958
attenuated	O	959-969
phenotype	O	970-979
,	O	979-980
showed	O	981-987
only	O	988-992
the	O	993-996
wild	O	997-1001
-	O	1001-1002
type	O	1002-1006
APC	B	1007-1010
protein	O	1011-1018
.	O	1018-1019

Our	O	1020-1023
study	O	1024-1029
indicates	O	1030-1039
that	O	1040-1044
chain	O	1045-1050
-	O	1050-1051
terminating	O	1051-1062
mutations	O	1063-1072
located	O	1073-1080
in	O	1081-1083
the	O	1084-1087
3	O	1088-1089
part	O	1090-1094
of	O	1095-1097
APC	B	1098-1101
do	O	1102-1104
not	O	1105-1108
result	O	1109-1115
in	O	1116-1118
detectable	O	1119-1129
truncated	O	1130-1139
polypeptides	O	1140-1152
and	O	1153-1156
we	O	1157-1159
hypothesize	O	1160-1171
that	O	1172-1176
this	O	1177-1181
is	O	1182-1184
likely	O	1185-1191
to	O	1192-1194
be	O	1195-1197
the	O	1198-1201
basis	O	1202-1207
for	O	1208-1211
the	O	1212-1215
observed	O	1216-1224
AAPC	B	1225-1229
phenotype	O	1230-1239
.	O	1239-1240
.	O	1239-1240

Absence	O	0-7
of	O	8-10
disease	O	11-18
phenotype	O	19-28
and	O	29-32
intergenerational	O	33-50
stability	O	51-60
of	O	61-63
the	O	64-67
CAG	O	68-71
repeat	O	72-78
in	O	79-81
transgenic	O	82-92
mice	O	93-97
expressing	O	98-108
the	O	109-112
human	O	113-118
Huntington	B	119-129
disease	I	130-137
transcript	O	138-148
.	O	148-149

The	O	150-153
mutation	O	154-162
underlying	O	163-173
Huntington	B	174-184
disease	I	185-192
(	O	193-194
HD	B	194-196
)	O	196-197
is	O	198-200
CAG	O	201-204
expansion	O	205-214
in	O	215-217
the	O	218-221
first	O	222-227
exon	O	228-232
of	O	233-235
the	O	236-239
HD	B	240-242
gene	O	243-247
.	O	247-248

In	O	249-251
order	O	252-257
to	O	258-260
investigate	O	261-272
the	O	273-276
role	O	277-281
of	O	282-284
CAG	O	285-288
expansion	O	289-298
in	O	299-301
the	O	302-305
pathogenesis	O	306-318
of	O	319-321
HD	B	322-324
,	O	324-325
we	O	326-328
have	O	329-333
produced	O	334-342
transgenic	O	343-353
mice	O	354-358
containing	O	359-369
the	O	370-373
full	O	374-378
length	O	379-385
human	O	386-391
HD	B	392-394
cDNA	O	395-399
with	O	400-404
44	O	405-407
CAG	O	408-411
repeats	O	412-419
.	O	419-420

By	O	421-423
1	O	424-425
year	O	426-430
,	O	430-431
these	O	432-437
mice	O	438-442
have	O	443-447
no	O	448-450
behavioral	B	451-461
abnormalities	I	462-475
and	O	476-479
morphometric	O	480-492
analysis	O	493-501
at	O	502-504
6	O	505-506
(	O	507-508
one	O	508-511
animal	O	512-518
)	O	518-519
and	O	520-523
9	O	524-525
(	O	526-527
two	O	527-530
animals	O	531-538
)	O	538-539
months	O	540-546
age	O	547-550
revealed	O	551-559
no	O	560-562
changes	O	563-570
.	O	570-571

Despite	O	572-579
high	O	580-584
levels	O	585-591
of	O	592-594
mRNA	O	595-599
expression	O	600-610
,	O	610-611
there	O	612-617
was	O	618-621
no	O	622-624
evidence	O	625-633
of	O	634-636
the	O	637-640
HD	B	641-643
gene	O	644-648
product	O	649-656
in	O	657-659
any	O	660-663
of	O	664-666
these	O	667-672
transgenic	O	673-683
mice	O	684-688
.	O	688-689

In	O	690-692
vitro	O	693-698
transfection	O	699-711
studies	O	712-719
indicated	O	720-729
that	O	730-734
the	O	735-738
inclusion	O	739-748
of	O	749-751
120	O	752-755
bp	O	756-758
of	O	759-761
the	O	762-765
5	O	766-767
UTR	O	768-771
in	O	772-774
the	O	775-778
cDNA	O	779-783
construct	O	784-793
and	O	794-797
the	O	798-801
presence	O	802-810
of	O	811-813
a	O	814-815
frameshift	O	816-826
mutation	O	827-835
at	O	836-838
nucleotide	O	839-849
2349	O	850-854
prevented	O	855-864
expression	O	865-875
of	O	876-878
the	O	879-882
HD	B	883-885
cDNA	O	886-890
.	O	890-891

These	O	892-897
findings	O	898-906
suggest	O	907-914
that	O	915-919
the	O	920-923
pathogenesis	O	924-936
of	O	937-939
HD	B	940-942
is	O	943-945
not	O	946-949
mediated	O	950-958
through	O	959-966
DNA	O	967-970
-	O	970-971
protein	O	971-978
interaction	O	979-990
and	O	991-994
that	O	995-999
presence	O	1000-1008
of	O	1009-1011
the	O	1012-1015
RNA	O	1016-1019
transcript	O	1020-1030
with	O	1031-1035
an	O	1036-1038
expanded	O	1039-1047
CAG	O	1048-1051
repeat	O	1052-1058
is	O	1059-1061
insufficient	O	1062-1074
to	O	1075-1077
cause	O	1078-1083
the	O	1084-1087
disease	O	1088-1095
.	O	1095-1096

Rather	O	1097-1103
,	O	1103-1104
translation	O	1105-1116
of	O	1117-1119
the	O	1120-1123
CAG	O	1124-1127
is	O	1128-1130
crucial	O	1131-1138
for	O	1139-1142
the	O	1143-1146
pathogenesis	O	1147-1159
of	O	1160-1162
HD	B	1163-1165
.	O	1165-1166

In	O	1167-1169
contrast	O	1170-1178
to	O	1179-1181
that	O	1182-1186
seen	O	1187-1191
in	O	1192-1194
humans	O	1195-1201
,	O	1201-1202
the	O	1203-1206
CAG	O	1207-1210
repeat	O	1211-1217
in	O	1218-1220
these	O	1221-1226
mice	O	1227-1231
was	O	1232-1235
remarkably	O	1236-1246
stable	O	1247-1253
in	O	1254-1256
97	O	1257-1259
meioses	O	1260-1267
.	O	1267-1268

This	O	1269-1273
suggests	O	1274-1282
that	O	1283-1287
genomic	O	1288-1295
sequences	O	1296-1305
may	O	1306-1309
play	O	1310-1314
a	O	1315-1316
critical	O	1317-1325
role	O	1326-1330
in	O	1331-1333
influencing	O	1334-1345
repeat	O	1346-1352
instability	O	1353-1364
.	O	1364-1365
.	O	1364-1365

Detection	O	0-9
of	O	10-12
heterozygous	O	13-25
mutations	O	26-35
in	O	36-38
BRCA1	O	39-44
using	O	45-50
high	O	51-55
density	O	56-63
oligonucleotide	O	64-79
arrays	O	80-86
and	O	87-90
two	O	91-94
-	O	94-95
colour	O	95-101
fluorescence	O	102-114
analysis	O	115-123
.	O	123-124

The	O	125-128
ability	O	129-136
to	O	137-139
scan	O	140-144
a	O	145-146
large	O	147-152
gene	O	153-157
rapidly	O	158-165
and	O	166-169
accurately	O	170-180
for	O	181-184
all	O	185-188
possible	O	189-197
heterozygous	O	198-210
mutations	O	211-220
in	O	221-223
large	O	224-229
numbers	O	230-237
of	O	238-240
patient	O	241-248
samples	O	249-256
will	O	257-261
be	O	262-264
critical	O	265-273
for	O	274-277
the	O	278-281
future	O	282-288
of	O	289-291
medicine	O	292-300
.	O	300-301

We	O	302-304
have	O	305-309
designed	O	310-318
high	O	319-323
-	O	323-324
density	O	324-331
arrays	O	332-338
consisting	O	339-349
of	O	350-352
over	O	353-357
96	O	358-360
,	O	360-361
600	O	362-365
oligonucleotides	O	366-382
20	O	383-385
-	O	385-386
nucleotides	O	386-397
(	O	398-399
nt	O	399-401
)	O	401-402
in	O	403-405
length	O	406-412
to	O	413-415
screen	O	416-422
for	O	423-426
a	O	427-428
wide	O	429-433
range	O	434-439
of	O	440-442
heterozygous	O	443-455
mutations	O	456-465
in	O	466-468
the	O	469-472
3	O	473-474
.	O	474-475
45	O	476-478
-	O	478-479
kilobases	O	479-488
(	O	489-490
kb	O	490-492
)	O	492-493
exon	O	494-498
11	O	499-501
of	O	502-504
the	O	505-508
hereditary	B	509-519
breast	I	520-526
and	I	527-530
ovarian	I	531-538
cancer	I	539-545
gene	O	546-550
BRCA1	O	551-556
.	O	556-557

Reference	O	558-567
and	O	568-571
test	O	572-576
samples	O	577-584
were	O	585-589
co	O	590-592
-	O	592-593
hybridized	O	593-603
to	O	604-606
these	O	607-612
arrays	O	613-619
and	O	620-623
differences	O	624-635
in	O	636-638
hybridization	O	639-652
patterns	O	653-661
quantitated	O	662-673
by	O	674-676
two	O	677-680
-	O	680-681
colour	O	681-687
analysis	O	688-696
.	O	696-697

Fourteen	O	698-706
of	O	707-709
fifteen	O	710-717
patient	O	718-725
samples	O	726-733
with	O	734-738
known	O	739-744
mutations	O	745-754
were	O	755-759
accurately	O	760-770
diagnosed	O	771-780
,	O	780-781
and	O	782-785
no	O	786-788
false	O	789-794
positive	O	795-803
mutations	O	804-813
were	O	814-818
identified	O	819-829
in	O	830-832
20	O	833-835
control	O	836-843
samples	O	844-851
.	O	851-852

Eight	O	853-858
single	O	859-865
nucleotide	O	866-876
polymorphisms	O	877-890
were	O	891-895
also	O	896-900
readily	O	901-908
detected	O	909-917
.	O	917-918

DNA	O	919-922
chip	O	923-927
-	O	927-928
based	O	928-933
assays	O	934-940
may	O	941-944
provide	O	945-952
a	O	953-954
valuable	O	955-963
new	O	964-967
technology	O	968-978
for	O	979-982
high	O	983-987
-	O	987-988
throughput	O	988-998
cost	O	999-1003
-	O	1003-1004
efficient	O	1004-1013
detection	O	1014-1023
of	O	1024-1026
genetic	O	1027-1034
alterations	O	1035-1046
.	O	1046-1047

Colchicine	O	0-10
in	O	11-13
breast	O	14-20
milk	O	21-25
of	O	26-28
patients	O	29-37
with	O	38-42
familial	B	43-51
Mediterranean	I	52-65
fever	I	66-71
.	O	71-72

OBJECTIVE	O	73-82
.	O	82-83

To	O	84-86
clarify	O	87-94
whether	O	95-102
colchicine	O	103-113
is	O	114-116
excreted	O	117-125
in	O	126-128
breast	O	129-135
milk	O	136-140
,	O	140-141
and	O	142-145
to	O	146-148
compare	O	149-156
its	O	157-160
concentrations	O	161-175
in	O	176-178
the	O	179-182
serum	O	183-188
and	O	189-192
breast	O	193-199
milk	O	200-204
of	O	205-207
lactating	O	208-217
women	O	218-223
who	O	224-227
have	O	228-232
familial	B	233-241
Mediterranean	I	242-255
fever	I	256-261
(	O	262-263
FMF	B	263-266
)	O	266-267
.	O	267-268

METHODS	O	269-276
.	O	276-277

Using	O	278-283
a	O	284-285
specific	O	286-294
radioimmunoassay	O	295-311
,	O	311-312
we	O	313-315
determined	O	316-326
colchicine	O	327-337
concentrations	O	338-352
in	O	353-355
the	O	356-359
serum	O	360-365
and	O	366-369
breast	O	370-376
milk	O	377-381
of	O	382-384
4	O	385-386
patients	O	387-395
at	O	396-398
various	O	399-406
time	O	407-411
points	O	412-418
,	O	418-419
following	O	420-429
oral	O	430-434
administration	O	435-449
of	O	450-452
the	O	453-456
drug	O	457-461
.	O	461-462

The	O	463-466
study	O	467-472
evaluated	O	473-482
4	O	483-484
patients	O	485-493
with	O	494-498
FMF	B	499-502
who	O	503-506
had	O	507-510
been	O	511-515
taking	O	516-522
colchicine	O	523-533
on	O	534-536
a	O	537-538
long	O	539-543
-	O	543-544
term	O	544-548
basis	O	549-554
.	O	554-555

RESULTS	O	556-563
.	O	563-564

Colchicine	O	565-575
was	O	576-579
found	O	580-585
to	O	586-588
be	O	589-591
excreted	O	592-600
in	O	601-603
breast	O	604-610
milk	O	611-615
.	O	615-616

Its	O	617-620
levels	O	621-627
ranged	O	628-634
between	O	635-642
1	O	643-644
.	O	644-645
9	O	646-647
and	O	648-651
8	O	652-653
.	O	653-654
6	O	655-656
ng	O	657-659
/	O	659-660
ml	O	660-662
,	O	662-663
which	O	664-669
were	O	670-674
similar	O	675-682
to	O	683-685
those	O	686-691
found	O	692-697
in	O	698-700
the	O	701-704
serum	O	705-710
(	O	711-712
parallel	O	712-720
concentration	O	721-734
time	O	735-739
curves	O	740-746
)	O	746-747
.	O	747-748

However	O	749-756
,	O	756-757
there	O	758-763
appeared	O	764-772
to	O	773-775
be	O	776-778
a	O	779-780
considerable	O	781-793
variation	O	794-803
in	O	804-806
colchicine	O	807-817
milk	O	818-822
concentration	O	823-836
among	O	837-842
the	O	843-846
different	O	847-856
patients	O	857-865
,	O	865-866
which	O	867-872
might	O	873-878
be	O	879-881
related	O	882-889
to	O	890-892
individual	O	893-903
breast	O	904-910
milk	O	911-915
composition	O	916-927
and	O	928-931
,	O	931-932
possibly	O	933-941
,	O	941-942
to	O	943-945
other	O	946-951
nutritional	O	952-963
or	O	964-966
metabolic	O	967-976
factors	O	977-984
.	O	984-985

CONCLUSION	O	986-996
.	O	996-997

The	O	998-1001
extensive	O	1002-1011
peripheral	O	1012-1022
tissue	O	1023-1029
binding	O	1030-1037
and	O	1038-1041
relatively	O	1042-1052
low	O	1053-1056
concentration	O	1057-1070
of	O	1071-1073
colchicine	O	1074-1084
in	O	1085-1087
breast	O	1088-1094
milk	O	1095-1099
suggests	O	1100-1108
that	O	1109-1113
the	O	1114-1117
amount	O	1118-1124
ingested	O	1125-1133
by	O	1134-1136
the	O	1137-1140
infant	O	1141-1147
is	O	1148-1150
small	O	1151-1156
.	O	1156-1157

Furthermore	O	1158-1169
,	O	1169-1170
based	O	1171-1176
on	O	1177-1179
our	O	1180-1183
clinical	O	1184-1192
experience	O	1193-1203
,	O	1203-1204
nursing	O	1205-1212
appears	O	1213-1220
to	O	1221-1223
be	O	1224-1226
safe	O	1227-1231
for	O	1232-1235
lactating	O	1236-1245
women	O	1246-1251
with	O	1252-1256
FMF	B	1257-1260
who	O	1261-1264
continue	O	1265-1273
to	O	1274-1276
take	O	1277-1281
colchicine	O	1282-1292
.	O	1292-1293

The	O	0-3
human	O	4-9
complement	O	10-20
C9	O	21-23
gene	O	24-28
:	O	28-29
identification	O	30-44
of	O	45-47
two	O	48-51
mutations	O	52-61
causing	O	62-69
deficiency	O	70-80
and	O	81-84
revision	O	85-93
of	O	94-96
the	O	97-100
gene	O	101-105
structure	O	106-115
.	O	115-116

The	O	117-120
ninth	O	121-126
component	O	127-136
of	O	137-139
human	O	140-145
complement	O	146-156
(	O	157-158
C9	O	158-160
)	O	160-161
is	O	162-164
the	O	165-168
last	O	169-173
of	O	174-176
the	O	177-180
terminal	O	181-189
complement	O	190-200
components	O	201-211
creating	O	212-220
the	O	221-224
membrane	O	225-233
attack	O	234-240
complex	O	241-248
.	O	248-249

C9	O	250-252
is	O	253-255
a	O	256-257
single	O	258-264
-	O	264-265
chain	O	265-270
serum	O	271-276
protein	O	277-284
that	O	285-289
is	O	290-292
encoded	O	293-300
by	O	301-303
a	O	304-305
gene	O	306-310
located	O	311-318
on	O	319-321
chromosome	O	322-332
5p	O	333-335
.	O	335-336

Deficiency	B	337-347
of	I	348-350
terminal	I	351-359
complement	I	360-370
components	I	371-381
is	O	382-384
generally	O	385-394
associated	O	395-405
with	O	406-410
recurrent	O	411-420
neisseria	B	421-430
infections	I	431-441
.	O	441-442

We	O	443-445
studied	O	446-453
a	O	454-455
previously	O	456-466
described	O	467-476
Swiss	O	477-482
family	O	483-489
with	O	490-494
inherited	B	495-504
C9	I	505-507
deficiency	I	508-518
.	O	518-519

To	O	520-522
identify	O	523-531
the	O	532-535
genetic	O	536-543
basis	O	544-549
of	O	550-552
C9	B	553-555
deficiency	I	556-566
,	O	566-567
we	O	568-570
developed	O	571-580
an	O	581-583
approach	O	584-592
using	O	593-598
exon	O	599-603
-	O	603-604
specific	O	604-612
PCR	O	613-616
and	O	617-620
direct	O	621-627
DNA	O	628-631
sequencing	O	632-642
.	O	642-643

As	O	644-646
a	O	647-648
cause	O	649-654
of	O	655-657
C9	B	658-660
deficiency	I	661-671
,	O	672-673
we	O	674-676
found	O	677-682
two	O	683-686
different	O	687-696
point	O	697-702
mutations	O	703-712
,	O	712-713
both	O	714-718
generating	O	719-729
TGA	O	730-733
stop	O	734-738
codons	O	739-745
in	O	746-748
the	O	749-752
coding	O	753-759
sequence	O	760-768
.	O	768-769

One	O	770-773
mutation	O	774-782
,	O	782-783
a	O	784-785
C	O	786-787
to	O	788-790
A	O	791-792
exchange	O	793-801
,	O	801-802
was	O	803-806
detected	O	807-815
in	O	816-818
exon	O	819-823
2	O	824-825
at	O	826-828
cDNA	O	829-833
position	O	834-842
166	O	843-846
,	O	846-847
the	O	848-851
other	O	852-857
,	O	857-858
a	O	859-860
C	O	861-862
to	O	863-865
T	O	866-867
exchange	O	868-876
,	O	876-877
was	O	878-881
located	O	882-889
in	O	890-892
exon	O	893-897
4	O	898-899
(	O	900-901
cDNA	O	901-905
position	O	906-914
464	O	915-918
)	O	918-919
.	O	919-920

In	O	921-923
family	O	924-930
studies	O	931-938
of	O	939-941
three	O	942-947
first	O	948-953
-	O	953-954
degree	O	954-960
relatives	O	961-970
with	O	971-975
heterozygous	O	976-988
C9	B	989-991
deficiency	I	992-1002
,	O	1002-1003
we	O	1004-1006
demonstrated	O	1007-1019
that	O	1020-1024
the	O	1025-1028
two	O	1029-1032
mutations	O	1033-1042
are	O	1043-1046
segregating	O	1047-1058
independently	O	1059-1072
.	O	1072-1073

Therefore	O	1074-1083
,	O	1083-1084
these	O	1085-1090
mutations	O	1091-1100
are	O	1101-1104
sufficient	O	1105-1115
to	O	1116-1118
explain	O	1119-1126
the	O	1127-1130
complete	O	1131-1139
deficiency	O	1140-1150
of	O	1151-1153
both	O	1154-1158
the	O	1159-1162
probands	O	1163-1171
studied	O	1172-1179
.	O	1179-1180

DNA	O	1181-1184
sequencing	O	1185-1195
of	O	1196-1198
the	O	1199-1202
exon	O	1203-1207
-	O	1207-1208
intron	O	1208-1214
junctions	O	1215-1224
revealed	O	1225-1233
a	O	1234-1235
number	O	1236-1242
of	O	1243-1245
revisions	O	1246-1255
regarding	O	1256-1265
the	O	1266-1269
boundaries	O	1270-1280
between	O	1281-1288
exons	O	1289-1294
4	O	1295-1296
,	O	1296-1297
5	O	1298-1299
,	O	1299-1300
and	O	1301-1304
6	O	1305-1306
as	O	1307-1309
well	O	1310-1314
as	O	1315-1317
between	O	1318-1325
exons	O	1326-1331
10	O	1332-1334
and	O	1335-1338
11	O	1339-1341
.	O	1341-1342

No	O	1343-1345
additional	O	1346-1356
introns	O	1357-1364
were	O	1365-1369
detected	O	1370-1378
in	O	1379-1381
exons	O	1382-1387
6	O	1388-1389
and	O	1390-1393
10	O	1394-1396
.	O	1396-1397

Furthermore	O	1398-1409
,	O	1409-1410
DNA	O	1411-1414
marker	O	1415-1421
studies	O	1422-1429
were	O	1430-1434
conducted	O	1435-1444
using	O	1445-1450
known	O	1451-1456
polymorphisms	O	1457-1470
of	O	1471-1473
the	O	1474-1477
C6	O	1478-1480
,	O	1480-1481
C7	O	1482-1484
,	O	1484-1485
and	O	1486-1489
C9	O	1490-1492
genes	O	1493-1498
,	O	1498-1499
confirming	O	1500-1510
the	O	1511-1514
linkage	O	1515-1522
of	O	1523-1525
the	O	1526-1529
observed	O	1530-1538
C9	O	1539-1541
mutations	O	1542-1551
with	O	1552-1556
defined	O	1557-1564
haplotypes	O	1565-1575
.	O	1575-1576
.	O	1575-1576

Molecular	O	0-9
heterogeneity	O	10-23
of	O	24-26
classical	B	27-36
and	I	37-40
Duarte	I	41-47
galactosemia	I	48-60
:	O	60-61
mutation	O	62-70
analysis	O	71-79
by	O	80-82
denaturing	O	83-93
gradient	O	94-102
gel	O	103-106
electrophoresis	O	107-122
.	O	122-123

Classical	B	124-133
galactosemia	I	134-146
is	O	147-149
caused	O	150-156
by	O	157-159
one	O	160-163
common	O	164-170
missense	O	171-179
mutation	O	180-188
(	O	189-190
Q188R	O	190-195
)	O	195-196
and	O	197-200
by	O	201-203
several	O	204-211
rare	O	212-216
mutations	O	217-226
in	O	227-229
the	O	230-233
galactose	O	234-243
-	O	243-244
1	O	244-245
-	O	243-244
phosphate	O	246-255
uridyltransferase	O	256-273
(	O	274-275
GALT	O	275-279
)	O	279-280
gene	O	281-285
.	O	285-286

The	O	287-290
most	O	291-295
common	O	296-302
variant	O	303-310
of	O	311-313
GALT	O	314-318
,	O	318-319
the	O	320-323
Duarte	O	324-330
variant	O	331-338
,	O	338-339
occurs	O	340-346
as	O	347-349
two	O	350-353
types	O	354-359
,	O	359-360
Duarte	O	361-367
-	O	367-368
1	O	368-369
(	O	370-371
D	O	371-372
-	O	372-373
1	O	373-374
)	O	374-375
and	O	376-379
Duarte	O	380-386
-	O	386-387
2	O	387-388
(	O	389-390
D	O	390-391
-	O	391-392
2	O	392-393
)	O	393-394
,	O	394-395
both	O	396-400
of	O	401-403
which	O	404-409
carry	O	410-415
the	O	416-419
sequence	O	420-428
change	O	429-435
N314D	O	436-441
.	O	441-442

D	O	443-444
-	O	444-445
1	O	445-446
increases	O	447-456
,	O	456-457
whereas	O	458-465
D	O	466-467
-	O	467-468
2	O	468-469
decreases	O	470-479
GALT	O	480-484
activity	O	485-493
.	O	493-494

To	O	495-497
study	O	498-503
the	O	504-507
molecular	O	508-517
genetics	O	518-526
of	O	527-529
classical	B	530-539
and	I	540-543
Duarte	I	544-550
galactosemia	I	551-563
,	O	563-564
we	O	565-567
analyzed	O	568-576
the	O	577-580
GALT	O	581-585
mutations	O	586-595
in	O	596-598
30	O	599-601
families	O	602-610
with	O	611-615
classical	B	616-625
galactosemia	I	626-638
,	O	638-639
in	O	640-642
10	O	643-645
families	O	646-654
with	O	655-659
the	O	660-663
D	O	664-665
-	O	665-666
2	O	666-667
variant	O	668-675
and	O	676-679
in	O	680-682
3	O	683-684
individuals	O	685-696
carrying	O	697-705
the	O	706-709
D	O	710-711
-	O	711-712
1	O	712-713
allele	O	714-720
by	O	721-723
denaturing	O	724-734
gradient	O	735-743
gel	O	744-747
electrophoresis	O	748-763
(	O	764-765
DGGE	O	765-769
)	O	769-770
.	O	770-771

DGGE	O	772-776
detected	O	777-785
59	O	786-788
of	O	789-791
the	O	792-795
60	O	796-798
classical	O	799-808
galactosemia	B	809-821
alleles	O	822-829
.	O	829-830

Q188R	O	831-836
accounted	O	837-846
for	O	847-850
60	O	851-853
%	O	853-854
,	O	854-855
K285N	O	856-861
accounted	O	862-871
for	O	872-875
28	O	876-878
%	O	878-879
of	O	880-882
these	O	883-888
alleles	O	889-896
.	O	896-897

Eight	O	898-903
novel	O	904-909
candidate	O	910-919
galactosemia	B	920-932
mutations	O	933-942
were	O	943-947
found	O	948-953
.	O	953-954

On	O	955-957
all	O	958-961
D	O	962-963
-	O	963-964
2	O	964-965
alleles	O	966-973
N314D	O	974-979
occurred	O	980-988
in	O	989-991
cis	O	992-995
with	O	996-1000
two	O	1001-1004
intronic	O	1005-1013
sequence	O	1014-1022
changes	O	1023-1030
,	O	1030-1031
on	O	1032-1034
the	O	1035-1038
D	O	1039-1040
-	O	1040-1041
1	O	1041-1042
alleles	O	1043-1050
in	O	1051-1053
cis	O	1054-1057
with	O	1058-1062
a	O	1063-1064
neutral	O	1065-1072
mutation	O	1073-1081
in	O	1082-1084
exon	O	1085-1089
7	O	1090-1091
.	O	1091-1092
We	O	1093-1095
conclude	O	1096-1104
that	O	1105-1109
the	O	1110-1113
mutations	O	1114-1123
causing	O	1124-1131
galactosemia	B	1132-1144
are	O	1145-1148
highly	O	1149-1155
heterogeneous	O	1156-1169
and	O	1170-1173
that	O	1174-1178
K285N	O	1179-1184
is	O	1185-1187
a	O	1188-1189
second	O	1190-1196
common	O	1197-1203
galactosemia	B	1204-1216
mutation	O	1217-1225
in	O	1226-1228
our	O	1229-1232
population	O	1233-1243
.	O	1243-1244
.	O	1243-1244

Nonsense	O	0-8
mutation	O	9-17
in	O	18-20
exon	O	21-25
3	O	26-27
of	O	28-30
the	O	31-34
proteolipid	O	35-46
protein	O	47-54
gene	O	55-59
(	O	60-61
PLP	O	61-64
)	O	64-65
in	O	66-68
a	O	69-70
family	O	71-77
with	O	78-82
an	O	83-85
unusual	O	86-93
form	O	94-98
of	O	99-101
Pelizaeus	B	102-111
-	I	111-112
Merzbacher	I	112-122
disease	I	123-130
.	O	130-131

We	O	132-134
report	O	135-141
a	O	142-143
G	O	144-145
-	O	145-146
-	O	145-146
>	O	148-149
A	O	150-151
transition	O	152-162
at	O	163-165
nucleotide	O	166-176
431	O	177-180
of	O	181-183
the	O	184-187
proteolipid	O	188-199
protein	O	200-207
gene	O	208-212
(	O	213-214
PLP	O	214-217
)	O	217-218
results	O	219-226
in	O	227-229
a	O	230-231
nonsense	O	232-240
codon	O	241-246
in	O	247-249
a	O	250-251
family	O	252-258
with	O	259-263
an	O	264-266
unusual	O	267-274
form	O	275-279
of	O	280-282
Pelizaeus	B	283-292
-	I	292-293
Merzbacher	I	293-303
disease	I	304-311
(	O	312-313
PMD	B	313-316
)	O	316-317
.	O	317-318

The	O	319-322
mutation	O	323-331
,	O	331-332
which	O	333-338
creates	O	339-346
a	O	347-348
second	O	349-355
AluI	O	356-360
restriction	O	361-372
site	O	373-377
,	O	377-378
results	O	379-386
in	O	387-389
a	O	390-391
nonsense	O	392-400
mutation	O	401-409
in	O	410-412
PLP	O	413-416
.	O	416-417

The	O	418-421
clinical	O	422-430
picture	O	431-438
resembles	O	439-448
somewhat	O	449-457
that	O	458-462
of	O	463-465
X	B	466-467
-	I	467-468
linked	I	468-474
spastic	I	475-482
paraplegia	I	483-493
(	O	494-495
SPG	B	495-498
)	O	498-499
.	O	499-500

It	O	501-503
differs	O	504-511
from	O	512-516
this	O	517-521
and	O	522-525
both	O	526-530
the	O	531-534
classical	O	535-544
and	O	545-548
connatal	O	549-557
forms	O	558-563
of	O	564-566
PMD	B	567-570
in	O	571-573
that	O	574-578
it	O	579-581
is	O	582-584
relatively	O	585-595
mild	O	596-600
in	O	601-603
form	O	604-608
,	O	608-609
onset	O	610-615
is	O	616-618
delayed	O	619-626
beyond	O	627-633
age	O	634-637
2	O	638-639
years	O	640-645
,	O	645-646
nystagmus	B	647-656
is	O	657-659
absent	O	660-666
,	O	666-667
tremors	B	668-675
are	O	676-679
prominent	O	680-689
,	O	689-690
mental	B	691-697
retardation	I	698-709
is	O	710-712
not	O	713-716
severe	O	717-723
,	O	723-724
some	O	725-729
patients	O	730-738
show	O	739-743
dementia	B	744-752
or	O	753-755
personality	B	756-767
disorders	I	768-777
,	O	777-778
the	O	779-782
disease	O	783-790
is	O	791-793
progressive	O	794-805
rather	O	806-812
than	O	813-817
static	O	818-824
in	O	825-827
some	O	828-832
,	O	832-833
and	O	834-837
several	O	838-845
females	O	846-853
show	O	854-858
signs	O	859-864
of	O	865-867
disease	O	868-875
.	O	875-876

The	O	877-880
nonsense	O	881-889
mutation	O	890-898
,	O	898-899
which	O	900-905
is	O	906-908
in	O	909-911
exon	O	912-916
3B	O	917-919
,	O	919-920
should	O	921-927
block	O	928-933
the	O	934-937
synthesis	O	938-947
of	O	948-950
normal	O	951-957
PLP	O	958-961
but	O	962-965
spare	O	966-971
DM20	O	972-976
,	O	976-977
the	O	978-981
isoform	O	982-989
whose	O	990-995
persistence	O	996-1007
has	O	1008-1011
been	O	1012-1016
associated	O	1017-1027
with	O	1028-1032
mild	O	1033-1037
forms	O	1038-1043
of	O	1044-1046
PLP	B	1047-1050
-	I	1050-1051
associated	I	1051-1061
disease	I	1062-1069
in	O	1070-1072
both	O	1073-1077
humans	O	1078-1084
and	O	1085-1088
mice	O	1089-1093
.	O	1093-1094
.	O	1093-1094

The	O	0-3
hybrid	O	4-10
PAX3	O	11-15
-	O	15-16
FKHR	O	16-20
fusion	O	21-27
protein	O	28-35
of	O	36-38
alveolar	B	39-47
rhabdomyosarcoma	I	48-64
transforms	O	65-75
fibroblasts	O	76-87
in	O	88-90
culture	O	91-98
.	O	98-99

Pediatric	B	100-109
alveolar	I	110-118
rhabdomyosarcoma	I	119-135
is	O	136-138
characterized	O	139-152
by	O	153-155
a	O	156-157
chromosomal	O	158-169
translocation	O	170-183
that	O	184-188
fuses	O	189-194
parts	O	195-200
of	O	201-203
the	O	204-207
PAX3	O	208-212
and	O	213-216
FKHR	O	217-221
genes	O	222-227
.	O	227-228

PAX3	O	229-233
codes	O	234-239
for	O	240-243
a	O	244-245
transcriptional	O	246-261
regulator	O	262-271
that	O	272-276
controls	O	277-285
developmental	O	286-299
programs	O	300-308
,	O	308-309
and	O	310-313
FKHR	O	314-318
codes	O	319-324
for	O	325-328
a	O	329-330
forkhead	O	331-339
-	O	339-340
winged	O	340-346
helix	O	347-352
protein	O	353-360
,	O	360-361
also	O	362-366
a	O	367-368
likely	O	369-375
transcription	O	376-389
factor	O	390-396
.	O	396-397

The	O	398-401
PAX3	O	402-406
-	O	406-407
FKHR	O	407-411
fusion	O	412-418
product	O	419-426
retains	O	427-434
the	O	435-438
DNA	O	439-442
binding	O	443-450
domains	O	451-458
of	O	459-461
the	O	462-465
PAX3	O	466-470
protein	O	471-478
and	O	479-482
the	O	483-486
putative	O	487-495
activator	O	496-505
domain	O	506-512
of	O	513-515
the	O	516-519
FKHR	O	520-524
protein	O	525-532
.	O	532-533

The	O	534-537
PAX3	O	538-542
-	O	542-543
FKHR	O	543-547
protein	O	548-555
has	O	556-559
been	O	560-564
shown	O	565-570
to	O	571-573
function	O	574-582
as	O	583-585
a	O	586-587
transcriptional	O	588-603
activator	O	604-613
.	O	613-614

Using	O	615-620
the	O	621-624
RCAS	O	625-629
retroviral	O	630-640
vector	O	641-647
,	O	647-648
we	O	649-651
have	O	652-656
introduced	O	657-667
the	O	668-671
PAX3	O	672-676
-	O	676-677
FKHR	O	677-681
gene	O	682-686
into	O	687-691
chicken	O	692-699
embryo	O	700-706
fibroblasts	O	707-718
.	O	718-719

Expression	O	720-730
of	O	731-733
the	O	734-737
PAX3	O	738-742
-	O	742-743
FKHR	O	743-747
protein	O	748-755
in	O	756-758
these	O	759-764
cells	O	765-770
leads	O	771-776
to	O	777-779
transformation	O	780-794
the	O	796-799
cells	O	800-805
become	O	806-812
enlarged	O	813-821
,	O	821-822
grow	O	823-827
tightly	O	828-835
packed	O	836-842
and	O	843-846
in	O	847-849
multiple	O	850-858
layers	O	859-865
,	O	865-866
and	O	867-870
acquire	O	871-878
the	O	879-882
ability	O	883-890
for	O	891-894
anchorage	O	895-904
-	O	904-905
independent	O	905-916
growth	O	917-923
.	O	923-924

This	O	925-929
cellular	O	930-938
transformation	O	939-953
in	O	954-956
vitro	O	957-962
will	O	963-967
facilitate	O	968-978
studies	O	979-986
on	O	987-989
the	O	990-993
mechanism	O	994-1003
of	O	1004-1006
PAX3	O	1007-1011
-	O	1011-1012
FKHR	O	1012-1016
-	O	1011-1012
induced	O	1017-1024
oncogenesis	O	1025-1036
.	O	1036-1037
.	O	1036-1037

A	O	0-1
clinical	O	2-10
overview	O	11-19
of	O	20-22
WT1	O	23-26
gene	O	27-31
mutations	O	32-41
.	O	41-42

Mutations	O	43-52
in	O	53-55
the	O	56-59
WT1	O	60-63
gene	O	64-68
were	O	69-73
anticipated	O	74-85
to	O	86-88
explain	O	89-96
the	O	97-100
genetic	O	101-108
basis	O	109-114
of	O	115-117
the	O	118-121
childhood	O	122-131
kidney	B	132-138
cancer	I	139-145
,	O	145-146
Wilms	B	147-152
tumour	I	153-159
(	O	160-161
WT	B	161-163
)	O	163-164
.	O	164-165

Six	O	166-169
years	O	170-175
on	O	176-178
,	O	178-179
we	O	180-182
review	O	183-189
100	O	190-193
reports	O	194-201
of	O	202-204
intragenic	O	205-215
WT1	O	216-219
mutations	O	220-229
and	O	230-233
examine	O	234-241
the	O	242-245
accompanying	O	246-258
clinical	O	259-267
phenotypes	O	268-278
.	O	278-279

While	O	280-285
only	O	286-290
5	O	291-292
%	O	292-293
of	O	294-296
sporadic	B	297-305
Wilms	I	306-311
tumours	I	312-319
have	O	320-324
intragenic	O	325-335
WT1	O	336-339
mutations	O	340-349
,	O	349-350
>	O	351-352
90	O	353-355
%	O	355-356
of	O	357-359
patients	O	360-368
with	O	369-373
the	O	374-377
Denys	B	378-383
-	I	383-384
Drash	I	384-389
syndrome	I	390-398
(	O	399-400
renal	B	400-405
nephropathy	I	406-417
,	O	417-418
gonadal	B	419-426
anomaly	I	427-434
,	O	434-435
predisposition	B	436-450
to	I	451-453
WT	I	454-456
)	O	456-457
carry	O	458-463
constitutional	O	464-478
intragenic	O	479-489
WT1	O	490-493
mutations	O	494-503
.	O	503-504

WT1	O	505-508
mutations	O	509-518
have	O	519-523
also	O	524-528
been	O	529-533
reported	O	534-542
in	O	543-545
juvenile	B	546-554
granulosa	I	555-564
cell	I	565-569
tumour	I	570-576
,	O	576-577
non	B	578-581
-	I	581-582
asbestos	I	582-590
related	I	591-598
mesothelioma	I	599-611
,	O	611-612
desmoplastic	B	613-625
small	I	626-631
round	I	632-637
cell	I	638-642
tumour	I	643-649
and	O	650-653
,	O	653-654
most	O	655-659
recently	O	660-668
,	O	668-669
acute	B	670-675
myeloid	I	676-683
leukemia	I	684-692
.	O	692-693
.	O	692-693

Dual	O	0-4
roles	O	5-10
of	O	11-13
ATM	O	14-17
in	O	18-20
the	O	21-24
cellular	O	25-33
response	O	34-42
to	O	43-45
radiation	O	46-55
and	O	56-59
in	O	60-62
cell	O	63-67
growth	O	68-74
control	O	75-82
.	O	82-83

The	O	84-87
gene	O	88-92
mutated	O	93-100
in	O	101-103
ataxia	B	104-110
-	I	110-111
telangiectasia	I	111-125
(	O	126-127
AT	B	127-129
)	O	129-130
patients	O	131-139
,	O	139-140
denoted	O	141-148
ATM	O	149-152
,	O	152-153
encodes	O	154-161
a	O	162-163
putative	O	164-172
protein	O	173-180
or	O	181-183
lipid	O	184-189
kinase	O	190-196
.	O	196-197

To	O	198-200
elucidate	O	201-210
the	O	211-214
functions	O	215-224
of	O	225-227
ATM	O	228-231
,	O	231-232
we	O	233-235
disrupted	O	236-245
the	O	246-249
mouse	O	250-255
ATM	O	256-259
gene	O	260-264
through	O	265-272
homologous	O	273-283
recombination	O	284-297
in	O	298-300
mice	O	301-305
.	O	305-306

Consistent	O	307-317
with	O	318-322
cellular	O	323-331
defects	O	332-339
of	O	340-342
AT	B	343-345
patients	O	346-354
,	O	354-355
the	O	356-359
ATM	O	360-363
-	O	363-364
/	O	364-365
-	O	363-364
cells	O	367-372
are	O	373-376
hypersensitive	O	377-391
to	O	392-394
gamma	O	395-400
-	O	400-401
irradiation	O	401-412
and	O	413-416
defective	O	417-426
in	O	427-429
cell	O	430-434
-	O	434-435
cycle	O	435-440
arrest	O	441-447
following	O	448-457
radiation	O	458-467
,	O	467-468
correlating	O	469-480
with	O	481-485
a	O	486-487
defective	O	488-497
up	O	498-500
-	O	500-501
regulation	O	501-511
of	O	512-514
p53	O	515-518
.	O	518-519

In	O	520-522
addition	O	523-531
,	O	531-532
ATM	O	533-536
-	O	536-537
/	O	537-538
-	O	536-537
mouse	O	540-545
thymocytes	O	546-556
are	O	557-560
more	O	561-565
resistant	O	566-575
to	O	576-578
apoptosis	O	579-588
induced	O	589-596
by	O	597-599
gamma	O	600-605
-	O	605-606
irradiation	O	606-617
than	O	618-622
normal	O	623-629
thymocytes	O	630-640
.	O	640-641

ATM	O	642-645
-	O	645-646
/	O	646-647
-	O	645-646
fibroblasts	O	649-660
are	O	661-664
inefficient	O	665-676
in	O	677-679
G1	O	680-682
to	O	683-685
S	O	686-687
-	O	687-688
phase	O	688-693
progression	O	694-705
following	O	706-715
serum	O	716-721
stimulation	O	722-733
and	O	734-737
senesce	O	738-745
after	O	746-751
only	O	752-756
a	O	757-758
few	O	759-762
passages	O	763-771
in	O	772-774
culture	O	775-782
.	O	782-783

They	O	784-788
have	O	789-793
an	O	794-796
increased	O	797-806
constitutive	O	807-819
level	O	820-825
of	O	826-828
p21CP1	O	829-835
/	O	835-836
WAF1	O	836-840
.	O	840-841

The	O	842-845
ATM	O	846-849
protein	O	850-857
is	O	858-860
therefore	O	861-870
critical	O	871-879
both	O	880-884
for	O	885-888
cellular	O	889-897
responses	O	898-907
to	O	908-910
ionizing	O	911-919
radiation	O	920-929
and	O	930-933
for	O	934-937
normal	O	938-944
cell	O	945-949
-	O	949-950
cycle	O	950-955
progression	O	956-967
.	O	967-968

ATM	O	969-972
+	O	973-974
/	O	974-975
-	O	975-976
fibroblasts	O	977-988
and	O	989-992
thymocytes	O	993-1003
showed	O	1004-1010
intermediately	O	1011-1025
defective	O	1026-1035
responses	O	1036-1045
to	O	1046-1048
irradiation	O	1049-1060
but	O	1061-1064
no	O	1065-1067
growth	O	1068-1074
defect	O	1075-1081
,	O	1081-1082
suggesting	O	1083-1093
that	O	1094-1098
the	O	1099-1102
increased	O	1103-1112
cancer	B	1113-1119
risk	O	1120-1124
of	O	1125-1127
AT	B	1128-1130
heterozygotes	O	1131-1144
could	O	1145-1150
be	O	1151-1153
attributable	O	1154-1166
to	O	1167-1169
poor	O	1170-1174
checkpoint	O	1175-1185
function	O	1186-1194
.	O	1194-1195
.	O	1194-1195

Identification	O	0-14
and	O	15-18
expression	O	19-29
of	O	30-32
eight	O	33-38
novel	O	39-44
mutations	O	45-54
among	O	55-60
non	O	61-64
-	O	64-65
Jewish	O	65-71
patients	O	72-80
with	O	81-85
Canavan	B	86-93
disease	I	94-101
.	O	101-102

Canavan	B	103-110
disease	I	111-118
is	O	119-121
inherited	O	122-131
as	O	132-134
an	O	135-137
autosomal	O	138-147
recessive	O	148-157
trait	O	158-163
that	O	164-168
is	O	169-171
caused	O	172-178
by	O	179-181
the	O	182-185
deficiency	B	186-196
of	I	197-199
aspartoacylase	I	200-214
(	O	215-216
ASPA	O	216-220
)	O	220-221
.	O	221-222

The	O	223-226
majority	O	227-235
of	O	236-238
patients	O	239-247
with	O	248-252
Canavan	B	253-260
disease	I	261-268
are	O	269-272
from	O	273-277
an	O	278-280
Ashkenazi	O	281-290
Jewish	O	291-297
background	O	298-308
.	O	308-309

Mutations	O	310-319
in	O	320-322
ASPA	O	323-327
that	O	328-332
lead	O	333-337
to	O	338-340
loss	O	341-345
of	O	346-348
enzymatic	O	349-358
activity	O	359-367
have	O	368-372
been	O	373-377
identified	O	378-388
,	O	388-389
and	O	390-393
E285A	O	394-399
and	O	400-403
Y231X	O	404-409
are	O	410-413
the	O	414-417
two	O	418-421
predominant	O	422-433
mutations	O	434-443
that	O	444-448
account	O	449-456
for	O	457-460
97	O	461-463
%	O	463-464
of	O	465-467
the	O	468-471
mutant	O	472-478
chromosomes	O	479-490
in	O	491-493
Ashkenazi	O	494-503
Jewish	O	504-510
patients	O	511-519
.	O	519-520

The	O	521-524
current	O	525-532
study	O	533-538
was	O	539-542
aimed	O	543-548
at	O	549-551
finding	O	552-559
the	O	560-563
molecular	O	564-573
basis	O	574-579
of	O	580-582
Canavan	B	583-590
disease	I	591-598
in	O	599-601
25	O	602-604
independent	O	605-616
patients	O	617-625
of	O	626-628
non	O	629-632
-	O	632-633
Jewish	O	633-639
background	O	640-650
.	O	650-651

Eight	O	652-657
novel	O	658-663
and	O	664-667
three	O	668-673
previously	O	674-684
characterized	O	685-698
mutations	O	699-708
accounted	O	709-718
for	O	719-722
80	O	723-725
%	O	725-726
(	O	727-728
40	O	728-730
/	O	730-731
50	O	731-733
)	O	733-734
of	O	735-737
mutant	O	738-744
chromosomes	O	745-756
.	O	756-757

The	O	758-761
A305E	O	762-767
missense	O	768-776
mutation	O	777-785
accounted	O	786-795
for	O	796-799
48	O	800-802
%	O	802-803
(	O	804-805
24	O	805-807
/	O	807-808
50	O	808-810
)	O	810-811
of	O	812-814
mutant	O	815-821
chromosomes	O	822-833
in	O	834-836
patients	O	837-845
of	O	846-848
western	O	849-856
European	O	857-865
descent	O	866-873
,	O	873-874
while	O	875-880
the	O	881-884
two	O	885-888
predominant	O	889-900
Jewish	O	901-907
mutations	O	908-917
each	O	918-922
accounted	O	923-932
for	O	933-936
a	O	937-938
single	O	939-945
mutant	O	946-952
chromosome	O	953-963
.	O	963-964

The	O	965-968
eight	O	969-974
novel	O	975-980
mutations	O	981-990
identified	O	991-1001
included	O	1002-1010
1	O	1011-1012
-	O	1012-1013
and	O	1014-1017
4	O	1018-1019
-	O	1019-1020
bp	O	1020-1022
deletions	O	1023-1032
(	O	1033-1034
32	O	1034-1036
deltaT	O	1037-1043
and	O	1044-1047
876	O	1048-1051
deltaAGAA	O	1052-1061
,	O	1061-1062
respectively	O	1063-1075
)	O	1075-1076
and	O	1077-1080
I16T	O	1081-1085
,	O	1085-1086
G27R	O	1087-1091
,	O	1091-1092
D114E	O	1093-1098
,	O	1098-1099
G123E	O	1100-1105
,	O	1105-1106
C152Y	O	1107-1112
,	O	1112-1113
and	O	1114-1117
R168C	O	1118-1123
missense	O	1124-1132
mutations	O	1133-1142
.	O	1142-1143

The	O	1144-1147
homozygous	O	1148-1158
32	O	1159-1161
deltaT	O	1162-1168
deletion	O	1169-1177
was	O	1178-1181
identified	O	1182-1192
in	O	1193-1195
the	O	1196-1199
only	O	1200-1204
known	O	1205-1210
patient	O	1211-1218
of	O	1219-1221
African	O	1222-1229
-	O	1229-1230
American	O	1230-1238
origin	O	1239-1245
with	O	1246-1250
Canavan	B	1251-1258
disease	I	1259-1266
.	O	1266-1267

The	O	1268-1271
heterozygosity	O	1272-1286
for	O	1287-1290
876	O	1291-1294
deltaAGAA	O	1295-1304
mutation	O	1305-1313
was	O	1314-1317
identified	O	1318-1328
in	O	1329-1331
three	O	1332-1337
independent	O	1338-1349
patients	O	1350-1358
from	O	1359-1363
England	O	1364-1371
.	O	1371-1372

Six	O	1373-1376
single	O	1377-1383
-	O	1383-1384
base	O	1384-1388
changes	O	1389-1396
leading	O	1397-1404
to	O	1405-1407
missense	O	1408-1416
mutations	O	1417-1426
were	O	1427-1431
identified	O	1432-1442
in	O	1443-1445
patients	O	1446-1454
from	O	1455-1459
Turkey	O	1460-1466
(	O	1467-1468
D114E	O	1468-1473
,	O	1473-1474
R168C	O	1475-1480
)	O	1480-1481
,	O	1481-1482
The	O	1483-1486
Netherlands	O	1487-1498
(	O	1499-1500
I16T	O	1500-1504
)	O	1504-1505
,	O	1505-1506
Germany	O	1507-1514
(	O	1515-1516
G27R	O	1516-1520
)	O	1520-1521
,	O	1521-1522
Ireland	O	1523-1530
(	O	1531-1532
C152Y	O	1532-1537
)	O	1537-1538
,	O	1538-1539
and	O	1540-1543
Canada	O	1544-1550
(	O	1551-1552
G123E	O	1552-1557
)	O	1557-1558
.	O	1558-1559

A	O	1560-1561
PCR	O	1562-1565
-	O	1565-1566
based	O	1566-1571
protocol	O	1572-1580
is	O	1581-1583
described	O	1584-1593
that	O	1594-1598
was	O	1599-1602
used	O	1603-1607
to	O	1608-1610
introduce	O	1611-1620
mutations	O	1621-1630
in	O	1631-1633
wild	O	1634-1638
-	O	1638-1639
type	O	1639-1643
cDNA	O	1644-1648
.	O	1648-1649

In	O	1650-1652
vitro	O	1653-1658
expression	O	1659-1669
of	O	1670-1672
mutant	O	1673-1679
cDNA	O	1680-1684
clones	O	1685-1691
demonstrated	O	1692-1704
that	O	1705-1709
all	O	1710-1713
of	O	1714-1716
these	O	1717-1722
mutations	O	1723-1732
led	O	1733-1736
to	O	1737-1739
a	O	1740-1741
deficiency	B	1742-1752
of	I	1753-1755
ASPA	I	1756-1760
and	O	1761-1764
should	O	1765-1771
therefore	O	1772-1781
result	O	1782-1788
in	O	1789-1791
Canavan	B	1792-1799
disease	I	1800-1807
.	O	1807-1808
.	O	1807-1808

BRCA1	O	0-5
mutations	O	6-15
in	O	16-18
women	O	19-24
attending	O	25-34
clinics	O	35-42
that	O	43-47
evaluate	O	48-56
the	O	57-60
risk	O	61-65
of	O	66-68
breast	B	69-75
cancer	I	76-82
.	O	82-83

BACKGROUND	O	84-94
To	O	96-98
define	O	99-105
the	O	106-109
incidence	O	110-119
of	O	120-122
BRCA1	O	123-128
mutations	O	129-138
among	O	139-144
patients	O	145-153
seen	O	154-158
in	O	159-161
clinics	O	162-169
that	O	170-174
evaluate	O	175-183
the	O	184-187
risk	O	188-192
of	O	193-195
breast	B	196-202
cancer	I	203-209
,	O	209-210
we	O	211-213
analyzed	O	214-222
DNA	O	223-226
samples	O	227-234
from	O	235-239
women	O	240-245
seen	O	246-250
in	O	251-253
this	O	254-258
setting	O	259-266
and	O	267-270
constructed	O	271-282
probability	O	283-294
tables	O	295-301
to	O	302-304
provide	O	305-312
estimates	O	313-322
of	O	323-325
the	O	326-329
likelihood	O	330-340
of	O	341-343
finding	O	344-351
a	O	352-353
BRCA1	O	354-359
mutation	O	360-368
in	O	369-371
individual	O	372-382
families	O	383-391
.	O	391-392

METHODS	O	393-400
Clinical	O	402-410
information	O	411-422
,	O	422-423
family	O	424-430
histories	O	431-440
,	O	440-441
and	O	442-445
blood	O	446-451
for	O	452-455
DNA	O	456-459
analysis	O	460-468
were	O	469-473
obtained	O	474-482
from	O	483-487
263	O	488-491
women	O	492-497
with	O	498-502
breast	B	503-509
cancer	I	510-516
.	O	516-517

Conformation	O	518-530
-	O	530-531
sensitive	O	531-540
gel	O	541-544
electrophoresis	O	545-560
and	O	561-564
DNA	O	565-568
sequencing	O	569-579
were	O	580-584
used	O	585-589
to	O	590-592
identify	O	593-601
BRCA1	O	602-607
mutations	O	608-617
.	O	617-618

RESULTS	O	619-626
BRCA1	O	628-633
mutations	O	634-643
were	O	644-648
identified	O	649-659
in	O	660-662
16	O	663-665
percent	O	666-673
of	O	674-676
women	O	677-682
with	O	683-687
a	O	688-689
family	O	690-696
history	O	697-704
of	O	705-707
breast	B	708-714
cancer	I	715-721
.	O	721-722

Only	O	723-727
7	O	728-729
percent	O	730-737
of	O	738-740
women	O	741-746
from	O	747-751
families	O	752-760
with	O	761-765
a	O	766-767
history	O	768-775
of	O	776-778
breast	B	779-785
cancer	I	786-792
but	O	793-796
not	O	797-800
ovarian	B	801-808
cancer	I	809-815
had	O	816-819
BRCA1	O	820-825
mutations	O	826-835
.	O	835-836

The	O	837-840
rates	O	841-846
were	O	847-851
higher	O	852-858
among	O	859-864
women	O	865-870
from	O	871-875
families	O	876-884
with	O	885-889
a	O	890-891
history	O	892-899
of	O	900-902
both	O	903-907
breast	B	908-914
and	I	915-918
ovarian	I	919-926
cancer	I	927-933
.	O	933-934

Among	O	935-940
family	O	941-947
members	O	948-955
,	O	955-956
an	O	957-959
average	O	960-967
age	O	968-971
of	O	972-974
less	O	975-979
than	O	980-984
55	O	985-987
years	O	988-993
at	O	994-996
the	O	997-1000
diagnosis	O	1001-1010
of	O	1011-1013
breast	B	1014-1020
cancer	I	1021-1027
,	O	1027-1028
the	O	1029-1032
presence	O	1033-1041
of	O	1042-1044
ovarian	B	1045-1052
cancer	I	1053-1059
,	O	1059-1060
the	O	1061-1064
presence	O	1065-1073
of	O	1074-1076
breast	B	1077-1083
and	I	1084-1087
ovarian	I	1088-1095
cancer	I	1096-1102
in	O	1103-1105
the	O	1106-1109
same	O	1110-1114
woman	O	1115-1120
,	O	1120-1121
and	O	1122-1125
Ashkenazi	O	1126-1135
Jewish	O	1136-1142
ancestry	O	1143-1151
were	O	1152-1156
all	O	1157-1160
associated	O	1161-1171
with	O	1172-1176
an	O	1177-1179
increased	O	1180-1189
risk	O	1190-1194
of	O	1195-1197
detecting	O	1198-1207
a	O	1208-1209
BRCA1	O	1210-1215
mutation	O	1216-1224
.	O	1224-1225

No	O	1226-1228
association	O	1229-1240
was	O	1241-1244
found	O	1245-1250
between	O	1251-1258
the	O	1259-1262
presence	O	1263-1271
of	O	1272-1274
bilateral	O	1275-1284
breast	B	1285-1291
cancer	I	1292-1298
or	O	1299-1301
the	O	1302-1305
number	O	1306-1312
of	O	1313-1315
breast	B	1316-1322
cancers	I	1323-1330
in	O	1331-1333
a	O	1334-1335
family	O	1336-1342
and	O	1343-1346
the	O	1347-1350
detection	O	1351-1360
of	O	1361-1363
a	O	1364-1365
BRCA1	O	1366-1371
mutation	O	1372-1380
,	O	1380-1381
or	O	1382-1384
between	O	1385-1392
the	O	1393-1396
position	O	1397-1405
of	O	1406-1408
the	O	1409-1412
mutation	O	1413-1421
in	O	1422-1424
the	O	1425-1428
BRCA1	O	1429-1434
gene	O	1435-1439
and	O	1440-1443
the	O	1444-1447
presence	O	1448-1456
of	O	1457-1459
ovarian	B	1460-1467
cancer	I	1468-1474
in	O	1475-1477
a	O	1478-1479
family	O	1480-1486
.	O	1486-1487

CONCLUSIONS	O	1488-1499
Among	O	1501-1506
women	O	1507-1512
with	O	1513-1517
breast	B	1518-1524
cancer	I	1525-1531
and	O	1532-1535
a	O	1536-1537
family	O	1538-1544
history	O	1545-1552
of	O	1553-1555
the	O	1556-1559
disease	O	1560-1567
,	O	1567-1568
the	O	1569-1572
percentage	O	1573-1583
with	O	1584-1588
BRCA1	O	1589-1594
coding	O	1595-1601
-	O	1601-1602
region	O	1602-1608
mutations	O	1609-1618
is	O	1619-1621
less	O	1622-1626
than	O	1627-1631
the	O	1632-1635
45	O	1636-1638
percent	O	1639-1646
predicted	O	1647-1656
by	O	1657-1659
genetic	O	1660-1667
-	O	1667-1668
linkage	O	1668-1675
analysis	O	1676-1684
.	O	1684-1685

These	O	1686-1691
results	O	1692-1699
suggest	O	1700-1707
that	O	1708-1712
even	O	1713-1717
in	O	1718-1720
a	O	1721-1722
referral	O	1723-1731
clinic	O	1732-1738
specializing	O	1739-1751
in	O	1752-1754
screening	O	1755-1764
women	O	1765-1770
from	O	1771-1775
high	O	1776-1780
-	O	1780-1781
risk	O	1781-1785
families	O	1786-1794
,	O	1794-1795
the	O	1796-1799
majority	O	1800-1808
of	O	1809-1811
tests	O	1812-1817
for	O	1818-1821
BRCA1	O	1822-1827
mutations	O	1828-1837
will	O	1838-1842
be	O	1843-1845
negative	O	1846-1854
and	O	1855-1858
therefore	O	1859-1868
uninformative	O	1869-1882
.	O	1882-1883
.	O	1882-1883

The	O	0-3
von	B	4-7
Hippel	I	8-14
-	I	14-15
Lindau	I	15-21
tumor	I	22-27
suppressor	O	28-38
gene	O	39-43
product	O	44-51
interacts	O	52-61
with	O	62-66
Sp1	O	67-70
to	O	71-73
repress	O	74-81
vascular	O	82-90
endothelial	O	91-102
growth	O	103-109
factor	O	110-116
promoter	O	117-125
activity	O	126-134
.	O	134-135

The	O	136-139
von	B	140-143
Hippel	I	144-150
-	I	150-151
Lindau	I	151-157
tumor	I	158-163
suppressor	O	164-174
gene	O	175-179
(	O	180-181
VHL	O	181-184
)	O	184-185
has	O	186-189
a	O	190-191
critical	O	192-200
role	O	201-205
in	O	206-208
the	O	209-212
pathogenesis	O	213-225
of	O	226-228
clear	B	229-234
-	I	234-235
cell	I	235-239
renal	I	240-245
cell	I	246-250
carcinoma	I	251-260
(	O	261-262
RCC	B	262-265
)	O	265-266
,	O	266-267
as	O	268-270
VHL	O	271-274
mutations	O	275-284
have	O	285-289
been	O	290-294
found	O	295-300
in	O	301-303
both	O	304-308
von	B	309-312
Hippel	I	313-319
-	I	319-320
Lindau	I	320-326
disease	I	327-334
-	I	334-335
associated	I	335-345
and	I	346-349
sporadic	I	350-358
RCCs	I	359-363
.	O	363-364

Recent	O	365-371
studies	O	372-379
suggest	O	380-387
that	O	388-392
vascular	O	393-401
endothelial	O	402-413
growth	O	414-420
factor	O	421-427
(	O	428-429
VEGF	O	429-433
)	O	433-434
mRNA	O	435-439
is	O	440-442
upregulated	O	443-454
in	O	455-457
RCC	B	458-461
-	I	461-462
and	I	463-466
von	I	467-470
Hippel	I	471-477
-	I	477-478
Lindau	I	478-484
disease	I	485-492
-	I	492-493
associated	I	493-503
tumors	I	504-510
.	O	510-511

We	O	512-514
have	O	515-519
therefore	O	520-529
assessed	O	530-538
the	O	539-542
effect	O	543-549
of	O	550-552
the	O	553-556
VHL	O	557-560
gene	O	561-565
product	O	566-573
on	O	574-576
VEGF	O	577-581
expression	O	582-592
.	O	592-593

VEGF	O	594-598
promoter	O	599-607
-	O	607-608
luciferase	O	608-618
constructs	O	619-629
were	O	630-634
transiently	O	635-646
cotransfected	O	647-660
with	O	661-665
a	O	666-667
wild	O	668-672
-	O	672-673
type	O	673-677
VHL	O	678-681
(	O	682-683
wt	O	683-685
-	O	685-686
VHL	O	686-689
)	O	689-690
vector	O	691-697
in	O	698-700
several	O	701-708
cell	O	709-713
lines	O	714-719
,	O	719-720
including	O	721-730
293	O	731-734
embryonic	O	735-744
kidney	O	745-751
and	O	752-755
RCC	B	756-759
cell	O	760-764
lines	O	765-770
.	O	770-771

wt	O	772-774
-	O	774-775
VHL	O	775-778
protein	O	779-786
inhibited	O	787-796
VEGF	O	797-801
promoter	O	802-810
activity	O	811-819
in	O	820-822
a	O	823-824
dose	O	825-829
-	O	829-830
dependent	O	830-839
manner	O	840-846
up	O	847-849
to	O	850-852
5	O	853-854
-	O	854-855
to	O	856-858
10	O	859-861
-	O	861-862
fold	O	862-866
.	O	866-867

Deletion	O	868-876
analysis	O	877-885
defined	O	886-893
a	O	894-895
144	O	896-899
-	O	899-900
bp	O	900-902
region	O	903-909
of	O	910-912
the	O	913-916
VEGF	O	917-921
promoter	O	922-930
necessary	O	931-940
for	O	941-944
VHL	O	945-948
repression	O	949-959
.	O	959-960

This	O	961-965
VHL	O	966-969
-	O	969-970
responsive	O	970-980
element	O	981-988
is	O	989-991
GC	O	992-994
rich	O	995-999
and	O	1000-1003
specifically	O	1004-1016
binds	O	1017-1022
the	O	1023-1026
transcription	O	1027-1040
factor	O	1041-1047
Sp1	O	1048-1051
in	O	1052-1054
crude	O	1055-1060
nuclear	O	1061-1068
extracts	O	1069-1077
.	O	1077-1078

In	O	1079-1081
Drosophila	O	1082-1092
cells	O	1093-1098
,	O	1098-1099
cotransfected	O	1100-1113
VHL	O	1114-1117
represses	O	1118-1127
Sp1	O	1128-1131
-	O	1131-1132
mediated	O	1132-1140
activation	O	1141-1151
but	O	1152-1155
not	O	1156-1159
basal	O	1160-1165
activity	O	1166-1174
of	O	1175-1177
the	O	1178-1181
VEGF	O	1182-1186
promoter	O	1187-1195
.	O	1195-1196

We	O	1197-1199
next	O	1200-1204
demonstrated	O	1205-1217
in	O	1218-1220
coimmunoprecipitates	O	1221-1241
that	O	1242-1246
VHL	O	1247-1250
and	O	1251-1254
Sp1	O	1255-1258
were	O	1259-1263
part	O	1264-1268
of	O	1269-1271
the	O	1272-1275
same	O	1276-1280
complex	O	1281-1288
and	O	1289-1292
,	O	1292-1293
by	O	1294-1296
using	O	1297-1302
a	O	1303-1304
glutathione	O	1305-1316
-	O	1316-1317
S	O	1317-1318
-	O	1316-1317
transferase	O	1319-1330
-	O	1316-1317
VHL	O	1331-1334
fusion	O	1335-1341
protein	O	1342-1349
and	O	1350-1353
purified	O	1354-1362
Sp1	O	1363-1366
,	O	1366-1367
that	O	1368-1372
VHL	O	1373-1376
and	O	1377-1380
Sp1	O	1381-1384
directly	O	1385-1393
interact	O	1394-1402
.	O	1402-1403

Furthermore	O	1404-1415
,	O	1415-1416
endogenous	O	1417-1427
VEGF	O	1428-1432
mRNA	O	1433-1437
levels	O	1438-1444
were	O	1445-1449
suppressed	O	1450-1460
in	O	1461-1463
permanent	O	1464-1473
RCC	B	1474-1477
cell	O	1478-1482
lines	O	1483-1488
expressing	O	1489-1499
wt	O	1500-1502
-	O	1502-1503
VHL	O	1503-1506
,	O	1506-1507
and	O	1508-1511
nuclear	O	1512-1519
run	O	1520-1523
-	O	1523-1524
on	O	1524-1526
studies	O	1527-1534
indicated	O	1535-1544
that	O	1545-1549
VHL	O	1550-1553
regulation	O	1554-1564
of	O	1565-1567
VEGF	O	1568-1572
occurs	O	1573-1579
at	O	1580-1582
least	O	1583-1588
partly	O	1589-1595
at	O	1596-1598
the	O	1599-1602
transcriptional	O	1603-1618
level	O	1619-1624
.	O	1624-1625

These	O	1626-1631
observations	O	1632-1644
support	O	1645-1652
a	O	1653-1654
new	O	1655-1658
mechanism	O	1659-1668
for	O	1669-1672
VHL	O	1673-1676
-	O	1676-1677
mediated	O	1677-1685
transcriptional	O	1686-1701
repression	O	1702-1712
via	O	1713-1716
a	O	1717-1718
direct	O	1719-1725
inhibitory	O	1726-1736
action	O	1737-1743
on	O	1744-1746
Sp1	O	1747-1750
and	O	1751-1754
suggest	O	1755-1762
that	O	1763-1767
loss	O	1768-1772
of	O	1773-1775
Sp1	O	1776-1779
inhibition	O	1780-1790
may	O	1791-1794
be	O	1795-1797
important	O	1798-1807
in	O	1808-1810
the	O	1811-1814
pathogenesis	O	1815-1827
of	O	1828-1830
von	B	1831-1834
Hippel	I	1835-1841
-	I	1841-1842
Lindau	I	1842-1848
disease	I	1849-1856
and	O	1857-1860
RCC	B	1861-1864
.	O	1864-1865
.	O	1864-1865

Germline	O	0-8
mutations	O	9-18
in	O	19-21
the	O	22-25
RB1	O	26-29
gene	O	30-34
in	O	35-37
patients	O	38-46
with	O	47-51
hereditary	B	52-62
retinoblastoma	I	63-77
.	O	77-78

We	O	79-81
have	O	82-86
analyzed	O	87-95
the	O	96-99
27	O	100-102
exons	O	103-108
and	O	109-112
the	O	113-116
promoter	O	117-125
region	O	126-132
of	O	133-135
the	O	136-139
RB1	O	140-143
gene	O	144-148
in	O	149-151
familial	B	152-160
or	I	161-163
sporadic	I	164-172
bilateral	I	173-182
retinoblastoma	I	183-197
by	O	198-200
using	O	201-206
single	O	207-213
-	O	213-214
strand	O	214-220
conformation	O	221-233
polymorphism	O	234-246
analysis	O	247-255
.	O	255-256

For	O	257-260
improvement	O	261-272
over	O	273-277
previous	O	278-286
studies	O	287-294
,	O	294-295
a	O	296-297
new	O	298-301
set	O	302-305
of	O	306-308
primers	O	309-316
has	O	317-320
been	O	321-325
designed	O	326-334
,	O	334-335
which	O	336-341
allow	O	342-347
for	O	348-351
amplification	O	352-365
of	O	366-368
the	O	369-372
coding	O	373-379
and	O	380-383
splicing	O	384-392
sequences	O	393-402
only	O	403-407
.	O	407-408

The	O	409-412
positioning	O	413-424
of	O	425-427
the	O	428-431
polymerase	O	432-442
chain	O	443-448
reaction	O	449-457
(	O	458-459
PCR	O	459-462
)	O	462-463
primers	O	464-471
was	O	472-475
such	O	476-480
that	O	481-485
the	O	486-489
resulting	O	490-499
PCR	O	500-503
products	O	504-512
were	O	513-517
of	O	518-520
different	O	521-530
sizes	O	531-536
,	O	536-537
which	O	538-543
enabled	O	544-551
us	O	552-554
to	O	555-557
analyze	O	558-565
two	O	566-569
different	O	570-579
exons	O	580-585
simultaneously	O	586-600
and	O	601-604
still	O	605-610
distinguish	O	611-622
between	O	623-630
the	O	631-634
banding	O	635-642
profiles	O	643-651
for	O	652-655
both	O	656-660
(	O	661-662
biplex	O	662-668
analysis	O	669-677
)	O	677-678
.	O	678-679

By	O	680-682
using	O	683-688
this	O	689-693
approach	O	694-702
,	O	702-703
we	O	704-706
were	O	707-711
able	O	712-716
to	O	717-719
identify	O	720-728
mutation	O	729-737
in	O	738-740
22	O	741-743
new	O	744-747
patients	O	748-756
,	O	756-757
but	O	758-761
the	O	762-765
overall	O	766-773
efficiency	O	774-784
of	O	785-787
the	O	788-791
procedure	O	792-801
when	O	802-806
we	O	807-809
used	O	810-814
a	O	815-816
single	O	817-823
-	O	823-824
pass	O	824-828
regimen	O	829-836
was	O	837-840
only	O	841-845
48	O	846-848
%	O	848-849
.	O	849-850

The	O	851-854
mutations	O	855-864
were	O	865-869
small	O	870-875
insertions	O	876-886
and	O	887-890
deletions	O	891-900
and	O	901-904
point	O	905-910
mutations	O	911-920
in	O	921-923
roughly	O	924-931
equal	O	932-937
proportions	O	938-949
.	O	949-950
.	O	949-950

Deletion	O	0-8
of	O	9-11
small	O	12-17
nuclear	O	18-25
ribonucleoprotein	O	26-43
polypeptide	O	44-55
N	O	56-57
(	O	58-59
SNRPN	O	59-64
)	O	64-65
in	O	66-68
Prader	B	69-75
-	I	75-76
Willi	I	76-81
syndrome	I	82-90
detected	O	91-99
by	O	100-102
fluorescence	O	103-115
in	O	116-118
situ	O	119-123
hybridization	O	124-137
:	O	137-138
two	O	139-142
sibs	O	143-147
with	O	148-152
the	O	153-156
typical	O	157-164
phenotype	O	165-174
without	O	175-182
a	O	183-184
cytogenetic	O	185-196
deletion	O	197-205
in	O	206-208
chromosome	O	209-219
15q	O	220-223
.	O	223-224

The	O	225-228
small	O	229-234
nuclear	O	235-242
ribonucleoprotein	O	243-260
polypeptide	O	261-272
N	O	273-274
(	O	275-276
SNRPN	O	276-281
)	O	281-282
gene	O	283-287
is	O	288-290
regarded	O	291-299
as	O	300-302
one	O	303-306
of	O	307-309
the	O	310-313
candidates	O	314-324
for	O	325-328
Prader	B	329-335
-	I	335-336
Willi	I	336-341
syndrome	I	342-350
(	O	351-352
PWS	B	352-355
)	O	355-356
.	O	356-357

We	O	358-360
describe	O	361-369
two	O	370-373
sibs	O	374-378
with	O	379-383
typical	O	384-391
PWS	B	392-395
presenting	O	396-406
deletion	O	407-415
of	O	416-418
SNRPN	O	419-424
detected	O	425-433
by	O	434-436
fluorescence	O	437-449
in	O	450-452
situ	O	453-457
hybridization	O	458-471
(	O	472-473
FISH	O	473-477
)	O	477-478
.	O	478-479

Neither	O	480-487
a	O	488-489
cytogenetically	O	490-505
detectable	O	506-516
15q12	O	517-522
deletion	O	523-531
nor	O	532-535
a	O	536-537
deletion	O	538-546
for	O	547-550
the	O	551-554
D15S11	O	555-561
,	O	561-562
D15S10	O	563-569
,	O	569-570
and	O	571-574
GABRB3	O	575-581
cosmid	O	582-588
probes	O	589-595
were	O	596-600
found	O	601-606
in	O	607-609
either	O	610-616
patient	O	617-624
.	O	624-625

This	O	626-630
implies	O	631-638
a	O	639-640
smaller	O	641-648
deletion	O	649-657
limited	O	658-665
to	O	666-668
the	O	669-672
PWS	B	673-676
critical	O	677-685
region	O	686-692
.	O	692-693

FISH	O	694-698
with	O	699-703
a	O	704-705
SNRPN	O	706-711
probe	O	712-717
will	O	718-722
permit	O	723-729
analysis	O	730-738
of	O	739-741
PWS	B	742-745
patients	O	746-754
with	O	755-759
limited	O	760-767
deletions	O	768-777
not	O	778-781
detectable	O	782-792
with	O	793-797
other	O	798-803
probes	O	804-810
.	O	810-811
.	O	810-811

The	O	0-3
mouse	O	4-9
homolog	O	10-17
of	O	18-20
the	O	21-24
Wiskott	B	25-32
-	I	32-33
Aldrich	I	33-40
syndrome	I	41-49
protein	O	50-57
(	O	58-59
WASP	O	59-63
)	O	63-64
gene	O	65-69
is	O	70-72
highly	O	73-79
conserved	O	80-89
and	O	90-93
maps	O	94-98
near	O	99-103
the	O	104-107
scurfy	O	108-114
(	O	115-116
sf	O	116-118
)	O	118-119
mutation	O	120-128
on	O	129-131
the	O	132-135
X	O	136-137
chromosome	O	138-148
.	O	148-149

The	O	150-153
mouse	O	154-159
WASP	O	160-164
gene	O	165-169
,	O	169-170
the	O	171-174
homolog	O	175-182
of	O	183-185
the	O	186-189
gene	O	190-194
mutated	O	195-202
in	O	203-205
Wiskott	B	206-213
-	I	213-214
Aldrich	I	214-221
syndrome	I	222-230
,	O	230-231
has	O	232-235
been	O	236-240
isolated	O	241-249
and	O	250-253
sequenced	O	254-263
.	O	263-264

the	O	265-268
predicted	O	269-278
amino	O	279-284
acid	O	285-289
sequence	O	290-298
is	O	299-301
86	O	302-304
%	O	304-305
identical	O	306-315
to	O	316-318
the	O	319-322
human	O	323-328
WASP	O	329-333
sequence	O	334-342
.	O	342-343

A	O	344-345
distinct	O	346-354
feature	O	355-362
of	O	363-365
the	O	366-369
mouse	O	370-375
gene	O	376-380
is	O	381-383
an	O	384-386
expanded	O	387-395
polymorphic	O	396-407
GGA	O	408-411
trinucleotide	O	412-425
repeat	O	426-432
that	O	433-437
codes	O	438-443
for	O	444-447
polyglycine	O	448-459
and	O	460-463
varies	O	464-470
from	O	471-475
15	O	476-478
to	O	479-481
17	O	482-484
triplets	O	485-493
in	O	494-496
different	O	497-506
Mus	O	507-510
musculus	O	511-519
strains	O	520-527
.	O	527-528

The	O	529-532
genomic	O	533-540
structure	O	541-550
of	O	551-553
the	O	554-557
mouse	O	558-563
WASP	O	564-568
gene	O	569-573
is	O	574-576
expressed	O	577-586
as	O	587-589
an	O	590-592
approximately	O	593-606
2	O	607-608
.	O	608-609
4	O	610-611
-	O	611-612
kb	O	612-614
mRNA	O	615-619
in	O	620-622
thymus	O	623-629
and	O	630-633
spleen	O	634-640
.	O	640-641

Chromosomal	O	642-653
mapping	O	654-661
in	O	662-664
an	O	665-667
interspecific	O	668-681
M	O	682-683
.	O	683-684
Musculus	O	685-693
/	O	693-694
M	O	685-686
.	O	695-696

spretus	O	697-704
backcross	O	705-714
placed	O	715-721
the	O	722-725
Wasp	O	726-730
locus	O	731-736
near	O	737-741
the	O	742-745
centromere	O	746-756
of	O	757-759
the	O	760-763
mouse	O	764-769
X	O	770-771
chromosome	O	772-782
,	O	782-783
inseparable	O	784-795
from	O	796-800
Gata1	O	801-806
,	O	806-807
Tcfe3	O	808-813
,	O	813-814
and	O	815-818
scurfy	O	819-825
(	O	826-827
sf	O	827-829
)	O	829-830
.	O	830-831

This	O	832-836
localization	O	837-849
makes	O	850-855
Wasp	O	856-860
a	O	861-862
candidate	O	863-872
for	O	873-876
involvement	O	877-888
in	O	889-891
scurfy	O	892-898
,	O	898-899
a	O	900-901
T	O	902-903
cell	O	904-908
-	O	908-909
mediated	O	909-917
fatal	B	918-923
lymphoreticular	I	924-939
disease	I	940-947
of	O	948-950
mice	O	951-955
that	O	956-960
has	O	961-964
previously	O	965-975
been	O	976-980
proposed	O	981-989
as	O	990-992
a	O	993-994
mouse	O	995-1000
homolog	O	1001-1008
of	O	1009-1011
Wiskott	B	1012-1019
-	I	1019-1020
Aldrich	I	1020-1027
syndrome	I	1028-1036
.	O	1036-1037

Northern	O	1038-1046
analysis	O	1047-1055
of	O	1056-1058
sf	O	1059-1061
tissue	O	1062-1068
samples	O	1069-1076
indicated	O	1077-1086
the	O	1087-1090
presence	O	1091-1099
of	O	1100-1102
WASP	O	1103-1107
mRNA	O	1108-1112
in	O	1113-1115
liver	O	1116-1121
and	O	1122-1125
skin	O	1126-1130
,	O	1130-1131
presumably	O	1132-1142
as	O	1143-1145
a	O	1146-1147
consequence	O	1148-1159
of	O	1160-1162
lymphocytic	O	1163-1174
infiltration	O	1175-1187
,	O	1187-1188
but	O	1189-1192
non	O	1193-1196
abnormalities	O	1197-1210
in	O	1211-1213
the	O	1214-1217
amount	O	1218-1224
or	O	1225-1227
size	O	1228-1232
of	O	1233-1235
mRNA	O	1236-1240
present	O	1241-1248
.	O	1248-1249

An	O	0-2
animal	O	3-9
model	O	10-15
for	O	16-19
Norrie	B	20-26
disease	I	27-34
(	O	35-36
ND	B	36-38
)	O	38-39
:	O	39-40
gene	O	41-45
targeting	O	46-55
of	O	56-58
the	O	59-62
mouse	O	63-68
ND	B	69-71
gene	O	72-76
.	O	76-77

In	O	78-80
order	O	81-86
to	O	87-89
elucidate	O	90-99
the	O	100-103
cellular	O	104-112
and	O	113-116
molecular	O	117-126
processes	O	127-136
which	O	137-142
are	O	143-146
involved	O	147-155
in	O	156-158
Norrie	B	159-165
disease	I	166-173
(	O	174-175
ND	B	175-177
)	O	177-178
,	O	178-179
we	O	180-182
have	O	183-187
used	O	188-192
gene	O	193-197
targeting	O	198-207
technology	O	208-218
to	O	219-221
generate	O	222-230
ND	B	231-233
mutant	O	234-240
mice	O	241-245
.	O	245-246

The	O	247-250
murine	O	251-257
homologue	O	258-267
of	O	268-270
the	O	271-274
ND	B	275-277
gene	O	278-282
was	O	283-286
cloned	O	287-293
and	O	294-297
shown	O	298-303
to	O	304-306
encode	O	307-313
a	O	314-315
polypeptide	O	316-327
that	O	328-332
shares	O	333-339
94	O	340-342
%	O	342-343
of	O	344-346
the	O	347-350
amino	O	351-356
acid	O	357-361
sequence	O	362-370
with	O	371-375
its	O	376-379
human	O	380-385
counterpart	O	386-397
.	O	397-398

RNA	O	399-402
in	O	403-405
situ	O	406-410
hybridization	O	411-424
revealed	O	425-433
expression	O	434-444
in	O	445-447
retina	O	448-454
,	O	454-455
brain	O	456-461
and	O	462-465
the	O	466-469
olfactory	O	470-479
bulb	O	480-484
and	O	485-488
epithelium	O	489-499
of	O	500-502
2	O	503-504
week	O	505-509
old	O	510-513
mice	O	514-518
.	O	518-519

Hemizygous	O	520-530
mice	O	531-535
carrying	O	536-544
a	O	545-546
replacement	O	547-558
mutation	O	559-567
in	O	568-570
exon	O	571-575
2	O	576-577
of	O	578-580
the	O	581-584
ND	B	585-587
gene	O	588-592
developed	O	593-602
retrolental	O	603-614
structures	O	615-625
in	O	626-628
the	O	629-632
vitreous	O	633-641
body	O	642-646
and	O	647-650
showed	O	651-657
an	O	658-660
overall	O	661-668
disorganization	O	669-684
of	O	685-687
the	O	688-691
retinal	O	692-699
ganglion	O	700-708
cell	O	709-713
layer	O	714-719
.	O	719-720

The	O	721-724
outer	O	725-730
plexiform	O	731-740
layer	O	741-746
disappears	O	747-757
occasionally	O	758-770
,	O	770-771
resulting	O	772-781
in	O	782-784
a	O	785-786
juxtaposed	O	787-797
inner	O	798-803
and	O	804-807
outer	O	808-813
nuclear	O	814-821
layer	O	822-827
.	O	827-828

At	O	829-831
the	O	832-835
same	O	836-840
regions	O	841-848
,	O	848-849
the	O	850-853
outer	O	854-859
segments	O	860-868
of	O	869-871
the	O	872-875
photoreceptor	O	876-889
cell	O	890-894
layer	O	895-900
are	O	901-904
no	O	905-907
longer	O	908-914
present	O	915-922
.	O	922-923

These	O	924-929
ocular	O	930-936
findings	O	937-945
are	O	946-949
consistent	O	950-960
with	O	961-965
observations	O	966-978
in	O	979-981
ND	B	982-984
patients	O	985-993
and	O	994-997
the	O	998-1001
generated	O	1002-1011
mouse	O	1012-1017
line	O	1018-1022
provides	O	1023-1031
a	O	1032-1033
faithful	O	1034-1042
model	O	1043-1048
for	O	1049-1052
study	O	1053-1058
of	O	1059-1061
early	O	1062-1067
pathogenic	O	1068-1078
events	O	1079-1085
in	O	1086-1088
this	O	1089-1093
severe	O	1094-1100
X	B	1101-1102
-	I	1102-1103
linked	I	1103-1109
recessive	I	1110-1119
neurological	I	1120-1132
disorder	I	1133-1141
.	O	1141-1142
.	O	1141-1142

Phenotypic	O	0-10
characterization	O	11-27
of	O	28-30
individuals	O	31-42
with	O	43-47
30	O	48-50
-	O	50-51
40	O	51-53
CAG	O	54-57
repeats	O	58-65
in	O	66-68
the	O	69-72
Huntington	B	73-83
disease	I	84-91
(	O	92-93
HD	B	93-95
)	O	95-96
gene	O	97-101
reveals	O	102-109
HD	B	110-112
cases	O	113-118
with	O	119-123
36	O	124-126
repeats	O	127-134
and	O	135-138
apparently	O	139-149
normal	O	150-156
elderly	O	157-164
individuals	O	165-176
with	O	177-181
36	O	182-184
-	O	184-185
39	O	185-187
repeats	O	188-195
.	O	195-196

Abnormal	O	197-205
CAG	O	206-209
expansions	O	210-220
in	O	221-223
the	O	224-227
IT	O	228-230
-	O	230-231
15	O	231-233
gene	O	234-238
are	O	239-242
associated	O	243-253
with	O	254-258
Huntington	B	259-269
disease	I	270-277
(	O	278-279
HD	B	279-281
)	O	281-282
.	O	282-283

In	O	284-286
the	O	287-290
diagnostic	O	291-301
setting	O	302-309
it	O	310-312
is	O	313-315
necessary	O	316-325
to	O	326-328
define	O	329-335
the	O	336-339
limits	O	340-346
of	O	347-349
the	O	350-353
CAG	O	354-357
size	O	358-362
ranges	O	363-369
on	O	370-372
normal	O	373-379
and	O	380-383
HD	B	384-386
-	O	386-387
associated	O	387-397
chromosomes	O	398-409
.	O	409-410

Most	O	411-415
large	O	416-421
analyses	O	422-430
that	O	431-435
defined	O	436-443
the	O	444-447
limits	O	448-454
of	O	455-457
the	O	458-461
normal	O	462-468
and	O	469-472
pathological	O	473-485
size	O	486-490
ranges	O	491-497
employed	O	498-506
PCR	O	507-510
assays	O	511-517
,	O	517-518
which	O	519-524
included	O	525-533
the	O	534-537
CAG	O	538-541
repeats	O	542-549
and	O	550-553
a	O	554-555
CCG	O	556-559
repeat	O	560-566
tract	O	567-572
that	O	573-577
was	O	578-581
thought	O	582-589
to	O	590-592
be	O	593-595
invariant	O	596-605
.	O	605-606

Many	O	607-611
of	O	612-614
these	O	615-620
experiments	O	621-632
found	O	633-638
an	O	639-641
overlap	O	642-649
between	O	650-657
the	O	658-661
normal	O	662-668
and	O	669-672
disease	O	673-680
size	O	681-685
ranges	O	686-692
.	O	692-693

Subsequent	O	694-704
findings	O	705-713
that	O	714-718
the	O	719-722
CCG	O	723-726
repeats	O	727-734
vary	O	735-739
by	O	740-742
8	O	743-744
trinucleotide	O	745-758
lengths	O	759-766
suggested	O	767-776
that	O	777-781
the	O	782-785
limits	O	786-792
of	O	793-795
the	O	796-799
normal	O	800-806
and	O	807-810
disease	O	811-818
size	O	819-823
ranges	O	824-830
should	O	831-837
be	O	838-840
reevaluated	O	841-852
with	O	853-857
assays	O	858-864
that	O	865-869
exclude	O	870-877
the	O	878-881
CCG	O	882-885
polymorphism	O	886-898
.	O	898-899

Since	O	900-905
patients	O	906-914
with	O	915-919
between	O	920-927
30	O	928-930
and	O	931-934
40	O	935-937
repeats	O	938-945
are	O	946-949
rare	O	950-954
,	O	954-955
a	O	956-957
consortium	O	958-968
was	O	969-972
assembled	O	973-982
to	O	983-985
collect	O	986-993
such	O	994-998
individuals	O	999-1010
.	O	1010-1011

All	O	1012-1015
178	O	1016-1019
samples	O	1020-1027
were	O	1028-1032
reanalyzed	O	1033-1043
in	O	1044-1046
Cambridge	O	1047-1056
by	O	1057-1059
using	O	1060-1065
assays	O	1066-1072
specific	O	1073-1081
for	O	1082-1085
the	O	1086-1089
CAG	O	1090-1093
repeats	O	1094-1101
.	O	1101-1102

We	O	1103-1105
have	O	1106-1110
optimized	O	1111-1120
methods	O	1121-1128
for	O	1129-1132
reliable	O	1133-1141
sizing	O	1142-1148
of	O	1149-1151
CAG	O	1152-1155
repeats	O	1156-1163
and	O	1164-1167
show	O	1168-1172
cases	O	1173-1178
that	O	1179-1183
demonstrate	O	1184-1195
the	O	1196-1199
dangers	O	1200-1207
of	O	1208-1210
using	O	1211-1216
PCR	O	1217-1220
assays	O	1221-1227
that	O	1228-1232
include	O	1233-1240
both	O	1241-1245
the	O	1246-1249
CAG	O	1250-1253
and	O	1254-1257
CCG	O	1258-1261
polymorphisms	O	1262-1275
.	O	1275-1276

Seven	O	1277-1282
HD	B	1283-1285
patients	O	1286-1294
had	O	1295-1298
36	O	1299-1301
repeats	O	1302-1309
,	O	1309-1310
which	O	1311-1316
confirms	O	1317-1325
that	O	1326-1330
this	O	1331-1335
allele	O	1336-1342
is	O	1343-1345
associated	O	1346-1356
with	O	1357-1361
disease	O	1362-1369
.	O	1369-1370

Individuals	O	1371-1382
without	O	1383-1390
apparent	O	1391-1399
symptoms	O	1400-1408
or	O	1409-1411
signs	O	1412-1417
of	O	1418-1420
HD	B	1421-1423
were	O	1424-1428
found	O	1429-1434
at	O	1435-1437
36	O	1438-1440
repeats	O	1441-1448
(	O	1449-1450
aged	O	1450-1454
74	O	1455-1457
,	O	1457-1458
78	O	1459-1461
,	O	1461-1462
79	O	1463-1465
,	O	1465-1466
and	O	1467-1470
87	O	1471-1473
years	O	1474-1479
)	O	1479-1480
,	O	1480-1481
37	O	1482-1484
repeats	O	1485-1492
(	O	1493-1494
aged	O	1494-1498
69	O	1499-1501
years	O	1502-1507
)	O	1507-1508
,	O	1508-1509
38	O	1510-1512
repeats	O	1513-1520
(	O	1521-1522
aged	O	1522-1526
69	O	1527-1529
and	O	1530-1533
90	O	1534-1536
years	O	1537-1542
)	O	1542-1543
,	O	1543-1544
and	O	1545-1548
39	O	1549-1551
repeats	O	1552-1559
(	O	1560-1561
aged	O	1561-1565
67	O	1566-1568
,	O	1568-1569
90	O	1570-1572
,	O	1572-1573
and	O	1574-1577
95	O	1578-1580
years	O	1581-1586
)	O	1586-1587
.	O	1587-1588

The	O	1589-1592
detailed	O	1593-1601
case	O	1602-1606
histories	O	1607-1616
of	O	1617-1619
an	O	1620-1622
exceptional	O	1623-1634
case	O	1635-1639
from	O	1640-1644
this	O	1645-1649
series	O	1650-1656
will	O	1657-1661
be	O	1662-1664
presented	O	1665-1674
a	O	1676-1677
95	O	1678-1680
-	O	1680-1681
year	O	1681-1685
-	O	1680-1681
old	O	1686-1689
man	O	1690-1693
with	O	1694-1698
39	O	1699-1701
repeats	O	1702-1709
who	O	1710-1713
did	O	1714-1717
not	O	1718-1721
have	O	1722-1726
classical	O	1727-1736
features	O	1737-1745
of	O	1746-1748
HD	B	1749-1751
.	O	1751-1752

The	O	1753-1756
apparently	O	1757-1767
healthy	O	1768-1775
survival	O	1776-1784
into	O	1785-1789
old	O	1790-1793
age	O	1794-1797
of	O	1798-1800
some	O	1801-1805
individuals	O	1806-1817
with	O	1818-1822
36	O	1823-1825
-	O	1825-1826
39	O	1826-1828
repeats	O	1829-1836
suggests	O	1837-1845
that	O	1846-1850
the	O	1851-1854
HD	B	1855-1857
mutation	O	1858-1866
may	O	1867-1870
not	O	1871-1874
always	O	1875-1881
be	O	1882-1884
fully	O	1885-1890
penetrant	O	1891-1900
.	O	1900-1901
.	O	1900-1901

HPRT	B	0-4
-	I	4-5
APRT	I	5-9
-	I	4-5
deficient	I	10-19
mice	O	20-24
are	O	25-28
not	O	29-32
a	O	33-34
model	O	35-40
for	O	41-44
lesch	B	45-50
-	I	50-51
nyhan	I	51-56
syndrome	I	57-65
.	O	65-66

Complete	B	67-75
hypoxanthine	I	76-88
-	I	88-89
guanine	I	89-96
phosphoribosyl	I	97-111
-	I	111-112
transferase	I	112-123
(	I	124-125
HPRT	I	125-129
)	I	129-130
deficiency	I	131-141
in	O	142-144
humans	O	145-151
results	O	152-159
in	O	160-162
the	O	163-166
Lesch	B	167-172
-	I	172-173
Nyhan	I	173-178
syndrome	I	179-187
which	O	188-193
is	O	194-196
characterized	O	197-210
,	O	210-211
among	O	212-217
other	O	218-223
features	O	224-232
,	O	232-233
by	O	234-236
compulsive	O	237-247
self	O	248-252
-	O	252-253
injurious	O	253-262
behavior	O	263-271
.	O	271-272

HPRT	B	273-277
-	I	277-278
deficient	I	278-287
mice	O	288-292
generated	O	293-302
using	O	303-308
mouse	O	309-314
embryonic	O	315-324
stem	O	325-329
cells	O	330-335
exhibit	O	336-343
none	O	344-348
of	O	349-351
the	O	352-355
behavioral	O	356-366
symptoms	O	367-375
associated	O	376-386
with	O	387-391
the	O	392-395
Lesch	B	396-401
-	I	401-402
Nyhan	I	402-407
syndrome	I	408-416
.	O	416-417

Administration	O	418-432
of	O	433-435
drugs	O	436-441
that	O	442-446
inhibit	O	447-454
adenine	O	455-462
phosphoribosyltransferase	O	463-488
(	O	489-490
APRT	O	490-494
)	O	494-495
in	O	496-498
HPRT	B	499-503
-	I	503-504
deficient	I	504-513
mice	O	514-518
has	O	519-522
produced	O	523-531
the	O	532-535
suggestion	O	536-546
that	O	547-551
deficiency	B	552-562
of	I	563-565
APRT	I	566-570
in	O	571-573
combination	O	574-585
with	O	586-590
HPRT	B	591-595
-	I	595-596
deficiency	I	596-606
in	O	607-609
mice	O	610-614
may	O	615-618
lead	O	619-623
to	O	624-626
self	O	627-631
-	O	631-632
mutilation	O	632-642
behavior	O	643-651
[	O	652-653
C	O	653-654
.	O	654-655

L	O	656-657
.	O	657-658
Wu	O	659-661
and	O	662-665
D	O	666-667
.	O	667-668
W	O	669-670
.	O	670-671
Melton	O	672-678
(	O	679-680
1993	O	680-684
)	O	684-685
Nature	O	686-692
Genet	O	693-698
.	O	698-699

3	O	700-701
,	O	701-702
235	O	703-706
-	O	706-707
240	O	707-710
]	O	710-711
.	O	711-712

To	O	713-715
test	O	716-720
this	O	721-725
proposition	O	726-737
,	O	737-738
we	O	739-741
bred	O	742-746
HPRT	B	747-751
-	I	751-752
APRT	I	752-756
-	I	751-752
deficient	I	757-766
mice	O	767-771
.	O	771-772

Although	O	773-781
the	O	782-785
doubly	O	786-792
-	O	792-793
deficient	O	793-802
mice	O	803-807
excrete	O	808-815
adenine	O	816-823
and	O	824-827
its	O	828-831
highly	O	832-838
insoluble	O	839-848
derivative	O	849-859
,	O	859-860
2	O	861-862
,	O	862-863
8	O	864-865
-	O	865-866
dihydroxyadenine	O	866-882
,	O	882-883
which	O	884-889
are	O	890-893
also	O	894-898
associated	O	899-909
with	O	910-914
human	O	915-920
APRT	B	921-925
deficiency	I	926-936
,	O	936-937
additional	O	938-948
abnormalities	O	949-962
or	O	963-965
any	O	966-969
self	O	970-974
-	O	974-975
injurious	O	975-984
behavior	O	985-993
were	O	994-998
not	O	999-1002
detected	O	1003-1011
.	O	1011-1012

Thus	O	1013-1017
,	O	1017-1018
APRT	B	1019-1023
-	I	1023-1024
HPRT	I	1024-1028
-	I	1023-1024
deficient	I	1029-1038
mice	O	1039-1043
,	O	1043-1044
which	O	1045-1050
are	O	1051-1054
devoid	O	1055-1061
of	O	1062-1064
any	O	1065-1068
purine	O	1069-1075
salvage	O	1076-1083
pathways	O	1084-1092
,	O	1092-1093
show	O	1094-1098
no	O	1099-1101
novel	O	1102-1107
phenotype	O	1108-1117
and	O	1118-1121
are	O	1122-1125
not	O	1126-1129
a	O	1130-1131
model	O	1132-1137
for	O	1138-1141
the	O	1142-1145
behavioral	B	1146-1156
abnormalities	I	1157-1170
associated	O	1171-1181
with	O	1182-1186
the	O	1187-1190
Lesch	B	1191-1196
-	I	1196-1197
Nyhan	I	1197-1202
syndrome	I	1203-1211
as	O	1212-1214
previously	O	1215-1225
suggested	O	1226-1235

Mice	O	0-4
lacking	O	5-12
the	O	13-16
myotonic	B	17-25
dystrophy	I	26-35
protein	O	36-43
kinase	O	44-50
develop	O	51-58
a	O	59-60
late	O	61-65
onset	O	66-71
progressive	O	72-83
myopathy	B	84-92
.	O	92-93

Myotonic	B	94-102
dystrophy	I	103-112
(	O	113-114
DM	B	114-116
)	O	116-117
is	O	118-120
an	O	121-123
autosomal	B	124-133
dominant	I	134-142
disorder	I	143-151
resulting	O	152-161
from	O	162-166
the	O	167-170
expansion	O	171-180
of	O	181-183
a	O	184-185
CTG	O	186-189
repeat	O	190-196
in	O	197-199
the	O	200-203
3	O	204-205
untranslated	O	206-218
region	O	219-225
of	O	226-228
a	O	229-230
putative	O	231-239
protein	O	240-247
kinase	O	248-254
(	O	255-256
DMPK	O	256-260
)	O	260-261
.	O	261-262

To	O	263-265
elucidate	O	266-275
the	O	276-279
role	O	280-284
of	O	285-287
DMPK	O	288-292
in	O	293-295
DM	B	296-298
pathogenesis	O	299-311
we	O	312-314
have	O	315-319
developed	O	320-329
Dmpk	B	330-334
deficient	I	335-344
(	O	345-346
Dmpk	O	346-350
-	O	350-351
/	O	351-352
-	O	350-351
)	O	353-354
mice	O	355-359
.	O	359-360

Dmpk	O	361-365
-	O	365-366
/	O	366-367
-	O	365-366
mice	O	368-372
develop	O	373-380
a	O	381-382
late	O	383-387
-	O	387-388
onset	O	388-393
,	O	393-394
progressive	B	395-406
skeletal	I	407-415
myopathy	I	416-424
that	O	425-429
shares	O	430-436
some	O	437-441
pathological	O	442-454
features	O	455-463
with	O	464-468
DM	B	469-471
.	O	471-472

Muscles	O	473-480
from	O	481-485
mature	O	486-492
mice	O	493-497
show	O	498-502
variation	O	503-512
in	O	513-515
fibre	O	516-521
size	O	522-526
,	O	526-527
increased	O	528-537
fibre	B	538-543
degeneration	I	544-556
and	O	557-560
fibrosis	B	561-569
.	O	569-570

Adult	O	571-576
Dmpk	O	577-581
-	O	581-582
/	O	582-583
-	O	581-582
mice	O	584-588
show	O	589-593
ultrastructural	O	594-609
changes	O	610-617
in	O	618-620
muscle	O	621-627
and	O	628-631
a	O	632-633
50	O	634-636
%	O	636-637
decrease	O	638-646
in	O	647-649
force	O	650-655
generation	O	656-666
compared	O	667-675
to	O	676-678
young	O	679-684
mice	O	685-689
.	O	689-690

Our	O	691-694
results	O	695-702
indicate	O	703-711
that	O	712-716
DMPK	O	717-721
may	O	722-725
be	O	726-728
necessary	O	729-738
for	O	739-742
the	O	743-746
maintenance	O	747-758
of	O	759-761
skeletal	O	762-770
muscle	O	771-777
structure	O	778-787
and	O	788-791
function	O	792-800
and	O	801-804
suggest	O	805-812
that	O	813-817
a	O	818-819
decrease	O	820-828
in	O	829-831
DMPK	O	832-836
levels	O	837-843
may	O	844-847
contribute	O	848-858
to	O	859-861
DM	B	862-864
pathology	O	865-874
.	O	874-875
.	O	874-875

Rapid	O	0-5
detection	O	6-15
of	O	16-18
regionally	O	19-29
clustered	O	30-39
germ	O	40-44
-	O	44-45
line	O	45-49
BRCA1	O	50-55
mutations	O	56-65
by	O	66-68
multiplex	O	69-78
heteroduplex	O	79-91
analysis	O	92-100
.	O	100-101

UKCCCR	O	102-108
Familial	O	109-117
Ovarian	B	118-125
Cancer	I	126-132
Study	O	133-138
Group	O	139-144
.	O	144-145

Germ	O	146-150
-	O	150-151
line	O	151-155
mutations	O	156-165
of	O	166-168
the	O	169-172
BRCA1	O	173-178
gene	O	179-183
are	O	184-187
responsible	O	188-199
for	O	200-203
a	O	204-205
substantial	O	206-217
proportion	O	218-228
of	O	229-231
families	O	232-240
with	O	241-245
multiple	O	246-254
cases	O	255-260
of	O	261-263
early	O	264-269
-	O	269-270
onset	O	270-275
breast	B	276-282
and	I	283-286
/	I	286-287
or	I	287-289
ovarian	I	290-297
cancer	I	298-304
.	O	304-305

Since	O	306-311
the	O	312-315
isolation	O	316-325
of	O	326-328
BRCA1	O	329-334
last	O	335-339
year	O	340-344
,	O	344-345
>	O	346-347
65	O	348-350
distinct	O	351-359
mutations	O	360-369
scattered	O	370-379
throughout	O	380-390
the	O	391-394
coding	O	395-401
region	O	402-408
have	O	409-413
been	O	414-418
detected	O	419-427
,	O	427-428
making	O	429-435
analysis	O	436-444
of	O	445-447
the	O	448-451
gene	O	452-456
time	O	457-461
consuming	O	462-471
and	O	472-475
technically	O	476-487
challenging	O	488-499
.	O	499-500

We	O	501-503
have	O	504-508
developed	O	509-518
a	O	519-520
multiplex	O	521-530
heteroduplex	O	531-543
analysis	O	544-552
that	O	553-557
is	O	558-560
designed	O	561-569
to	O	570-572
analyze	O	573-580
one	O	581-584
-	O	584-585
quarter	O	585-592
of	O	593-595
the	O	596-599
coding	O	600-606
sequence	O	607-615
in	O	616-618
a	O	619-620
single	O	621-627
-	O	627-628
step	O	628-632
screening	O	633-642
procedure	O	643-652
and	O	653-656
that	O	657-661
will	O	662-666
detect	O	667-673
approximately	O	674-687
50	O	688-690
%	O	690-691
of	O	692-694
all	O	695-698
BRCA1	O	699-704
mutations	O	705-714
so	O	715-717
far	O	718-721
reported	O	722-730
in	O	731-733
breast	B	734-740
/	I	740-741
ovarian	I	741-748
cancer	I	749-755
families	O	756-764
.	O	764-765

We	O	766-768
have	O	769-773
used	O	774-778
this	O	779-783
technique	O	784-793
to	O	794-796
analyze	O	797-804
BRCA1	O	805-810
in	O	811-813
162	O	814-817
families	O	818-826
with	O	827-831
a	O	832-833
history	O	834-841
of	O	842-844
breast	B	845-851
and	I	852-855
/	I	855-856
or	I	856-858
ovarian	I	859-866
cancer	I	867-873
and	O	874-877
identified	O	878-888
12	O	889-891
distinct	O	892-900
mutations	O	901-910
in	O	911-913
35	O	914-916
families	O	917-925
.	O	925-926
.	O	925-926

LPP	O	0-3
,	O	3-4
the	O	5-8
preferred	O	9-18
fusion	O	19-25
partner	O	26-33
gene	O	34-38
of	O	39-41
HMGIC	O	42-47
in	O	48-50
lipomas	B	51-58
,	O	58-59
is	O	60-62
a	O	63-64
novel	O	65-70
member	O	71-77
of	O	78-80
the	O	81-84
LIM	O	85-88
protein	O	89-96
gene	O	97-101
family	O	102-108
.	O	108-109

A	O	110-111
major	O	112-117
cytogenetic	O	118-129
subgroup	O	130-138
of	O	139-141
lipomas	B	142-149
is	O	150-152
characterized	O	153-166
by	O	167-169
recurrent	O	170-179
chromosome	O	180-190
aberrations	O	191-202
,	O	202-203
mainly	O	204-210
translocations	O	211-225
,	O	225-226
that	O	227-231
involve	O	232-239
chromosome	O	240-250
segment	O	251-258
12q13	O	259-264
-	O	264-265
q15	O	265-268
.	O	268-269

Multiple	O	270-278
chromosomes	O	279-290
have	O	291-295
been	O	296-300
found	O	301-306
as	O	307-309
the	O	310-313
translocation	O	314-327
partners	O	328-336
of	O	337-339
chromosome	O	340-350
12	O	351-353
but	O	354-357
3q27	O	358-362
-	O	362-363
q28	O	363-366
is	O	367-369
preferentially	O	370-384
involved	O	385-393
.	O	393-394

In	O	395-397
previous	O	398-406
studies	O	407-414
,	O	414-415
it	O	416-418
has	O	419-422
been	O	423-427
shown	O	428-433
that	O	434-438
the	O	439-442
high	O	443-447
mobility	O	448-456
group	O	457-462
(	O	463-464
HMG	O	464-467
)	O	467-468
protein	O	469-476
gene	O	477-481
HMGIC	O	482-487
at	O	488-490
12q15	O	491-496
is	O	497-499
consistently	O	500-512
rearranged	O	513-523
as	O	524-526
a	O	527-528
consequence	O	529-540
of	O	541-543
these	O	544-549
translocations	O	550-564
.	O	564-565

Here	O	566-570
,	O	570-571
we	O	572-574
report	O	575-581
the	O	582-585
identification	O	586-600
and	O	601-604
characterization	O	605-621
of	O	622-624
the	O	625-628
chromosome	O	629-639
3	O	640-641
-	O	641-642
derived	O	642-649
translocation	O	650-663
partner	O	664-671
gene	O	672-676
,	O	676-677
which	O	678-683
we	O	684-686
have	O	687-691
designated	O	692-702
LPP	O	703-706
(	O	707-708
lipoma	B	708-714
preferred	O	715-724
partner	O	725-732
gene	O	733-737
)	O	737-738
.	O	738-739

Using	O	740-745
3	O	746-747
-	O	747-748
RACE	O	748-752
analysis	O	753-761
of	O	762-764
HMGIC	O	765-770
fusion	O	771-777
transcripts	O	778-789
in	O	790-792
lipoma	B	793-799
cell	O	800-804
line	O	805-809
Li	O	810-812
-	O	812-813
501	O	813-816
/	O	816-817
SV40	O	817-821
,	O	821-822
ectopic	O	823-830
genetic	O	831-838
sequences	O	839-848
were	O	849-853
obtained	O	854-862
,	O	862-863
which	O	864-869
by	O	870-872
CASH	O	873-877
(	O	878-879
chromosome	O	879-889
assignment	O	890-900
using	O	901-906
somatic	O	907-914
cell	O	915-919
hybrids	O	920-927
)	O	927-928
and	O	929-932
FISH	O	933-937
(	O	938-939
fluorescence	O	939-951
in	O	952-954
situ	O	955-959
hybridization	O	960-973
)	O	973-974
analysis	O	975-983
were	O	984-988
found	O	989-994
to	O	995-997
originate	O	998-1007
from	O	1008-1012
chromosome	O	1013-1023
segment	O	1024-1031
3q27	O	1032-1036
-	O	1036-1037
q28	O	1037-1040
.	O	1040-1041

In	O	1042-1044
Northern	O	1045-1053
blot	O	1054-1058
analysis	O	1059-1067
,	O	1067-1068
an	O	1069-1071
mRNA	O	1072-1076
of	O	1077-1079
over	O	1080-1084
10	O	1085-1087
kb	O	1088-1090
was	O	1091-1094
detected	O	1095-1103
by	O	1104-1106
these	O	1107-1112
ectopic	O	1113-1120
sequences	O	1121-1130
in	O	1131-1133
a	O	1134-1135
variety	O	1136-1143
of	O	1144-1146
human	O	1147-1152
tissues	O	1153-1160
but	O	1161-1164
not	O	1165-1168
in	O	1169-1171
brain	O	1172-1177
and	O	1178-1181
peripheral	O	1182-1192
blood	O	1193-1198
leukocytes	O	1199-1209
.	O	1209-1210

Upon	O	1211-1215
partial	O	1216-1223
cDNA	O	1224-1228
cloning	O	1229-1236
,	O	1236-1237
features	O	1238-1246
of	O	1247-1249
the	O	1250-1253
genetic	O	1254-1261
organization	O	1262-1274
of	O	1275-1277
LPP	O	1278-1281
were	O	1282-1286
established	O	1287-1298
.	O	1298-1299

The	O	1300-1303
gene	O	1304-1308
was	O	1309-1312
found	O	1313-1318
to	O	1319-1321
span	O	1322-1326
a	O	1327-1328
genomic	O	1329-1336
region	O	1337-1343
of	O	1344-1346
over	O	1347-1351
400	O	1352-1355
kb	O	1356-1358
.	O	1358-1359

Nucleotide	O	1360-1370
sequence	O	1371-1379
analysis	O	1380-1388
of	O	1389-1391
a	O	1392-1393
composite	O	1394-1403
cDNA	O	1404-1408
of	O	1409-1411
LPP	O	1412-1415
revealed	O	1416-1424
an	O	1425-1427
open	O	1428-1432
reading	O	1433-1440
frame	O	1441-1446
of	O	1447-1449
1836	O	1450-1454
nucleotides	O	1455-1466
encoding	O	1467-1475
a	O	1476-1477
proline	O	1478-1485
-	O	1485-1486
rich	O	1486-1490
protein	O	1491-1498
containing	O	1499-1509
a	O	1510-1511
leucine	O	1512-1519
-	O	1519-1520
zipper	O	1520-1526
motif	O	1527-1532
in	O	1533-1535
its	O	1536-1539
amino	O	1540-1545
-	O	1545-1546
terminal	O	1546-1554
region	O	1555-1561
and	O	1562-1565
three	O	1566-1571
LIM	O	1572-1575
domains	O	1576-1583
in	O	1584-1586
its	O	1587-1590
carboxy	O	1591-1598
-	O	1598-1599
terminal	O	1599-1607
region	O	1608-1614
.	O	1614-1615

The	O	1616-1619
LPP	O	1620-1623
-	O	1623-1624
encoded	O	1624-1631
protein	O	1632-1639
should	O	1640-1646
be	O	1647-1649
classified	O	1650-1660
as	O	1661-1663
a	O	1664-1665
novel	O	1666-1671
member	O	1672-1678
of	O	1679-1681
the	O	1682-1685
group	O	1686-1691
3	O	1692-1693
proteins	O	1694-1702
of	O	1703-1705
the	O	1706-1709
LIM	O	1710-1713
protein	O	1714-1721
gene	O	1722-1726
family	O	1727-1733
.	O	1733-1734

Using	O	1735-1740
reverse	O	1741-1748
transcriptase	O	1749-1762
combined	O	1763-1771
with	O	1772-1776
polymerase	O	1777-1787
chain	O	1788-1793
reactions	O	1794-1803
in	O	1804-1806
the	O	1807-1810
analysis	O	1811-1819
of	O	1820-1822
a	O	1823-1824
number	O	1825-1831
of	O	1832-1834
lipoma	B	1835-1841
cell	O	1842-1846
lines	O	1847-1852
and	O	1853-1856
primary	B	1857-1864
lipomas	I	1865-1872
,	O	1872-1873
it	O	1874-1876
appeared	O	1877-1885
that	O	1886-1890
LPP	O	1891-1894
is	O	1895-1897
frequently	O	1898-1908
rearranged	O	1909-1919
also	O	1920-1924
in	O	1925-1927
cases	O	1928-1933
without	O	1934-1941
a	O	1942-1943
cytogenetically	O	1944-1959
detectable	O	1960-1970
involvement	O	1971-1982
of	O	1983-1985
3q27	O	1986-1990
-	O	1990-1991
q28	O	1991-1994
.	O	1994-1995

Two	O	1996-1999
alternative	O	2000-2011
HMGIC	O	2012-2017
/	O	2017-2018
LPP	O	2018-2021
hybrid	O	2022-2028
transcripts	O	2029-2040
have	O	2041-2045
been	O	2046-2050
detected	O	2051-2059
;	O	2059-2060
the	O	2061-2064
difference	O	2065-2075
between	O	2076-2083
them	O	2084-2088
is	O	2089-2091
mainly	O	2092-2098
the	O	2099-2102
presence	O	2103-2111
of	O	2112-2114
either	O	2115-2121
two	O	2122-2125
or	O	2126-2128
three	O	2129-2134
LIM	O	2135-2138
domains	O	2139-2146
in	O	2147-2149
the	O	2150-2153
predicted	O	2154-2163
HMGI	O	2164-2168
-	O	2168-2169
C	O	2169-2170
/	O	2170-2171
LPP	O	2171-2174
fusion	O	2175-2181
proteins	O	2182-2190
.	O	2190-2191
.	O	2190-2191

Exon	O	0-4
-	O	4-5
intron	O	5-11
structure	O	12-21
of	O	22-24
the	O	25-28
human	O	29-34
neuronal	O	35-43
nicotinic	O	44-53
acetylcholine	O	54-67
receptor	O	68-76
alpha	O	77-82
4	O	83-84
subunit	O	85-92
(	O	93-94
CHRNA4	O	94-100
)	O	100-101
.	O	101-102

The	O	103-106
human	O	107-112
neuronal	O	113-121
nicotinic	O	122-131
acetylcholine	O	132-145
receptor	O	146-154
alpha	O	155-160
4	O	161-162
subunit	O	163-170
gene	O	171-175
(	O	176-177
CHRNA4	O	177-183
)	O	183-184
is	O	185-187
located	O	188-195
in	O	196-198
the	O	199-202
candidate	O	203-212
region	O	213-219
for	O	220-223
three	O	224-229
different	O	230-239
phenotypes	O	240-250
benign	B	252-258
familial	I	259-267
neonatal	I	268-276
convulsions	I	277-288
,	O	288-289
autosomal	B	290-299
dominant	I	300-308
nocturnal	I	309-318
frontal	I	319-326
lobe	I	327-331
epilepsy	I	332-340
,	O	340-341
and	O	342-345
low	O	346-349
-	O	349-350
voltage	O	350-357
EEG	O	358-361
.	O	361-362

Recently	O	363-371
,	O	371-372
a	O	373-374
missense	O	375-383
mutation	O	384-392
in	O	393-395
transmembrane	O	396-409
domain	O	410-416
2	O	417-418
of	O	419-421
CHRNA4	O	422-428
was	O	429-432
found	O	433-438
to	O	439-441
be	O	442-444
associated	O	445-455
with	O	456-460
autosomal	B	461-470
dominant	I	471-479
nocturnal	I	480-489
frontal	I	490-497
lobe	I	498-502
epilepsy	I	503-511
in	O	512-514
one	O	515-518
extended	O	519-527
pedigree	O	528-536
.	O	536-537

We	O	538-540
have	O	541-545
determined	O	546-556
the	O	557-560
genomic	O	561-568
organization	O	569-581
of	O	582-584
CHRNA4	O	585-591
,	O	591-592
which	O	593-598
consists	O	599-607
of	O	608-610
six	O	611-614
exons	O	615-620
distributed	O	621-632
over	O	633-637
approximately	O	638-651
17	O	652-654
kb	O	655-657
of	O	658-660
genomic	O	661-668
DNA	O	669-672
.	O	672-673

The	O	674-677
nucleotide	O	678-688
sequence	O	689-697
obtained	O	698-706
from	O	707-711
the	O	712-715
genomic	O	716-723
regions	O	724-731
adjacent	O	732-740
to	O	741-743
the	O	744-747
exon	O	748-752
boundaries	O	753-763
enabled	O	764-771
us	O	772-774
to	O	775-777
develop	O	778-785
a	O	786-787
set	O	788-791
of	O	792-794
primer	O	795-801
pairs	O	802-807
for	O	808-811
PCR	O	812-815
amplification	O	816-829
of	O	830-832
the	O	833-836
complete	O	837-845
coding	O	846-852
region	O	853-859
.	O	859-860

The	O	861-864
sequence	O	865-873
analysis	O	874-882
provides	O	883-891
the	O	892-895
basis	O	896-901
for	O	902-905
a	O	906-907
comprehensive	O	908-921
mutation	O	922-930
screening	O	931-940
of	O	941-943
CHRNA4	O	944-950
in	O	951-953
the	O	954-957
above	O	958-963
-	O	963-964
mentioned	O	964-973
phenotypes	O	974-984
and	O	985-988
possibly	O	989-997
in	O	998-1000
other	O	1001-1006
types	O	1007-1012
of	O	1013-1015
idiopathic	B	1016-1026
epilepsies	I	1027-1037
.	O	1037-1038
.	O	1037-1038

A	O	0-1
novel	O	2-7
homeodomain	O	8-19
-	O	19-20
encoding	O	20-28
gene	O	29-33
is	O	34-36
associated	O	37-47
with	O	48-52
a	O	53-54
large	O	55-60
CpG	O	61-64
island	O	65-71
interrupted	O	72-83
by	O	84-86
the	O	87-90
myotonic	B	91-99
dystrophy	I	100-109
unstable	O	110-118
(	O	119-120
CTG	O	120-123
)	O	123-124
n	O	124-125
repeat	O	126-132
.	O	132-133

Myotonic	B	134-142
dystrophy	I	143-152
(	O	153-154
DM	B	154-156
)	O	156-157
is	O	158-160
associated	O	161-171
with	O	172-176
a	O	177-178
(	O	179-180
CTG	O	180-183
)	O	183-184
n	O	185-186
trinucleotide	O	187-200
repeat	O	201-207
expansion	O	208-217
in	O	218-220
the	O	221-224
3	O	225-226
-	O	226-227
untranslated	O	227-239
region	O	240-246
of	O	247-249
a	O	250-251
protein	O	252-259
kinase	O	260-266
-	O	266-267
encoding	O	267-275
gene	O	276-280
,	O	280-281
DMPK	O	282-286
,	O	286-287
which	O	288-293
maps	O	294-298
to	O	299-301
chromosome	O	302-312
19q13	O	313-318
.	O	318-319

3	O	320-321
.	O	321-322
Characterisation	O	323-339
of	O	340-342
the	O	343-346
expression	O	347-357
of	O	358-360
this	O	361-365
gene	O	366-370
in	O	371-373
patient	O	374-381
tissues	O	382-389
has	O	390-393
thus	O	394-398
far	O	399-402
generated	O	403-412
conflicting	O	413-424
data	O	425-429
on	O	430-432
alterations	O	433-444
in	O	445-447
the	O	448-451
steady	O	452-458
state	O	459-464
levels	O	465-471
of	O	472-474
DMPK	O	475-479
mRNA	O	480-484
,	O	484-485
and	O	486-489
on	O	490-492
the	O	493-496
final	O	497-502
DMPK	O	503-507
protein	O	508-515
levels	O	516-522
in	O	523-525
the	O	526-529
presence	O	530-538
of	O	539-541
the	O	542-545
expansion	O	546-555
.	O	555-556

The	O	557-560
DM	B	561-563
region	O	564-570
of	O	571-573
chromosome	O	574-584
19	O	585-587
is	O	588-590
gene	O	591-595
rich	O	596-600
,	O	600-601
and	O	602-605
it	O	606-608
is	O	609-611
possible	O	612-620
that	O	621-625
the	O	626-629
repeat	O	630-636
expansion	O	637-646
may	O	647-650
lead	O	651-655
to	O	656-658
dysfunction	O	659-670
of	O	671-673
a	O	674-675
number	O	676-682
of	O	683-685
transcription	O	686-699
units	O	700-705
in	O	706-708
the	O	709-712
vicinity	O	713-721
,	O	721-722
perhaps	O	723-730
as	O	731-733
a	O	734-735
consequence	O	736-747
of	O	748-750
chromatin	O	751-760
disruption	O	761-771
.	O	771-772

We	O	773-775
have	O	776-780
searched	O	781-789
for	O	790-793
genes	O	794-799
associated	O	800-810
with	O	811-815
a	O	816-817
CpG	O	818-821
island	O	822-828
at	O	829-831
the	O	832-835
3	O	836-837
end	O	838-841
of	O	842-844
DMPK	O	845-849
.	O	849-850

Sequencing	O	851-861
of	O	862-864
this	O	865-869
region	O	870-876
shows	O	877-882
that	O	883-887
the	O	888-891
island	O	892-898
extends	O	899-906
over	O	907-911
3	O	912-913
.	O	913-914
5	O	915-916
kb	O	917-919
and	O	920-923
is	O	924-926
interrupted	O	927-938
by	O	939-941
the	O	942-945
(	O	946-947
CTG	O	947-950
)	O	950-951
n	O	952-953
repeat	O	954-960
.	O	960-961

Comparison	O	962-972
of	O	973-975
genomic	O	976-983
sequences	O	984-993
downstream	O	994-1004
(	O	1005-1006
centromeric	O	1006-1017
)	O	1017-1018
of	O	1019-1021
the	O	1022-1025
repeat	O	1026-1032
in	O	1033-1035
human	O	1036-1041
and	O	1042-1045
mouse	O	1046-1051
identified	O	1052-1062
regions	O	1063-1070
of	O	1071-1073
significant	O	1074-1085
homology	O	1086-1094
.	O	1094-1095

These	O	1096-1101
correspond	O	1102-1112
to	O	1113-1115
exons	O	1116-1121
of	O	1122-1124
a	O	1125-1126
gene	O	1127-1131
predicted	O	1132-1141
to	O	1142-1144
encode	O	1145-1151
a	O	1152-1153
homeodomain	O	1154-1165
protein	O	1166-1173
.	O	1173-1174

RT	O	1175-1177
-	O	1177-1178
PCR	O	1178-1181
analysis	O	1182-1190
shows	O	1191-1196
that	O	1197-1201
this	O	1202-1206
gene	O	1207-1211
,	O	1211-1212
which	O	1213-1218
we	O	1219-1221
have	O	1222-1226
called	O	1227-1233
DM	B	1234-1236
locus	O	1237-1242
-	O	1242-1243
associated	O	1243-1253
homeodomain	O	1254-1265
protein	O	1266-1273
(	O	1274-1275
DMAHP	O	1275-1280
)	O	1280-1281
,	O	1281-1282
is	O	1283-1285
expressed	O	1286-1295
in	O	1296-1298
a	O	1299-1300
number	O	1301-1307
of	O	1308-1310
human	O	1311-1316
tissues	O	1317-1324
,	O	1324-1325
including	O	1326-1335
skeletal	O	1336-1344
muscle	O	1345-1351
,	O	1351-1352
heart	O	1353-1358
and	O	1359-1362
brain	O	1363-1368
.	O	1368-1369

Missense	O	0-8
mutations	O	9-18
in	O	19-21
the	O	22-25
Fas	O	26-29
gene	O	30-34
resulting	O	35-44
in	O	45-47
autoimmune	B	48-58
lymphoproliferative	I	59-78
syndrome	I	79-87
:	O	87-88
a	O	89-90
molecular	O	91-100
and	O	101-104
immunological	O	105-118
analysis	O	119-127
.	O	127-128

Programmed	O	129-139
cell	O	140-144
death	O	145-150
(	O	151-152
or	O	152-154
apoptosis	O	155-164
)	O	164-165
is	O	166-168
a	O	169-170
physiological	O	171-184
process	O	185-192
essential	O	193-202
to	O	203-205
the	O	206-209
normal	O	210-216
development	O	217-228
and	O	229-232
homeostatic	O	233-244
maintenance	O	245-256
of	O	257-259
the	O	260-263
immune	O	264-270
system	O	271-277
.	O	277-278

The	O	279-282
Fas	O	283-286
/	O	286-287
Apo	O	287-290
-	O	290-291
1	O	291-292
receptor	O	293-301
plays	O	302-307
a	O	308-309
crucial	O	310-317
role	O	318-322
in	O	323-325
the	O	326-329
regulation	O	330-340
of	O	341-343
apoptosis	O	344-353
,	O	353-354
as	O	355-357
demonstrated	O	358-370
by	O	371-373
lymphoproliferation	O	374-393
in	O	394-396
MRL	O	397-400
-	O	400-401
lpr	O	401-404
/	O	404-405
lpr	O	401-404
mice	O	409-413
and	O	414-417
by	O	418-420
the	O	421-424
recently	O	425-433
described	O	434-443
autoimmune	B	444-454
lymphoproliferative	I	455-474
syndrome	I	475-483
(	O	484-485
ALPS	B	485-489
)	O	489-490
in	O	491-493
humans	O	494-500
,	O	500-501
both	O	502-506
of	O	507-509
which	O	510-515
are	O	516-519
due	O	520-523
to	O	524-526
mutations	O	527-536
in	O	537-539
the	O	540-543
Fas	O	544-547
gene	O	548-552
.	O	552-553

We	O	554-556
describe	O	557-565
a	O	566-567
novel	O	568-573
family	O	574-580
with	O	581-585
ALPS	B	586-590
in	O	591-593
which	O	594-599
three	O	600-605
affected	O	606-614
siblings	O	615-623
carry	O	624-629
two	O	630-633
distinct	O	634-642
missense	O	643-651
mutations	O	652-661
on	O	662-664
both	O	665-669
the	O	670-673
Fas	O	674-677
gene	O	678-682
alleles	O	683-690
and	O	691-694
show	O	695-699
lack	O	700-704
of	O	705-707
Fas	O	708-711
-	O	711-712
induced	O	712-719
apoptosis	O	720-729
.	O	729-730

The	O	731-734
children	O	735-743
share	O	744-749
common	O	750-756
clinical	O	757-765
features	O	766-774
including	O	775-784
splenomegaly	B	785-797
and	O	798-801
lymphadenopathy	B	802-817
,	O	817-818
but	O	819-822
only	O	823-827
one	O	828-831
developed	O	832-841
severe	O	842-848
autoimmune	B	849-859
manifestations	I	860-874
.	O	874-875

In	O	876-878
all	O	879-882
three	O	883-888
siblings	O	889-897
,	O	897-898
we	O	899-901
demonstrated	O	902-914
the	O	915-918
presence	O	919-927
of	O	928-930
anergic	O	931-938
CD3	O	939-942
+	O	943-944
CD4	O	945-948
-	O	948-949
CD8	O	949-952
-	O	948-949
(	O	954-955
double	O	955-961
negative	O	962-970
,	O	970-971
[	O	972-973
DN	O	973-975
]	O	975-976
)	O	976-977
T	O	978-979
cells	O	980-985
;	O	985-986
moreover	O	987-995
,	O	995-996
a	O	997-998
chronic	O	999-1006
lymphocyte	O	1007-1017
activation	O	1018-1028
was	O	1029-1032
found	O	1033-1038
,	O	1038-1039
as	O	1040-1042
demonstrated	O	1043-1055
by	O	1056-1058
the	O	1059-1062
presence	O	1063-1071
of	O	1072-1074
high	O	1075-1079
levels	O	1080-1086
of	O	1087-1089
HLA	O	1090-1093
-	O	1093-1094
DR	O	1094-1096
expression	O	1097-1107
on	O	1108-1110
peripheral	O	1111-1121
CD3	O	1122-1125
+	O	1126-1127
cells	O	1128-1133
and	O	1134-1137
by	O	1138-1140
the	O	1141-1144
presence	O	1145-1153
of	O	1154-1156
high	O	1157-1161
levels	O	1162-1168
of	O	1169-1171
serum	O	1172-1177
activation	O	1178-1188
markers	O	1189-1196
such	O	1197-1201
as	O	1202-1204
soluble	O	1205-1212
interleukin	O	1213-1224
-	O	1224-1225
2	O	1225-1226
receptor	O	1227-1235
(	O	1236-1237
slL	O	1237-1240
-	O	1240-1241
2R	O	1241-1243
)	O	1243-1244
and	O	1245-1248
soluble	O	1249-1256
CD30	O	1257-1261
(	O	1262-1263
sCD30	O	1263-1268
)	O	1268-1269
.	O	1269-1270
.	O	1269-1270

Common	O	0-6
BRCA1	O	7-12
variants	O	13-21
and	O	22-25
susceptibility	O	26-40
to	O	41-43
breast	B	44-50
and	I	51-54
ovarian	I	55-62
cancer	I	63-69
in	O	70-72
the	O	73-76
general	O	77-84
population	O	85-95
.	O	95-96

Most	O	97-101
multiple	O	102-110
case	O	111-115
families	O	116-124
of	O	125-127
young	O	128-133
onset	O	134-139
breast	B	140-146
cancer	I	147-153
and	O	154-157
ovarian	B	158-165
cancer	I	166-172
are	O	173-176
thought	O	177-184
to	O	185-187
be	O	188-190
due	O	191-194
to	O	195-197
highly	O	198-204
penetrant	O	205-214
mutations	O	215-224
in	O	225-227
the	O	228-231
predisposing	O	232-244
genes	O	245-250
BRCA1	O	251-256
and	O	257-260
BRCA2	O	261-266
.	O	266-267

However	O	268-275
,	O	275-276
these	O	277-282
mutations	O	283-292
are	O	293-296
uncommon	O	297-305
in	O	306-308
the	O	309-312
population	O	313-323
and	O	324-327
they	O	328-332
probably	O	333-341
account	O	342-349
for	O	350-353
only	O	354-358
a	O	359-360
few	O	361-364
percent	O	365-372
of	O	373-375
all	O	376-379
breast	B	380-386
cancer	I	387-393
incidence	O	394-403
.	O	403-404

A	O	405-406
much	O	407-411
larger	O	412-418
fraction	O	419-427
of	O	428-430
breast	B	431-437
cancer	I	438-444
might	O	445-450
,	O	450-451
in	O	452-454
principle	O	455-464
,	O	464-465
be	O	466-468
due	O	469-472
to	O	473-475
common	O	476-482
variants	O	483-491
which	O	492-497
confer	O	498-504
more	O	505-509
modest	O	510-516
individual	O	517-527
risks	O	528-533
.	O	533-534

There	O	535-540
are	O	541-544
several	O	545-552
common	O	553-559
polymorphisms	O	560-573
in	O	574-576
the	O	577-580
BRCA1	O	581-586
gene	O	587-591
which	O	592-597
generate	O	598-606
amino	O	607-612
acid	O	613-617
substitutions	O	618-631
.	O	631-632

We	O	633-635
have	O	636-640
examined	O	641-649
the	O	650-653
frequency	O	654-663
of	O	664-666
four	O	667-671
of	O	672-674
these	O	675-680
polymorphisms	O	681-694
Gln356Arg	O	696-705
,	O	705-706
Pro871Leu	O	707-716
,	O	716-717
Glu1038Gly	O	718-728
and	O	729-732
Ser1613Gly	O	733-743
in	O	744-746
large	O	747-752
series	O	753-759
of	O	760-762
breast	B	763-769
and	I	770-773
ovarian	I	774-781
cancer	I	782-788
cases	O	789-794
and	O	795-798
matched	O	799-806
controls	O	807-815
.	O	815-816

Due	O	817-820
to	O	821-823
strong	O	824-830
linkage	O	831-838
disequilibrium	O	839-853
,	O	853-854
these	O	855-860
four	O	861-865
sites	O	866-871
generate	O	872-880
only	O	881-885
three	O	886-891
haplotypes	O	892-902
with	O	903-907
a	O	908-909
frequency	O	910-919
>	O	920-921
1	O	922-923
.	O	923-924
3	O	925-926
%	O	926-927
.	O	927-928

The	O	929-932
most	O	933-937
common	O	938-944
haplotypes	O	945-955
,	O	955-956
defined	O	957-964
by	O	965-967
the	O	968-971
alleles	O	972-979
Gln356Pro871Glu1038Ser1613	O	980-1006
and	O	1007-1010
Gln356Leu871Gly1038Gly1613	O	1011-1037
,	O	1037-1038
have	O	1039-1043
frequencies	O	1044-1055
of	O	1056-1058
0	O	1059-1060
.	O	1060-1061
57	O	1062-1064
and	O	1065-1068
0	O	1069-1070
.	O	1070-1071
32	O	1072-1074
respectively	O	1075-1087
,	O	1087-1088
and	O	1089-1092
these	O	1093-1098
frequencies	O	1099-1110
do	O	1111-1113
not	O	1114-1117
differ	O	1118-1124
significantly	O	1125-1138
between	O	1139-1146
patient	O	1147-1154
and	O	1155-1158
control	O	1159-1166
groups	O	1167-1173
.	O	1173-1174

Thus	O	1175-1179
the	O	1180-1183
most	O	1184-1188
common	O	1189-1195
polymorphisms	O	1196-1209
of	O	1210-1212
the	O	1213-1216
BRCA1	O	1217-1222
gene	O	1223-1227
do	O	1228-1230
not	O	1231-1234
make	O	1235-1239
a	O	1240-1241
significant	O	1242-1253
contribution	O	1254-1266
to	O	1267-1269
breast	B	1270-1276
or	I	1277-1279
ovarian	I	1280-1287
cancer	I	1288-1294
risk	O	1295-1299
.	O	1299-1300

However	O	1301-1308
,	O	1308-1309
our	O	1310-1313
data	O	1314-1318
suggest	O	1319-1326
that	O	1327-1331
the	O	1332-1335
Arg356	O	1336-1342
allele	O	1343-1349
may	O	1350-1353
have	O	1354-1358
a	O	1359-1360
different	O	1361-1370
genotype	O	1371-1379
distribution	O	1380-1392
in	O	1393-1395
breast	B	1396-1402
cancer	I	1403-1409
patients	O	1410-1418
from	O	1419-1423
that	O	1424-1428
in	O	1429-1431
controls	O	1432-1440
(	O	1441-1442
Arg356	O	1442-1448
homozygotes	O	1449-1460
are	O	1461-1464
more	O	1465-1469
frequent	O	1470-1478
in	O	1479-1481
the	O	1482-1485
control	O	1486-1493
groups	O	1494-1500
,	O	1500-1501
P	O	1502-1503
=	O	1504-1505
0	O	1506-1507
.	O	1507-1508
01	O	1509-1511
)	O	1511-1512
,	O	1512-1513
indicating	O	1514-1524
that	O	1525-1529
it	O	1530-1532
may	O	1533-1536
be	O	1537-1539
protective	O	1540-1550
against	O	1551-1558
breast	B	1559-1565
cancer	I	1566-1572
.	O	1572-1573

If	O	1574-1576
this	O	1577-1581
finding	O	1582-1589
can	O	1590-1593
be	O	1594-1596
confirmed	O	1597-1606
,	O	1606-1607
it	O	1608-1610
may	O	1611-1614
provide	O	1615-1622
an	O	1623-1625
insight	O	1626-1633
into	O	1634-1638
the	O	1639-1642
structural	O	1643-1653
features	O	1654-1662
of	O	1663-1665
the	O	1666-1669
BRCA1	O	1670-1675
protein	O	1676-1683
that	O	1684-1688
are	O	1689-1692
important	O	1693-1702
for	O	1703-1706
its	O	1707-1710
function	O	1711-1719
.	O	1719-1720

Mutation	O	0-8
of	O	9-11
the	O	12-15
VHL	O	16-19
gene	O	20-24
is	O	25-27
associated	O	28-38
exclusively	O	39-50
with	O	51-55
the	O	56-59
development	O	60-71
of	O	72-74
non	B	75-78
-	I	78-79
papillary	I	79-88
renal	I	89-94
cell	I	95-99
carcinomas	I	100-110
.	O	110-111

To	O	112-114
define	O	115-121
the	O	122-125
possible	O	126-134
role	O	135-139
of	O	140-142
the	O	143-146
VHL	B	147-150
gene	O	151-155
in	O	156-158
the	O	159-162
development	O	163-174
of	O	175-177
sporadic	B	178-186
renal	I	187-192
cell	I	193-197
carcinomas	I	198-208
,	O	208-209
91	O	210-212
different	O	213-222
parenchymal	B	223-234
tumours	I	235-242
of	I	243-245
the	I	246-249
kidney	I	250-256
have	O	257-261
been	O	262-266
investigated	O	267-279
for	O	280-283
mutation	O	284-292
of	O	293-295
the	O	296-299
VHL	B	300-303
gene	O	304-308
by	O	309-311
single	O	312-318
strand	O	319-325
conformation	O	326-338
polymorphism	O	339-351
(	O	352-353
SSCP	O	353-357
)	O	357-358
and	O	359-362
/	O	362-363
or	O	363-365
heteroduplex	O	366-378
(	O	379-380
HD	O	380-382
)	O	382-383
techniques	O	384-394
.	O	394-395

Chromosome	O	396-406
3p	O	407-409
deletion	O	410-418
was	O	419-422
detected	O	423-431
in	O	432-434
98	O	435-437
per	O	438-441
cent	O	442-446
of	O	447-449
non	B	450-453
-	I	453-454
papillary	I	454-463
renal	I	464-469
cell	I	470-474
carcinomas	I	475-485
and	O	486-489
in	O	490-492
25	O	493-495
per	O	496-499
cent	O	500-504
of	O	505-507
chromophobe	O	508-519
renal	B	520-525
cell	I	526-530
carcinomas	I	531-541
.	O	541-542

In	O	543-545
22	O	546-548
of	O	549-551
the	O	552-555
43	O	556-558
non	B	559-562
-	I	562-563
papillary	I	563-572
renal	I	573-578
cell	I	579-583
carcinomas	I	584-594
,	O	594-595
abnormally	O	596-606
migrating	O	607-616
DNA	O	617-620
bands	O	621-626
were	O	627-631
detected	O	632-640
by	O	641-643
SSCP	O	644-648
and	O	649-652
/	O	652-653
or	O	653-655
HD	O	656-658
analysis	O	659-667
.	O	667-668

No	O	669-671
mobility	O	672-680
shift	O	681-686
was	O	687-690
seen	O	691-695
in	O	696-698
any	O	699-702
of	O	703-705
the	O	706-709
23	O	710-712
chromophobe	O	713-724
renal	B	725-730
cell	I	731-735
carcinomas	I	736-746
.	O	746-747

In	O	748-750
addition	O	751-759
,	O	759-760
15	O	761-763
papillary	B	764-773
renal	I	774-779
cell	I	780-784
tumours	I	785-792
and	O	793-796
ten	O	797-800
renal	B	801-806
oncocytomas	I	807-818
,	O	818-819
which	O	820-825
are	O	826-829
characterized	O	830-843
by	O	844-846
genetic	O	847-854
changes	O	855-862
other	O	863-868
than	O	869-873
loss	O	874-878
of	O	879-881
chromosome	O	882-892
3p	O	893-895
sequences	O	896-905
,	O	905-906
were	O	907-911
analysed	O	912-920
for	O	921-924
mutation	O	925-933
of	O	934-936
the	O	937-940
VHL	B	941-944
gene	O	945-949
.	O	949-950

None	O	951-955
of	O	956-958
these	O	959-964
tumours	B	965-972
showed	O	973-979
abnormal	O	980-988
migration	O	989-998
patterns	O	999-1007
.	O	1007-1008

The	O	1009-1012
results	O	1013-1020
indicate	O	1021-1029
that	O	1030-1034
mutation	O	1035-1043
of	O	1044-1046
the	O	1047-1050
VHL	B	1051-1054
gene	O	1055-1059
is	O	1060-1062
associated	O	1063-1073
exclusively	O	1074-1085
with	O	1086-1090
the	O	1091-1094
development	O	1095-1106
of	O	1107-1109
non	B	1110-1113
-	I	1113-1114
papillary	I	1114-1123
renal	I	1124-1129
cell	I	1130-1134
carcinoma	I	1135-1144
.	O	1144-1145
.	O	1144-1145

Comparative	O	0-11
genome	O	12-18
mapping	O	19-26
of	O	27-29
the	O	30-33
ataxia	B	34-40
-	I	40-41
telangiectasia	I	41-55
region	O	56-62
in	O	63-65
mouse	O	66-71
,	O	71-72
rat	O	73-76
,	O	76-77
and	O	78-81
Syrian	O	82-88
hamster	O	89-96
.	O	96-97

Chromosomal	O	98-109
locations	O	110-119
of	O	120-122
the	O	123-126
Atm	O	127-130
(	O	131-132
ataxia	B	132-138
-	I	138-139
telangiectasia	I	139-153
(	O	154-155
AT	B	155-157
)	O	157-158
-	O	159-160
mutated	O	160-167
)	O	167-168
and	O	169-172
Acat1	O	173-178
(	O	179-180
mitochondrial	O	180-193
acetoacetyl	O	194-205
-	O	205-206
CoA	O	206-209
thiolase	O	210-218
)	O	218-219
genes	O	220-225
in	O	226-228
mouse	O	229-234
,	O	234-235
rat	O	236-239
,	O	239-240
and	O	241-244
Syrian	O	245-251
hamster	O	252-259
were	O	260-264
determined	O	265-275
by	O	276-278
direct	O	279-285
R	O	286-287
-	O	287-288
banding	O	288-295
FISH	O	296-300
.	O	300-301

Both	O	302-306
genes	O	307-312
were	O	313-317
colocalized	O	318-329
to	O	330-332
the	O	333-336
C	O	337-338
-	O	338-339
D	O	339-340
band	O	341-345
of	O	346-348
mouse	O	349-354
chromosome	O	355-365
9	O	366-367
,	O	367-368
the	O	369-372
proximal	O	373-381
end	O	382-385
of	O	386-388
q24	O	389-392
.	O	392-393
1	O	394-395
of	O	396-398
rat	O	399-402
chromosome	O	403-413
8	O	414-415
,	O	415-416
and	O	417-420
qa4	O	421-424
-	O	424-425
qa5	O	425-428
of	O	429-431
Syrian	O	432-438
hamster	O	439-446
chromosome	O	447-457
12	O	458-460
.	O	460-461

The	O	462-465
regions	O	466-473
in	O	474-476
the	O	477-480
mouse	O	481-486
and	O	487-490
rat	O	491-494
were	O	495-499
homologous	O	500-510
to	O	511-513
human	O	514-519
chromosome	O	520-530
11q	O	531-534
.	O	534-535

Fine	O	536-540
genetic	O	541-548
linkage	O	549-556
mapping	O	557-564
of	O	565-567
the	O	568-571
mouse	O	572-577
AT	B	578-580
region	O	581-587
was	O	588-591
performed	O	592-601
using	O	602-607
the	O	608-611
interspecific	O	612-625
backcross	O	626-635
mice	O	636-640
.	O	640-641

Atm	O	642-645
,	O	645-646
Acat1	O	647-652
,	O	652-653
and	O	654-657
Npat	O	658-662
,	O	662-663
which	O	664-669
is	O	670-672
a	O	673-674
new	O	675-678
gene	O	679-683
isolated	O	684-692
from	O	693-697
the	O	698-701
AT	O	702-704
region	O	705-711
,	O	711-712
and	O	713-716
12	O	717-719
flanking	O	720-728
microsatellite	O	729-743
DNA	O	744-747
markers	O	748-755
were	O	756-760
examined	O	761-769
.	O	769-770

No	O	771-773
recombinations	O	774-788
were	O	789-793
found	O	794-799
among	O	800-805
the	O	806-809
Atm	O	810-813
,	O	813-814
Npat	O	815-819
,	O	819-820
Acat1	O	821-826
,	O	826-827
and	O	828-831
D9Mit6	O	832-838
loci	O	839-843
,	O	843-844
and	O	845-848
these	O	849-854
loci	O	855-859
were	O	860-864
mapped	O	865-871
2	O	872-873
.	O	873-874
0	O	875-876
cM	O	877-879
distal	O	880-886
to	O	887-889
D9Mit99	O	890-897
and	O	898-901
1	O	902-903
.	O	903-904
3	O	905-906
cM	O	907-909
proximal	O	910-918
to	O	919-921
D9Mit102	O	922-930
.	O	930-931

Comparison	O	932-942
of	O	943-945
the	O	946-949
linkage	O	950-957
map	O	958-961
of	O	962-964
mouse	O	965-970
chromosome	O	971-981
9	O	982-983
(	O	984-985
MMU9	O	985-989
)	O	989-990
and	O	991-994
that	O	995-999
of	O	1000-1002
human	O	1003-1008
chromosome	O	1009-1019
11	O	1020-1022
(	O	1023-1024
HSA11	O	1024-1029
)	O	1029-1030
indicates	O	1031-1040
that	O	1041-1045
there	O	1046-1051
is	O	1052-1054
a	O	1055-1056
chromosomal	O	1057-1068
rearrangement	O	1069-1082
due	O	1083-1086
to	O	1087-1089
an	O	1090-1092
inversion	O	1093-1102
between	O	1103-1110
Ets1	O	1111-1115
and	O	1116-1119
Atm	O	1120-1123
-	O	1123-1124
Npat	O	1124-1128
-	O	1123-1124
Acat1	O	1129-1134
and	O	1135-1138
that	O	1139-1143
the	O	1144-1147
inversion	O	1148-1157
of	O	1158-1160
MMU9	O	1161-1165
originated	O	1166-1176
from	O	1177-1181
the	O	1182-1185
chromosomal	O	1186-1197
breakage	O	1198-1206
at	O	1207-1209
the	O	1210-1213
boundary	O	1214-1222
between	O	1223-1230
Gria4	O	1231-1236
and	O	1237-1240
Atm	O	1241-1244
-	O	1244-1245
Npat	O	1245-1249
-	O	1244-1245
Acat1	O	1250-1255
on	O	1256-1258
HSA11	O	1259-1264
.	O	1264-1265

This	O	1266-1270
type	O	1271-1275
of	O	1276-1278
inversion	O	1279-1288
appeared	O	1289-1297
to	O	1298-1300
be	O	1301-1303
conserved	O	1304-1313
in	O	1314-1316
the	O	1317-1320
three	O	1321-1326
rodent	O	1327-1333
species	O	1334-1341
,	O	1341-1342
mouse	O	1343-1348
,	O	1348-1349
rat	O	1350-1353
,	O	1353-1354
and	O	1355-1358
Syrian	O	1359-1365
hamster	O	1366-1373
,	O	1373-1374
using	O	1375-1380
additional	O	1381-1391
comparative	O	1392-1403
mapping	O	1404-1411
data	O	1412-1416
with	O	1417-1421
the	O	1422-1425
Rck	O	1426-1429
gene	O	1430-1434

Tumor	B	0-5
suppression	O	6-17
and	O	18-21
apoptosis	O	22-31
of	O	32-34
human	O	35-40
prostate	B	41-49
carcinoma	I	50-59
mediated	O	60-68
by	O	69-71
a	O	72-73
genetic	O	74-81
locus	O	82-87
within	O	88-94
human	O	95-100
chromosome	O	101-111
10pter	O	112-118
-	O	118-119
q11	O	119-122
.	O	122-123

Prostate	B	124-132
cancer	I	133-139
is	O	140-142
the	O	143-146
second	O	147-153
leading	O	154-161
cause	O	162-167
of	O	168-170
male	O	171-175
cancer	B	176-182
deaths	O	183-189
in	O	190-192
the	O	193-196
United	O	197-203
States	O	204-210
.	O	210-211

Yet	O	212-215
,	O	215-216
despite	O	217-224
a	O	225-226
large	O	227-232
international	O	233-246
effort	O	247-253
,	O	253-254
little	O	255-261
is	O	262-264
known	O	265-270
about	O	271-276
the	O	277-280
molecular	O	281-290
mechanisms	O	291-301
that	O	302-306
underlie	O	307-315
this	O	316-320
devastating	O	321-332
disease	O	333-340
.	O	340-341

Prostate	O	342-350
secretory	O	351-360
epithelial	O	361-371
cells	O	372-377
and	O	378-381
androgen	O	382-390
-	O	390-391
dependent	O	391-400
prostate	B	401-409
carcinomas	I	410-420
undergo	O	421-428
apoptosis	O	429-438
in	O	439-441
response	O	442-450
to	O	451-453
androgen	O	454-462
deprivation	O	463-474
and	O	475-478
,	O	478-479
furthermore	O	480-491
,	O	491-492
most	O	493-497
prostate	B	498-506
carcinomas	I	507-517
become	O	518-524
androgen	O	525-533
independent	O	534-545
and	O	546-549
refractory	O	550-560
to	O	561-563
further	O	564-571
therapeutic	O	572-583
manipulations	O	584-597
during	O	598-604
disease	O	605-612
progression	O	613-624
.	O	624-625

Definition	O	626-636
of	O	637-639
the	O	640-643
genetic	O	644-651
events	O	652-658
that	O	659-663
trigger	O	664-671
apoptosis	O	672-681
in	O	682-684
the	O	685-688
prostate	O	689-697
could	O	698-703
provide	O	704-711
important	O	712-721
insights	O	722-730
into	O	731-735
critical	O	736-744
pathways	O	745-753
in	O	754-756
normal	O	757-763
development	O	764-775
as	O	776-778
well	O	779-783
as	O	784-786
elucidate	O	787-796
the	O	797-800
perturbations	O	801-814
of	O	815-817
those	O	818-823
key	O	824-827
pathways	O	828-836
in	O	837-839
neoplastic	O	840-850
transformation	O	851-865
.	O	865-866

We	O	867-869
report	O	870-876
the	O	877-880
functional	O	881-891
definition	O	892-902
of	O	903-905
a	O	906-907
novel	O	908-913
genetic	O	914-921
locus	O	922-927
within	O	928-934
human	O	935-940
chromosome	O	941-951
10pter	O	952-958
-	O	958-959
q11	O	959-962
that	O	963-967
mediates	O	968-976
both	O	977-981
in	O	982-984
vivo	O	985-989
tumor	O	990-995
suppression	O	996-1007
and	O	1008-1011
in	O	1012-1014
vitro	O	1015-1020
apoptosis	O	1021-1030
of	O	1031-1033
prostatic	B	1034-1043
adenocarcinoma	I	1044-1058
cells	O	1059-1064
.	O	1064-1065

A	O	1066-1067
defined	O	1068-1075
fragment	O	1076-1084
of	O	1085-1087
human	O	1088-1093
chromosome	O	1094-1104
10	O	1105-1107
was	O	1108-1111
transferred	O	1112-1123
via	O	1124-1127
microcell	O	1128-1137
fusion	O	1138-1144
into	O	1145-1149
a	O	1150-1151
prostate	B	1152-1160
adenocarcinoma	I	1161-1175
cell	O	1176-1180
line	O	1181-1185
.	O	1185-1186

Microcell	O	1187-1196
hybrids	O	1197-1204
containing	O	1205-1215
only	O	1216-1220
the	O	1221-1224
region	O	1225-1231
10pter	O	1232-1238
-	O	1238-1239
q11	O	1239-1242
were	O	1243-1247
suppressed	O	1248-1258
for	O	1259-1262
tumorigenicity	O	1263-1277
following	O	1278-1287
injection	O	1288-1297
of	O	1298-1300
microcell	O	1301-1310
hybrids	O	1311-1318
into	O	1319-1323
nude	O	1324-1328
mice	O	1329-1333
.	O	1333-1334

Furthermore	O	1335-1346
,	O	1346-1347
the	O	1348-1351
complemented	O	1352-1364
hybrids	O	1365-1372
undergo	O	1373-1380
programmed	O	1381-1391
cell	O	1392-1396
death	O	1397-1402
in	O	1403-1405
vitro	O	1406-1411
via	O	1412-1415
a	O	1416-1417
mechanism	O	1418-1427
that	O	1428-1432
does	O	1433-1437
not	O	1438-1441
require	O	1442-1449
nuclear	O	1450-1457
localization	O	1458-1470
of	O	1471-1473
p53	O	1474-1477
.	O	1477-1478

These	O	1479-1484
data	O	1485-1489
functionally	O	1490-1502
define	O	1503-1509
a	O	1510-1511
novel	O	1512-1517
genetic	O	1518-1525
locus	O	1526-1531
,	O	1531-1532
designated	O	1533-1543
PAC1	O	1544-1548
,	O	1548-1549
for	O	1550-1553
prostate	O	1554-1562
adenocarcinoma	O	1563-1577
1	O	1578-1579
,	O	1579-1580
involved	O	1581-1589
in	O	1590-1592
tumor	O	1593-1598
suppression	O	1599-1610
of	O	1611-1613
human	O	1614-1619
prostate	B	1620-1628
carcinoma	I	1629-1638
and	O	1639-1642
furthermore	O	1643-1654
strongly	O	1655-1663
suggest	O	1664-1671
that	O	1672-1676
the	O	1677-1680
cell	O	1681-1685
death	O	1686-1691
pathway	O	1692-1699
can	O	1700-1703
be	O	1704-1706
functionally	O	1707-1719
restored	O	1720-1728
in	O	1729-1731
prostatic	B	1732-1741
adenocarcinoma	I	1742-1756
.	O	1756-1757
.	O	1756-1757

Phenotypic	O	0-10
and	O	11-14
genotypic	O	15-24
overlap	O	25-32
between	O	33-40
atelosteogenesis	B	41-57
type	I	58-62
2	I	63-64
and	O	65-68
diastrophic	B	69-80
dysplasia	I	81-90
.	O	90-91

Mutations	O	92-101
in	O	102-104
the	O	105-108
diastrophic	B	109-120
dysplasia	I	121-130
sulfate	O	131-138
transporter	O	139-150
gene	O	151-155
DTDST	O	156-161
have	O	162-166
been	O	167-171
associated	O	172-182
with	O	183-187
a	O	188-189
family	O	190-196
of	O	197-199
chondrodysplasias	B	200-217
that	O	218-222
comprises	O	223-232
,	O	232-233
in	O	234-236
order	O	237-242
of	O	243-245
increasing	O	246-256
severity	O	257-265
,	O	265-266
diastrophic	B	267-278
dysplasia	I	279-288
(	O	289-290
DTD	B	290-293
)	O	293-294
,	O	294-295
atelosteogenesis	B	296-312
type	I	313-317
2	I	318-319
(	O	320-321
AO2	B	321-324
)	O	324-325
,	O	325-326
and	O	327-330
achondrogenesis	B	331-346
type	I	347-351
1B	I	352-354
(	O	355-356
ACG1B	B	356-361
)	O	361-362
.	O	362-363

To	O	364-366
learn	O	367-372
more	O	373-377
about	O	378-383
the	O	384-387
molecular	O	388-397
basis	O	398-403
of	O	404-406
DTDST	B	407-412
chondrodysplasias	I	413-430
and	O	431-434
about	O	435-440
genotype	O	441-449
-	O	449-450
phenotype	O	450-459
correlations	O	460-472
,	O	472-473
we	O	474-476
studied	O	477-484
fibroblast	O	485-495
cultures	O	496-504
of	O	505-507
three	O	508-513
new	O	514-517
patients	O	518-526
one	O	528-531
with	O	532-536
AO	B	537-539
-	I	539-540
2	I	540-541
,	O	541-542
one	O	543-546
with	O	547-551
DTD	B	552-555
,	O	555-556
and	O	557-560
one	O	561-564
with	O	565-569
an	O	570-572
intermediate	O	573-585
phenotype	O	586-595
(	O	596-597
AO2	B	597-600
/	O	600-601
DTD	B	601-604
)	O	604-605
.	O	605-606

Reduced	O	607-614
incorporation	O	615-628
of	O	629-631
inorganic	O	632-641
sulfate	O	642-649
into	O	650-654
macromolecules	O	655-669
was	O	670-673
found	O	674-679
in	O	680-682
all	O	683-686
three	O	687-692
.	O	692-693

Each	O	694-698
of	O	699-701
the	O	702-705
three	O	706-711
patients	O	712-720
was	O	721-724
found	O	725-730
to	O	731-733
be	O	734-736
heterozygous	O	737-749
for	O	750-753
a	O	754-755
c862t	O	756-761
transition	O	762-772
predicting	O	773-783
a	O	784-785
R279W	O	786-791
substitution	O	792-804
in	O	805-807
the	O	808-811
third	O	812-817
extracellular	O	818-831
loop	O	832-836
of	O	837-839
DTDST	O	840-845
.	O	845-846

In	O	847-849
two	O	850-853
patients	O	854-862
(	O	863-864
DTD	B	864-867
and	O	868-871
AO2	B	872-875
/	O	875-876
DTD	B	876-879
)	O	879-880
,	O	880-881
no	O	882-884
other	O	885-890
structural	O	891-901
mutation	O	902-910
was	O	911-914
found	O	915-920
,	O	920-921
but	O	922-925
polymerase	O	926-936
chain	O	937-942
reaction	O	943-951
amplification	O	952-965
and	O	966-969
single	O	970-976
-	O	976-977
strand	O	977-983
conformation	O	984-996
polymorphism	O	997-1009
analysis	O	1010-1018
of	O	1019-1021
fibroblast	O	1022-1032
cDNA	O	1033-1037
showed	O	1038-1044
reduced	O	1045-1052
mRNA	O	1053-1057
levels	O	1058-1064
of	O	1065-1067
the	O	1068-1071
wild	O	1072-1076
-	O	1076-1077
type	O	1077-1081
DTDST	O	1082-1087
allele	O	1088-1094
these	O	1096-1101
two	O	1102-1105
patients	O	1106-1114
may	O	1115-1118
be	O	1119-1121
compound	O	1122-1130
heterozygotes	O	1131-1144
for	O	1145-1148
the	O	1149-1152
"	O	1153-1154
Finnish	O	1155-1162
"	O	1163-1164
mutation	O	1165-1173
(	O	1174-1175
as	O	1175-1177
yet	O	1178-1181
uncharacterized	O	1182-1197
at	O	1198-1200
the	O	1201-1204
DNA	O	1205-1208
level	O	1209-1214
)	O	1214-1215
,	O	1215-1216
which	O	1217-1222
causes	O	1223-1229
reduced	O	1230-1237
expression	O	1238-1248
of	O	1249-1251
DTDST	O	1252-1257
.	O	1257-1258

The	O	1259-1262
third	O	1263-1268
patient	O	1269-1276
(	O	1277-1278
with	O	1278-1282
AO2	B	1283-1286
)	O	1286-1287
had	O	1288-1291
the	O	1292-1295
R279W	O	1296-1301
mutation	O	1302-1310
compounded	O	1311-1321
with	O	1322-1326
a	O	1327-1328
novel	O	1329-1334
mutation	O	1335-1343
,	O	1343-1344
the	O	1345-1348
deletion	O	1349-1357
of	O	1358-1360
cytosine	O	1361-1369
418	O	1370-1373
(	O	1374-1375
delta	O	1375-1380
c418	O	1381-1385
)	O	1385-1386
,	O	1386-1387
predicting	O	1388-1398
a	O	1399-1400
frameshift	O	1401-1411
with	O	1412-1416
premature	O	1417-1426
termination	O	1427-1438
.	O	1438-1439

Also	O	1440-1444
the	O	1445-1448
delta	O	1449-1454
c418	O	1455-1459
allele	O	1460-1466
was	O	1467-1470
underrepresented	O	1471-1487
in	O	1488-1490
the	O	1491-1494
cDNA	O	1495-1499
,	O	1499-1500
in	O	1501-1503
accordance	O	1504-1514
with	O	1515-1519
previous	O	1520-1528
observations	O	1529-1541
that	O	1542-1546
premature	O	1547-1556
stop	O	1557-1561
codons	O	1562-1568
reduce	O	1569-1575
mRNA	O	1576-1580
levels	O	1581-1587
.	O	1587-1588

The	O	1589-1592
presence	O	1593-1601
of	O	1602-1604
the	O	1605-1608
DTDST	O	1609-1614
R279W	O	1615-1620
mutation	O	1621-1629
in	O	1630-1632
a	O	1633-1634
total	O	1635-1640
of	O	1641-1643
11	O	1644-1646
patients	O	1647-1655
with	O	1656-1660
AO2	B	1661-1664
or	O	1665-1667
DTD	B	1668-1671
emphasizes	O	1672-1682
the	O	1683-1686
overlap	O	1687-1694
between	O	1695-1702
these	O	1703-1708
conditions	O	1709-1719
.	O	1719-1720

This	O	1721-1725
mutation	O	1726-1734
has	O	1735-1738
not	O	1739-1742
been	O	1743-1747
found	O	1748-1753
so	O	1754-1756
far	O	1757-1760
in	O	1761-1763
8	O	1764-1765
analyzed	O	1766-1774
ACG1B	B	1775-1780
patients	O	1781-1789
,	O	1789-1790
suggesting	O	1791-1801
that	O	1802-1806
it	O	1807-1809
allows	O	1810-1816
some	O	1817-1821
residual	O	1822-1830
activity	O	1831-1839
of	O	1840-1842
the	O	1843-1846
sulfate	O	1847-1854
transporter	O	1855-1866
.	O	1866-1867
.	O	1866-1867

Cloning	O	0-7
of	O	8-10
the	O	11-14
homogentisate	O	15-28
1	O	29-30
,	O	30-31
2	O	31-32
-	O	32-33
dioxygenase	O	33-44
gene	O	45-49
,	O	49-50
the	O	51-54
key	O	55-58
enzyme	O	59-65
of	O	66-68
alkaptonuria	B	69-81
in	O	82-84
mouse	O	85-90
.	O	90-91

We	O	92-94
determined	O	95-105
48	O	106-108
amino	O	109-114
acid	O	115-119
residues	O	120-128
from	O	129-133
five	O	134-138
peptides	O	139-147
from	O	148-152
the	O	153-156
homogeneous	O	157-168
monomer	O	169-176
of	O	177-179
homogentisate	O	180-193
1	O	194-195
,	O	195-196
2	O	197-198
-	O	198-199
dioxygenase	O	199-210
(	O	211-212
HGO	O	212-215
;	O	215-216
E	O	217-218
.	O	218-219
C	O	220-221
.	O	221-222
1	O	223-224
.	O	224-225
13	O	226-228
.	O	228-229
11	O	230-232
.	O	232-233
15	O	234-236
)	O	236-237
of	O	238-240
mouse	O	241-246
liver	O	247-252
.	O	252-253

After	O	254-259
digestion	O	260-269
with	O	270-274
trypsin	O	275-282
,	O	282-283
peptides	O	284-292
were	O	293-297
separated	O	298-307
by	O	308-310
reversed	O	311-319
phase	O	320-325
chromatography	O	326-340
and	O	341-344
amino	O	345-350
acid	O	351-355
sequenced	O	356-365
.	O	365-366

The	O	367-370
deduced	O	371-378
codon	O	379-384
sequence	O	385-393
of	O	394-396
three	O	397-402
peptides	O	403-411
was	O	412-415
used	O	416-420
to	O	421-423
derive	O	424-430
degenerated	O	431-442
oligomeres	O	443-453
.	O	453-454

By	O	455-457
combining	O	458-467
these	O	468-473
oligos	O	474-480
,	O	480-481
we	O	482-484
were	O	485-489
able	O	490-494
to	O	495-497
amplify	O	498-505
fragments	O	506-515
from	O	516-520
100	O	521-524
to	O	525-527
300	O	528-531
bases	O	532-537
(	O	538-539
b	O	539-540
)	O	540-541
from	O	542-546
mouse	O	547-552
liver	O	553-558
cDNA	O	559-563
by	O	564-566
polymerase	O	567-577
chain	O	578-583
reaction	O	584-592
after	O	593-598
reverse	O	599-606
transcription	O	607-620
(	O	621-622
RT	O	622-624
-	O	624-625
PCR	O	625-628
)	O	628-629
.	O	629-630

A	O	631-632
fragment	O	633-641
of	O	642-644
200	O	645-648
b	O	649-650
was	O	651-654
cloned	O	655-661
and	O	662-665
used	O	666-670
as	O	671-673
a	O	674-675
probe	O	676-681
to	O	682-684
screen	O	685-691
a	O	692-693
mouse	O	694-699
liver	O	700-705
cDNA	O	706-710
library	O	711-718
.	O	718-719

One	O	720-723
clone	O	724-729
from	O	730-734
this	O	735-739
library	O	740-747
contained	O	748-757
the	O	758-761
complete	O	762-770
cDNA	O	771-775
-	O	775-776
insert	O	776-782
for	O	783-786
HGO	O	787-790
as	O	791-793
determined	O	794-804
by	O	805-807
sequencing	O	808-818
.	O	818-819

The	O	820-823
cDNA	O	824-828
encodes	O	829-836
for	O	837-840
a	O	841-842
protein	O	843-850
of	O	851-853
50	O	854-856
kDa	O	857-860
,	O	860-861
as	O	862-864
predicted	O	865-874
.	O	874-875

The	O	876-879
cDNA	O	880-884
of	O	885-887
mouse	O	888-893
HGO	O	894-897
has	O	898-901
an	O	902-904
overall	O	905-912
identity	O	913-921
of	O	922-924
41	O	925-927
%	O	927-928
to	O	929-931
the	O	932-935
corresponding	O	936-949
gene	O	950-954
hmgA	O	955-959
from	O	960-964
Aspergillus	O	965-976
.	O	976-977

Sequence	O	978-986
similarities	O	987-999
to	O	1000-1002
human	O	1003-1008
expressed	O	1009-1018
sequence	O	1019-1027
tags	O	1028-1032
(	O	1033-1034
EST	O	1034-1037
)	O	1037-1038
clones	O	1039-1045
ranged	O	1046-1052
from	O	1053-1057
70	O	1058-1060
%	O	1060-1061
to	O	1062-1064
20	O	1065-1067
%	O	1067-1068
.	O	1068-1069

The	O	1070-1073
positions	O	1074-1083
of	O	1084-1086
122	O	1087-1090
conserved	O	1091-1100
amino	O	1101-1106
acids	O	1107-1112
could	O	1113-1118
be	O	1119-1121
determined	O	1122-1132
by	O	1133-1135
multiple	O	1136-1144
sequence	O	1145-1153
alignment	O	1154-1163
.	O	1163-1164

We	O	1165-1167
identified	O	1168-1178
one	O	1179-1182
first	O	1183-1188
intron	O	1189-1195
of	O	1196-1198
928	O	1199-1202
b	O	1203-1204
in	O	1205-1207
the	O	1208-1211
mouse	O	1212-1217
gene	O	1218-1222
.	O	1222-1223

The	O	1224-1227
gene	O	1228-1232
for	O	1233-1236
HGO	O	1237-1240
seems	O	1241-1246
to	O	1247-1249
be	O	1250-1252
expressed	O	1253-1262
in	O	1263-1265
various	O	1266-1273
tissues	O	1274-1281
,	O	1281-1282
as	O	1283-1285
shown	O	1286-1291
by	O	1292-1294
RT	O	1295-1297
-	O	1297-1298
PCR	O	1298-1301
on	O	1302-1304
different	O	1305-1314
cDNAs	O	1315-1320
.	O	1320-1321

FISH	O	1322-1326
experiments	O	1327-1338
with	O	1339-1343
the	O	1344-1347
whole	O	1348-1353
murine	O	1354-1360
cDNA	O	1361-1365
as	O	1366-1368
probe	O	1369-1374
clearly	O	1375-1382
revealed	O	1383-1391
signals	O	1392-1399
at	O	1400-1402
the	O	1403-1406
human	O	1407-1412
chromosomal	O	1413-1424
band	O	1425-1429
3q13	O	1430-1434
.	O	1434-1435

3	O	1436-1437
-	O	1437-1438
q21	O	1438-1441
.	O	1441-1442

This	O	1443-1447
corresponds	O	1448-1459
well	O	1460-1464
to	O	1465-1467
the	O	1468-1471
previous	O	1472-1480
assignment	O	1481-1491
of	O	1492-1494
the	O	1495-1498
locus	O	1499-1504
for	O	1505-1508
the	O	1509-1512
human	O	1513-1518
alkaptonuria	B	1519-1531
gene	O	1532-1536
(	O	1537-1538
AKU	O	1538-1541
)	O	1541-1542
to	O	1543-1545
the	O	1546-1549
same	O	1550-1554
chromosomal	O	1555-1566
region	O	1567-1573
by	O	1574-1576
multipoint	O	1577-1587
linkage	O	1588-1595
analysis	O	1596-1604
.	O	1604-1605

We	O	1606-1608
therefore	O	1609-1618
conclude	O	1619-1627
that	O	1628-1632
the	O	1633-1636
HGO	O	1637-1640
cDNA	O	1641-1645
encodes	O	1646-1653
the	O	1654-1657
gene	O	1658-1662
responsible	O	1663-1674
for	O	1675-1678
alkaptonuria	B	1679-1691
.	O	1691-1692

Abnormal	O	0-8
myotonic	B	9-17
dystrophy	I	18-27
protein	O	28-35
kinase	O	36-42
levels	O	43-49
produce	O	50-57
only	O	58-62
mild	O	63-67
myopathy	B	68-76
in	O	77-79
mice	O	80-84
.	O	84-85

Myotonic	B	86-94
dystrophy	I	95-104
(	O	105-106
DM	B	106-108
)	O	108-109
is	O	110-112
commonly	O	113-121
associated	O	122-132
with	O	133-137
CTG	O	138-141
repeat	O	142-148
expansions	O	149-159
within	O	160-166
the	O	167-170
gene	O	171-175
for	O	176-179
DM	O	180-182
-	O	182-183
protein	O	183-190
kinase	O	191-197
(	O	198-199
DMPK	O	199-203
)	O	203-204
.	O	204-205

The	O	206-209
effect	O	210-216
of	O	217-219
altered	O	220-227
expression	O	228-238
levels	O	239-245
of	O	246-248
DMPK	O	249-253
,	O	253-254
which	O	255-260
is	O	261-263
ubiquitously	O	264-276
expressed	O	277-286
in	O	287-289
all	O	290-293
muscle	O	294-300
cell	O	301-305
lineages	O	306-314
during	O	315-321
development	O	322-333
,	O	333-334
was	O	335-338
examined	O	339-347
by	O	348-350
disrupting	O	351-361
the	O	362-365
endogenous	O	366-376
Dmpk	O	377-381
gene	O	382-386
and	O	387-390
overexpressing	O	391-405
a	O	406-407
normal	O	408-414
human	O	415-420
DMPK	O	421-425
transgene	O	426-435
in	O	436-438
mice	O	439-443
.	O	443-444

Nullizygous	O	445-456
(	O	457-458
-	O	458-459
/	O	459-460
-	O	458-459
)	O	461-462
mice	O	463-467
showed	O	468-474
only	O	475-479
inconsistent	O	480-492
and	O	493-496
minor	O	497-502
size	O	503-507
changes	O	508-515
in	O	516-518
head	O	519-523
and	O	524-527
neck	O	528-532
muscle	O	533-539
fibres	O	540-546
at	O	547-549
older	O	550-555
age	O	556-559
,	O	559-560
animals	O	561-568
with	O	569-573
the	O	574-577
highest	O	578-585
DMPK	O	586-590
transgene	O	591-600
expression	O	601-611
showed	O	612-618
hypertrophic	B	619-631
cardiomyopathy	I	632-646
and	O	647-650
enhanced	O	651-659
neonatal	O	660-668
mortality	O	669-678
.	O	678-679

However	O	680-687
,	O	687-688
both	O	689-693
models	O	694-700
lack	O	701-705
other	O	706-711
frequent	O	712-720
DM	B	721-723
symptoms	O	724-732
including	O	733-742
the	O	743-746
fibre	O	747-752
-	O	752-753
type	O	753-757
dependent	O	758-767
atrophy	B	768-775
,	O	775-776
myotonia	B	777-785
,	O	785-786
cataract	B	787-795
and	O	796-799
male	B	800-804
-	I	804-805
infertility	I	805-816
.	O	816-817

These	O	818-823
results	O	824-831
strengthen	O	832-842
the	O	843-846
contention	O	847-857
that	O	858-862
simple	O	863-869
loss	O	870-874
-	O	874-875
or	O	876-878
gain	O	879-883
-	O	883-884
of	O	884-886
-	O	883-884
expression	O	887-897
of	O	898-900
DMPK	O	901-905
is	O	906-908
not	O	909-912
the	O	913-916
only	O	917-921
crucial	O	922-929
requirement	O	930-941
for	O	942-945
development	O	946-957
of	O	958-960
the	O	961-964
disease	O	965-972
.	O	972-973
.	O	972-973

Molecular	O	0-9
bases	O	10-15
of	O	16-18
combined	B	19-27
subtotal	I	28-36
deficiencies	I	37-49
of	I	50-52
C6	I	53-55
and	I	56-59
C7	I	60-62
:	O	62-63
their	O	64-69
effects	O	70-77
in	O	78-80
combination	O	81-92
with	O	93-97
other	O	98-103
C6	B	104-106
and	I	107-110
C7	I	111-113
deficiencies	I	114-126
.	O	126-127

Combined	B	128-136
subtotal	I	137-145
deficiency	I	146-156
of	I	157-159
C6	I	160-162
and	I	163-166
C7	I	167-169
,	O	169-170
in	O	171-173
which	O	174-179
both	O	180-184
proteins	O	185-193
are	O	194-197
expressed	O	198-207
at	O	208-210
very	O	211-215
low	O	216-219
levels	O	220-226
,	O	226-227
has	O	228-231
been	O	232-236
observed	O	237-245
in	O	246-248
homozygous	O	249-259
form	O	260-264
in	O	265-267
two	O	268-271
families	O	272-280
.	O	280-281

A	O	282-283
defect	O	284-290
at	O	291-293
the	O	294-297
5	O	298-299
splice	O	300-306
donor	O	307-312
site	O	313-317
of	O	318-320
intron	O	321-327
15	O	328-330
of	O	331-333
the	O	334-337
C6	O	338-340
gene	O	341-345
explains	O	346-354
the	O	355-358
low	O	359-362
molecular	O	363-372
weight	O	373-379
of	O	380-382
the	O	383-386
C6	O	387-389
protein	O	390-397
and	O	398-401
is	O	402-404
probably	O	405-413
responsible	O	414-425
for	O	426-429
its	O	430-433
low	O	434-437
expressed	O	438-447
concentration	O	448-461
.	O	461-462

The	O	463-466
C7	O	467-469
defect	O	470-476
is	O	477-479
more	O	480-484
enigmatic	O	485-494
the	O	496-499
protein	O	500-507
is	O	508-510
of	O	511-513
normal	O	514-520
molecular	O	521-530
weight	O	531-537
,	O	537-538
low	O	539-542
circulating	O	543-554
concentration	O	555-568
,	O	568-569
and	O	570-573
altered	O	574-581
isoelectric	O	582-593
point	O	594-599
.	O	599-600

An	O	601-603
Arg	O	604-607
>	O	608-609
Ser	O	610-613
codon	O	614-619
substitution	O	620-632
in	O	633-635
exon	O	636-640
11	O	641-643
is	O	644-646
the	O	647-650
only	O	651-655
molecular	O	656-665
alteration	O	666-676
within	O	677-683
the	O	684-687
mature	O	688-694
C7	O	695-697
protein	O	698-705
.	O	705-706

These	O	707-712
defects	O	713-720
are	O	721-724
associated	O	725-735
with	O	736-740
a	O	741-742
characteristic	O	743-757
set	O	758-761
of	O	762-764
polymorphic	O	765-776
DNA	O	777-780
markers	O	781-788
in	O	789-791
the	O	792-795
C6	O	796-798
/	O	798-799
C7	O	799-801
region	O	802-808
,	O	808-809
forming	O	810-817
a	O	818-819
distinct	O	820-828
haplotype	O	829-838
.	O	838-839

The	O	840-843
haplotype	O	844-853
has	O	854-857
been	O	858-862
found	O	863-868
in	O	869-871
combination	O	872-883
with	O	884-888
a	O	889-890
number	O	891-897
of	O	898-900
other	O	901-906
haplotypes	O	907-917
containing	O	918-928
defective	O	929-938
genes	O	939-944
that	O	945-949
lead	O	950-954
either	O	955-961
to	O	962-964
C6	B	965-967
or	I	968-970
C7	I	971-973
deficiency	I	974-984
,	O	984-985
but	O	986-989
with	O	990-994
different	O	995-1004
consequences	O	1005-1017
.	O	1017-1018

Where	O	1019-1024
it	O	1025-1027
is	O	1028-1030
combined	O	1031-1039
with	O	1040-1044
a	O	1045-1046
C6	B	1047-1049
-	I	1049-1050
deficient	I	1050-1059
gene	O	1060-1064
,	O	1064-1065
the	O	1066-1069
serum	O	1070-1075
C7	O	1076-1078
levels	O	1079-1085
can	O	1086-1089
be	O	1090-1092
surprisingly	O	1093-1105
high	O	1106-1110
,	O	1110-1111
possibly	O	1112-1120
because	O	1121-1128
there	O	1129-1134
is	O	1135-1137
no	O	1138-1140
C6	O	1141-1143
generating	O	1144-1154
C56	O	1155-1158
to	O	1159-1161
consume	O	1162-1169
the	O	1170-1173
C7	O	1174-1176
.	O	1176-1177

In	O	1178-1180
contrast	O	1181-1189
,	O	1189-1190
where	O	1191-1196
the	O	1197-1200
C7	O	1201-1203
genes	O	1204-1209
are	O	1210-1213
both	O	1214-1218
defective	O	1219-1228
(	O	1229-1230
but	O	1230-1233
still	O	1234-1239
partially	O	1240-1249
functional	O	1250-1260
)	O	1260-1261
,	O	1261-1262
there	O	1263-1268
may	O	1269-1272
be	O	1273-1275
a	O	1276-1277
profound	O	1278-1286
deficit	O	1287-1294
of	O	1295-1297
circulating	O	1298-1309
C7	O	1310-1312
because	O	1313-1320
there	O	1321-1326
is	O	1327-1329
ample	O	1330-1335
C6	O	1336-1338
to	O	1339-1341
produce	O	1342-1349
C56	O	1350-1353
and	O	1354-1357
consume	O	1358-1365
the	O	1366-1369
already	O	1370-1377
small	O	1378-1383
amount	O	1384-1390
of	O	1391-1393
C7	O	1394-1396
.	O	1396-1397

Each	O	1398-1402
molecular	O	1403-1412
defect	O	1413-1419
has	O	1420-1423
also	O	1424-1428
been	O	1429-1433
found	O	1434-1439
in	O	1440-1442
isolation	O	1443-1452
and	O	1453-1456
has	O	1457-1460
the	O	1461-1464
expected	O	1465-1473
effect	O	1474-1480
.	O	1480-1481
.	O	1480-1481

Constitutively	O	0-14
methylated	O	15-25
CpG	O	26-29
dinucleotides	O	30-43
as	O	44-46
mutation	O	47-55
hot	O	56-59
spots	O	60-65
in	O	66-68
the	O	69-72
retinoblastoma	B	73-87
gene	O	88-92
(	O	93-94
RB1	O	94-97
)	O	97-98
.	O	98-99

A	O	100-101
wide	O	102-106
spectrum	O	107-115
of	O	116-118
mutations	O	119-128
,	O	128-129
ranging	O	130-137
from	O	138-142
point	O	143-148
mutations	O	149-158
to	O	159-161
large	O	162-167
deletions	O	168-177
,	O	177-178
have	O	179-183
been	O	184-188
described	O	189-198
in	O	199-201
the	O	202-205
retinoblastoma	B	206-220
gene	O	221-225
(	O	226-227
RB1	O	227-230
)	O	230-231
.	O	231-232

Mutations	O	233-242
have	O	243-247
been	O	248-252
found	O	253-258
throughout	O	259-269
the	O	270-273
gene	O	274-278
;	O	278-279
however	O	280-287
,	O	287-288
these	O	289-294
genetic	O	295-302
alterations	O	303-314
do	O	315-317
not	O	318-321
appear	O	322-328
to	O	329-331
be	O	332-334
homogeneously	O	335-348
distributed	O	349-360
.	O	360-361

In	O	362-364
particular	O	365-375
,	O	375-376
a	O	377-378
significant	O	379-390
proportion	O	391-401
of	O	402-404
disease	O	405-412
-	O	412-413
causing	O	413-420
mutations	O	421-430
results	O	431-438
in	O	439-441
the	O	442-445
premature	O	446-455
termination	O	456-467
of	O	468-470
protein	O	471-478
synthesis	O	479-488
,	O	488-489
and	O	490-493
the	O	494-497
majority	O	498-506
of	O	507-509
these	O	510-515
mutations	O	516-525
occur	O	526-531
as	O	532-534
C	O	535-536
-	O	536-537
-	O	536-537
>	O	539-540
T	O	541-542
transitions	O	543-554
at	O	555-557
CpG	O	558-561
dinucleotides	O	562-575
(	O	576-577
CpGs	O	577-581
)	O	581-582
.	O	582-583

Such	O	584-588
recurrent	O	589-598
CpG	O	599-602
mutations	O	603-612
,	O	612-613
including	O	614-623
those	O	624-629
found	O	630-635
in	O	636-638
RB1	O	639-642
,	O	642-643
are	O	644-647
likely	O	648-654
the	O	655-658
result	O	659-665
of	O	666-668
the	O	669-672
deamination	O	673-684
of	O	685-687
5	O	688-689
-	O	689-690
methylcytosine	O	690-704
within	O	705-711
these	O	712-717
CpGs	O	718-722
.	O	722-723

In	O	724-726
the	O	727-730
present	O	731-738
study	O	739-744
,	O	744-745
we	O	746-748
used	O	749-753
the	O	754-757
sodiumbisulfite	O	758-773
conversion	O	774-784
method	O	785-791
to	O	792-794
detect	O	795-801
cytosine	O	802-810
methylation	O	811-822
in	O	823-825
representative	O	826-840
exons	O	841-846
of	O	847-849
RB1	O	850-853
.	O	853-854

We	O	855-857
analyzed	O	858-866
DNA	O	867-870
from	O	871-875
a	O	876-877
variety	O	878-885
of	O	886-888
tissues	O	889-896
and	O	897-900
specifically	O	901-913
targeted	O	914-922
CGA	O	923-926
codons	O	927-933
in	O	934-936
RB1	O	937-940
,	O	940-941
where	O	942-947
recurrent	O	948-957
premature	O	958-967
termination	O	968-979
mutations	O	980-989
have	O	990-994
been	O	995-999
reported	O	1000-1008
.	O	1008-1009

We	O	1010-1012
found	O	1013-1018
that	O	1019-1023
DNA	O	1024-1027
methylation	O	1028-1039
within	O	1040-1046
RB1	O	1047-1050
exons	O	1051-1056
8	O	1057-1058
,	O	1058-1059
14	O	1060-1062
,	O	1062-1063
25	O	1064-1066
,	O	1066-1067
and	O	1068-1071
27	O	1072-1074
appeared	O	1075-1083
to	O	1084-1086
be	O	1087-1089
restricted	O	1090-1100
to	O	1101-1103
CpGs	O	1104-1108
,	O	1108-1109
including	O	1110-1119
six	O	1120-1123
CGA	O	1124-1127
codons	O	1128-1134
.	O	1134-1135

Other	O	1136-1141
codons	O	1142-1148
containing	O	1149-1159
methylated	O	1160-1170
cytosines	O	1171-1180
have	O	1181-1185
not	O	1186-1189
been	O	1190-1194
reported	O	1195-1203
to	O	1204-1206
be	O	1207-1209
mutated	O	1210-1217
.	O	1217-1218

Therefore	O	1219-1228
,	O	1228-1229
disease	O	1230-1237
-	O	1237-1238
causing	O	1238-1245
mutations	O	1246-1255
at	O	1256-1258
CpGs	O	1259-1263
in	O	1264-1266
RB1	O	1267-1270
appear	O	1271-1277
to	O	1278-1280
be	O	1281-1283
determined	O	1284-1294
by	O	1295-1297
several	O	1298-1305
factors	O	1306-1313
,	O	1313-1314
including	O	1315-1324
the	O	1325-1328
constitutive	O	1329-1341
presence	O	1342-1350
of	O	1351-1353
DNA	O	1354-1357
methylation	O	1358-1369
at	O	1370-1372
cytosines	O	1373-1382
within	O	1383-1389
CpGs	O	1390-1394
,	O	1394-1395
the	O	1396-1399
specific	O	1400-1408
codon	O	1409-1414
within	O	1415-1421
which	O	1422-1427
the	O	1428-1431
methylated	O	1432-1442
cytosine	O	1443-1451
is	O	1452-1454
located	O	1455-1462
,	O	1462-1463
and	O	1464-1467
the	O	1468-1471
particular	O	1472-1482
region	O	1483-1489
of	O	1490-1492
the	O	1493-1496
gene	O	1497-1501
within	O	1502-1508
which	O	1509-1514
that	O	1515-1519
codon	O	1520-1525
resides	O	1526-1533
.	O	1533-1534
.	O	1533-1534

The	O	0-3
TSG101	O	4-10
tumor	B	11-16
susceptibility	O	17-31
gene	O	32-36
is	O	37-39
located	O	40-47
in	O	48-50
chromosome	O	51-61
11	O	62-64
band	O	65-69
p15	O	70-73
and	O	74-77
is	O	78-80
mutated	O	81-88
in	O	89-91
human	O	92-97
breast	B	98-104
cancer	I	105-111
.	O	111-112

Recent	O	113-119
work	O	120-124
has	O	125-128
identified	O	129-139
a	O	140-141
mouse	O	142-147
gene	O	148-152
(	O	153-154
tsg101	O	154-160
)	O	160-161
whose	O	162-167
inactivation	O	168-180
in	O	181-183
fibroblasts	O	184-195
results	O	196-203
in	O	204-206
cellular	O	207-215
transformation	O	216-230
and	O	231-234
the	O	235-238
ability	O	239-246
to	O	247-249
produce	O	250-257
metastatic	B	258-268
tumors	I	269-275
in	O	276-278
nude	O	279-283
mice	O	284-288
.	O	288-289

Here	O	290-294
,	O	294-295
we	O	296-298
report	O	299-305
that	O	306-310
the	O	311-314
human	O	315-320
homolog	O	321-328
,	O	328-329
TSG101	O	330-336
,	O	336-337
which	O	338-343
we	O	344-346
isolated	O	347-355
and	O	356-359
mapped	O	360-366
to	O	367-369
chromosome	O	370-380
11	O	381-383
,	O	383-384
bands	O	385-390
15	O	391-393
.	O	393-394
1	O	395-396
-	O	396-397
15	O	397-399
1	O	400-401
-	O	401-402
15	O	402-404
.	O	404-405

2	O	406-407
,	O	407-408
a	O	409-410
region	O	411-417
proposed	O	418-426
to	O	427-429
contain	O	430-437
tumor	B	438-443
suppressor	O	444-454
gene	O	455-459
(	O	460-461
s	O	461-462
)	O	462-463
,	O	463-464
is	O	465-467
mutated	O	468-475
at	O	476-478
high	O	479-483
frequency	O	484-493
in	O	494-496
human	O	497-502
breast	B	503-509
cancer	I	510-516
.	O	516-517

In	O	518-520
7	O	521-522
of	O	523-525
15	O	526-528
uncultured	O	529-539
primary	O	540-547
human	O	548-553
breast	B	554-560
carcinomas	I	561-571
,	O	571-572
intragenic	O	573-583
deletions	O	584-593
were	O	594-598
shown	O	599-604
in	O	605-607
TSG101	O	608-614
genomic	O	615-622
DNA	O	623-626
and	O	627-630
transcripts	O	631-642
by	O	643-645
gel	O	646-649
and	O	650-653
sequence	O	654-662
analysis	O	663-671
,	O	671-672
and	O	673-676
mutations	O	677-686
affecting	O	687-696
two	O	697-700
TSG101	O	701-707
alleles	O	708-715
were	O	716-720
identified	O	721-731
in	O	732-734
four	O	735-739
of	O	740-742
these	O	743-748
cancers	B	749-756
.	O	756-757

No	O	758-760
TSG101	O	761-767
defects	O	768-775
were	O	776-780
found	O	781-786
in	O	787-789
matched	O	790-797
normal	O	798-804
breast	O	805-811
tissue	O	812-818
from	O	819-823
the	O	824-827
breast	B	828-834
cancer	I	835-841
patients	O	842-850
.	O	850-851

These	O	852-857
findings	O	858-866
strongly	O	867-875
implicate	O	876-885
TSG101	O	886-892
mutations	O	893-902
in	O	903-905
human	O	906-911
breast	B	912-918
cancer	I	919-925

The	O	0-3
Emery	B	4-9
-	I	9-10
Dreifuss	I	10-18
muscular	I	19-27
dystrophy	I	28-37
protein	O	38-45
,	O	45-46
emerin	O	47-53
,	O	53-54
is	O	55-57
a	O	58-59
nuclear	O	60-67
membrane	O	68-76
protein	O	77-84
.	O	84-85

A	O	86-87
large	O	88-93
fragment	O	94-102
of	O	103-105
emerin	O	106-112
cDNA	O	113-117
was	O	118-121
prepared	O	122-130
by	O	131-133
PCR	O	134-137
and	O	138-141
expressed	O	142-151
as	O	152-154
a	O	155-156
recombinant	O	157-168
protein	O	169-176
in	O	177-179
Escherichia	O	180-191
coli	O	192-196
.	O	196-197

Using	O	198-203
this	O	204-208
as	O	209-211
immunogen	O	212-221
,	O	221-222
we	O	223-225
prepared	O	226-234
a	O	235-236
panel	O	237-242
of	O	243-245
12	O	246-248
monoclonal	O	249-259
antibodies	O	260-270
which	O	271-276
recognise	O	277-286
at	O	287-289
least	O	290-295
four	O	296-300
different	O	301-310
epitopes	O	311-319
on	O	320-322
emerin	O	323-329
in	O	330-332
order	O	333-338
to	O	339-341
ensure	O	342-348
that	O	349-353
emerin	O	354-360
can	O	361-364
be	O	365-367
distinguished	O	368-381
from	O	382-386
non	O	387-390
-	O	390-391
specific	O	391-399
cross	O	400-405
-	O	405-406
reacting	O	406-414
proteins	O	415-423
.	O	423-424

All	O	425-428
the	O	429-432
mAbs	O	433-437
recognised	O	438-448
a	O	449-450
34	O	451-453
kDa	O	454-457
protein	O	458-465
in	O	466-468
all	O	469-472
tissues	O	473-480
tested	O	481-487
,	O	487-488
though	O	489-495
minor	O	496-501
emerin	O	502-508
-	O	508-509
related	O	509-516
bands	O	517-522
were	O	523-527
also	O	528-532
detected	O	533-541
in	O	542-544
some	O	545-549
tissues	O	550-557
.	O	557-558

Immunofluorescence	O	559-577
microscopy	O	578-588
showed	O	589-595
that	O	596-600
emerin	O	601-607
is	O	608-610
located	O	611-618
at	O	619-621
the	O	622-625
nuclear	O	626-633
rim	O	634-637
in	O	638-640
all	O	641-644
tissues	O	645-652
examined	O	653-661
.	O	661-662

A	O	663-664
muscle	O	665-671
biopsy	O	672-678
from	O	679-683
an	O	684-686
Emery	B	687-692
-	I	692-693
Dreifuss	I	693-701
muscular	I	702-710
dystrophy	I	711-720
(	O	721-722
EMDM	B	722-726
)	O	726-727
patient	O	728-735
showed	O	736-742
complete	O	743-751
absence	O	752-759
of	O	760-762
emerin	O	763-769
by	O	770-772
both	O	773-777
Western	O	778-785
blotting	O	786-794
and	O	795-798
immunohistochemistry	O	799-819
,	O	819-820
suggesting	O	821-831
a	O	832-833
simple	O	834-840
diagnostic	O	841-851
antibody	O	852-860
test	O	861-865
for	O	866-869
EDMD	B	870-874
families	O	875-883
.	O	883-884

Biochemical	O	885-896
fractionation	O	897-910
of	O	911-913
brain	O	914-919
and	O	920-923
liver	O	924-929
tissues	O	930-937
showed	O	938-944
that	O	945-949
emerin	O	950-956
was	O	957-960
present	O	961-968
in	O	969-971
nuclei	O	972-978
purified	O	979-987
by	O	988-990
centrifugation	O	991-1005
through	O	1006-1013
65	O	1014-1016
%	O	1016-1017
sucrose	O	1018-1025
and	O	1026-1029
was	O	1030-1033
absent	O	1034-1040
from	O	1041-1045
soluble	O	1046-1053
fractions	O	1054-1063
(	O	1064-1065
post	O	1065-1069
-	O	1069-1070
100	O	1070-1073
,	O	1073-1074
000	O	1075-1078
g	O	1079-1080
)	O	1080-1081
.	O	1081-1082
From	O	1083-1087
these	O	1088-1093
results	O	1094-1101
,	O	1101-1102
together	O	1103-1111
with	O	1112-1116
sequence	O	1117-1125
and	O	1126-1129
structural	O	1130-1140
homologies	O	1141-1151
between	O	1152-1159
emerin	O	1160-1166
,	O	1166-1167
thymopoietins	O	1168-1181
and	O	1182-1185
the	O	1186-1189
nuclear	O	1190-1197
lamina	O	1198-1204
-	O	1204-1205
associated	O	1205-1215
protein	O	1216-1223
,	O	1223-1224
LAP2	O	1225-1229
,	O	1229-1230
we	O	1231-1233
suggest	O	1234-1241
that	O	1242-1246
emerin	O	1247-1253
will	O	1254-1258
prove	O	1259-1264
to	O	1265-1267
be	O	1268-1270
one	O	1271-1274
member	O	1275-1281
of	O	1282-1284
a	O	1285-1286
family	O	1287-1293
of	O	1294-1296
inner	O	1297-1302
nuclear	O	1303-1310
membrane	O	1311-1319
proteins	O	1320-1328
.	O	1328-1329
.	O	1328-1329

Influence	O	0-9
of	O	10-12
PAX6	O	13-17
gene	O	18-22
dosage	O	23-29
on	O	30-32
development	O	33-44
:	O	44-45
overexpression	O	46-60
causes	O	61-67
severe	O	68-74
eye	B	75-78
abnormalities	I	79-92
.	O	92-93

Aniridia	B	94-102
in	O	103-105
man	O	106-109
and	O	110-113
Small	O	114-119
eye	O	120-123
in	O	124-126
mice	O	127-131
are	O	132-135
semidominant	B	136-148
developmental	I	149-162
disorders	I	163-172
caused	O	173-179
by	O	180-182
mutations	O	183-192
within	O	193-199
the	O	200-203
paired	O	204-210
box	O	211-214
gene	O	215-219
PAX6	O	220-224
.	O	224-225

Whereas	O	226-233
heterozygotes	O	234-247
suffer	O	248-254
from	O	255-259
iris	B	260-264
hypoplasia	I	265-275
,	O	275-276
homozygous	O	277-287
mice	O	288-292
lack	O	293-297
eyes	O	298-302
and	O	303-306
nasal	O	307-312
cavities	O	313-321
and	O	322-325
exhibit	O	326-333
brain	B	334-339
abnormalities	I	340-353
.	O	353-354

To	O	355-357
investigate	O	358-369
the	O	370-373
role	O	374-378
of	O	379-381
gene	O	382-386
dosage	O	387-393
in	O	394-396
more	O	397-401
detail	O	402-408
,	O	408-409
we	O	410-412
have	O	413-417
generated	O	418-427
yeast	O	428-433
artificial	O	434-444
chromosome	O	445-455
transgenic	O	456-466
mice	O	467-471
carrying	O	472-480
the	O	481-484
human	O	485-490
PAX6	O	491-495
locus	O	496-501
.	O	501-502

When	O	503-507
crossed	O	508-515
onto	O	516-520
the	O	521-524
Small	O	525-530
eye	O	531-534
background	O	535-545
,	O	545-546
the	O	547-550
transgene	O	551-560
rescues	O	561-568
the	O	569-572
mutant	O	573-579
phenotype	O	580-589
.	O	589-590

Strikingly	O	591-601
,	O	601-602
mice	O	603-607
carrying	O	608-616
multiple	O	617-625
copies	O	626-632
on	O	633-635
a	O	636-637
wild	O	638-642
-	O	642-643
type	O	643-647
background	O	648-658
show	O	659-663
specific	O	664-672
developmental	B	673-686
abnormalities	I	687-700
of	I	701-703
the	I	704-707
eye	I	708-711
,	O	711-712
but	O	713-716
not	O	717-720
of	O	721-723
other	O	724-729
tissues	O	730-737
expressing	O	738-748
the	O	749-752
gene	O	753-757
.	O	757-758

Thus	O	759-763
,	O	763-764
at	O	765-767
least	O	768-773
five	O	774-778
different	O	779-788
eye	O	789-792
phenotypes	O	793-803
are	O	804-807
associated	O	808-818
with	O	819-823
changes	O	824-831
in	O	832-834
PAX6	O	835-839
expression	O	840-850
.	O	850-851

We	O	852-854
provide	O	855-862
evidence	O	863-871
that	O	872-876
not	O	877-880
only	O	881-885
reduced	O	886-893
,	O	893-894
but	O	895-898
also	O	899-903
increased	O	904-913
levels	O	914-920
of	O	921-923
transcriptional	O	924-939
regulators	O	940-950
can	O	951-954
cause	O	955-960
developmental	B	961-974
defects	I	975-982
.	O	982-983
.	O	982-983

Founding	O	0-8
BRCA1	O	9-14
mutations	O	15-24
in	O	25-27
hereditary	B	28-38
breast	I	39-45
and	I	46-49
ovarian	I	50-57
cancer	I	58-64
in	O	65-67
southern	O	68-76
Sweden	O	77-83
.	O	83-84

Nine	O	85-89
different	O	90-99
germ	O	100-104
-	O	104-105
line	O	105-109
mutations	O	110-119
in	O	120-122
the	O	123-126
BRCA1	O	127-132
breast	B	133-139
and	I	140-143
ovarian	I	144-151
cancer	I	152-158
susceptibility	O	159-173
gene	O	174-178
were	O	179-183
identified	O	184-194
in	O	195-197
15	O	198-200
of	O	201-203
47	O	204-206
kindreds	O	207-215
from	O	216-220
southern	O	221-229
Sweden	O	230-236
,	O	236-237
by	O	238-240
use	O	241-244
of	O	245-247
SSCP	O	248-252
and	O	253-256
heteroduplex	O	257-269
analysis	O	270-278
of	O	279-281
all	O	282-285
exons	O	286-291
and	O	292-295
flanking	O	296-304
intron	O	305-311
region	O	312-318
and	O	319-322
by	O	323-325
a	O	326-327
protein	O	328-335
-	O	335-336
truncation	O	336-346
test	O	347-351
for	O	352-355
exon	O	356-360
11	O	361-363
,	O	363-364
followed	O	365-373
by	O	374-376
direct	O	377-383
sequencing	O	384-394
.	O	394-395

All	O	396-399
but	O	400-403
one	O	404-407
of	O	408-410
the	O	411-414
mutations	O	415-424
are	O	425-428
predicted	O	429-438
to	O	439-441
give	O	442-446
rise	O	447-451
to	O	452-454
premature	O	455-464
translation	O	465-476
termination	O	477-488
and	O	489-492
include	O	493-500
seven	O	501-506
frameshift	O	507-517
insertions	O	518-528
or	O	529-531
deletions	O	532-541
,	O	541-542
a	O	543-544
nonsense	O	545-553
mutation	O	554-562
,	O	562-563
and	O	564-567
a	O	568-569
splice	O	570-576
acceptor	O	577-585
site	O	586-590
mutation	O	591-599
.	O	599-600

The	O	601-604
remaining	O	605-614
mutation	O	615-623
is	O	624-626
a	O	627-628
missense	O	629-637
mutation	O	638-646
(	O	647-648
Cys61Gly	O	648-656
)	O	656-657
in	O	658-660
the	O	661-664
zinc	O	665-669
-	O	669-670
binding	O	670-677
motif	O	678-683
.	O	683-684

Four	O	685-689
novel	O	690-695
Swedish	O	696-703
founding	O	704-712
mutations	O	713-722
were	O	723-727
identified	O	728-738
the	O	740-743
nucleotide	O	744-754
2595	O	755-759
deletion	O	760-768
A	O	769-770
was	O	771-774
found	O	775-780
in	O	781-783
five	O	784-788
families	O	789-797
,	O	797-798
the	O	799-802
C	O	803-804
1806	O	805-809
T	O	810-811
nonsense	O	812-820
mutation	O	821-829
in	O	830-832
three	O	833-838
families	O	839-847
,	O	847-848
the	O	849-852
3166	O	853-857
insertion	O	858-867
TGAGA	O	868-873
in	O	874-876
three	O	877-882
families	O	883-891
,	O	891-892
and	O	893-896
the	O	897-900
nucleotide	O	901-911
1201	O	912-916
deletion	O	917-925
11	O	926-928
in	O	929-931
two	O	932-935
families	O	936-944
.	O	944-945

Analysis	O	946-954
of	O	955-957
the	O	958-961
intragenic	O	962-972
polymorphism	O	973-985
D17S855	O	986-993
supports	O	994-1002
common	O	1003-1009
origins	O	1010-1017
of	O	1018-1020
the	O	1021-1024
mutations	O	1025-1034
.	O	1034-1035

Eleven	O	1036-1042
of	O	1043-1045
the	O	1046-1049
15	O	1050-1052
kindreds	O	1053-1061
manifesting	O	1062-1073
BRCA1	O	1074-1079
mutations	O	1080-1089
were	O	1090-1094
breast	B	1095-1101
-	I	1101-1102
ovarian	I	1102-1109
cancer	I	1110-1116
families	O	1117-1125
,	O	1125-1126
several	O	1127-1134
of	O	1135-1137
them	O	1138-1142
with	O	1143-1147
a	O	1148-1149
predominant	O	1150-1161
ovarian	B	1162-1169
cancer	I	1170-1176
phenotype	O	1177-1186
.	O	1186-1187

The	O	1188-1191
set	O	1192-1195
of	O	1196-1198
32	O	1199-1201
families	O	1202-1210
in	O	1211-1213
which	O	1214-1219
no	O	1220-1222
BRCA1	O	1223-1228
alterations	O	1229-1240
were	O	1241-1245
detected	O	1246-1254
included	O	1255-1263
1	O	1264-1265
breast	B	1266-1272
-	I	1272-1273
ovarian	I	1273-1280
cancer	I	1281-1287
kindred	O	1288-1295
manifesting	O	1296-1307
clear	O	1308-1313
linkage	O	1314-1321
to	O	1322-1324
the	O	1325-1328
BRCA1	O	1329-1334
region	O	1335-1341
and	O	1342-1345
loss	O	1346-1350
of	O	1351-1353
the	O	1354-1357
wild	O	1358-1362
-	O	1362-1363
type	O	1363-1367
chromosome	O	1368-1378
in	O	1379-1381
associated	O	1382-1392
tumors	B	1393-1399
.	O	1399-1400

Other	O	1401-1406
tumor	B	1407-1412
types	O	1413-1418
found	O	1419-1424
in	O	1425-1427
BRCA1	O	1428-1433
mutation	O	1434-1442
/	O	1442-1443
haplotype	O	1443-1452
carriers	O	1453-1461
included	O	1462-1470
prostatic	B	1471-1480
,	I	1480-1481
pancreas	I	1482-1490
,	I	1490-1491
skin	I	1492-1496
,	I	1496-1497
and	I	1498-1501
lung	I	1502-1506
cancer	I	1507-1513
,	O	1513-1514
a	O	1515-1516
malignant	B	1517-1526
melanoma	I	1527-1535
,	O	1535-1536
an	O	1537-1539
oligodendroglioma	B	1540-1557
,	O	1557-1558
and	O	1559-1562
a	O	1563-1564
carcinosarcoma	B	1565-1579
.	O	1579-1580

In	O	1581-1583
all	O	1584-1587
,	O	1587-1588
12	O	1589-1591
of	O	1592-1594
16	O	1595-1597
kindreds	O	1598-1606
manifesting	O	1607-1618
BRCA1	O	1619-1624
mutation	O	1625-1633
or	O	1634-1636
linkage	O	1637-1644
contained	O	1645-1654
ovarian	B	1655-1662
cancer	I	1663-1669
,	O	1669-1670
as	O	1671-1673
compared	O	1674-1682
with	O	1683-1687
only	O	1688-1692
6	O	1693-1694
of	O	1695-1697
the	O	1698-1701
remaining	O	1702-1711
31	O	1712-1714
families	O	1715-1723
(	O	1724-1725
P	O	1725-1726
<	O	1727-1728
.	O	1728-1729
001	O	1730-1733
)	O	1733-1734
.	O	1734-1735

The	O	1736-1739
present	O	1740-1747
study	O	1748-1753
confirms	O	1754-1762
the	O	1763-1766
involvement	O	1767-1778
of	O	1779-1781
BRCA1	O	1782-1787
in	O	1788-1790
disease	O	1791-1798
predisposition	O	1799-1813
for	O	1814-1817
a	O	1818-1819
subset	O	1820-1826
of	O	1827-1829
hereditary	B	1830-1840
breast	I	1841-1847
cancer	I	1848-1854
families	O	1855-1863
often	O	1864-1869
characterized	O	1870-1883
by	O	1884-1886
ovarian	B	1887-1894
cancers	I	1895-1902
.	O	1902-1903

The	O	0-3
DCC	O	4-7
protein	O	8-15
and	O	16-19
prognosis	O	20-29
in	O	30-32
colorectal	B	33-43
cancer	I	44-50
.	O	50-51

BACKGROUND	O	52-62
Allelic	O	64-71
loss	O	72-76
of	O	77-79
chromosome	O	80-90
18q	O	91-94
predicts	O	95-103
a	O	104-105
poor	O	106-110
outcome	O	111-118
in	O	119-121
patients	O	122-130
with	O	131-135
stage	B	136-141
II	I	142-144
colorectal	I	145-155
cancer	I	156-162
.	O	162-163

Although	O	164-172
the	O	173-176
specific	O	177-185
gene	O	186-190
inactivated	O	191-202
by	O	203-205
this	O	206-210
allelic	O	211-218
loss	O	219-223
has	O	224-227
not	O	228-231
been	O	232-236
elucidated	O	237-247
,	O	247-248
the	O	249-252
DCC	O	253-256
(	O	257-258
deleted	O	258-265
in	O	266-268
colorectal	B	269-279
cancer	I	280-286
)	O	286-287
gene	O	288-292
is	O	293-295
a	O	296-297
candidate	O	298-307
.	O	307-308

We	O	309-311
investigated	O	312-324
whether	O	325-332
the	O	333-336
expression	O	337-347
of	O	348-350
the	O	351-354
DCC	O	355-358
protein	O	359-366
in	O	367-369
tumor	B	370-375
cells	O	376-381
is	O	382-384
a	O	385-386
prognostic	O	387-397
marker	O	398-404
in	O	405-407
colorectal	B	408-418
carcinoma	I	419-428
.	O	428-429

METHODS	O	430-437
The	O	439-442
expression	O	443-453
of	O	454-456
DCC	O	457-460
was	O	461-464
evaluated	O	465-474
immunohistochemically	O	475-496
in	O	497-499
132	O	500-503
paraffin	O	504-512
-	O	512-513
embedded	O	513-521
samples	O	522-529
from	O	530-534
patients	O	535-543
with	O	544-548
curatively	O	549-559
resected	O	560-568
stage	B	569-574
II	I	575-577
and	I	578-581
III	I	582-585
colorectal	I	586-596
carcinomas	I	597-607
.	O	607-608

The	O	609-612
Cox	O	613-616
proportional	O	617-629
-	O	629-630
hazards	O	630-637
model	O	638-643
was	O	644-647
used	O	648-652
to	O	653-655
adjust	O	656-662
for	O	663-666
covariates	O	667-677
including	O	678-687
age	O	688-691
,	O	691-692
sex	O	693-696
,	O	696-697
tumor	B	698-703
site	O	704-708
,	O	708-709
degree	O	710-716
of	O	717-719
tumor	B	720-725
differentiation	O	726-741
,	O	741-742
and	O	743-746
use	O	747-750
of	O	751-753
adjuvant	O	754-762
therapy	O	763-770
.	O	770-771

RESULTS	O	772-779
The	O	781-784
expression	O	785-795
of	O	796-798
DCC	O	799-802
was	O	803-806
a	O	807-808
strong	O	809-815
positive	O	816-824
predictive	O	825-835
factor	O	836-842
for	O	843-846
survival	O	847-855
in	O	856-858
both	O	859-863
stage	B	864-869
II	I	870-872
and	I	873-876
stage	I	877-882
III	I	883-886
colorectal	I	887-897
carcinomas	I	898-908
.	O	908-909

In	O	910-912
patients	O	913-921
with	O	922-926
stage	O	927-932
II	O	933-935
disease	O	936-943
whose	O	944-949
tumors	B	950-956
expressed	O	957-966
DCC	O	967-970
,	O	970-971
the	O	972-975
five	O	976-980
-	O	980-981
year	O	981-985
survival	O	986-994
rate	O	995-999
was	O	1000-1003
94	O	1004-1006
.	O	1006-1007
3	O	1008-1009
percent	O	1010-1017
,	O	1017-1018
whereas	O	1019-1026
in	O	1027-1029
patients	O	1030-1038
with	O	1039-1043
DCC	B	1044-1047
-	I	1047-1048
negative	I	1048-1056
tumors	I	1057-1063
,	O	1063-1064
the	O	1065-1068
survival	O	1069-1077
rate	O	1078-1082
was	O	1083-1086
61	O	1087-1089
.	O	1089-1090

6	O	1091-1092
percent	O	1093-1100
(	O	1101-1102
P	O	1102-1103
<	O	1104-1105
0	O	1106-1107
.	O	1107-1108
001	O	1109-1112
)	O	1112-1113
.	O	1113-1114

In	O	1115-1117
patients	O	1118-1126
with	O	1127-1131
stage	B	1132-1137
III	I	1138-1141
disease	I	1142-1149
,	O	1149-1150
the	O	1151-1154
respective	O	1155-1165
survival	O	1166-1174
rates	O	1175-1180
were	O	1181-1185
59	O	1186-1188
.	O	1188-1189
3	O	1190-1191
percent	O	1192-1199
and	O	1200-1203
33	O	1204-1206
.	O	1206-1207
2	O	1208-1209
percent	O	1210-1217
(	O	1218-1219
P	O	1219-1220
=	O	1221-1222
0	O	1223-1224
.	O	1224-1225
03	O	1226-1228
)	O	1228-1229
.	O	1229-1230

CONCLUSIONS	O	1231-1242
DCC	O	1244-1247
is	O	1248-1250
a	O	1251-1252
prognostic	O	1253-1263
marker	O	1264-1270
in	O	1271-1273
patients	O	1274-1282
with	O	1283-1287
stage	B	1288-1293
II	I	1294-1296
or	I	1297-1299
stage	I	1300-1305
III	I	1306-1309
colorectal	I	1310-1320
cancer	I	1321-1327
.	O	1327-1328

In	O	1329-1331
stage	B	1332-1337
II	I	1338-1340
colorectal	I	1341-1351
carcinomas	I	1352-1362
,	O	1362-1363
the	O	1364-1367
absence	O	1368-1375
of	O	1376-1378
DCC	O	1379-1382
identifies	O	1383-1393
a	O	1394-1395
subgroup	O	1396-1404
of	O	1405-1407
patients	O	1408-1416
with	O	1417-1421
lesions	O	1422-1429
that	O	1430-1434
behave	O	1435-1441
like	O	1442-1446
stage	B	1447-1452
III	I	1453-1456
cancers	I	1457-1464
.	O	1464-1465

These	O	1466-1471
findings	O	1472-1480
may	O	1481-1484
thus	O	1485-1489
have	O	1490-1494
therapeutic	O	1495-1506
implications	O	1507-1519
in	O	1520-1522
this	O	1523-1527
group	O	1528-1533
of	O	1534-1536
patients	O	1537-1545

Gene	O	0-4
therapy	O	5-12
for	O	13-16
phenylketonuria	B	17-32
.	O	32-33

Classical	O	34-43
phenylketonuria	B	44-59
(	O	60-61
PKU	B	61-64
)	O	64-65
is	O	66-68
an	O	69-71
autosomal	B	72-81
recessive	I	82-91
disorder	I	92-100
caused	O	101-107
by	O	108-110
a	O	111-112
deficiency	B	113-123
of	I	124-126
hepatic	I	127-134
phenylalanine	I	135-148
hydroxylase	I	149-160
(	O	161-162
PAH	O	162-165
)	O	165-166
.	O	166-167

Limitations	O	168-179
of	O	180-182
the	O	183-186
current	O	187-194
dietary	O	195-202
treatment	O	203-212
for	O	213-216
PKU	B	217-220
have	O	221-225
led	O	226-229
to	O	230-232
the	O	233-236
development	O	237-248
of	O	249-251
potential	O	252-261
treatments	O	262-272
based	O	273-278
on	O	279-281
somatic	O	282-289
gene	O	290-294
transfer	O	295-303
.	O	303-304

Three	O	305-310
different	O	311-320
vector	O	321-327
systems	O	328-335
have	O	336-340
been	O	341-345
examined	O	346-354
.	O	354-355

Vectors	O	356-363
derived	O	364-371
from	O	372-376
a	O	377-378
recombinant	O	379-390
retrovirus	O	391-401
or	O	402-404
a	O	405-406
DNA	O	407-410
/	O	410-411
protein	O	411-418
complex	O	419-426
can	O	427-430
efficiently	O	431-442
transduce	O	443-452
the	O	453-456
PAH	O	457-460
cDNA	O	461-465
into	O	466-470
PAH	B	471-474
-	I	474-475
deficient	I	475-484
hepatocytes	O	485-496
in	O	497-499
vitro	O	500-505
,	O	505-506
but	O	507-510
the	O	511-514
application	O	515-526
of	O	527-529
these	O	530-535
vector	O	536-542
systems	O	543-550
is	O	551-553
presently	O	554-563
limited	O	564-571
by	O	572-574
their	O	575-580
low	O	581-584
transduction	O	585-597
efficiency	O	598-608
in	O	609-611
vivo	O	612-616
.	O	616-617

In	O	618-620
contrast	O	621-629
,	O	629-630
a	O	631-632
vector	O	633-639
derived	O	640-647
from	O	648-652
a	O	653-654
recombinant	O	655-666
adenovirus	O	667-677
can	O	678-681
restore	O	682-689
10	O	690-692
%	O	692-693
-	O	694-695
80	O	695-697
%	O	697-698
of	O	699-701
normal	O	702-708
hepatic	O	709-716
PAH	O	717-720
activity	O	721-729
into	O	730-734
PAH	B	735-738
-	I	738-739
deficient	I	739-748
mice	O	749-753
,	O	753-754
which	O	755-760
completely	O	761-771
normalizes	O	772-782
serum	O	783-788
phenylalanine	O	789-802
levels	O	803-809
.	O	809-810

This	O	811-815
treatment	O	816-825
is	O	826-828
transient	O	829-838
and	O	839-842
cannot	O	843-849
be	O	850-852
effectively	O	853-864
re	O	865-867
-	O	867-868
administered	O	868-880
due	O	881-884
to	O	885-887
the	O	888-891
presence	O	892-900
of	O	901-903
neutralizing	O	904-916
antibodies	O	917-927
directed	O	928-936
against	O	937-944
the	O	945-948
recombinant	O	949-960
adenoviral	O	961-971
vector	O	972-978
.	O	978-979

However	O	980-987
,	O	987-988
these	O	989-994
findings	O	995-1003
suggest	O	1004-1011
that	O	1012-1016
PKU	B	1017-1020
can	O	1021-1024
be	O	1025-1027
completely	O	1028-1038
corrected	O	1039-1048
by	O	1049-1051
somatic	O	1052-1059
gene	O	1060-1064
therapy	O	1065-1072
,	O	1072-1073
and	O	1074-1077
provide	O	1078-1085
some	O	1086-1090
direction	O	1091-1100
for	O	1101-1104
the	O	1105-1108
future	O	1109-1115
development	O	1116-1127
of	O	1128-1130
adenoviral	O	1131-1141
vectors	O	1142-1149
.	O	1149-1150
.	O	1149-1150

Identification	O	0-14
of	O	15-17
a	O	18-19
RING	O	20-24
protein	O	25-32
that	O	33-37
can	O	38-41
interact	O	42-50
in	O	51-53
vivo	O	54-58
with	O	59-63
the	O	64-67
BRCA1	O	68-73
gene	O	74-78
product	O	79-86
.	O	86-87

The	O	88-91
hereditary	B	92-102
breast	I	103-109
and	I	110-113
ovarian	I	114-121
cancer	I	122-128
gene	O	129-133
,	O	133-134
BRCA1	O	135-140
,	O	140-141
encodes	O	142-149
a	O	150-151
large	O	152-157
polypeptide	O	158-169
that	O	170-174
contains	O	175-183
the	O	184-187
cysteine	O	188-196
-	O	196-197
rich	O	197-201
RING	O	202-206
motif	O	207-212
,	O	212-213
a	O	214-215
zinc	O	216-220
-	O	220-221
binding	O	221-228
domain	O	229-235
found	O	236-241
in	O	242-244
a	O	245-246
variety	O	247-254
of	O	255-257
regulatory	O	258-268
proteins	O	269-277
.	O	277-278

Here	O	279-283
we	O	284-286
describe	O	287-295
a	O	296-297
novel	O	298-303
protein	O	304-311
that	O	312-316
interacts	O	317-326
in	O	327-329
vivo	O	330-334
with	O	335-339
the	O	340-343
N	O	344-345
-	O	345-346
terminal	O	346-354
region	O	355-361
of	O	362-364
BRCA1	O	365-370
.	O	370-371

This	O	372-376
BRCA1	O	377-382
-	O	382-383
associated	O	383-393
RING	O	394-398
domain	O	399-405
(	O	406-407
BARD1	O	407-412
)	O	412-413
protein	O	414-421
contains	O	422-430
an	O	431-433
N	O	434-435
-	O	435-436
terminal	O	436-444
RING	O	445-449
motif	O	450-455
,	O	455-456
three	O	457-462
tandem	O	463-469
ankyrin	O	470-477
repeats	O	478-485
,	O	485-486
and	O	487-490
a	O	491-492
C	O	493-494
-	O	494-495
terminal	O	495-503
sequence	O	504-512
with	O	513-517
significant	O	518-529
homology	O	530-538
to	O	539-541
the	O	542-545
phylogenetically	O	546-562
conserved	O	563-572
BRCT	O	573-577
domains	O	578-585
that	O	586-590
lie	O	591-594
near	O	595-599
the	O	600-603
C	O	604-605
terminus	O	606-614
of	O	615-617
BRCA1	O	618-623
.	O	623-624

The	O	625-628
BARD1	O	629-634
/	O	634-635
BRCA1	O	635-640
interaction	O	641-652
is	O	653-655
disrupted	O	656-665
by	O	666-668
BRCA1	O	669-674
missense	O	675-683
mutations	O	684-693
that	O	694-698
segregate	O	699-708
with	O	709-713
breast	B	714-720
cancer	I	721-727
susceptibility	O	728-742
,	O	742-743
indicating	O	744-754
that	O	755-759
BARD1	O	760-765
may	O	766-769
be	O	770-772
involved	O	773-781
in	O	782-784
mediating	O	785-794
tumour	B	795-801
suppression	O	802-813
by	O	814-816
BRCA1	O	817-822
.	O	822-823
.	O	822-823

Wiskott	B	0-7
-	I	7-8
Aldrich	I	8-15
syndrome	I	16-24
:	O	24-25
no	O	26-28
strict	O	29-35
genotype	O	36-44
-	O	44-45
phenotype	O	45-54
correlations	O	55-67
but	O	68-71
clustering	O	72-82
of	O	83-85
missense	O	86-94
mutations	O	95-104
in	O	105-107
the	O	108-111
amino	O	112-117
-	O	117-118
terminal	O	118-126
part	O	127-131
of	O	132-134
the	O	135-138
WASP	O	139-143
gene	O	144-148
product	O	149-156
.	O	156-157

The	O	158-161
Wiskott	B	162-169
-	I	169-170
Aldrich	I	170-177
syndrome	I	178-186
protein	O	187-194
(	O	195-196
WASP	O	196-200
)	O	200-201
gene	O	202-206
was	O	207-210
found	O	211-216
to	O	217-219
be	O	220-222
mutated	O	223-230
in	O	231-233
patients	O	234-242
presenting	O	243-253
with	O	254-258
WAS	B	259-262
and	O	263-266
in	O	267-269
patients	O	270-278
showing	O	279-286
X	B	287-288
-	I	288-289
linked	I	289-295
thrombocytopenia	I	296-312
.	O	312-313

Mutation	O	314-322
analysis	O	323-331
in	O	332-334
19	O	335-337
families	O	338-346
of	O	347-349
German	O	350-356
,	O	356-357
Swiss	O	358-363
and	O	364-367
Turkish	O	368-375
descent	O	376-383
by	O	384-386
single	O	387-393
-	O	393-394
strand	O	394-400
conformation	O	401-413
polymorphism	O	414-426
and	O	427-430
sequencing	O	431-441
resulted	O	442-450
in	O	451-453
the	O	454-457
detection	O	458-467
of	O	468-470
seven	O	471-476
novel	O	477-482
and	O	483-486
10	O	487-489
known	O	490-495
mutations	O	496-505
.	O	505-506

A	O	507-508
striking	O	509-517
clustering	O	518-528
of	O	529-531
missense	O	532-540
mutations	O	541-550
in	O	551-553
the	O	554-557
first	O	558-563
four	O	564-568
exons	O	569-574
contrasted	O	575-585
with	O	586-590
a	O	591-592
random	O	593-599
distribution	O	600-612
of	O	613-615
nonsense	O	616-624
mutations	O	625-634
.	O	634-635

More	O	636-640
than	O	641-645
85	O	646-648
%	O	648-649
of	O	650-652
all	O	653-656
known	O	657-662
missense	O	663-671
mutations	O	672-681
were	O	682-686
localized	O	687-696
in	O	697-699
the	O	700-703
amino	O	704-709
-	O	709-710
terminal	O	710-718
stretch	O	719-726
of	O	727-729
the	O	730-733
WASP	O	734-738
gene	O	739-743
product	O	744-751
;	O	751-752
this	O	753-757
region	O	758-764
contained	O	765-774
a	O	775-776
mutational	O	777-787
hot	O	788-791
spot	O	792-796
at	O	797-799
codon	O	800-805
86	O	806-808
.	O	808-809

No	O	810-812
genotype	O	813-821
-	O	821-822
phenotype	O	822-831
correlation	O	832-843
emerged	O	844-851
after	O	852-857
a	O	858-859
comparison	O	860-870
of	O	871-873
the	O	874-877
identified	O	878-888
mutations	O	889-898
with	O	899-903
the	O	904-907
resulting	O	908-917
clinical	O	918-926
picture	O	927-934
for	O	935-938
a	O	939-940
classical	O	941-950
WAS	B	951-954
phenotype	O	955-964
.	O	964-965

A	O	966-967
substitution	O	968-980
at	O	981-983
codon	O	984-989
86	O	990-992
resulted	O	993-1001
in	O	1002-1004
an	O	1005-1007
extremely	O	1008-1017
variable	O	1018-1026
expression	O	1027-1037
of	O	1038-1040
the	O	1041-1044
disease	O	1045-1052
in	O	1053-1055
a	O	1056-1057
large	O	1058-1063
Swiss	O	1064-1069
family	O	1070-1076
.	O	1076-1077

An	O	1078-1080
extended	O	1081-1089
homology	O	1090-1098
search	O	1099-1105
revealed	O	1106-1114
a	O	1115-1116
distant	O	1117-1124
relationship	O	1125-1137
of	O	1138-1140
this	O	1141-1145
stretch	O	1146-1153
to	O	1154-1156
the	O	1157-1160
vasodilator	O	1161-1172
-	O	1172-1173
stimulated	O	1173-1183
phosphoprotein	O	1184-1198
(	O	1199-1200
VASP	O	1200-1204
)	O	1204-1205
,	O	1205-1206
which	O	1207-1212
is	O	1213-1215
involved	O	1216-1224
in	O	1225-1227
the	O	1228-1231
maintenance	O	1232-1243
of	O	1244-1246
cyto	O	1247-1251
-	O	1251-1252
architecture	O	1252-1264
by	O	1265-1267
interacting	O	1268-1279
with	O	1280-1284
actin	O	1285-1290
-	O	1290-1291
like	O	1291-1295
filaments	O	1296-1305
.	O	1305-1306
.	O	1305-1306

Autosomal	O	0-9
dominant	O	10-18
primary	O	19-26
hyperparathyroidism	B	27-46
and	I	47-50
jaw	I	51-54
tumor	I	55-60
syndrome	I	61-69
associated	O	70-80
with	O	81-85
renal	B	86-91
hamartomas	I	92-102
and	O	103-106
cystic	B	107-113
kidney	I	114-120
disease	I	121-128
:	O	128-129
linkage	O	130-137
to	O	138-140
1q21	O	141-145
-	O	145-146
q32	O	146-149
and	O	150-153
loss	O	154-158
of	O	159-161
the	O	162-165
wild	O	166-170
type	O	171-175
allele	O	176-182
in	O	183-185
renal	B	186-191
hamartomas	I	192-202
.	O	202-203

Hereditary	B	204-214
hyperparathyroidism	I	215-234
-	I	234-235
jaw	I	235-238
tumor	I	239-244
syndrome	I	245-253
(	O	254-255
HPT	B	255-258
-	I	258-259
JT	I	259-261
)	O	261-262
is	O	263-265
an	O	266-268
autosomal	B	269-278
dominant	I	279-287
disease	I	288-295
(	O	296-297
OMIM	O	297-301
145001	O	302-308
)	O	308-309
that	O	310-314
has	O	315-318
recently	O	319-327
been	O	328-332
mapped	O	333-339
to	O	340-342
chromosomal	O	343-354
region	O	355-361
1q21	O	362-366
-	O	366-367
q32	O	367-370
(	O	371-372
HRPT2	O	372-377
)	O	377-378
.	O	378-379

Here	O	380-384
we	O	385-387
report	O	388-394
two	O	395-398
families	O	399-407
with	O	408-412
HPT	B	413-416
-	I	416-417
JT	I	417-419
syndrome	I	420-428
in	O	429-431
which	O	432-437
adult	B	438-443
renal	I	444-449
hamartomas	I	450-460
or	O	461-463
cystic	B	464-470
kidney	I	471-477
disease	I	478-485
were	O	486-490
prominent	O	491-500
associated	O	501-511
features	O	512-520
,	O	520-521
possibly	O	522-530
representing	O	531-543
a	O	544-545
new	O	546-549
phenotypic	O	550-560
variant	O	561-568
of	O	569-571
the	O	572-575
HPT	B	576-579
-	I	579-580
JT	I	580-582
syndrome	I	583-591
.	O	591-592

In	O	593-595
the	O	596-599
first	O	600-605
family	O	606-612
,	O	612-613
renal	B	614-619
lesions	I	620-627
were	O	628-632
present	O	633-640
in	O	641-643
five	O	644-648
out	O	649-652
of	O	653-655
six	O	656-659
affected	O	660-668
individuals	O	669-680
,	O	680-681
whereas	O	682-689
HPT	B	690-693
and	O	694-697
JT	B	698-700
were	O	701-705
seen	O	706-710
in	O	711-713
four	O	714-718
and	O	719-722
two	O	723-726
cases	O	727-732
,	O	732-733
respectively	O	734-746
.	O	746-747

In	O	748-750
the	O	751-754
second	O	755-761
family	O	762-768
,	O	768-769
JT	B	770-772
was	O	773-776
found	O	777-782
in	O	783-785
three	O	786-791
of	O	792-794
the	O	795-798
five	O	799-803
affected	O	804-812
individuals	O	813-824
and	O	825-828
two	O	829-832
affected	O	833-841
members	O	842-849
also	O	850-854
exhibited	O	855-864
polycystic	B	865-875
kidney	I	876-882
disease	I	883-890
.	O	890-891

The	O	892-895
possibility	O	896-907
of	O	908-910
the	O	911-914
latter	O	915-921
cosegregating	O	922-935
as	O	936-938
a	O	939-940
separate	O	941-949
autosomal	O	950-959
dominant	O	960-968
gene	O	969-973
can	O	974-977
not	O	978-981
be	O	982-984
ruled	O	985-990
out	O	991-994
.	O	994-995

A	O	996-997
sex	O	998-1001
-	O	1001-1002
dependent	O	1002-1011
penetrance	O	1012-1022
of	O	1023-1025
primary	B	1026-1033
HPT	I	1034-1037
,	O	1037-1038
resulting	O	1039-1048
in	O	1049-1051
predominantly	O	1052-1065
male	O	1066-1070
-	O	1070-1071
affected	O	1071-1079
cases	O	1080-1085
was	O	1086-1089
evident	O	1090-1097
in	O	1098-1100
the	O	1101-1104
two	O	1105-1108
families	O	1109-1117
.	O	1117-1118

Twenty	O	1119-1125
microsatellite	O	1126-1140
markers	O	1141-1148
in	O	1149-1151
the	O	1152-1155
HRPT2	O	1156-1161
region	O	1162-1168
were	O	1169-1173
typed	O	1174-1179
,	O	1179-1180
in	O	1181-1183
addition	O	1184-1192
to	O	1193-1195
markers	O	1196-1203
in	O	1204-1206
the	O	1207-1210
multiple	B	1211-1219
endocrine	I	1220-1229
neoplasia	I	1230-1239
(	I	1240-1241
MEN	I	1241-1244
)	I	1244-1245
types	I	1246-1251
1	I	1252-1253
and	I	1254-1257
2	I	1258-1259
regions	O	1260-1267
at	O	1268-1270
11q13	O	1271-1276
and	O	1277-1280
10q11	O	1281-1286
.	O	1286-1287

The	O	1288-1291
disease	O	1292-1299
in	O	1300-1302
these	O	1303-1308
two	O	1309-1312
kindreds	O	1313-1321
was	O	1322-1325
linked	O	1326-1332
to	O	1333-1335
five	O	1336-1340
markers	O	1341-1348
in	O	1349-1351
the	O	1352-1355
1q21	O	1356-1360
-	O	1360-1361
q32	O	1361-1364
region	O	1365-1371
(	O	1372-1373
logarithm	O	1373-1382
-	O	1382-1383
of	O	1383-1385
-	O	1382-1383
odds	O	1386-1390
scores	O	1391-1397
3	O	1399-1400
.	O	1400-1401
2	O	1402-1403
-	O	1403-1404
4	O	1404-1405
2	O	1406-1407
-	O	1407-1408
4	O	1408-1409
.	O	1409-1410

2	O	1411-1412
)	O	1412-1413
,	O	1413-1414
whereas	O	1415-1422
linkage	O	1423-1430
to	O	1431-1433
the	O	1434-1437
MEN1	B	1438-1442
and	O	1443-1446
MEN2	B	1447-1451
regions	O	1452-1459
was	O	1460-1463
excluded	O	1464-1472
.	O	1472-1473

Meiotic	O	1474-1481
recombinations	O	1482-1496
detected	O	1497-1505
in	O	1506-1508
affected	O	1509-1517
individuals	O	1518-1529
placed	O	1530-1536
the	O	1537-1540
locus	O	1541-1546
telomeric	O	1547-1556
of	O	1557-1559
D1S215	O	1560-1566
,	O	1566-1567
thus	O	1568-1572
narrowing	O	1573-1582
the	O	1583-1586
HRPT2	O	1587-1592
region	O	1593-1599
from	O	1600-1604
>	O	1605-1606
60	O	1607-1609
to	O	1610-1612
approximately	O	1613-1626
34	O	1627-1629
centimorgans	O	1630-1642
.	O	1642-1643

Loss	O	1644-1648
of	O	1649-1651
heterozygosity	O	1652-1666
was	O	1667-1670
studied	O	1671-1678
in	O	1679-1681
seven	O	1682-1687
renal	B	1688-1693
hamartomas	I	1694-1704
from	O	1705-1709
two	O	1710-1713
affected	O	1714-1722
individuals	O	1723-1734
in	O	1735-1737
the	O	1738-1741
first	O	1742-1747
family	O	1748-1754
,	O	1754-1755
as	O	1756-1758
well	O	1759-1763
as	O	1764-1766
in	O	1767-1769
a	O	1770-1771
jaw	B	1772-1775
tumor	I	1776-1781
and	O	1782-1785
a	O	1786-1787
parathyroid	B	1788-1799
tumor	I	1800-1805
from	O	1806-1810
the	O	1811-1814
second	O	1815-1821
family	O	1822-1828
.	O	1828-1829

All	O	1830-1833
renal	B	1834-1839
hamartomas	I	1840-1850
showed	O	1851-1857
loss	O	1858-1862
of	O	1863-1865
heterozygosity	O	1866-1880
at	O	1881-1883
the	O	1884-1887
1q21	O	1888-1892
-	O	1892-1893
q32	O	1893-1896
region	O	1897-1903
.	O	1903-1904

The	O	1905-1908
losses	O	1909-1915
invariably	O	1916-1926
involved	O	1927-1935
the	O	1936-1939
wild	O	1940-1944
type	O	1945-1949
allele	O	1950-1956
derived	O	1957-1964
from	O	1965-1969
the	O	1970-1973
unaffected	O	1974-1984
parent	O	1985-1991
,	O	1991-1992
suggesting	O	1993-2003
the	O	2004-2007
inactivation	O	2008-2020
of	O	2021-2023
a	O	2024-2025
tumor	B	2026-2031
suppressor	O	2032-2042
gene	O	2043-2047
in	O	2048-2050
this	O	2051-2055
region	O	2056-2062

Heterodimer	O	0-11
formation	O	12-21
and	O	22-25
activity	O	26-34
in	O	35-37
the	O	38-41
human	O	42-47
enzyme	O	48-54
galactose	O	55-64
-	O	64-65
1	O	65-66
-	O	64-65
phosphate	O	67-76
uridylyltransferase	O	77-96
.	O	96-97

One	O	98-101
of	O	102-104
the	O	105-108
fundamental	O	109-120
questions	O	121-130
concerning	O	131-141
expression	O	142-152
and	O	153-156
function	O	157-165
of	O	166-168
dimeric	O	169-176
enzymes	O	177-184
involves	O	185-193
the	O	194-197
impact	O	198-204
of	O	205-207
naturally	O	208-217
occurring	O	218-227
mutations	O	228-237
on	O	238-240
subunit	O	241-248
assembly	O	249-257
and	O	258-261
heterodimer	O	262-273
activity	O	274-282
.	O	282-283

This	O	284-288
question	O	289-297
is	O	298-300
of	O	301-303
particular	O	304-314
interest	O	315-323
for	O	324-327
the	O	328-331
human	O	332-337
enzyme	O	338-344
galactose	O	345-354
-	O	354-355
l	O	347-348
-	O	354-355
phosphate	O	357-366
uridylyl	O	367-375
-	O	375-376
transferase	O	376-387
(	O	388-389
GALT	O	389-393
)	O	393-394
,	O	394-395
impairment	O	396-406
of	O	407-409
which	O	410-415
results	O	416-423
in	O	424-426
the	O	427-430
inherited	B	431-440
metabolic	I	441-450
disorder	I	451-459
galactosemia	B	460-472
,	O	472-473
because	O	474-481
many	O	482-486
if	O	487-489
not	O	490-493
most	O	494-498
patients	O	499-507
studied	O	508-515
to	O	516-518
date	O	519-523
are	O	524-527
compound	O	528-536
heterozygotes	O	537-550
rather	O	551-557
than	O	558-562
true	O	563-567
molecular	O	568-577
homozygotes	O	578-589
.	O	589-590

Furthermore	O	591-602
,	O	602-603
the	O	604-607
broad	O	608-613
range	O	614-619
of	O	620-622
phenotypic	O	623-633
severity	O	634-642
observed	O	643-651
in	O	652-654
these	O	655-660
patients	O	661-669
raises	O	670-676
the	O	677-680
possibility	O	681-692
that	O	693-697
allelic	O	698-705
combination	O	706-717
,	O	717-718
not	O	719-722
just	O	723-727
allelic	O	728-735
constitution	O	736-748
,	O	748-749
may	O	750-753
play	O	754-758
some	O	759-763
role	O	764-768
in	O	769-771
determining	O	772-783
outcome	O	784-791
.	O	791-792

In	O	793-795
the	O	796-799
work	O	800-804
described	O	805-814
herein	O	815-821
,	O	821-822
we	O	823-825
have	O	826-830
selected	O	831-839
two	O	840-843
distinct	O	844-852
naturally	O	853-862
occurring	O	863-872
null	O	873-877
mutations	O	878-887
of	O	888-890
GALT	O	891-895
,	O	895-896
Q188R	O	897-902
and	O	903-906
R333W	O	907-912
,	O	912-913
and	O	914-917
asked	O	918-923
the	O	924-927
questions	O	928-937
(	O	938-939
i	O	939-940
)	O	940-941
what	O	942-946
are	O	947-950
the	O	951-954
impacts	O	955-962
of	O	963-965
these	O	966-971
mutations	O	972-981
on	O	982-984
subunit	O	985-992
assembly	O	993-1001
,	O	1001-1002
and	O	1003-1006
(	O	1007-1008
ii	O	1008-1010
)	O	1010-1011
if	O	1012-1014
heterodimers	O	1015-1027
do	O	1028-1030
form	O	1031-1035
,	O	1035-1036
are	O	1037-1040
they	O	1041-1045
active	O	1046-1052
?	O	1053-1054

To	O	1055-1057
answer	O	1058-1064
these	O	1065-1070
questions	O	1071-1080
,	O	1080-1081
we	O	1082-1084
have	O	1085-1089
established	O	1090-1101
a	O	1102-1103
yeast	O	1104-1109
system	O	1110-1116
for	O	1117-1120
the	O	1121-1124
coexpression	O	1125-1137
of	O	1138-1140
epitope	O	1141-1148
-	O	1148-1149
tagged	O	1149-1155
alleles	O	1156-1163
of	O	1164-1166
human	O	1167-1172
GALT	O	1173-1177
and	O	1178-1181
investigated	O	1182-1194
both	O	1195-1199
the	O	1200-1203
extent	O	1204-1210
of	O	1211-1213
specific	O	1214-1222
GALT	O	1223-1227
subunit	O	1228-1235
interactions	O	1236-1248
and	O	1249-1252
the	O	1253-1256
activity	O	1257-1265
of	O	1266-1268
defined	O	1269-1276
heterodimer	O	1277-1288
pools	O	1289-1294
.	O	1294-1295

We	O	1296-1298
have	O	1299-1303
found	O	1304-1309
that	O	1310-1314
both	O	1315-1319
homodimers	O	1320-1330
and	O	1331-1334
heterodimers	O	1335-1347
do	O	1348-1350
form	O	1351-1355
involving	O	1356-1365
each	O	1366-1370
of	O	1371-1373
the	O	1374-1377
mutant	O	1378-1384
subunits	O	1385-1393
tested	O	1394-1400
and	O	1401-1404
that	O	1405-1409
both	O	1410-1414
heterodimer	O	1415-1426
pools	O	1427-1432
retain	O	1433-1439
substantial	O	1440-1451
enzymatic	O	1452-1461
activity	O	1462-1470
.	O	1470-1471

These	O	1472-1477
results	O	1478-1485
are	O	1486-1489
significant	O	1490-1501
not	O	1502-1505
only	O	1506-1510
in	O	1511-1513
terms	O	1514-1519
of	O	1520-1522
their	O	1523-1528
implications	O	1529-1541
for	O	1542-1545
furthering	O	1546-1556
our	O	1557-1560
understanding	O	1561-1574
of	O	1575-1577
galactosemia	B	1578-1590
and	O	1591-1594
GALT	O	1595-1599
holoenzyme	O	1600-1610
structure	O	1611-1620
-	O	1620-1621
function	O	1621-1629
relationships	O	1630-1643
but	O	1644-1647
also	O	1648-1652
because	O	1653-1660
the	O	1661-1664
system	O	1665-1671
described	O	1672-1681
may	O	1682-1685
serve	O	1686-1691
as	O	1692-1694
a	O	1695-1696
model	O	1697-1702
for	O	1703-1706
similar	O	1707-1714
studies	O	1715-1722
of	O	1723-1725
other	O	1726-1731
complexes	O	1732-1741
composed	O	1742-1750
of	O	1751-1753
multiple	O	1754-1762
subunits	O	1763-1771
.	O	1771-1772
.	O	1771-1772

BRCA1	O	0-5
R841W	O	6-11
:	O	11-12
a	O	13-14
strong	O	15-21
candidate	O	22-31
for	O	32-35
a	O	36-37
common	O	38-44
mutation	O	45-53
with	O	54-58
moderate	O	59-67
phenotype	O	68-77
.	O	77-78

BRCA1	O	79-84
mutations	O	85-94
cause	O	95-100
increased	O	101-110
risk	O	111-115
for	O	116-119
breast	B	120-126
and	I	127-130
ovarian	I	131-138
cancer	I	139-145
,	O	145-146
frequently	O	147-157
of	O	158-160
early	O	161-166
onset	O	167-172
.	O	172-173

Many	O	174-178
different	O	179-188
mutations	O	189-198
occur	O	199-204
in	O	205-207
BRCA1	O	208-213
,	O	213-214
including	O	215-224
several	O	225-232
examples	O	233-241
of	O	242-244
recurrent	O	245-254
mutations	O	255-264
,	O	264-265
each	O	266-270
of	O	271-273
which	O	274-279
accounts	O	280-288
for	O	289-292
a	O	293-294
significant	O	295-306
number	O	307-313
of	O	314-316
families	O	317-325
with	O	326-330
heritable	O	331-340
cancer	B	341-347
predisposition	O	348-362
.	O	362-363

These	O	364-369
common	O	370-376
mutations	O	377-386
have	O	387-391
an	O	392-394
etiological	O	395-406
role	O	407-411
in	O	412-414
many	O	415-419
breast	B	420-426
and	I	427-430
ovarian	I	431-438
cancer	I	439-445
cases	O	446-451
and	O	452-455
provide	O	456-463
the	O	464-467
opportunity	O	468-479
to	O	480-482
examine	O	483-490
genotype	O	491-499
-	O	499-500
phenotype	O	500-509
correlations	O	510-522
and	O	523-526
genotype	O	527-535
-	O	535-536
environment	O	536-547
interactions	O	548-560
in	O	561-563
individuals	O	564-575
with	O	576-580
the	O	581-584
identical	O	585-594
BRCA1	O	595-600
lesion	O	601-607
.	O	607-608

We	O	609-611
report	O	612-618
a	O	619-620
novel	O	621-626
missense	O	627-635
change	O	636-642
in	O	643-645
BRCA1	O	646-651
,	O	651-652
2640	O	653-657
C	O	658-659
-	O	659-660
-	O	659-660
>	O	662-663
T	O	664-665
(	O	666-667
R841W	O	667-672
)	O	672-673
,	O	673-674
found	O	675-680
in	O	681-683
3	O	684-685
cases	O	686-691
from	O	692-696
a	O	697-698
subject	O	699-706
group	O	707-712
of	O	713-715
305	O	716-719
breast	B	720-726
and	I	727-730
79	I	731-733
ovarian	I	734-741
cancer	I	742-748
cases	O	749-754
from	O	755-759
Orange	O	760-766
County	O	767-773
,	O	773-774
CA	O	775-777
.	O	777-778

These	O	779-784
are	O	785-788
consecutive	O	789-800
,	O	800-801
population	O	802-812
-	O	812-813
based	O	813-818
cases	O	819-824
not	O	825-828
selected	O	829-837
for	O	838-841
age	O	842-845
or	O	846-848
family	O	849-855
history	O	856-863
.	O	863-864

In	O	865-867
all	O	868-871
three	O	872-877
cases	O	878-883
,	O	883-884
there	O	885-890
is	O	891-893
a	O	894-895
strong	O	896-902
family	O	903-909
history	O	910-917
of	O	918-920
breast	B	921-927
,	I	927-928
ovarian	I	929-936
,	I	936-937
or	I	938-940
other	I	941-946
cancers	I	947-954
possibly	O	955-963
related	O	964-971
to	O	972-974
a	O	975-976
BRCA1	O	977-982
defect	O	983-989
and	O	990-993
family	O	994-1000
members	O	1001-1008
showed	O	1009-1015
a	O	1016-1017
high	O	1018-1022
concordance	O	1023-1034
of	O	1035-1037
cancer	B	1038-1044
incidence	O	1045-1054
with	O	1055-1059
the	O	1060-1063
presence	O	1064-1072
of	O	1073-1075
R841W	O	1076-1081
.	O	1081-1082

The	O	1083-1086
age	O	1087-1090
of	O	1091-1093
cancer	B	1094-1100
onset	O	1101-1106
was	O	1107-1110
not	O	1111-1114
always	O	1115-1121
distinct	O	1122-1130
from	O	1131-1135
typical	O	1136-1143
sporadic	O	1144-1152
cases	O	1153-1158
.	O	1158-1159

Testing	O	1160-1167
of	O	1168-1170
a	O	1171-1172
sample	O	1173-1179
of	O	1180-1182
413	O	1183-1186
unrelated	O	1187-1196
individuals	O	1197-1208
to	O	1209-1211
examine	O	1212-1219
the	O	1220-1223
hypothesis	O	1224-1234
that	O	1235-1239
R841W	O	1240-1245
might	O	1246-1251
be	O	1252-1254
a	O	1255-1256
rare	O	1257-1261
polymorphism	O	1262-1274
detected	O	1275-1283
one	O	1284-1287
additional	O	1288-1298
instance	O	1299-1307
in	O	1308-1310
a	O	1311-1312
woman	O	1313-1318
with	O	1319-1323
breast	B	1324-1330
cancer	I	1331-1337
diagnosed	O	1338-1347
at	O	1348-1350
age	O	1351-1354
77	O	1355-1357
years	O	1358-1363
,	O	1363-1364
and	O	1365-1368
cancer	B	1369-1375
in	O	1376-1378
one	O	1379-1382
parent	O	1383-1389
.	O	1389-1390

R841W	O	1391-1396
is	O	1397-1399
likely	O	1400-1406
to	O	1407-1409
be	O	1410-1412
an	O	1413-1415
etiologically	O	1416-1429
significant	O	1430-1441
lesion	O	1442-1448
with	O	1449-1453
involvement	O	1454-1465
in	O	1466-1468
close	O	1469-1474
to	O	1475-1477
1	O	1478-1479
%	O	1479-1480
(	O	1481-1482
95	O	1482-1484
%	O	1484-1485
confidence	O	1486-1496
interval	O	1497-1505
of	O	1506-1508
0	O	1509-1510
-	O	1510-1511
1	O	1511-1512
.	O	1512-1513

7	O	1514-1515
%	O	1515-1516
)	O	1516-1517
of	O	1518-1520
all	O	1521-1524
breast	B	1525-1531
and	I	1532-1535
ovarian	I	1536-1543
cancers	I	1544-1551
in	O	1552-1554
this	O	1555-1559
population	O	1560-1570
.	O	1570-1571

Independent	O	0-11
origin	O	12-18
of	O	19-21
single	O	22-28
and	O	29-32
double	O	33-39
mutations	O	40-49
in	O	50-52
the	O	53-56
human	O	57-62
glucose	O	63-70
6	O	71-72
-	O	72-73
phosphate	O	73-82
dehydrogenase	O	83-96
gene	O	97-101
.	O	101-102

The	O	103-106
vast	O	107-111
majority	O	112-120
of	O	121-123
both	O	124-128
polymorphic	O	129-140
and	O	141-144
sporadic	O	145-153
G6PD	O	154-158
variants	O	159-167
are	O	168-171
due	O	172-175
to	O	176-178
single	O	179-185
missense	O	186-194
mutations	O	195-204
.	O	204-205

In	O	206-208
the	O	209-212
four	O	213-217
polymorphic	O	218-229
variants	O	230-238
that	O	239-243
have	O	244-248
two	O	249-252
point	O	253-258
mutations	O	259-268
,	O	268-269
one	O	270-273
of	O	274-276
the	O	277-280
mutations	O	281-290
is	O	291-293
always	O	294-300
376	O	301-304
A	O	305-306
-	O	306-307
-	O	306-307
>	O	309-310
G	O	311-312
(	O	313-314
126	O	314-317
Asn	O	318-321
-	O	321-322
-	O	321-322
>	O	324-325
Asp	O	326-329
)	O	329-330
,	O	330-331
which	O	332-337
on	O	338-340
its	O	341-344
own	O	345-348
gives	O	349-354
rise	O	355-359
to	O	360-362
the	O	363-366
nondeficient	O	367-379
polymorphic	O	380-391
variant	O	392-399
,	O	399-400
G6PD	O	401-405
A	O	406-407
.	O	407-408
In	O	409-411
a	O	412-413
study	O	414-419
of	O	420-422
G6PD	B	423-427
deficient	I	428-437
patients	O	438-446
who	O	447-450
presented	O	451-460
with	O	461-465
clinical	O	466-474
favism	B	475-481
in	O	482-484
Spain	O	485-490
,	O	490-491
we	O	492-494
have	O	495-499
found	O	500-505
a	O	506-507
new	O	508-511
polymorphic	O	512-523
variant	O	524-531
that	O	532-536
we	O	537-539
have	O	540-544
called	O	545-551
G6PD	O	552-556
Malaga	O	557-563
,	O	563-564
whose	O	565-570
only	O	571-575
abnormality	O	576-587
is	O	588-590
a	O	591-592
542	O	593-596
A	O	597-598
-	O	598-599
-	O	598-599
>	O	601-602
T	O	603-604
(	O	605-606
181	O	606-609
Asp	O	610-613
-	O	613-614
-	O	613-614
>	O	616-617
Val	O	618-621
)	O	621-622
mutation	O	623-631
.	O	631-632

This	O	633-637
is	O	638-640
the	O	641-644
same	O	645-649
mutation	O	650-658
as	O	659-661
previously	O	662-672
found	O	673-678
in	O	679-681
association	O	682-693
with	O	694-698
the	O	699-702
mutation	O	703-711
of	O	712-714
G6PD	O	715-719
A	O	720-721
in	O	722-724
the	O	725-728
double	O	729-735
mutant	O	736-742
,	O	742-743
G6PD	O	744-748
Santamaria	O	749-759
.	O	759-760

G6PD	O	761-765
Malaga	O	766-772
is	O	773-775
associated	O	776-786
with	O	787-791
enzyme	B	792-798
deficiency	I	799-809
(	O	810-811
class	O	811-816
III	O	817-820
)	O	820-821
,	O	821-822
and	O	823-826
the	O	827-830
enzymic	O	831-838
properties	O	839-849
of	O	850-852
G6PD	O	853-857
Malaga	O	858-864
and	O	865-868
G6PD	O	869-873
Santamaria	O	874-884
are	O	885-888
quite	O	889-894
similar	O	895-902
,	O	902-903
indicating	O	904-914
that	O	915-919
in	O	920-922
this	O	923-927
case	O	928-932
the	O	933-936
effects	O	937-944
of	O	945-947
the	O	948-951
two	O	952-955
mutations	O	956-965
are	O	966-969
additive	O	970-978
rather	O	979-985
than	O	986-990
synergistic	O	991-1002
.	O	1002-1003

G6PD	O	1004-1008
Santamaria	O	1009-1019
might	O	1020-1025
have	O	1026-1030
been	O	1031-1035
produced	O	1036-1044
by	O	1045-1047
recombination	O	1048-1061
between	O	1062-1069
G6PD	O	1070-1074
A	O	1075-1076
and	O	1077-1080
G6PD	O	1081-1085
Malaga	O	1086-1092
;	O	1092-1093
however	O	1094-1101
haplotype	O	1102-1111
analysis	O	1112-1120
,	O	1120-1121
including	O	1122-1131
the	O	1132-1135
use	O	1136-1139
of	O	1140-1142
a	O	1143-1144
new	O	1145-1148
silent	O	1149-1155
polymorphism	O	1156-1168
,	O	1168-1169
suggests	O	1170-1178
that	O	1179-1183
the	O	1184-1187
same	O	1188-1192
542	O	1193-1196
A	O	1197-1198
-	O	1198-1199
-	O	1198-1199
>	O	1201-1202
T	O	1203-1204
mutation	O	1205-1213
has	O	1214-1217
taken	O	1218-1223
place	O	1224-1229
independently	O	1230-1243
in	O	1244-1246
a	O	1247-1248
G6PD	O	1249-1253
B	O	1254-1255
gene	O	1256-1260
to	O	1261-1263
give	O	1264-1268
G6PD	O	1269-1273
Malaga	O	1274-1280
and	O	1281-1284
in	O	1285-1287
a	O	1288-1289
G6PD	O	1290-1294
A	O	1295-1296
gene	O	1297-1301
to	O	1302-1304
give	O	1305-1309
G6PD	O	1310-1314
Santamaria	O	1315-1325
.	O	1325-1326

These	O	1327-1332
findings	O	1333-1341
help	O	1342-1346
to	O	1347-1349
outline	O	1350-1357
the	O	1358-1361
relationship	O	1362-1374
and	O	1375-1378
evolution	O	1379-1388
of	O	1389-1391
mutations	O	1392-1401
in	O	1402-1404
the	O	1405-1408
human	O	1409-1414
G6PD	O	1415-1419
locus	O	1420-1425
.	O	1425-1426
.	O	1425-1426

FISH	O	0-4
studies	O	5-12
in	O	13-15
a	O	16-17
patient	O	18-25
with	O	26-30
sporadic	B	31-39
aniridia	I	40-48
and	O	49-52
t	O	53-54
(	O	54-55
7	O	55-56
;	O	56-57
11	O	57-59
)	O	59-60
(	O	61-62
q31	O	62-65
.	O	65-66
2	O	66-67
;	O	67-68
p13	O	68-71
)	O	71-72
.	O	65-66

A	O	74-75
2	O	76-77
year	O	78-82
old	O	83-86
female	O	87-93
presenting	O	94-104
with	O	105-109
bilateral	B	110-119
sporadic	I	120-128
aniridia	I	129-137
was	O	138-141
found	O	142-147
to	O	148-150
have	O	151-155
an	O	156-158
apparently	O	159-169
balanced	O	170-178
reciprocal	O	179-189
translocation	O	190-203
with	O	204-208
a	O	209-210
chromosome	O	211-221
11	O	222-224
breakpoint	O	225-235
within	O	236-242
band	O	243-247
p13	O	248-251
.	O	251-252

Fluorescence	O	253-265
in	O	266-268
situ	O	269-273
hybridisation	O	274-287
(	O	288-289
FISH	O	289-293
)	O	293-294
studies	O	295-302
with	O	303-307
distal	O	308-314
11p13	O	315-320
specific	O	321-329
cosmids	O	330-337
showed	O	338-344
that	O	345-349
the	O	350-353
chromosome	O	354-364
11	O	365-367
breakpoint	O	368-378
lay	O	379-382
between	O	383-390
the	O	391-394
aniridia	B	395-403
(	O	404-405
PAX6	O	405-409
)	O	409-410
locus	O	411-416
and	O	417-420
a	O	421-422
region	O	423-429
approximately	O	430-443
100	O	444-447
kb	O	448-450
distal	O	451-457
to	O	458-460
PAX6	O	461-465
defined	O	466-473
by	O	474-476
the	O	477-480
cosmid	O	481-487
FO2121	O	488-494
.	O	494-495

Although	O	496-504
this	O	505-509
patient	O	510-517
did	O	518-521
not	O	522-525
have	O	526-530
a	O	531-532
detectable	O	533-543
deletion	O	544-552
within	O	553-559
PAX6	O	560-564
,	O	564-565
her	O	566-569
aniridia	B	570-578
may	O	579-582
have	O	583-587
resulted	O	588-596
from	O	597-601
a	O	602-603
disruption	O	604-614
of	O	615-617
the	O	618-621
distal	O	622-628
chromatin	O	629-638
domain	O	639-645
containing	O	646-656
either	O	657-663
enhancers	O	664-673
or	O	674-676
regulators	O	677-687
for	O	688-691
PAX6	O	692-696
.	O	696-697

This	O	698-702
case	O	703-707
may	O	708-711
therefore	O	712-721
be	O	722-724
another	O	725-732
example	O	733-740
of	O	741-743
aniridia	B	744-752
caused	O	753-759
by	O	760-762
a	O	763-764
position	O	765-773
effect	O	774-780
as	O	781-783
recently	O	784-792
described	O	793-802
in	O	803-805
two	O	806-809
familial	B	810-818
aniridia	I	819-827
patients	O	828-836
in	O	837-839
which	O	840-845
the	O	846-849
phenotype	O	850-859
cosegregated	O	860-872
with	O	873-877
chromosome	B	878-888
abnormalities	I	889-902
with	O	903-907
11p13	O	908-913
breakpoints	O	914-925
.	O	925-926
.	O	925-926

Ovarian	B	0-7
cancer	I	8-14
risk	O	15-19
in	O	20-22
BRCA1	O	23-28
carriers	O	29-37
is	O	38-40
modified	O	41-49
by	O	50-52
the	O	53-56
HRAS1	O	57-62
variable	O	63-71
number	O	72-78
of	O	79-81
tandem	O	82-88
repeat	O	89-95
(	O	96-97
VNTR	O	97-101
)	O	101-102
locus	O	103-108
.	O	108-109

Women	O	110-115
who	O	116-119
carry	O	120-125
a	O	126-127
mutation	O	128-136
in	O	137-139
the	O	140-143
BRCA1	O	144-149
gene	O	150-154
(	O	155-156
on	O	156-158
chromosome	O	159-169
17q21	O	170-175
)	O	175-176
,	O	176-177
have	O	178-182
an	O	183-185
80	O	186-188
%	O	188-189
risk	O	190-194
of	O	195-197
breast	B	198-204
cancer	I	205-211
and	O	212-215
a	O	216-217
40	O	218-220
%	O	220-221
risk	O	222-226
of	O	227-229
ovarian	B	230-237
cancer	I	238-244
by	O	245-247
the	O	248-251
age	O	252-255
of	O	256-258
70	O	259-261
(	O	262-263
ref	O	263-266
.	O	266-267

1	O	268-269
)	O	269-270
.	O	270-271

The	O	272-275
variable	O	276-284
penetrance	O	285-295
of	O	296-298
BRCA1	O	299-304
suggests	O	305-313
that	O	314-318
other	O	319-324
genetic	O	325-332
and	O	333-336
non	O	337-340
-	O	340-341
genetic	O	341-348
factors	O	349-356
play	O	357-361
a	O	362-363
role	O	364-368
in	O	369-371
tumourigenesis	O	372-386
in	O	387-389
these	O	390-395
individuals	O	396-407
.	O	407-408

The	O	409-412
HRAS1	O	413-418
variable	O	419-427
number	O	428-434
of	O	435-437
tandem	O	438-444
repeats	O	445-452
(	O	453-454
VNTR	O	454-458
)	O	458-459
polymorphism	O	460-472
,	O	472-473
located	O	474-481
1	O	482-483
kilobase	O	484-492
(	O	493-494
kb	O	494-496
)	O	496-497
downstream	O	498-508
of	O	509-511
the	O	512-515
HRAS1	O	516-521
proto	O	522-527
-	O	527-528
oncogene	O	528-536
(	O	537-538
chromosome	O	538-548
11p15	O	549-554
.	O	554-555

5	O	556-557
)	O	557-558
is	O	559-561
one	O	562-565
possible	O	566-574
genetic	O	575-582
modifier	O	583-591
of	O	592-594
cancer	B	595-601
penetrance	O	602-612
.	O	612-613

Individuals	O	614-625
who	O	626-629
have	O	630-634
rare	O	635-639
alleles	O	640-647
of	O	648-650
the	O	651-654
VNTR	O	655-659
have	O	660-664
an	O	665-667
increased	O	668-677
risk	O	678-682
of	O	683-685
certain	O	686-693
types	O	694-699
of	O	700-702
cancers	B	703-710
,	O	710-711
including	O	712-721
breast	B	722-728
cancer	I	729-735
(	O	736-737
2	O	737-738
-	O	738-739
4	O	739-740
)	O	740-741
.	O	741-742

To	O	743-745
investigate	O	746-757
whether	O	758-765
the	O	766-769
presence	O	770-778
of	O	779-781
rare	O	782-786
HRAS1	O	787-792
alleles	O	793-800
increases	O	801-810
susceptibility	O	811-825
to	O	826-828
hereditary	B	829-839
breast	I	840-846
and	I	847-850
ovarian	I	851-858
cancer	I	859-865
,	O	865-866
we	O	867-869
have	O	870-874
typed	O	875-880
a	O	881-882
panel	O	883-888
of	O	889-891
307	O	892-895
female	O	896-902
BRCA1	O	903-908
carriers	O	909-917
at	O	918-920
this	O	921-925
locus	O	926-931
using	O	932-937
a	O	938-939
PCR	O	940-943
-	O	943-944
based	O	944-949
technique	O	950-959
.	O	959-960

The	O	961-964
risk	O	965-969
for	O	970-973
ovarian	B	974-981
cancer	I	982-988
was	O	989-992
2	O	993-994
.	O	994-995
11	O	996-998
times	O	999-1004
greater	O	1005-1012
for	O	1013-1016
BRCA1	O	1017-1022
carriers	O	1023-1031
harbouring	O	1032-1042
one	O	1043-1046
or	O	1047-1049
two	O	1050-1053
rare	O	1054-1058
HRAS1	O	1059-1064
alleles	O	1065-1072
,	O	1072-1073
compared	O	1074-1082
to	O	1083-1085
carriers	O	1086-1094
with	O	1095-1099
only	O	1100-1104
common	O	1105-1111
alleles	O	1112-1119
(	O	1120-1121
P	O	1121-1122
=	O	1123-1124
0	O	1125-1126
.	O	1126-1127
015	O	1128-1131
)	O	1131-1132
.	O	1132-1133

The	O	1134-1137
magnitude	O	1138-1147
of	O	1148-1150
the	O	1151-1154
relative	O	1155-1163
risk	O	1164-1168
associated	O	1169-1179
with	O	1180-1184
a	O	1185-1186
rare	O	1187-1191
HRAS1	O	1192-1197
allele	O	1198-1204
was	O	1205-1208
not	O	1209-1212
altered	O	1213-1220
by	O	1221-1223
adjusting	O	1224-1233
for	O	1234-1237
the	O	1238-1241
other	O	1242-1247
known	O	1248-1253
risk	O	1254-1258
factors	O	1259-1266
for	O	1267-1270
hereditary	B	1271-1281
ovarian	I	1282-1289
cancer	I	1290-1296
(	O	1297-1298
5	O	1298-1299
)	O	1299-1300
.	O	1300-1301

Susceptibility	O	1302-1316
to	O	1317-1319
breast	B	1320-1326
cancer	I	1327-1333
did	O	1334-1337
not	O	1338-1341
appear	O	1342-1348
to	O	1349-1351
be	O	1352-1354
affected	O	1355-1363
by	O	1364-1366
the	O	1367-1370
presence	O	1371-1379
of	O	1380-1382
rare	O	1383-1387
HRAS1	O	1388-1393
alleles	O	1394-1401
.	O	1401-1402

This	O	1403-1407
study	O	1408-1413
is	O	1414-1416
the	O	1417-1420
first	O	1421-1426
to	O	1427-1429
show	O	1430-1434
the	O	1435-1438
effect	O	1439-1445
of	O	1446-1448
a	O	1449-1450
modifying	O	1451-1460
gene	O	1461-1465
on	O	1466-1468
the	O	1469-1472
penetrance	O	1473-1483
of	O	1484-1486
an	O	1487-1489
inherited	B	1490-1499
cancer	I	1500-1506
syndrome	I	1507-1515

A	O	0-1
previously	O	2-12
undescribed	O	13-24
mutation	O	25-33
within	O	34-40
the	O	41-44
tetramerisation	O	45-60
domain	O	61-67
of	O	68-70
TP53	O	71-75
in	O	76-78
a	O	79-80
family	O	81-87
with	O	88-92
Li	B	93-95
-	I	95-96
Fraumeni	I	96-104
syndrome	I	105-113
.	O	113-114

We	O	115-117
report	O	118-124
details	O	125-132
of	O	133-135
a	O	136-137
family	O	138-144
with	O	145-149
classic	O	150-157
Li	B	158-160
-	I	160-161
Fraumeni	I	161-169
syndrome	I	170-178
in	O	179-181
which	O	182-187
there	O	188-193
is	O	194-196
a	O	197-198
mutation	O	199-207
in	O	208-210
codon	O	211-216
344	O	217-220
of	O	221-223
the	O	224-227
tumour	B	228-234
suppressor	O	235-245
gene	O	246-250
TP53	O	251-255
.	O	255-256

Codon	O	257-262
344	O	263-266
is	O	267-269
a	O	270-271
key	O	272-275
residue	O	276-283
within	O	284-290
the	O	291-294
tetramerisation	O	295-310
domain	O	311-317
,	O	317-318
and	O	319-322
the	O	323-326
amino	O	327-332
acid	O	333-337
substitution	O	338-350
of	O	351-353
a	O	354-355
proline	O	356-363
for	O	364-367
a	O	368-369
leucine	O	370-377
is	O	378-380
predicted	O	381-390
to	O	391-393
have	O	394-398
profound	O	399-407
implications	O	408-420
for	O	421-424
tetramerisation	O	425-440
and	O	441-444
potentially	O	445-456
DNA	O	457-460
binding	O	461-468
.	O	468-469

This	O	470-474
is	O	475-477
the	O	478-481
first	O	482-487
report	O	488-494
of	O	495-497
a	O	498-499
mutation	O	500-508
at	O	509-511
this	O	512-516
residue	O	517-524
in	O	525-527
either	O	528-534
sporadic	B	535-543
tumours	I	544-551
or	O	552-554
in	O	555-557
the	O	558-561
germline	O	562-570
and	O	571-574
the	O	575-578
first	O	579-584
report	O	585-591
of	O	592-594
a	O	595-596
germline	O	597-605
mutation	O	606-614
within	O	615-621
the	O	622-625
tetramerisation	O	626-641
domain	O	642-648
.	O	648-649

The	O	650-653
family	O	654-660
does	O	661-665
not	O	666-669
appear	O	670-676
to	O	677-679
be	O	680-682
remarkable	O	683-693
in	O	694-696
the	O	697-700
spectrum	O	701-709
of	O	710-712
tumours	B	713-720
,	O	720-721
and	O	722-725
there	O	726-731
is	O	732-734
loss	O	735-739
of	O	740-742
the	O	743-746
wild	O	747-751
-	O	751-752
type	O	752-756
allele	O	757-763
in	O	764-766
a	O	767-768
leiomyosarcoma	B	769-783
from	O	784-788
the	O	789-792
proband	O	793-800
.	O	800-801

A	O	802-803
cell	O	804-808
line	O	809-813
has	O	814-817
been	O	818-822
established	O	823-834
from	O	835-839
the	O	840-843
tumour	B	844-850
of	O	851-853
the	O	854-857
proband	O	858-865
and	O	866-869
cytogenetic	O	870-881
and	O	882-885
molecular	O	886-895
studies	O	896-903
carried	O	904-911
out	O	912-915
,	O	915-916
providing	O	917-926
an	O	927-929
extensive	O	930-939
analysis	O	940-948
in	O	949-951
this	O	952-956
family	O	957-963
.	O	963-964
.	O	963-964

Trinucleotide	O	0-13
repeat	O	14-20
expansion	O	21-30
at	O	31-33
the	O	34-37
myotonic	B	38-46
dystrophy	I	47-56
locus	O	57-62
reduces	O	63-70
expression	O	71-81
of	O	82-84
DMAHP	O	85-90
.	O	90-91

Myotonic	B	92-100
dystrophy	I	101-110
,	O	110-111
or	O	112-114
dystrophia	B	115-125
myotonica	I	126-135
(	O	136-137
DM	B	137-139
)	O	139-140
,	O	140-141
is	O	142-144
an	O	145-147
autosomal	B	148-157
dominant	I	158-166
multisystem	I	167-178
disorder	I	179-187
caused	O	188-194
by	O	195-197
the	O	198-201
expansion	O	202-211
of	O	212-214
a	O	215-216
CTG	O	217-220
trinucleotide	O	221-234
repeat	O	235-241
in	O	242-244
the	O	245-248
3	O	249-250
untranslated	O	251-263
region	O	264-270
of	O	271-273
the	O	274-277
DMPK	O	278-282
protein	O	283-290
kinase	O	291-297
gene	O	298-302
on	O	303-305
chromosome	O	306-316
19q13	O	317-322
.	O	322-323

3	O	324-325
(	O	326-327
refs	O	327-331
1	O	332-333
-	O	333-334
3	O	334-335
)	O	335-336
.	O	336-337

Although	O	338-346
the	O	347-350
DM	B	351-353
mutation	O	354-362
was	O	363-366
identified	O	367-377
more	O	378-382
than	O	383-387
five	O	388-392
years	O	393-398
ago	O	399-402
,	O	402-403
the	O	404-407
pathogenic	O	408-418
mechanisms	O	419-429
underlying	O	430-440
this	O	441-445
most	O	446-450
prevalent	O	451-460
form	O	461-465
of	O	466-468
hereditary	O	469-479
adult	O	480-485
neuromuscular	B	486-499
disease	I	500-507
remain	O	508-514
elusive	O	515-522
.	O	522-523

Previous	O	524-532
work	O	533-537
from	O	538-542
our	O	543-546
laboratory	O	547-557
demonstrated	O	558-570
that	O	571-575
a	O	576-577
DNase	O	578-583
l	O	584-585
-	O	585-586
hypersensitive	O	586-600
site	O	601-605
located	O	606-613
adjacent	O	614-622
to	O	623-625
the	O	626-629
repeats	O	630-637
on	O	638-640
the	O	641-644
wild	O	645-649
-	O	649-650
type	O	650-654
allele	O	655-661
is	O	662-664
eliminated	O	665-675
by	O	676-678
repeat	O	679-685
expansion	O	686-695
,	O	695-696
indicating	O	697-707
that	O	708-712
large	O	713-718
CTG	O	719-722
-	O	722-723
repeat	O	723-729
arrays	O	730-736
may	O	737-740
be	O	741-743
associated	O	744-754
with	O	755-759
a	O	760-761
local	O	762-767
chromatin	O	768-777
environment	O	778-789
that	O	790-794
represses	O	795-804
gene	O	805-809
expression	O	810-820
.	O	820-821

Here	O	822-826
we	O	827-829
report	O	830-836
that	O	837-841
the	O	842-845
hypersensitive	O	846-860
site	O	861-865
contains	O	866-874
an	O	875-877
enhancer	O	878-886
element	O	887-894
that	O	895-899
regulates	O	900-909
transcription	O	910-923
of	O	924-926
the	O	927-930
adjacent	O	931-939
DMAHP	O	940-945
homeobox	O	946-954
gene	O	955-959
.	O	959-960

Analysis	O	961-969
of	O	970-972
DMAHP	O	973-978
expression	O	979-989
in	O	990-992
the	O	993-996
cells	O	997-1002
of	O	1003-1005
DM	B	1006-1008
patients	O	1009-1017
with	O	1018-1022
loss	O	1023-1027
of	O	1028-1030
the	O	1031-1034
hypersensitive	O	1035-1049
site	O	1050-1054
revealed	O	1055-1063
a	O	1064-1065
two	O	1066-1069
-	O	1069-1070
to	O	1071-1073
fourfold	O	1074-1082
reduction	O	1083-1092
in	O	1093-1095
steady	O	1096-1102
-	O	1102-1103
state	O	1103-1108
DMAHP	O	1109-1114
transcript	O	1115-1125
levels	O	1126-1132
relative	O	1133-1141
to	O	1142-1144
wild	O	1145-1149
-	O	1149-1150
type	O	1150-1154
controls	O	1155-1163
.	O	1163-1164

Allele	O	1165-1171
-	O	1171-1172
specific	O	1172-1180
analysis	O	1181-1189
of	O	1190-1192
DMAHP	O	1193-1198
expression	O	1199-1209
showed	O	1210-1216
that	O	1217-1221
steady	O	1222-1228
-	O	1228-1229
state	O	1229-1234
transcript	O	1235-1245
levels	O	1246-1252
from	O	1253-1257
the	O	1258-1261
expanded	O	1262-1270
allele	O	1271-1277
were	O	1278-1282
greatly	O	1283-1290
reduced	O	1291-1298
in	O	1299-1301
comparison	O	1302-1312
to	O	1313-1315
those	O	1316-1321
from	O	1322-1326
the	O	1327-1330
wild	O	1331-1335
-	O	1335-1336
type	O	1336-1340
allele	O	1341-1347
.	O	1347-1348

Together	O	1349-1357
,	O	1357-1358
these	O	1359-1364
results	O	1365-1372
demonstrate	O	1373-1384
that	O	1385-1389
CTG	O	1390-1393
-	O	1393-1394
repeat	O	1394-1400
expansions	O	1401-1411
can	O	1412-1415
suppress	O	1416-1424
local	O	1425-1430
gene	O	1431-1435
expression	O	1436-1446
and	O	1447-1450
implicate	O	1451-1460
DMAHP	O	1461-1466
in	O	1467-1469
DM	B	1470-1472
pathogenesis	O	1473-1485
.	O	1485-1486

A	O	0-1
mutation	O	2-10
in	O	11-13
autosomal	B	14-23
dominant	I	24-32
myotonia	I	33-41
congenita	I	42-51
affects	O	52-59
pore	O	60-64
properties	O	65-75
of	O	76-78
the	O	79-82
muscle	O	83-89
chloride	O	90-98
channel	O	99-106
.	O	106-107

Autosomal	B	108-117
dominant	I	118-126
myotonia	I	127-135
congenita	I	136-145
is	O	146-148
an	O	149-151
inherited	B	152-161
disorder	I	162-170
of	I	171-173
skeletal	I	174-182
muscle	I	183-189
caused	O	190-196
by	O	197-199
mutations	O	200-209
in	O	210-212
a	O	213-214
voltage	O	215-222
-	O	222-223
gated	O	223-228
Cl	O	229-231
-	O	231-232
channel	O	233-240
gene	O	241-245
(	O	246-247
CLCN1	O	247-252
,	O	252-253
7q35	O	254-258
)	O	258-259
.	O	259-260

Here	O	261-265
,	O	265-266
we	O	267-269
report	O	270-276
that	O	277-281
a	O	282-283
mutation	O	284-292
predicting	O	293-303
the	O	304-307
substitution	O	308-320
of	O	321-323
Gly	O	324-327
230	O	328-331
by	O	332-334
glutamic	O	335-343
acid	O	344-348
(	O	349-350
G230E	O	350-355
)	O	355-356
between	O	357-364
segments	O	365-373
D3	O	374-376
and	O	377-380
D4	O	381-383
dramatically	O	384-396
alters	O	397-403
the	O	404-407
pore	O	408-412
properties	O	413-423
of	O	424-426
a	O	427-428
recombinant	O	429-440
human	O	441-446
muscle	O	447-453
Cl	O	454-456
-	O	456-457
channel	O	458-465
(	O	466-467
hCIC	O	467-471
-	O	471-472
1	O	472-473
)	O	473-474
expressed	O	475-484
in	O	485-487
a	O	488-489
mammalian	O	490-499
cell	O	500-504
line	O	505-509
(	O	510-511
tsA201	O	511-517
)	O	517-518
.	O	518-519

The	O	520-523
G230E	O	524-529
mutation	O	530-538
causes	O	539-545
substantial	O	546-557
changes	O	558-565
in	O	566-568
anion	O	569-574
and	O	575-578
cation	O	579-585
selectivity	O	586-597
as	O	598-600
well	O	601-605
as	O	606-608
a	O	609-610
fundamental	O	611-622
change	O	623-629
in	O	630-632
rectification	O	633-646
of	O	647-649
the	O	650-653
current	O	654-661
-	O	661-662
voltage	O	662-669
relationship	O	670-682
.	O	682-683

Whereas	O	684-691
wild	O	692-696
-	O	696-697
type	O	697-701
channels	O	702-710
are	O	711-714
characterized	O	715-728
by	O	729-731
pronounced	O	732-742
inward	O	743-749
rectification	O	750-763
and	O	764-767
a	O	768-769
Cl	O	770-772
>	O	773-774
thiocyanate	O	775-786
>	O	787-788
Br	O	789-791
>	O	792-793
NO	O	794-796
(	O	797-798
3	O	798-799
)	O	799-800
>	O	801-802
I	O	803-804
>	O	805-806
CH	O	807-809
(	O	810-811
3	O	811-812
)	O	812-813
SO	O	814-816
(	O	817-818
3	O	818-819
)	O	819-820
selectivity	O	821-832
,	O	832-833
G230E	O	834-839
exhibits	O	840-848
outward	O	849-856
rectification	O	857-870
at	O	871-873
positive	O	874-882
potentials	O	883-893
and	O	894-897
a	O	898-899
thiocyanate	O	900-911
>	O	912-913
NO	O	914-916
(	O	917-918
3	O	918-919
)	O	919-920
>	O	921-922
I	O	923-924
>	O	925-926
Br	O	927-929
>	O	930-931
Cl	O	932-934
>	O	935-936
CH	O	937-939
(	O	940-941
3	O	941-942
)	O	942-943
SO	O	944-946
(	O	947-948
3	O	948-949
)	O	949-950
selectivity	O	951-962
.	O	962-963

Furthermore	O	964-975
,	O	975-976
the	O	977-980
cation	O	981-987
-	O	987-988
to	O	988-990
-	O	987-988
anion	O	991-996
permeability	O	997-1009
ratio	O	1010-1015
of	O	1016-1018
the	O	1019-1022
mutant	O	1023-1029
is	O	1030-1032
much	O	1033-1037
greater	O	1038-1045
than	O	1046-1050
that	O	1051-1055
of	O	1056-1058
the	O	1059-1062
wild	O	1063-1067
-	O	1067-1068
type	O	1068-1072
channel	O	1073-1080
.	O	1080-1081

Voltage	O	1082-1089
-	O	1089-1090
dependent	O	1090-1099
blocks	O	1100-1106
by	O	1107-1109
intracellular	O	1110-1123
and	O	1124-1127
extracellular	O	1128-1141
iodide	O	1142-1148
help	O	1149-1153
to	O	1154-1156
distinguish	O	1157-1168
two	O	1169-1172
distinct	O	1173-1181
ion	O	1182-1185
binding	O	1186-1193
sites	O	1194-1199
within	O	1200-1206
the	O	1207-1210
hClC	O	1211-1215
-	O	1215-1216
1	O	1216-1217
conduction	O	1218-1228
pathway	O	1229-1236
.	O	1236-1237

Both	O	1238-1242
binding	O	1243-1250
sites	O	1251-1256
are	O	1257-1260
preserved	O	1261-1270
in	O	1271-1273
the	O	1274-1277
mutant	O	1278-1284
but	O	1285-1288
have	O	1289-1293
decreased	O	1294-1303
affinities	O	1304-1314
for	O	1315-1318
iodide	O	1319-1325
.	O	1325-1326

These	O	1327-1332
findings	O	1333-1341
suggest	O	1342-1349
that	O	1350-1354
Gly	O	1355-1358
230	O	1359-1362
is	O	1363-1365
critical	O	1366-1374
for	O	1375-1378
normal	O	1379-1385
ion	O	1386-1389
conductance	O	1390-1401
in	O	1402-1404
hClC	O	1405-1409
-	O	1409-1410
1	O	1410-1411
and	O	1412-1415
that	O	1416-1420
this	O	1421-1425
residue	O	1426-1433
resides	O	1434-1441
within	O	1442-1448
the	O	1449-1452
channel	O	1453-1460
pore	O	1461-1465
.	O	1465-1466
.	O	1465-1466

Mutation	O	0-8
analysis	O	9-17
of	O	18-20
BRCA1	O	21-26
and	O	27-30
BRCA2	O	31-36
in	O	37-39
a	O	40-41
male	B	42-46
breast	I	47-53
cancer	I	54-60
population	O	61-71
.	O	71-72

A	O	73-74
population	O	75-85
-	O	85-86
based	O	86-91
series	O	92-98
of	O	99-101
54	O	102-104
male	B	105-109
breast	I	110-116
cancer	I	117-123
cases	O	124-129
from	O	130-134
Southern	O	135-143
California	O	144-154
were	O	155-159
analyzed	O	160-168
for	O	169-172
germ	O	173-177
-	O	177-178
line	O	178-182
mutations	O	183-192
in	O	193-195
the	O	196-199
inherited	B	200-209
breast	I	210-216
/	I	216-217
ovarian	I	217-224
cancer	I	225-231
genes	O	232-237
,	O	237-238
BRCA1	O	239-244
and	O	245-248
BRCA2	O	249-254
.	O	254-255

Nine	O	256-260
(	O	261-262
17	O	262-264
%	O	264-265
)	O	265-266
of	O	267-269
the	O	270-273
patients	O	274-282
had	O	283-286
a	O	287-288
family	O	289-295
history	O	296-303
of	O	304-306
breast	B	307-313
and	I	314-317
/	I	317-318
or	I	318-320
ovarian	I	321-328
cancer	I	329-335
in	O	336-338
at	O	339-341
least	O	342-347
one	O	348-351
first	O	352-357
-	O	357-358
degree	O	358-364
relative	O	365-373
.	O	373-374

A	O	375-376
further	O	377-384
seven	O	385-390
(	O	391-392
13	O	392-394
%	O	394-395
)	O	395-396
of	O	397-399
the	O	400-403
patients	O	404-412
reported	O	413-421
breast	B	422-428
/	I	428-429
ovarian	I	429-436
cancer	I	437-443
in	O	444-446
at	O	447-449
least	O	450-455
one	O	456-459
second	O	460-466
-	O	466-467
degree	O	467-473
relative	O	474-482
and	O	483-486
in	O	487-489
no	O	490-492
first	O	493-498
-	O	498-499
degree	O	499-505
relatives	O	506-515
.	O	515-516

No	O	517-519
germ	O	520-524
-	O	524-525
line	O	525-529
BRCA1	O	530-535
mutations	O	536-545
were	O	546-550
found	O	551-556
.	O	556-557

Two	O	558-561
male	B	562-566
breast	I	567-573
cancer	I	574-580
patients	O	581-589
(	O	590-591
4	O	591-592
%	O	592-593
of	O	594-596
the	O	597-600
total	O	601-606
)	O	606-607
were	O	608-612
found	O	613-618
to	O	619-621
carry	O	622-627
novel	O	628-633
truncating	O	634-644
mutations	O	645-654
in	O	655-657
the	O	658-661
BRCA2	O	662-667
gene	O	668-672
.	O	672-673

Only	O	674-678
one	O	679-682
of	O	683-685
the	O	686-689
two	O	690-693
male	B	694-698
breast	I	699-705
cancer	I	706-712
patients	O	713-721
carrying	O	722-730
a	O	731-732
BRCA2	O	733-738
mutation	O	739-747
had	O	748-751
a	O	752-753
family	O	754-760
history	O	761-768
of	O	769-771
cancer	B	772-778
,	O	778-779
with	O	780-784
one	O	785-788
case	O	789-793
of	O	794-796
ovarian	B	797-804
cancer	I	805-811
in	O	812-814
a	O	815-816
first	O	817-822
-	O	822-823
degree	O	823-829
relative	O	830-838
.	O	838-839

The	O	840-843
remaining	O	844-853
eight	O	854-859
cases	O	860-865
(	O	866-867
89	O	867-869
%	O	869-870
)	O	870-871
of	O	872-874
male	B	875-879
breast	I	880-886
cancer	I	887-893
with	O	894-898
a	O	899-900
family	O	901-907
history	O	908-915
of	O	916-918
breast	B	919-925
/	I	925-926
ovarian	I	926-933
cancer	I	934-940
in	O	941-943
first	O	944-949
-	O	949-950
degree	O	950-956
relatives	O	957-966
remain	O	967-973
unaccounted	O	974-985
for	O	986-989
by	O	990-992
mutations	O	993-1002
in	O	1003-1005
either	O	1006-1012
the	O	1013-1016
BRCA1	O	1017-1022
gene	O	1023-1027
or	O	1028-1030
the	O	1031-1034
BRCA2	O	1035-1040
gene	O	1041-1045
.	O	1045-1046
.	O	1045-1046

Expression	O	0-10
of	O	11-13
the	O	14-17
von	B	18-21
Hippel	I	22-28
-	I	28-29
Lindau	I	29-35
disease	I	36-43
tumour	I	44-50
suppressor	O	51-61
gene	O	62-66
during	O	67-73
human	O	74-79
embryogenesis	O	80-93
.	O	93-94

The	O	95-98
von	B	99-102
Hippel	I	103-109
-	I	109-110
Lindau	I	110-116
(	I	117-118
VHL	I	118-121
)	I	121-122
disease	I	123-130
product	O	131-138
is	O	139-141
thought	O	142-149
to	O	150-152
down	O	153-157
-	O	157-158
regulate	O	158-166
transcription	O	167-180
by	O	181-183
antagonizing	O	184-196
elongin	O	197-204
-	O	204-205
enhanced	O	205-213
transcriptional	O	214-229
elongation	O	230-240
.	O	240-241

Germline	O	242-250
VHL	B	251-254
gene	O	255-259
mutations	O	260-269
predispose	O	270-280
to	O	281-283
the	O	284-287
development	O	288-299
of	O	300-302
retinal	B	303-310
,	I	310-311
cerebellar	I	312-322
and	I	323-326
spinal	I	327-333
haemangioblastomas	I	334-352
,	O	352-353
renal	B	354-359
cell	I	360-364
carcinoma	I	365-374
and	O	375-378
phaeochromocytoma	B	379-396
.	O	396-397

In	O	398-400
addition	O	401-409
,	O	409-410
somatic	O	411-418
Inactivation	O	419-431
of	O	432-434
the	O	435-438
VHL	B	439-442
gene	O	443-447
is	O	448-450
frequent	O	451-459
in	O	460-462
sporadic	B	463-471
renal	I	472-477
cell	I	478-482
carcinoma	I	483-492
and	O	493-496
haemangioblastoma	B	497-514
.	O	514-515

Regulation	O	516-526
of	O	527-529
transcript	O	530-540
elongation	O	541-551
is	O	552-554
an	O	555-557
important	O	558-567
control	O	568-575
mechanism	O	576-585
for	O	586-589
gene	O	590-594
expression	O	595-605
and	O	606-609
the	O	610-613
VHL	B	614-617
gene	O	618-622
might	O	623-628
modify	O	629-635
the	O	636-639
expression	O	640-650
of	O	651-653
proto	O	654-659
-	O	659-660
oncogenes	O	660-669
and	O	670-673
growth	O	674-680
suppressor	O	681-691
genes	O	692-697
during	O	698-704
embryogenesis	O	705-718
.	O	718-719

We	O	720-722
therefore	O	723-732
investigated	O	733-745
the	O	746-749
expression	O	750-760
of	O	761-763
VHL	B	764-767
mRNA	O	768-772
during	O	773-779
human	O	780-785
embryogenesis	O	786-799
by	O	800-802
in	O	803-805
situ	O	806-810
hybridization	O	811-824
studies	O	825-832
at	O	833-835
4	O	836-837
,	O	837-838
6	O	839-840
and	O	841-844
10	O	845-847
weeks	O	848-853
post	O	854-858
conception	O	859-869
.	O	869-870

Although	O	871-879
VHL	B	880-883
mRNA	O	884-888
was	O	889-892
expressed	O	893-902
in	O	903-905
all	O	906-909
three	O	910-915
germ	O	916-920
layers	O	921-927
,	O	927-928
strong	O	929-935
expression	O	936-946
was	O	947-950
noted	O	951-956
in	O	957-959
the	O	960-963
central	O	964-971
nervous	O	972-979
system	O	980-986
,	O	986-987
kidneys	O	988-995
,	O	995-996
testis	O	997-1003
and	O	1004-1007
lung	O	1008-1012
.	O	1012-1013

Within	O	1014-1020
the	O	1021-1024
kidney	O	1025-1031
,	O	1031-1032
VHL	B	1033-1036
mRNA	O	1037-1041
was	O	1042-1045
differentially	O	1046-1060
expressed	O	1061-1070
within	O	1071-1077
renal	O	1078-1083
tubules	O	1084-1091
suggesting	O	1092-1102
that	O	1103-1107
the	O	1108-1111
VHL	B	1112-1115
gene	O	1116-1120
product	O	1121-1128
may	O	1129-1132
have	O	1133-1137
a	O	1138-1139
specific	O	1140-1148
role	O	1149-1153
in	O	1154-1156
kidney	O	1157-1163
development	O	1164-1175
.	O	1175-1176

Two	O	1177-1180
alternatively	O	1181-1194
spliced	O	1195-1202
VHL	B	1203-1206
mRNAs	O	1207-1212
characterized	O	1213-1226
by	O	1227-1229
inclusion	O	1230-1239
(	O	1240-1241
isoform	O	1241-1248
I	O	1249-1250
)	O	1250-1251
or	O	1252-1254
exclusion	O	1255-1264
(	O	1265-1266
isoform	O	1266-1273
II	O	1274-1276
)	O	1276-1277
of	O	1278-1280
exon	O	1281-1285
2	O	1286-1287
are	O	1288-1291
transcribed	O	1292-1303
in	O	1304-1306
adult	O	1307-1312
tissues	O	1313-1320
.	O	1320-1321

To	O	1322-1324
investigate	O	1325-1336
if	O	1337-1339
the	O	1340-1343
two	O	1344-1347
isoforms	O	1348-1356
are	O	1357-1360
differentially	O	1361-1375
expressed	O	1376-1385
during	O	1386-1392
embryogenesis	O	1393-1406
,	O	1406-1407
VHL	B	1408-1411
mRNA	O	1412-1416
was	O	1417-1420
reverse	O	1421-1428
transcribed	O	1429-1440
from	O	1441-1445
13	O	1446-1448
fetal	O	1449-1454
tissues	O	1455-1462
(	O	1463-1464
8	O	1464-1465
-	O	1465-1466
10	O	1466-1468
weeks	O	1469-1474
gestation	O	1475-1484
)	O	1484-1485
.	O	1485-1486

The	O	1487-1490
quantitative	O	1491-1503
distribution	O	1504-1516
of	O	1517-1519
VHL	B	1520-1523
mRNA	O	1524-1528
within	O	1529-1535
fetal	O	1536-1541
tissues	O	1542-1549
reflected	O	1550-1559
that	O	1560-1564
seen	O	1565-1569
by	O	1570-1572
in	O	1573-1575
situ	O	1576-1580
hybridization	O	1581-1594
and	O	1595-1598
the	O	1599-1602
ratio	O	1603-1608
of	O	1609-1611
the	O	1612-1615
two	O	1616-1619
VHL	B	1620-1623
isoforms	O	1624-1632
was	O	1633-1636
similar	O	1637-1644
between	O	1645-1652
tissues	O	1653-1660
.	O	1660-1661

Although	O	1662-1670
the	O	1671-1674
genes	O	1675-1680
regulated	O	1681-1690
by	O	1691-1693
the	O	1694-1697
VHL	B	1698-1701
gene	O	1702-1706
product	O	1707-1714
have	O	1715-1719
not	O	1720-1723
yet	O	1724-1727
been	O	1728-1732
identified	O	1733-1743
,	O	1743-1744
our	O	1745-1748
findings	O	1749-1757
are	O	1758-1761
compatible	O	1762-1772
with	O	1773-1777
the	O	1778-1781
hypothesis	O	1782-1792
that	O	1793-1797
VHL	B	1798-1801
-	O	1801-1802
mediated	O	1802-1810
control	O	1811-1818
of	O	1819-1821
transcriptional	O	1822-1837
elongation	O	1838-1848
may	O	1849-1852
have	O	1853-1857
a	O	1858-1859
role	O	1860-1864
in	O	1865-1867
normal	O	1868-1874
human	O	1875-1880
development	O	1881-1892
.	O	1892-1893
.	O	1892-1893

Screening	O	0-9
for	O	10-13
ESR	O	14-17
mutations	O	18-27
in	O	28-30
breast	B	31-37
and	I	38-41
ovarian	I	42-49
cancer	I	50-56
patients	O	57-65
.	O	65-66

In	O	67-69
the	O	70-73
present	O	74-81
study	O	82-87
,	O	87-88
leukocyte	O	89-98
DNA	O	99-102
from	O	103-107
143	O	108-111
patients	O	112-120
with	O	121-125
familial	O	126-134
clustering	O	135-145
of	O	146-148
breast	B	149-155
and	I	156-159
/	I	159-160
or	I	160-162
ovarian	I	163-170
cancer	I	171-177
and	O	178-181
tumour	B	182-188
DNA	O	189-192
from	O	193-197
96	O	198-200
breast	B	201-207
carcinomas	I	208-218
were	O	219-223
screened	O	224-232
for	O	233-236
base	O	237-241
mutations	O	242-251
in	O	252-254
the	O	255-258
estrogen	O	259-267
receptor	O	268-276
gene	O	277-281
(	O	282-283
ESR	O	283-286
)	O	286-287
.	O	287-288

Three	O	289-294
patients	O	295-303
with	O	304-308
a	O	309-310
family	O	311-317
history	O	318-325
of	O	326-328
cancer	B	329-335
were	O	336-340
carrying	O	341-349
a	O	350-351
Gly160Cys	O	352-361
germline	O	362-370
substitution	O	371-383
.	O	383-384

This	O	385-389
alteration	O	390-400
was	O	401-404
also	O	405-409
detected	O	410-418
in	O	419-421
eight	O	422-427
(	O	428-429
four	O	429-433
females	O	434-441
and	O	442-445
four	O	446-450
males	O	451-456
)	O	456-457
of	O	458-460
729	O	461-464
controls	O	465-473
(	O	474-475
366	O	475-478
female	O	479-485
,	O	485-486
363	O	487-490
males	O	491-496
)	O	496-497
,	O	497-498
indicating	O	499-509
that	O	510-514
the	O	515-518
substitution	O	519-531
probably	O	532-540
represents	O	541-551
a	O	552-553
polymorphism	O	554-566
.	O	566-567

However	O	568-575
,	O	575-576
in	O	577-579
the	O	580-583
229	O	584-587
female	O	588-594
controls	O	595-603
in	O	604-606
whom	O	607-611
family	O	612-618
history	O	619-626
of	O	627-629
cancer	B	630-636
was	O	637-640
known	O	641-646
,	O	646-647
one	O	648-651
of	O	652-654
two	O	655-658
who	O	659-662
had	O	663-666
a	O	667-668
sister	O	669-675
with	O	676-680
breast	B	681-687
cancer	I	688-694
was	O	695-698
carrying	O	699-707
the	O	708-711
variant	O	712-719
allele	O	720-726
.	O	726-727

Hence	O	728-733
,	O	733-734
a	O	735-736
possible	O	737-745
clinical	O	746-754
significance	O	755-767
of	O	768-770
the	O	771-774
glycine	O	775-782
into	O	783-787
cysteine	O	788-796
cannot	O	797-803
be	O	804-806
completely	O	807-817
ruled	O	818-823
out	O	824-827
and	O	828-831
should	O	832-838
be	O	839-841
further	O	842-849
investigated	O	850-862
.	O	862-863

Somatic	O	864-871
mutations	O	872-881
were	O	882-886
not	O	887-890
detected	O	891-899
in	O	900-902
any	O	903-906
of	O	907-909
the	O	910-913
tumours	B	914-921
studied	O	922-929
,	O	929-930
and	O	931-934
the	O	935-938
present	O	939-946
data	O	947-951
do	O	952-954
not	O	955-958
provide	O	959-966
support	O	967-974
for	O	975-978
somatic	O	979-986
ESR	O	987-990
base	O	991-995
mutations	O	996-1005
as	O	1006-1008
an	O	1009-1011
important	O	1012-1021
mechanism	O	1022-1031
for	O	1032-1035
hormonal	O	1036-1044
therapy	O	1045-1052
resistance	O	1053-1063
in	O	1064-1066
estrogen	B	1067-1075
receptor	I	1076-1084
-	I	1084-1085
positive	I	1085-1093
breast	I	1094-1100
carcinomas	I	1101-1111
.	O	1111-1112
.	O	1111-1112

Increased	O	0-9
coronary	B	10-18
heart	I	19-24
disease	I	25-32
in	O	33-35
Japanese	O	36-44
-	O	44-45
American	O	45-53
men	O	54-57
with	O	58-62
mutation	O	63-71
in	O	72-74
the	O	75-78
cholesteryl	O	79-90
ester	O	91-96
transfer	O	97-105
protein	O	106-113
gene	O	114-118
despite	O	119-126
increased	O	127-136
HDL	O	137-140
levels	O	141-147
.	O	147-148

Plasma	O	149-155
high	O	156-160
density	O	161-168
lipoprotein	O	169-180
(	O	181-182
HDL	O	182-185
)	O	185-186
levels	O	187-193
are	O	194-197
strongly	O	198-206
genetically	O	207-218
determined	O	219-229
and	O	230-233
show	O	234-238
a	O	239-240
general	O	241-248
inverse	O	249-256
relationship	O	257-269
with	O	270-274
coronary	B	275-283
heart	I	284-289
disease	I	290-297
(	O	298-299
CHD	B	299-302
)	O	302-303
.	O	303-304

The	O	305-308
cholesteryl	O	309-320
ester	O	321-326
transfer	O	327-335
protein	O	336-343
(	O	344-345
CETP	O	345-349
)	O	349-350
mediates	O	351-359
the	O	360-363
transfer	O	364-372
of	O	373-375
cholesteryl	O	376-387
esters	O	388-394
from	O	395-399
HDL	O	400-403
to	O	404-406
other	O	407-412
lipoproteins	O	413-425
and	O	426-429
is	O	430-432
a	O	433-434
key	O	435-438
participant	O	439-450
in	O	451-453
the	O	454-457
reverse	O	458-465
transport	O	466-475
of	O	476-478
cholesterol	O	479-490
from	O	491-495
the	O	496-499
periphery	O	500-509
to	O	510-512
the	O	513-516
liver	O	517-522
.	O	522-523

A	O	524-525
high	O	526-530
prevalence	O	531-541
of	O	542-544
two	O	545-548
different	O	549-558
CETP	O	559-563
gene	O	564-568
mutations	O	569-578
(	O	579-580
D442G	O	580-585
,	O	585-586
5	O	587-588
.	O	588-589
1	O	590-591
%	O	591-592
;	O	592-593
intron	O	594-600
14G	O	601-604
A	O	606-607
,	O	607-608
0	O	609-610
.	O	610-611
5	O	612-613
%	O	613-614
)	O	614-615
,	O	615-616
was	O	617-620
found	O	621-626
in	O	627-629
3	O	630-631
,	O	631-632
469	O	633-636
men	O	637-640
of	O	641-643
Japanese	O	644-652
ancestry	O	653-661
in	O	662-664
the	O	665-668
Honolulu	O	669-677
Heart	O	678-683
Program	O	684-691
and	O	692-695
mutations	O	696-705
were	O	706-710
associated	O	711-721
with	O	722-726
decreased	O	727-736
CETP	O	737-741
(	O	742-743
-	O	743-744
35	O	744-746
%	O	746-747
)	O	747-748
and	O	749-752
increased	O	753-762
HDL	O	763-766
chol	O	767-771
levels	O	772-778
(	O	779-780
+	O	780-781
10	O	782-784
%	O	784-785
for	O	786-789
D442G	O	790-795
)	O	795-796
.	O	796-797

However	O	798-805
,	O	805-806
the	O	807-810
overall	O	811-818
prevalence	O	819-829
of	O	830-832
definite	O	833-841
CHD	B	842-845
was	O	846-849
21	O	850-852
%	O	852-853
in	O	854-856
men	O	857-860
with	O	861-865
mutations	O	866-875
and	O	876-879
16	O	880-882
%	O	882-883
in	O	884-886
men	O	887-890
without	O	891-898
mutations	O	899-908
.	O	908-909

The	O	910-913
relative	O	914-922
risk	O	923-927
(	O	928-929
RR	O	929-931
)	O	931-932
of	O	933-935
CHD	B	936-939
was	O	940-943
1	O	944-945
.	O	945-946
43	O	947-949
in	O	950-952
men	O	953-956
with	O	957-961
mutations	O	962-971
(	O	972-973
P	O	973-974
<	O	975-976
.	O	976-977
05	O	978-980
)	O	980-981
;	O	981-982
after	O	983-988
adjustment	O	989-999
for	O	1000-1003
CHD	B	1004-1007
risk	O	1008-1012
factors	O	1013-1020
,	O	1020-1021
the	O	1022-1025
RR	O	1026-1028
was	O	1029-1032
1	O	1033-1034
.	O	1034-1035
55	O	1036-1038
(	O	1039-1040
P	O	1040-1041
=	O	1042-1043
.	O	1043-1044
02	O	1045-1047
)	O	1047-1048
;	O	1048-1049
after	O	1050-1055
additional	O	1056-1066
adjustment	O	1067-1077
for	O	1078-1081
HDL	O	1082-1085
levels	O	1086-1092
,	O	1092-1093
the	O	1094-1097
RR	O	1098-1100
was	O	1101-1104
1	O	1105-1106
.	O	1106-1107
68	O	1108-1110
(	O	1111-1112
P	O	1112-1113
=	O	1114-1115
.	O	1115-1116
008	O	1117-1120
)	O	1120-1121
.	O	1121-1122

Similar	O	1123-1130
RR	O	1131-1133
values	O	1134-1140
were	O	1141-1145
obtained	O	1146-1154
for	O	1155-1158
the	O	1159-1162
D442G	O	1163-1168
mutation	O	1169-1177
alone	O	1178-1183
.	O	1183-1184

Increased	O	1185-1194
CHD	B	1195-1198
in	O	1199-1201
men	O	1202-1205
with	O	1206-1210
mutations	O	1211-1220
was	O	1221-1224
primarily	O	1225-1234
observed	O	1235-1243
for	O	1244-1247
HDL	O	1248-1251
chol	O	1252-1256
41	O	1257-1259
-	O	1259-1260
60	O	1260-1262
mg	O	1263-1265
/	O	1265-1266
dl	O	1266-1268
;	O	1268-1269
for	O	1270-1273
HDL	O	1274-1277
chol	O	1278-1282
>	O	1283-1284
60	O	1285-1287
mg	O	1288-1290
/	O	1290-1291
dl	O	1291-1293
men	O	1294-1297
with	O	1298-1302
and	O	1303-1306
without	O	1307-1314
mutations	O	1315-1324
had	O	1325-1328
low	O	1329-1332
CHD	B	1333-1336
prevalence	O	1337-1347
.	O	1347-1348

Thus	O	1349-1353
,	O	1353-1354
genetic	O	1355-1362
CETP	B	1363-1367
deficiency	I	1368-1378
appears	O	1379-1386
to	O	1387-1389
be	O	1390-1392
an	O	1393-1395
independent	O	1396-1407
risk	O	1408-1412
factor	O	1413-1419
for	O	1420-1423
CHD	B	1424-1427
,	O	1427-1428
primarily	O	1429-1438
due	O	1439-1442
to	O	1443-1445
increased	O	1446-1455
CHD	B	1456-1459
prevalence	O	1460-1470
in	O	1471-1473
men	O	1474-1477
with	O	1478-1482
the	O	1483-1486
D442G	O	1487-1492
mutation	O	1493-1501
and	O	1502-1505
HDL	O	1506-1509
cholesterol	O	1510-1521
between	O	1522-1529
41	O	1530-1532
and	O	1533-1536
60	O	1537-1539
mg	O	1540-1542
/	O	1542-1543
dl	O	1543-1545
.	O	1545-1546

The	O	1547-1550
findings	O	1551-1559
suggest	O	1560-1567
that	O	1568-1572
both	O	1573-1577
HDL	O	1578-1581
concentration	O	1582-1595
and	O	1596-1599
the	O	1600-1603
dynamics	O	1604-1612
of	O	1613-1615
cholesterol	O	1616-1627
transport	O	1628-1637
through	O	1638-1645
HDL	O	1646-1649
(	O	1650-1651
i	O	1651-1652
.	O	1652-1653

e	O	1654-1655
.	O	1655-1656
,	O	1656-1657
reverse	O	1658-1665
cholesterol	O	1666-1677
transport	O	1678-1687
)	O	1687-1688
determine	O	1689-1698
the	O	1699-1702
anti	O	1703-1707
-	O	1707-1708
atherogenicity	O	1708-1722
of	O	1723-1725
the	O	1726-1729
HDL	O	1730-1733
fraction	O	1734-1742
.	O	1742-1743

Analysis	O	0-8
of	O	9-11
meiotic	O	12-19
segregation	O	20-31
,	O	31-32
using	O	33-38
single	O	39-45
-	O	45-46
sperm	O	46-51
typing	O	52-58
:	O	58-59
meiotic	O	60-67
drive	O	68-73
at	O	74-76
the	O	77-80
myotonic	B	81-89
dystrophy	I	90-99
locus	O	100-105
.	O	105-106

Meiotic	O	107-114
drive	O	115-120
at	O	121-123
the	O	124-127
myotonic	B	128-136
dystrophy	I	137-146
(	O	147-148
DM	B	148-150
)	O	150-151
locus	O	152-157
has	O	158-161
recently	O	162-170
been	O	171-175
suggested	O	176-185
as	O	186-188
being	O	189-194
responsible	O	195-206
for	O	207-210
maintaining	O	211-222
the	O	223-226
frequency	O	227-236
,	O	236-237
in	O	238-240
the	O	241-244
human	O	245-250
population	O	251-261
,	O	261-262
of	O	263-265
DM	B	266-268
chromosomes	O	269-280
capable	O	281-288
of	O	289-291
expansion	O	292-301
to	O	302-304
the	O	305-308
disease	O	309-316
state	O	317-322
.	O	322-323

In	O	324-326
order	O	327-332
to	O	333-335
test	O	336-340
this	O	341-345
hypothesis	O	346-356
,	O	356-357
we	O	358-360
have	O	361-365
studied	O	366-373
samples	O	374-381
of	O	382-384
single	O	385-391
sperm	O	392-397
from	O	398-402
three	O	403-408
individuals	O	409-420
heterozygous	O	421-433
at	O	434-436
the	O	437-440
DM	B	441-443
locus	O	444-449
,	O	449-450
each	O	451-455
with	O	456-460
one	O	461-464
allele	O	465-471
larger	O	472-478
and	O	479-482
one	O	483-486
allele	O	487-493
smaller	O	494-501
than	O	502-506
19	O	507-509
CTG	O	510-513
repeats	O	514-521
.	O	521-522

To	O	523-525
guard	O	526-531
against	O	532-539
the	O	540-543
possible	O	544-552
problem	O	553-560
of	O	561-563
differential	O	564-576
PCR	O	577-580
amplification	O	581-594
rates	O	595-600
based	O	601-606
on	O	607-609
the	O	610-613
lengths	O	614-621
of	O	622-624
the	O	625-628
alleles	O	629-636
,	O	636-637
the	O	638-641
sperm	O	642-647
were	O	648-652
also	O	653-657
typed	O	658-663
at	O	664-666
another	O	667-674
closely	O	675-682
linked	O	683-689
marker	O	690-696
whose	O	697-702
allele	O	703-709
size	O	710-714
was	O	715-718
unrelated	O	719-728
to	O	729-731
the	O	732-735
allele	O	736-742
size	O	743-747
at	O	748-750
the	O	751-754
DM	B	755-757
locus	O	758-763
.	O	763-764

Using	O	765-770
statistical	O	771-782
models	O	783-789
specifically	O	790-802
designed	O	803-811
to	O	812-814
study	O	815-820
single	O	821-827
-	O	827-828
sperm	O	828-833
segregation	O	834-845
data	O	846-850
,	O	850-851
we	O	852-854
find	O	855-859
no	O	860-862
evidence	O	863-871
of	O	872-874
meiotic	O	875-882
segregation	O	883-894
distortion	O	895-905
.	O	905-906

The	O	907-910
upper	O	911-916
limit	O	917-922
of	O	923-925
the	O	926-929
two	O	930-933
-	O	933-934
sided	O	934-939
95	O	940-942
%	O	942-943
confidence	O	944-954
interval	O	955-963
for	O	964-967
the	O	968-971
estimate	O	972-980
of	O	981-983
the	O	984-987
common	O	988-994
segregation	O	995-1006
probability	O	1007-1018
for	O	1019-1022
the	O	1023-1026
three	O	1027-1032
donors	O	1033-1039
is	O	1040-1042
at	O	1043-1045
or	O	1046-1048
below	O	1049-1054
.	O	1054-1055

515	O	1056-1059
for	O	1060-1063
all	O	1064-1067
models	O	1068-1074
considered	O	1075-1085
,	O	1085-1086
and	O	1087-1090
no	O	1091-1093
statistically	O	1094-1107
significant	O	1108-1119
difference	O	1120-1130
from	O	1131-1135
.	O	1135-1136

5	O	1137-1138
is	O	1139-1141
detected	O	1142-1150
in	O	1151-1153
any	O	1154-1157
of	O	1158-1160
the	O	1161-1164
models	O	1165-1171
.	O	1171-1172

This	O	1173-1177
suggests	O	1178-1186
that	O	1187-1191
any	O	1192-1195
greater	O	1196-1203
amount	O	1204-1210
of	O	1211-1213
segregation	O	1214-1225
distortion	O	1226-1236
at	O	1237-1239
the	O	1240-1243
myotonic	B	1244-1252
dystrophy	I	1253-1262
locus	O	1263-1268
must	O	1269-1273
result	O	1274-1280
from	O	1281-1285
events	O	1286-1292
following	O	1293-1302
sperm	O	1303-1308
ejaculation	O	1309-1320
.	O	1320-1321

Isolation	O	0-9
of	O	10-12
full	O	13-17
-	O	17-18
length	O	18-24
ATM	O	25-28
cDNA	O	29-33
and	O	34-37
correction	O	38-48
of	O	49-51
the	O	52-55
ataxia	B	56-62
-	I	62-63
telangiectasia	I	63-77
cellular	O	78-86
phenotype	O	87-96
.	O	96-97

A	O	98-99
gene	O	100-104
mutated	O	105-112
in	O	113-115
the	O	116-119
human	O	120-125
genetic	B	126-133
disorder	I	134-142
ataxia	B	143-149
-	I	149-150
telangiectasia	I	150-164
(	O	165-166
A	B	166-167
-	I	167-168
T	I	168-169
)	O	169-170
,	O	170-171
ATM	O	172-175
,	O	175-176
was	O	177-180
recently	O	181-189
identified	O	190-200
by	O	201-203
positional	O	204-214
cloning	O	215-222
.	O	222-223

ATM	O	224-227
is	O	228-230
a	O	231-232
member	O	233-239
of	O	240-242
the	O	243-246
phosphatidylinositol	O	247-267
-	O	267-268
3	O	268-269
-	O	267-268
kinase	O	270-276
superfamily	O	277-288
,	O	288-289
some	O	290-294
of	O	295-297
which	O	298-303
are	O	304-307
protein	O	308-315
kinases	O	316-323
and	O	324-327
appear	O	328-334
to	O	335-337
have	O	338-342
important	O	343-352
roles	O	353-358
in	O	359-361
cell	O	362-366
cycle	O	367-372
control	O	373-380
and	O	381-384
radiation	O	385-394
signal	O	395-401
transduction	O	402-414
.	O	414-415

We	O	416-418
describe	O	419-427
herein	O	428-434
,	O	434-435
to	O	436-438
our	O	439-442
knowledge	O	443-452
,	O	452-453
for	O	454-457
the	O	458-461
first	O	462-467
time	O	468-472
,	O	472-473
the	O	474-477
cloning	O	478-485
of	O	486-488
a	O	489-490
full	O	491-495
-	O	495-496
length	O	496-502
cDNA	O	503-507
for	O	508-511
ATM	O	512-515
and	O	516-519
correction	O	520-530
of	O	531-533
multiple	O	534-542
aspects	O	543-550
of	O	551-553
the	O	554-557
radio	O	558-563
-	O	563-564
sensitive	O	564-573
phenotype	O	574-583
of	O	584-586
A	B	587-588
-	I	588-589
T	I	589-590
cells	O	591-596
by	O	597-599
transfection	O	600-612
with	O	613-617
this	O	618-622
cDNA	O	623-627
.	O	627-628

Overexpression	O	629-643
of	O	644-646
ATM	O	647-650
cDNA	O	651-655
in	O	656-658
A	B	659-660
-	I	660-661
T	I	661-662
cells	O	663-668
enhanced	O	669-677
the	O	678-681
survival	O	682-690
of	O	691-693
these	O	694-699
cells	O	700-705
in	O	706-708
response	O	709-717
to	O	718-720
radiation	O	721-730
exposure	O	731-739
,	O	739-740
decreased	O	741-750
radiation	O	751-760
-	O	760-761
induced	O	761-768
chromosome	O	769-779
aberrations	O	780-791
,	O	791-792
reduced	O	793-800
radio	O	801-806
-	O	806-807
resistant	O	807-816
DNA	O	817-820
synthesis	O	821-830
,	O	830-831
and	O	832-835
partially	O	836-845
corrected	O	846-855
defective	O	856-865
cell	O	866-870
cycle	O	871-876
checkpoints	O	877-888
and	O	889-892
induction	O	893-902
of	O	903-905
stress	O	906-912
-	O	912-913
activated	O	913-922
protein	O	923-930
kinase	O	931-937
.	O	937-938

This	O	939-943
correction	O	944-954
of	O	955-957
the	O	958-961
defects	O	962-969
in	O	970-972
A	B	973-974
-	I	974-975
T	I	975-976
cells	O	977-982
provides	O	983-991
further	O	992-999
evidence	O	1000-1008
of	O	1009-1011
the	O	1012-1015
multiplicity	O	1016-1028
of	O	1029-1031
effector	O	1032-1040
functions	O	1041-1050
of	O	1051-1053
the	O	1054-1057
ATM	O	1058-1061
protein	O	1062-1069
and	O	1070-1073
suggests	O	1074-1082
possible	O	1083-1091
approaches	O	1092-1102
to	O	1103-1105
gene	O	1106-1110
therapy	O	1111-1118
.	O	1118-1119
.	O	1118-1119

The	O	0-3
spectrum	O	4-12
of	O	13-15
RB1	O	16-19
germ	O	20-24
-	O	24-25
line	O	25-29
mutations	O	30-39
in	O	40-42
hereditary	B	43-53
retinoblastoma	I	54-68
.	O	68-69

We	O	70-72
have	O	73-77
searched	O	78-86
for	O	87-90
germ	O	91-95
-	O	95-96
line	O	96-100
RB1	O	101-104
mutations	O	105-114
in	O	115-117
119	O	118-121
patients	O	122-130
with	O	131-135
hereditary	B	136-146
retinoblastoma	I	147-161
.	O	161-162

Previous	O	163-171
investigations	O	172-186
by	O	187-189
Southern	O	190-198
blot	O	199-203
hybridization	O	204-217
and	O	218-221
PCR	O	222-225
fragment	O	226-234
-	O	234-235
length	O	235-241
analysis	O	242-250
had	O	251-254
revealed	O	255-263
mutations	O	264-273
in	O	274-276
48	O	277-279
patients	O	280-288
.	O	288-289

Here	O	290-294
we	O	295-297
report	O	298-304
on	O	305-307
the	O	308-311
analysis	O	312-320
of	O	321-323
the	O	324-327
remaining	O	328-337
71	O	338-340
patients	O	341-349
.	O	349-350

By	O	351-353
applying	O	354-362
heteroduplex	O	363-375
analysis	O	376-384
,	O	384-385
nonisotopic	O	386-397
SSCP	O	398-402
,	O	402-403
and	O	404-407
direct	O	408-414
sequencing	O	415-425
,	O	425-426
we	O	427-429
detected	O	430-438
germ	O	439-443
-	O	443-444
line	O	444-448
mutations	O	449-458
resulting	O	459-468
in	O	469-471
premature	O	472-481
termination	O	482-493
codons	O	494-500
or	O	501-503
disruption	O	504-514
of	O	515-517
splice	O	518-524
signals	O	525-532
in	O	533-535
51	O	536-538
(	O	539-540
72	O	540-542
%	O	542-543
)	O	543-544
of	O	545-547
the	O	548-551
71	O	552-554
patients	O	555-563
.	O	563-564

Four	O	565-569
patients	O	570-578
also	O	579-583
showed	O	584-590
rare	O	591-595
sequence	O	596-604
variants	O	605-613
.	O	613-614

No	O	615-617
region	O	618-624
of	O	625-627
the	O	628-631
RB1	O	632-635
gene	O	636-640
was	O	641-644
preferentially	O	645-659
involved	O	660-668
in	O	669-671
single	O	672-678
base	O	679-683
substitutions	O	684-697
.	O	697-698

Recurrent	O	699-708
transitions	O	709-720
were	O	721-725
observed	O	726-734
at	O	735-737
most	O	738-742
of	O	743-745
the	O	746-749
14	O	750-752
codons	O	753-759
within	O	760-766
the	O	767-770
RB1	O	771-774
.	O	774-775

No	O	776-778
mutation	O	779-787
was	O	788-791
observed	O	792-800
in	O	801-803
exons	O	804-809
25	O	810-812
-	O	812-813
27	O	813-815
,	O	815-816
although	O	817-825
this	O	826-830
region	O	831-837
contains	O	838-846
two	O	847-850
CGA	O	851-854
codons	O	855-861
.	O	861-862

This	O	863-867
suggests	O	868-876
that	O	877-881
mutations	O	882-891
within	O	892-898
the	O	899-902
3	O	903-904
-	O	904-905
terminal	O	905-913
region	O	914-920
of	O	921-923
the	O	924-927
RB1	O	928-931
gene	O	932-936
may	O	937-940
not	O	941-944
be	O	945-947
oncogenic	O	948-957
.	O	957-958

When	O	959-963
these	O	964-969
data	O	970-974
were	O	975-979
combined	O	980-988
with	O	989-993
the	O	994-997
results	O	998-1005
of	O	1006-1008
our	O	1009-1012
previous	O	1013-1021
investigations	O	1022-1036
,	O	1036-1037
mutations	O	1038-1047
were	O	1048-1052
identified	O	1053-1063
in	O	1064-1066
a	O	1067-1068
total	O	1069-1074
of	O	1075-1077
99	O	1078-1080
(	O	1081-1082
83	O	1082-1084
%	O	1084-1085
)	O	1085-1086
of	O	1087-1089
119	O	1090-1093
patients	O	1094-1102
.	O	1102-1103

The	O	1104-1107
spectrum	O	1108-1116
comprises	O	1117-1126
15	O	1127-1129
%	O	1129-1130
large	O	1131-1136
deletions	O	1137-1146
,	O	1146-1147
26	O	1148-1150
%	O	1150-1151
small	O	1152-1157
length	O	1158-1164
alterations	O	1165-1176
,	O	1176-1177
and	O	1178-1181
42	O	1182-1184
%	O	1184-1185
base	O	1186-1190
substitutions	O	1191-1204
.	O	1204-1205

No	O	1206-1208
correlation	O	1209-1220
between	O	1221-1228
the	O	1229-1232
location	O	1233-1241
of	O	1242-1244
frameshift	O	1245-1255
or	O	1256-1258
nonsense	O	1259-1267
mutations	O	1268-1277
and	O	1278-1281
phenotypic	O	1282-1292
features	O	1293-1301
,	O	1301-1302
including	O	1303-1312
age	O	1313-1316
at	O	1317-1319
diagnosis	O	1320-1329
,	O	1329-1330
the	O	1331-1334
number	O	1335-1341
of	O	1342-1344
tumor	B	1345-1350
foci	O	1351-1355
,	O	1355-1356
and	O	1357-1360
manifestation	O	1361-1374
of	O	1375-1377
nonocular	B	1378-1387
tumors	I	1388-1394
was	O	1395-1398
observed	O	1399-1407
.	O	1407-1408
.	O	1407-1408

Wiskott	B	0-7
-	I	7-8
Aldrich	I	8-15
syndrome	I	16-24
protein	O	25-32
,	O	32-33
a	O	34-35
novel	O	36-41
effector	O	42-50
for	O	51-54
the	O	55-58
GTPase	O	59-65
CDC42Hs	O	66-73
,	O	73-74
is	O	75-77
implicated	O	78-88
in	O	89-91
actin	O	92-97
polymerization	O	98-112
.	O	112-113

The	O	114-117
Rho	O	118-121
family	O	122-128
of	O	129-131
GTPases	O	132-139
control	O	140-147
diverse	O	148-155
biological	O	156-166
processes	O	167-176
,	O	176-177
including	O	178-187
cell	O	188-192
morphology	O	193-203
and	O	204-207
mitogenesis	O	208-219
.	O	219-220

We	O	221-223
have	O	224-228
identified	O	229-239
WASP	O	240-244
,	O	244-245
the	O	246-249
protein	O	250-257
that	O	258-262
is	O	263-265
defective	O	266-275
in	O	276-278
Wiskott	B	279-286
-	I	286-287
Aldrich	I	287-294
syndrome	I	295-303
(	O	304-305
WAS	B	305-308
)	O	308-309
,	O	309-310
as	O	311-313
a	O	314-315
novel	O	316-321
effector	O	322-330
for	O	331-334
CDC42Hs	O	335-342
,	O	342-343
but	O	344-347
not	O	348-351
for	O	352-355
the	O	356-359
other	O	360-365
Rho	O	366-369
family	O	370-376
members	O	377-384
,	O	384-385
Rac	O	386-389
and	O	390-393
Rho	O	394-397
.	O	397-398

This	O	399-403
interaction	O	404-415
is	O	416-418
dependent	O	419-428
on	O	429-431
the	O	432-435
presence	O	436-444
of	O	445-447
the	O	448-451
G	O	452-453
protein	O	454-461
-	O	461-462
binding	O	462-469
domain	O	470-476
.	O	476-477

Cellular	O	478-486
expression	O	487-497
of	O	498-500
epitope	O	501-508
-	O	508-509
tagged	O	509-515
WASP	O	516-520
produces	O	521-529
clusters	O	530-538
of	O	539-541
WASP	O	542-546
that	O	547-551
are	O	552-555
highly	O	556-562
enriched	O	563-571
in	O	572-574
polymerized	O	575-586
actin	O	587-592
.	O	592-593

This	O	594-598
clustering	O	599-609
is	O	610-612
not	O	613-616
observed	O	617-625
with	O	626-630
a	O	631-632
C	O	633-634
-	O	634-635
terminally	O	635-645
deleted	O	646-653
WASP	O	654-658
and	O	659-662
is	O	663-665
inhibited	O	666-675
by	O	676-678
coexpression	O	679-691
with	O	692-696
dominant	O	697-705
negative	O	706-714
CDC42Hs	O	715-722
-	O	722-723
N17	O	723-726
,	O	726-727
but	O	728-731
not	O	732-735
with	O	736-740
dominant	O	741-749
negative	O	750-758
forms	O	759-764
of	O	765-767
Rac	O	768-771
or	O	772-774
Rho	O	775-778
.	O	778-779

Thus	O	780-784
,	O	784-785
WASP	O	786-790
provides	O	791-799
a	O	800-801
novel	O	802-807
link	O	808-812
between	O	813-820
CDC42Hs	O	821-828
and	O	829-832
the	O	833-836
actin	O	837-842
cytoskeleton	O	843-855
,	O	855-856
which	O	857-862
suggests	O	863-871
a	O	872-873
molecular	O	874-883
mechanism	O	884-893
for	O	894-897
many	O	898-902
of	O	903-905
the	O	906-909
cellular	O	910-918
abnormalities	O	919-932
in	O	933-935
WAS	B	936-939
.	O	939-940

The	O	941-944
WASP	O	945-949
sequence	O	950-958
contains	O	959-967
two	O	968-971
novel	O	972-977
domains	O	978-985
that	O	986-990
are	O	991-994
homologous	O	995-1005
to	O	1006-1008
other	O	1009-1014
proteins	O	1015-1023
involved	O	1024-1032
in	O	1033-1035
action	O	1036-1042
organization	O	1043-1055
.	O	1055-1056
.	O	1055-1056

Adult	B	0-5
onset	I	6-11
globoid	I	12-19
cell	I	20-24
leukodystrophy	I	25-39
(	O	40-41
Krabbe	B	41-47
disease	I	48-55
)	O	55-56
:	O	56-57
analysis	O	58-66
of	O	67-69
galactosylceramidase	O	70-90
cDNA	O	91-95
from	O	96-100
four	O	101-105
Japanese	O	106-114
patients	O	115-123
.	O	123-124

We	O	125-127
examined	O	128-136
galactosylceramidase	O	137-157
(	O	158-159
GALC	O	159-163
)	O	163-164
cDNA	O	165-169
in	O	170-172
four	O	173-177
Japanese	O	178-186
patients	O	187-195
with	O	196-200
adult	B	201-206
onset	I	207-212
globoid	I	213-220
cell	I	221-225
leukodystrophy	I	226-240
(	O	241-242
Krabbe	B	242-248
disease	I	249-256
;	O	256-257
AO	B	258-260
-	I	260-261
GLD	I	261-264
)	O	264-265
by	O	266-268
polymerase	O	269-279
chain	O	280-285
reaction	O	286-294
/	O	294-295
single	O	295-301
-	O	301-302
strand	O	302-308
conformation	O	309-321
polymorphism	O	322-334
(	O	335-336
PCR	O	336-339
-	O	339-340
SSCP	O	340-344
)	O	344-345
analysis	O	346-354
,	O	354-355
subsequent	O	356-366
sequence	O	367-375
determination	O	376-389
,	O	389-390
and	O	391-394
restriction	O	395-406
enzyme	O	407-413
digestion	O	414-423
of	O	424-426
PCR	O	427-430
products	O	431-439
,	O	439-440
initial	O	441-448
symptoms	O	449-457
were	O	458-462
the	O	463-466
onset	O	467-472
of	O	473-475
slowly	O	476-482
progressive	O	483-494
spastic	B	495-502
paraplegia	I	503-513
from	O	514-518
the	O	519-522
middle	O	523-529
of	O	530-532
the	O	533-536
second	O	537-543
decade	O	544-550
,	O	550-551
and	O	552-555
all	O	556-559
patients	O	560-568
had	O	569-572
diminished	B	573-583
GALC	I	584-588
activity	I	589-597
in	O	598-600
their	O	601-606
leukocytes	O	607-617
.	O	617-618

We	O	619-621
identified	O	622-632
three	O	633-638
missense	O	639-647
mutations	O	648-657
(	O	658-659
I66M	O	659-663
,	O	663-664
G270D	O	665-670
,	O	670-671
L618S	O	672-677
)	O	677-678
and	O	679-682
one	O	683-686
exon	O	687-691
-	O	691-692
6	O	692-693
skipping	O	694-702
(	O	703-704
535	O	704-707
-	O	707-708
573del	O	708-714
)	O	714-715
.	O	715-716

Two	O	717-720
of	O	721-723
the	O	724-727
patients	O	728-736
had	O	737-740
only	O	741-745
the	O	746-749
I66M	O	750-754
mutant	O	755-761
mRNA	O	762-766
,	O	766-767
and	O	768-771
one	O	772-775
only	O	776-780
the	O	781-784
G27OD	O	785-790
mutant	O	791-797
mRNA	O	798-802
.	O	802-803

The	O	804-807
fourth	O	808-814
patient	O	815-822
carried	O	823-830
a	O	831-832
compound	O	833-841
heterozygous	O	842-854
mutation	O	855-863
of	O	864-866
535	O	867-870
-	O	870-871
573del	O	871-877
and	O	878-881
L618S	O	882-887
.	O	887-888

To	O	889-891
determine	O	892-901
the	O	902-905
enzymatic	O	906-915
activities	O	916-926
produced	O	927-935
by	O	936-938
these	O	939-944
mutations	O	945-954
,	O	954-955
we	O	956-958
constructed	O	959-970
mutated	O	971-978
GALC	O	979-983
cDNAs	O	984-989
and	O	990-993
expressed	O	994-1003
them	O	1004-1008
in	O	1009-1011
COS	O	1012-1015
-	O	1015-1016
1	O	1016-1017
cells	O	1018-1023
.	O	1023-1024

Three	O	1025-1030
mutations	O	1031-1040
,	O	1040-1041
viz	O	1042-1045
.	O	1045-1046
,	O	1046-1047
G270D	O	1048-1053
,	O	1053-1054
L618S	O	1055-1060
,	O	1060-1061
and	O	1062-1065
exon	O	1066-1070
-	O	1070-1071
6	O	1071-1072
skipping	O	1073-1081
(	O	1082-1083
535	O	1083-1086
-	O	1086-1087
573del	O	1087-1093
)	O	1093-1094
,	O	1094-1095
produced	O	1096-1104
diminished	B	1105-1115
GALC	I	1116-1120
activity	I	1121-1129
as	O	1130-1132
expected	O	1133-1141
.	O	1141-1142

The	O	1143-1146
I66M	O	1147-1151
mutation	O	1152-1160
in	O	1161-1163
the	O	1164-1167
wild	O	1168-1172
-	O	1172-1173
type	O	1173-1177
GALC	O	1178-1182
cDNA	O	1183-1187
(	O	1188-1189
I289	O	1189-1193
)	O	1193-1194
had	O	1195-1198
normal	O	1199-1205
activity	O	1206-1214
,	O	1214-1215
but	O	1216-1219
when	O	1220-1224
this	O	1225-1229
mutation	O	1230-1238
and	O	1239-1242
the	O	1243-1246
V289	O	1247-1251
polymorphism	O	1252-1264
were	O	1265-1269
introduced	O	1270-1280
into	O	1281-1285
the	O	1286-1289
same	O	1290-1294
allele	O	1295-1301
,	O	1301-1302
it	O	1303-1305
had	O	1306-1309
decreased	O	1310-1319
activity	O	1320-1328
.	O	1328-1329

Thus	O	1330-1334
,	O	1334-1335
the	O	1336-1339
combination	O	1340-1351
of	O	1352-1354
a	O	1355-1356
unique	O	1357-1363
mutation	O	1364-1372
and	O	1373-1376
polymorphism	O	1377-1389
causes	O	1390-1396
conformational	O	1397-1411
change	O	1412-1418
in	O	1419-1421
the	O	1422-1425
GALC	O	1426-1430
enzyme	O	1431-1437
,	O	1437-1438
resulting	O	1439-1448
in	O	1449-1451
low	O	1452-1455
enzymatic	O	1456-1465
activity	O	1466-1474
.	O	1474-1475

AO	B	1476-1478
-	I	1478-1479
GLD	I	1479-1482
mutations	O	1483-1492
,	O	1492-1493
including	O	1494-1503
those	O	1504-1509
found	O	1510-1515
here	O	1516-1520
,	O	1520-1521
are	O	1522-1525
located	O	1526-1533
in	O	1534-1536
the	O	1537-1540
N	O	1541-1542
-	O	1542-1543
terminus	O	1543-1551
(	O	1552-1553
I66M	O	1553-1557
,	O	1557-1558
G270D	O	1559-1564
,	O	1564-1565
535	O	1566-1569
-	O	1569-1570
573del	O	1570-1576
)	O	1576-1577
or	O	1578-1580
C	O	1581-1582
-	O	1582-1583
terminus	O	1583-1591
(	O	1592-1593
L618S	O	1593-1598
)	O	1598-1599
of	O	1600-1602
the	O	1603-1606
GALC	O	1607-1611
enzyme	O	1612-1618
,	O	1618-1619
whereas	O	1620-1627
the	O	1628-1631
reported	O	1632-1640
mutations	O	1641-1650
in	O	1651-1653
the	O	1654-1657
infantile	O	1658-1667
form	O	1668-1672
(	O	1673-1674
IF	B	1674-1676
-	I	1676-1677
GLD	I	1677-1680
)	O	1680-1681
are	O	1682-1685
in	O	1686-1688
the	O	1689-1692
central	O	1693-1700
domain	O	1701-1707
.	O	1707-1708

This	O	1709-1713
difference	O	1714-1724
in	O	1725-1727
mutation	O	1728-1736
sites	O	1737-1742
may	O	1743-1746
affect	O	1747-1753
the	O	1754-1757
clinical	O	1758-1766
features	O	1767-1775
of	O	1776-1778
GLD	B	1779-1782
.	O	1782-1783

BRCA1	O	0-5
is	O	6-8
secreted	O	9-17
and	O	18-21
exhibits	O	22-30
properties	O	31-41
of	O	42-44
a	O	45-46
granin	O	47-53
.	O	53-54

Germline	O	55-63
mutations	O	64-73
in	O	74-76
BRCA1	O	77-82
are	O	83-86
responsible	O	87-98
for	O	99-102
most	O	103-107
cases	O	108-113
of	O	114-116
inherited	B	117-126
breast	I	127-133
and	I	134-137
ovarian	I	138-145
cancer	I	146-152
.	O	153-154

However	O	155-162
,	O	162-163
the	O	164-167
function	O	168-176
of	O	177-179
the	O	180-183
BRCA1	O	184-189
protein	O	190-197
has	O	198-201
remained	O	202-210
elusive	O	211-218
.	O	218-219

We	O	220-222
now	O	223-226
show	O	227-231
that	O	232-236
BRCA1	O	237-242
encodes	O	243-250
a	O	251-252
190	O	253-256
-	O	256-257
kD	O	257-259
protein	O	260-267
with	O	268-272
sequence	O	273-281
homology	O	282-290
and	O	291-294
biochemical	O	295-306
analogy	O	307-314
to	O	315-317
the	O	318-321
granin	O	322-328
protein	O	329-336
family	O	337-343
.	O	343-344

Interestingly	O	345-358
,	O	358-359
BRCA2	O	360-365
also	O	366-370
includes	O	371-379
a	O	380-381
motif	O	382-387
similar	O	388-395
to	O	396-398
the	O	399-402
granin	O	403-409
consensus	O	410-419
at	O	420-422
the	O	423-426
C	O	427-428
terminus	O	429-437
of	O	438-440
the	O	441-444
protein	O	445-452
.	O	452-453

Both	O	454-458
BRCA1	O	459-464
and	O	465-468
the	O	469-472
granins	O	473-480
localize	O	481-489
to	O	490-492
secretory	O	493-502
vesicles	O	503-511
,	O	511-512
are	O	513-516
secreted	O	517-525
by	O	526-528
a	O	529-530
regulated	O	531-540
pathway	O	541-548
,	O	548-549
are	O	550-553
post	O	554-558
-	O	558-559
translationally	O	559-574
glycosylated	O	575-587
and	O	588-591
are	O	592-595
responsive	O	596-606
to	O	607-609
hormones	O	610-618
.	O	618-619

As	O	620-622
a	O	623-624
regulated	O	625-634
secretory	O	635-644
protein	O	645-652
,	O	652-653
BRCA1	O	654-659
appears	O	660-667
to	O	668-670
function	O	671-679
by	O	680-682
a	O	683-684
mechanism	O	685-694
not	O	695-698
previously	O	699-709
described	O	710-719
for	O	720-723
tumour	B	724-730
suppressor	O	731-741
gene	O	742-746
products	O	747-755
.	O	755-756
.	O	755-756

Insulin	O	0-7
gene	O	8-12
region	O	13-19
contributes	O	20-31
to	O	32-34
genetic	O	35-42
susceptibility	O	43-57
to	O	58-60
,	O	60-61
but	O	62-65
may	O	66-69
not	O	70-73
to	O	74-76
low	O	77-80
incidence	O	81-90
of	O	91-93
,	O	93-94
insulin	B	95-102
-	I	102-103
dependent	I	103-112
diabetes	I	113-121
mellitus	I	122-130
in	O	131-133
Japanese	O	134-142
.	O	142-143

In	O	144-146
the	O	147-150
Caucasian	O	151-160
population	O	161-171
,	O	171-172
it	O	173-175
has	O	176-179
been	O	180-184
demonstrated	O	185-197
that	O	198-202
the	O	203-206
insulin	O	207-214
gene	O	215-219
(	O	220-221
INS	O	221-224
)	O	224-225
region	O	226-232
contains	O	233-241
the	O	242-245
insulin	B	246-253
-	I	253-254
dependent	I	254-263
diabetes	I	264-272
mellitus	I	273-281
locus	O	282-287
(	O	288-289
IDDM2	O	289-294
)	O	294-295
.	O	295-296

In	O	297-299
the	O	300-303
Japanese	O	304-312
population	O	313-323
,	O	323-324
however	O	325-332
,	O	332-333
there	O	334-339
has	O	340-343
been	O	344-348
no	O	349-351
report	O	352-358
demonstrating	O	359-372
the	O	373-376
contribution	O	377-389
of	O	390-392
IDDM2	O	393-398
to	O	399-401
the	O	402-405
pathogenesis	O	406-418
of	O	419-421
IDDM	B	422-426
.	O	426-427

We	O	428-430
conducted	O	431-440
an	O	441-443
association	O	444-455
study	O	456-461
of	O	462-464
IDDM	B	465-469
in	O	470-472
a	O	473-474
large	O	475-480
number	O	481-487
of	O	488-490
Japanese	O	491-499
subjects	O	500-508
with	O	509-513
multiple	O	514-522
polymorphisms	O	523-536
in	O	537-539
INS	O	540-543
region	O	544-550
.	O	550-551

We	O	552-554
found	O	555-560
a	O	561-562
significant	O	563-574
association	O	575-586
of	O	587-589
the	O	590-593
INS	O	594-597
region	O	598-604
with	O	605-609
IDDM	B	610-614
.	O	614-615

Alleles	O	616-623
positively	O	624-634
associated	O	635-645
with	O	646-650
IDDM	B	651-655
in	O	656-658
INS	O	659-662
region	O	663-669
were	O	670-674
the	O	675-678
same	O	679-683
as	O	684-686
those	O	687-692
positively	O	693-703
-	O	703-704
associated	O	704-714
with	O	715-719
IDDM	B	720-724
in	O	725-727
Caucasian	O	728-737
population	O	738-748
,	O	748-749
although	O	750-758
positively	O	759-769
-	O	769-770
associated	O	770-780
alleles	O	781-788
are	O	789-792
very	O	793-797
common	O	798-804
(	O	805-806
allele	O	806-812
frequencies	O	813-824
>	O	825-826
0	O	827-828
.	O	828-829
9	O	830-831
)	O	831-832
in	O	833-835
the	O	836-839
Japanese	O	840-848
general	O	849-856
population	O	857-867
.	O	867-868

These	O	869-874
data	O	875-879
suggest	O	880-887
that	O	888-892
IDDM2	O	893-898
is	O	899-901
involved	O	902-910
in	O	911-913
the	O	914-917
genetic	O	918-925
susceptibility	O	926-940
to	O	941-943
IDDM	B	944-948
in	O	949-951
Japanese	O	952-960
.	O	960-961

The	O	962-965
high	O	966-970
frequencies	O	971-982
of	O	983-985
disease	O	986-993
-	O	993-994
associated	O	994-1004
alleles	O	1005-1012
in	O	1013-1015
the	O	1016-1019
general	O	1020-1027
population	O	1028-1038
suggest	O	1039-1046
that	O	1047-1051
IDDM2	O	1052-1057
locus	O	1058-1063
is	O	1064-1066
not	O	1067-1070
responsible	O	1071-1082
for	O	1083-1086
the	O	1087-1090
low	O	1091-1094
incidence	O	1095-1104
of	O	1105-1107
IDDM	B	1108-1112
in	O	1113-1115
Japanese	O	1116-1124
.	O	1124-1125

Association	O	0-11
of	O	12-14
anxiety	B	15-22
-	I	22-23
related	I	23-30
traits	I	31-37
with	O	38-42
a	O	43-44
polymorphism	O	45-57
in	O	58-60
the	O	61-64
serotonin	O	65-74
transporter	O	75-86
gene	O	87-91
regulatory	O	92-102
region	O	103-109
.	O	109-110

Transporter	O	111-122
-	O	122-123
facilitated	O	123-134
uptake	O	135-141
of	O	142-144
serotonin	O	145-154
(	O	155-156
5	O	156-157
-	O	157-158
hydroxytryptamine	O	158-175
or	O	176-178
5	O	179-180
-	O	180-181
HT	O	181-183
)	O	183-184
has	O	185-188
been	O	189-193
implicated	O	194-204
in	O	205-207
anxiety	B	208-215
in	O	216-218
humans	O	219-225
and	O	226-229
animal	O	230-236
models	O	237-243
and	O	244-247
is	O	248-250
the	O	251-254
site	O	255-259
of	O	260-262
action	O	263-269
of	O	270-272
widely	O	273-279
used	O	280-284
uptake	O	285-291
-	O	291-292
inhibiting	O	292-302
antidepressant	O	303-317
and	O	318-321
antianxiety	O	322-333
drugs	O	334-339
.	O	339-340

Human	O	341-346
5	O	347-348
-	O	348-349
HT	O	349-351
transporter	O	352-363
(	O	364-365
5	O	365-366
-	O	366-367
HTT	O	367-370
)	O	370-371
gene	O	372-376
transcription	O	377-390
is	O	391-393
modulated	O	394-403
by	O	404-406
a	O	407-408
common	O	409-415
polymorphism	O	416-428
in	O	429-431
its	O	432-435
upstream	O	436-444
regulatory	O	445-455
region	O	456-462
.	O	462-463

The	O	464-467
short	O	468-473
variant	O	474-481
of	O	482-484
the	O	485-488
polymorphism	O	489-501
reduces	O	502-509
the	O	510-513
transcriptional	O	514-529
efficiency	O	530-540
of	O	541-543
the	O	544-547
5	O	548-549
-	O	549-550
HTT	O	550-553
gene	O	554-558
promoter	O	559-567
,	O	567-568
resulting	O	569-578
in	O	579-581
decreased	O	582-591
5	O	592-593
-	O	593-594
HTT	O	594-597
expression	O	598-608
and	O	609-612
5	O	613-614
-	O	614-615
HT	O	615-617
uptake	O	618-624
in	O	625-627
lymphoblasts	O	628-640
.	O	640-641

Association	O	642-653
studies	O	654-661
in	O	662-664
two	O	665-668
independent	O	669-680
samples	O	681-688
totaling	O	689-697
505	O	698-701
individuals	O	702-713
revealed	O	714-722
that	O	723-727
the	O	728-731
5	O	732-733
-	O	733-734
HTT	O	734-737
polymorphism	O	738-750
accounts	O	751-759
for	O	760-763
3	O	764-765
to	O	766-768
4	O	769-770
percent	O	771-778
of	O	779-781
total	O	782-787
variation	O	788-797
and	O	798-801
7	O	802-803
to	O	804-806
9	O	807-808
percent	O	809-816
of	O	817-819
inherited	O	820-829
variance	O	830-838
in	O	839-841
anxiety	B	842-849
-	I	849-850
related	I	850-857
personality	I	858-869
traits	I	870-876
in	O	877-879
individuals	O	880-891
as	O	892-894
well	O	895-899
as	O	900-902
sibships	O	903-911
.	O	911-912
.	O	911-912

Cloning	O	0-7
and	O	8-11
characterization	O	12-28
of	O	29-31
human	O	32-37
very	O	38-42
-	O	42-43
long	O	43-47
-	O	42-43
chain	O	48-53
acyl	O	54-58
-	O	58-59
CoA	O	59-62
dehydrogenase	O	63-76
cDNA	O	77-81
,	O	81-82
chromosomal	O	83-94
assignment	O	95-105
of	O	106-108
the	O	109-112
gene	O	113-117
and	O	118-121
identification	O	122-136
in	O	137-139
four	O	140-144
patients	O	145-153
of	O	154-156
nine	O	157-161
different	O	162-171
mutations	O	172-181
within	O	182-188
the	O	189-192
VLCAD	O	193-198
gene	O	199-203
.	O	203-204

Very	O	205-209
-	O	209-210
long	O	210-214
-	O	209-210
chain	O	215-220
acyl	O	221-225
-	O	225-226
CoA	O	226-229
dehydrogenase	O	230-243
(	O	244-245
VLCAD	O	245-250
)	O	250-251
is	O	252-254
one	O	255-258
of	O	259-261
four	O	262-266
straight	O	267-275
-	O	275-276
chain	O	276-281
acyl	O	282-286
-	O	286-287
CoA	O	287-290
dehydrogenase	O	291-304
(	O	305-306
ACD	O	306-309
)	O	309-310
enzymes	O	311-318
,	O	318-319
which	O	320-325
are	O	326-329
all	O	330-333
nuclear	O	334-341
encoded	O	342-349
mitochondrial	O	350-363
flavoproteins	O	364-377
catalyzing	O	378-388
the	O	389-392
initial	O	393-400
step	O	401-405
in	O	406-408
fatty	O	409-414
acid	O	415-419
beta	O	420-424
-	O	424-425
oxidation	O	425-434
.	O	434-435

We	O	436-438
have	O	439-443
used	O	444-448
the	O	449-452
very	O	453-457
fast	O	458-462
,	O	462-463
Rapid	O	464-469
Amplification	O	470-483
of	O	484-486
cDNA	O	487-491
Ends	O	492-496
(	O	497-498
RACE	O	498-502
)	O	502-503
based	O	504-509
strategy	O	510-518
to	O	519-521
obtain	O	522-528
the	O	529-532
sequence	O	533-541
of	O	542-544
cDNAs	O	545-550
encoding	O	551-559
human	O	560-565
VLCAD	O	566-571
from	O	572-576
placenta	O	577-585
and	O	586-589
fibroblasts	O	590-601
.	O	601-602

Alignment	O	603-612
of	O	613-615
the	O	616-619
predicted	O	620-629
amino	O	630-635
acid	O	636-640
sequence	O	641-649
of	O	650-652
human	O	653-658
VLCAD	O	659-664
with	O	665-669
those	O	670-675
of	O	676-678
the	O	679-682
other	O	683-688
human	O	689-694
ACD	O	695-698
enzymes	O	699-706
revealed	O	707-715
extensive	O	716-725
sequence	O	726-734
homology	O	735-743
.	O	743-744

Moreover	O	745-753
,	O	753-754
human	O	755-760
VLCAD	O	761-766
and	O	767-770
human	O	771-776
acyl	O	777-781
-	O	781-782
CoA	O	782-785
oxidase	O	786-793
showed	O	794-800
extensive	O	801-810
sequence	O	811-819
homology	O	820-828
corroborating	O	829-842
the	O	843-846
notion	O	847-853
that	O	854-858
these	O	859-864
genes	O	865-870
are	O	871-874
evolutionarily	O	875-889
related	O	890-897
.	O	897-898

Southern	O	899-907
blot	O	908-912
analysis	O	913-921
of	O	922-924
genomic	O	925-932
DNA	O	933-936
from	O	937-941
hybrid	O	942-948
cell	O	949-953
lines	O	954-959
was	O	960-963
used	O	964-968
to	O	969-971
localize	O	972-980
the	O	981-984
VLCAD	O	985-990
gene	O	991-995
to	O	996-998
human	O	999-1004
chromosome	O	1005-1015
17p11	O	1016-1021
.	O	1021-1022

2	O	1023-1024
-	O	1024-1025
p11	O	1025-1028
.	O	1028-1029

13105	O	1030-1035
.	O	1035-1036

Using	O	1037-1042
Northern	O	1043-1051
and	O	1052-1055
Western	O	1056-1063
blot	O	1064-1068
analysis	O	1069-1077
to	O	1078-1080
investigate	O	1081-1092
the	O	1093-1096
tissue	O	1097-1103
specific	O	1104-1112
distribution	O	1113-1125
of	O	1126-1128
VLCAD	O	1129-1134
mRNA	O	1135-1139
and	O	1140-1143
protein	O	1144-1151
in	O	1152-1154
several	O	1155-1162
human	O	1163-1168
tissues	O	1169-1176
we	O	1177-1179
showed	O	1180-1186
that	O	1187-1191
VLCAD	O	1192-1197
is	O	1198-1200
most	O	1201-1205
abundant	O	1206-1214
in	O	1215-1217
heart	O	1218-1223
and	O	1224-1227
skeletal	O	1228-1236
muscle	O	1237-1243
.	O	1243-1244

This	O	1245-1249
agrees	O	1250-1256
well	O	1257-1261
with	O	1262-1266
the	O	1267-1270
fact	O	1271-1275
that	O	1276-1280
cardiac	O	1281-1288
and	O	1289-1292
muscle	O	1293-1299
symptoms	O	1300-1308
are	O	1309-1312
characteristic	O	1313-1327
for	O	1328-1331
patients	O	1332-1340
with	O	1341-1345
VLCAD	B	1346-1351
deficiency	I	1352-1362
.	O	1362-1363

Northern	O	1364-1372
blot	O	1373-1377
analysis	O	1378-1386
and	O	1387-1390
sequencing	O	1391-1401
of	O	1402-1404
cloned	O	1405-1411
PCR	O	1412-1415
amplified	O	1416-1425
VLCAD	O	1426-1431
cDNA	O	1432-1436
from	O	1437-1441
four	O	1442-1446
unrelated	O	1447-1456
patients	O	1457-1465
with	O	1466-1470
VLCAD	B	1471-1476
deficiency	I	1477-1487
showed	O	1488-1494
that	O	1495-1499
VLCAD	O	1500-1505
mRNA	O	1506-1510
was	O	1511-1514
undetectable	O	1515-1527
in	O	1528-1530
one	O	1531-1534
patient	O	1535-1542
and	O	1543-1546
that	O	1547-1551
the	O	1552-1555
other	O	1556-1561
three	O	1562-1567
have	O	1568-1572
mutations	O	1573-1582
in	O	1583-1585
both	O	1586-1590
VLCAD	O	1591-1596
alleles	O	1597-1604
.	O	1604-1605

Western	O	1606-1613
blot	O	1614-1618
analysis	O	1619-1627
of	O	1628-1630
patient	O	1631-1638
fibroblasts	O	1639-1650
showed	O	1651-1657
that	O	1658-1662
the	O	1663-1666
identified	O	1667-1677
mutations	O	1678-1687
result	O	1688-1694
in	O	1695-1697
severely	O	1698-1706
reduced	O	1707-1714
amounts	O	1715-1722
of	O	1723-1725
VLCAD	O	1726-1731
protein	O	1732-1739
.	O	1739-1740

Genetic	O	0-7
bases	O	8-13
of	O	14-16
human	O	17-22
complement	B	23-33
C7	I	34-36
deficiency	I	37-47
.	O	47-48

Complement	B	49-59
C7	I	60-62
deficiency	I	63-73
(	O	74-75
C7D	B	75-78
)	O	78-79
is	O	80-82
associated	O	83-93
frequently	O	94-104
with	O	105-109
recurrent	O	110-119
bacterial	B	120-129
infections	I	130-140
,	O	140-141
especially	O	142-152
meningitis	B	153-163
caused	O	164-170
by	O	171-173
Neisseria	B	174-183
meningitidis	I	184-196
.	O	196-197

We	O	198-200
report	O	201-207
in	O	208-210
this	O	211-215
work	O	216-220
the	O	221-224
molecular	O	225-234
bases	O	235-240
of	O	241-243
C7D	B	244-247
in	O	248-250
two	O	251-254
unrelated	O	255-264
Japanese	O	265-273
males	O	274-279
.	O	279-280

We	O	281-283
used	O	284-288
exon	O	289-293
-	O	293-294
specific	O	294-302
PCR	O	303-306
/	O	306-307
single	O	307-313
-	O	313-314
strand	O	314-320
conformation	O	321-333
polymorphism	O	334-346
analysis	O	347-355
as	O	356-358
a	O	359-360
screening	O	361-370
step	O	371-375
for	O	376-379
mutations	O	380-389
.	O	389-390

Subsequent	O	391-401
direct	O	402-408
sequencing	O	409-419
of	O	420-422
the	O	423-426
target	O	427-433
exons	O	434-439
identified	O	440-450
homozygous	O	451-461
mutations	O	462-471
in	O	472-474
exon	O	475-479
16	O	480-482
of	O	483-485
case	O	486-490
1	O	491-492
and	O	493-496
in	O	497-499
exon	O	500-504
15	O	505-507
of	O	508-510
case	O	511-515
2	O	516-517
.	O	517-518
The	O	519-522
mutation	O	523-531
of	O	532-534
case	O	535-539
1	O	540-541
was	O	542-545
a	O	546-547
homozygous	O	548-558
T	O	559-560
to	O	561-563
A	O	564-565
transversion	O	566-578
at	O	579-581
nucleotide	O	582-592
2250	O	593-597
,	O	597-598
the	O	599-602
third	O	603-608
nucleotide	O	609-619
of	O	620-622
the	O	623-626
codon	O	627-632
TGT	O	633-636
for	O	637-640
Cys728	O	641-647
,	O	647-648
leading	O	649-656
to	O	657-659
a	O	660-661
stop	O	662-666
codon	O	667-672
TGA	O	673-676
(	O	677-678
C728X	O	678-683
)	O	683-684
.	O	684-685

In	O	686-688
case	O	689-693
2	O	694-695
,	O	695-696
a	O	697-698
homozygous	O	699-709
2	O	710-711
-	O	711-712
bp	O	712-714
deletion	O	715-723
(	O	724-725
2137delTG	O	725-734
/	O	734-735
2138delGT	O	735-744
/	O	734-735
2139delTG	O	745-754
)	O	754-755
caused	O	756-762
a	O	763-764
frameshift	O	765-775
,	O	775-776
generating	O	777-787
a	O	788-789
premature	O	790-799
termination	O	800-811
codon	O	812-817
4	O	818-819
to	O	820-822
6	O	823-824
nucleotides	O	825-836
downstream	O	837-847
.	O	847-848

Family	O	849-855
study	O	856-861
in	O	862-864
case	O	865-869
1	O	870-871
confirmed	O	872-881
the	O	882-885
genetic	O	886-893
nature	O	894-900
of	O	901-903
the	O	904-907
defect	O	908-914
.	O	914-915

Moreover	O	916-924
,	O	924-925
we	O	926-928
detected	O	929-937
a	O	938-939
novel	O	940-945
polymorphism	O	946-958
in	O	959-961
intron	O	962-968
11	O	969-971
that	O	972-976
presumably	O	977-987
is	O	988-990
linked	O	991-997
to	O	998-1000
the	O	1001-1004
mutation	O	1005-1013
responsible	O	1014-1025
for	O	1026-1029
C7D	B	1030-1033
in	O	1034-1036
case	O	1037-1041
1	O	1042-1043
.	O	1043-1044

Our	O	1045-1048
results	O	1049-1056
indicate	O	1057-1065
that	O	1066-1070
the	O	1071-1074
pathogenesis	O	1075-1087
of	O	1088-1090
C7D	B	1091-1094
is	O	1095-1097
heterogeneous	O	1098-1111
like	O	1112-1116
most	O	1117-1121
of	O	1122-1124
the	O	1125-1128
other	O	1129-1134
deficiencies	B	1135-1147
of	I	1148-1150
complement	I	1151-1161
components	I	1162-1172
.	O	1172-1173
.	O	1172-1173

Defective	O	0-9
dimerization	O	10-22
of	O	23-25
von	B	26-29
Willebrand	I	30-40
factor	O	41-47
subunits	O	48-56
due	O	57-60
to	O	61-63
a	O	64-65
Cys	O	66-69
-	O	69-70
>	O	70-71
Arg	O	72-75
mutation	O	76-84
in	O	85-87
type	B	88-92
IID	I	93-96
von	I	97-100
Willebrand	I	101-111
disease	I	112-119
.	O	119-120

The	O	121-124
same	O	125-129
heterozygous	O	130-142
T	O	143-144
-	O	145-146
>	O	147-148
C	O	149-150
transition	O	151-161
at	O	162-164
nt	O	165-167
8567	O	168-172
of	O	173-175
the	O	176-179
von	B	180-183
Willebrand	I	184-194
factor	O	195-201
(	O	202-203
vWF	O	203-206
)	O	206-207
transcript	O	208-218
was	O	219-222
found	O	223-228
in	O	229-231
two	O	232-235
unrelated	O	236-245
patients	O	246-254
with	O	255-259
type	B	260-264
IID	I	265-268
von	I	269-272
Willebrand	I	273-283
disease	I	284-291
,	O	291-292
with	O	293-297
no	O	298-300
other	O	301-306
apparent	O	307-315
abnormality	O	316-327
.	O	327-328

In	O	329-331
one	O	332-335
family	O	336-342
,	O	342-343
both	O	344-348
alleles	O	349-356
were	O	357-361
normal	O	362-368
in	O	369-371
the	O	372-375
parents	O	376-383
and	O	384-387
one	O	388-391
sister	O	392-398
;	O	398-399
thus	O	400-404
,	O	404-405
the	O	406-409
mutation	O	410-418
originated	O	419-429
de	O	430-432
novo	O	433-437
in	O	438-440
the	O	441-444
proposita	O	445-454
.	O	454-455

The	O	456-459
second	O	460-466
patient	O	467-474
also	O	475-479
had	O	480-483
asymptomatic	O	484-496
parents	O	497-504
who	O	505-508
,	O	508-509
however	O	510-517
,	O	517-518
were	O	519-523
not	O	524-527
available	O	528-537
for	O	538-541
study	O	542-547
.	O	547-548

The	O	549-552
structural	O	553-563
consequences	O	564-576
of	O	577-579
the	O	580-583
identified	O	584-594
mutation	O	595-603
,	O	603-604
resulting	O	605-614
in	O	615-617
the	O	618-621
CyS2010	O	622-629
-	O	630-631
>	O	632-633
Arg	O	634-637
substitution	O	638-650
,	O	650-651
were	O	652-656
evaluated	O	657-666
by	O	667-669
expression	O	670-680
of	O	681-683
the	O	684-687
vWF	O	688-691
carboxyl	O	692-700
-	O	700-701
terminal	O	701-709
domain	O	710-716
containing	O	717-727
residues	O	728-736
1366	O	737-741
-	O	741-742
2050	O	742-746
.	O	746-747

Insect	O	748-754
cells	O	755-760
infected	O	761-769
with	O	770-774
recombinant	O	775-786
baculovirus	O	787-798
expressing	O	799-809
normal	O	810-816
vWF	O	817-820
sequence	O	821-829
secreted	O	830-838
a	O	839-840
disulfide	O	841-850
linked	O	851-857
dimeric	O	858-865
molecule	O	866-874
with	O	875-879
an	O	880-882
apparent	O	883-891
molecular	O	892-901
mass	O	902-906
of	O	907-909
150	O	910-913
kDa	O	914-917
before	O	918-924
reduction	O	925-934
,	O	934-935
yielding	O	936-944
a	O	945-946
single	O	947-953
band	O	954-958
of	O	959-961
80	O	962-964
kDa	O	965-968
after	O	969-974
disulfide	O	975-984
bond	O	985-989
reduction	O	990-999
.	O	999-1000

In	O	1001-1003
contrast	O	1004-1012
,	O	1012-1013
cells	O	1014-1019
expressing	O	1020-1030
the	O	1031-1034
mutant	O	1035-1041
fragment	O	1042-1050
secreted	O	1051-1059
a	O	1060-1061
monomeric	O	1062-1071
molecule	O	1072-1080
of	O	1081-1083
apparent	O	1084-1092
molecular	O	1093-1102
mass	O	1103-1107
of	O	1108-1110
80	O	1111-1113
kDa	O	1114-1117
,	O	1117-1118
which	O	1119-1124
remained	O	1125-1133
unchanged	O	1134-1143
after	O	1144-1149
reduction	O	1150-1159
.	O	1159-1160

We	O	1161-1163
conclude	O	1164-1172
that	O	1173-1177
CyS2010	O	1178-1185
is	O	1186-1188
essential	O	1189-1198
for	O	1199-1202
normal	O	1203-1209
dimerization	O	1210-1222
of	O	1223-1225
vWF	O	1226-1229
subunits	O	1230-1238
through	O	1239-1246
disulfide	O	1247-1256
bonding	O	1257-1264
of	O	1265-1267
carboxyl	O	1268-1276
-	O	1276-1277
terminal	O	1277-1285
domains	O	1286-1293
and	O	1294-1297
that	O	1298-1302
a	O	1303-1304
heterozygous	O	1305-1317
mutation	O	1318-1326
in	O	1327-1329
the	O	1330-1333
corresponding	O	1334-1347
codon	O	1348-1353
is	O	1354-1356
responsible	O	1357-1368
for	O	1369-1372
defective	O	1373-1382
multimer	O	1383-1391
formation	O	1392-1401
in	O	1402-1404
type	B	1405-1409
IID	I	1410-1413
von	I	1414-1417
Willebrand	I	1418-1428
disease	I	1429-1436
.	O	1436-1437
.	O	1436-1437

Ataxia	B	0-6
-	I	6-7
telangiectasia	I	7-21
:	O	21-22
founder	O	23-30
effect	O	31-37
among	O	38-43
north	O	44-49
African	O	50-57
Jews	O	58-62
.	O	62-63

The	O	64-67
ATM	O	68-71
gene	O	72-76
is	O	77-79
responsible	O	80-91
for	O	92-95
the	O	96-99
autosomal	B	100-109
recessive	I	110-119
disorder	I	120-128
ataxia	B	129-135
-	I	135-136
telangiectasia	I	136-150
(	O	151-152
A	B	152-153
-	I	153-154
T	I	154-155
)	O	155-156
,	O	156-157
characterized	O	158-171
by	O	172-174
cerebellar	B	175-185
degeneration	I	186-198
,	O	198-199
immunodeficiency	B	200-216
and	O	217-220
cancer	B	221-227
predisposition	I	228-242
.	O	242-243

A	B	244-245
-	I	245-246
T	I	246-247
carriers	O	248-256
were	O	257-261
reported	O	262-270
to	O	271-273
be	O	274-276
moderately	O	277-287
cancer	B	288-294
-	I	294-295
prone	I	295-300
.	O	300-301

A	O	302-303
wide	O	304-308
variety	O	309-316
of	O	317-319
A	B	320-321
-	I	321-322
T	I	322-323
mutations	O	324-333
,	O	333-334
most	O	335-339
of	O	340-342
which	O	343-348
are	O	349-352
unique	O	353-359
to	O	360-362
single	O	363-369
families	O	370-378
,	O	378-379
were	O	380-384
identified	O	385-395
in	O	396-398
various	O	399-406
ethnic	O	407-413
groups	O	414-420
,	O	420-421
precluding	O	422-432
carrier	O	433-440
screening	O	441-450
with	O	451-455
mutation	O	456-464
-	O	464-465
specific	O	465-473
assays	O	474-480
.	O	480-481

However	O	482-489
,	O	489-490
a	O	491-492
single	O	493-499
mutation	O	500-508
was	O	509-512
observed	O	513-521
in	O	522-524
32	O	525-527
/	O	527-528
33	O	528-530
defective	O	531-540
ATM	O	541-544
alleles	O	545-552
in	O	553-555
Jewish	O	556-562
A	B	563-564
-	I	564-565
T	I	565-566
families	O	567-575
of	O	576-578
North	O	579-584
African	O	585-592
origin	O	593-599
,	O	599-600
coming	O	601-607
from	O	608-612
various	O	613-620
regions	O	621-628
of	O	629-631
Morocco	O	632-639
and	O	640-643
Tunisia	O	644-651
.	O	651-652

This	O	653-657
mutation	O	658-666
,	O	666-667
103C	O	668-672
-	O	672-673
-	O	672-673
>	O	675-676
T	O	677-678
,	O	678-679
results	O	680-687
in	O	688-690
a	O	691-692
stop	O	693-697
codon	O	698-703
at	O	704-706
position	O	707-715
35	O	716-718
of	O	719-721
the	O	722-725
ATM	O	726-729
protein	O	730-737
.	O	737-738

In	O	739-741
keeping	O	742-749
with	O	750-754
the	O	755-758
nature	O	759-765
of	O	766-768
this	O	769-773
mutation	O	774-782
,	O	782-783
various	O	784-791
antibodies	O	792-802
directed	O	803-811
against	O	812-819
the	O	820-823
ATM	O	824-827
protein	O	828-835
failed	O	836-842
to	O	843-845
defect	O	846-852
this	O	853-857
protein	O	858-865
in	O	866-868
patient	O	869-876
cells	O	877-882
.	O	882-883

A	O	884-885
rapid	O	886-891
carrier	O	892-899
detection	O	900-909
assay	O	910-915
detected	O	916-924
this	O	925-929
mutation	O	930-938
in	O	939-941
three	O	942-947
out	O	948-951
of	O	952-954
488	O	955-958
ATM	O	959-962
alleles	O	963-970
of	O	971-973
Jewish	O	974-980
Moroccan	O	981-989
or	O	990-992
Tunisian	O	993-1001
origin	O	1002-1008
.	O	1008-1009

This	O	1010-1014
founder	O	1015-1022
effect	O	1023-1029
provides	O	1030-1038
a	O	1039-1040
unique	O	1041-1047
opportunity	O	1048-1059
for	O	1060-1063
population	O	1064-1074
-	O	1074-1075
based	O	1075-1080
screening	O	1081-1090
for	O	1091-1094
A	B	1095-1096
-	I	1096-1097
T	I	1097-1098
carriers	O	1099-1107
in	O	1108-1110
a	O	1111-1112
large	O	1113-1118
Jewish	O	1119-1125
community	O	1126-1135
.	O	1135-1136
.	O	1135-1136

Mutations	O	0-9
associated	O	10-20
with	O	21-25
variant	O	26-33
phenotypes	O	34-44
in	O	45-47
ataxia	B	48-54
-	I	54-55
telangiectasia	I	55-69
.	O	69-70

We	O	71-73
have	O	74-78
identified	O	79-89
14	O	90-92
families	O	93-101
with	O	102-106
ataxia	B	107-113
-	I	113-114
telangiectasia	I	114-128
(	O	129-130
A	B	130-131
-	I	131-132
T	I	132-133
)	O	133-134
in	O	135-137
which	O	138-143
mutation	O	144-152
of	O	153-155
the	O	156-159
ATM	O	160-163
gene	O	164-168
is	O	169-171
associated	O	172-182
with	O	183-187
a	O	188-189
less	O	190-194
severe	O	195-201
clinical	O	202-210
and	O	211-214
cellular	O	215-223
phenotype	O	224-233
(	O	234-235
approximately	O	235-248
10	O	249-251
%	O	251-252
-	O	253-254
15	O	254-256
%	O	256-257
of	O	258-260
A	B	261-262
-	I	262-263
T	I	263-264
families	O	265-273
identified	O	274-284
in	O	285-287
the	O	288-291
United	O	292-298
Kingdom	O	299-306
)	O	306-307
.	O	307-308

In	O	309-311
10	O	312-314
of	O	315-317
these	O	318-323
families	O	324-332
,	O	332-333
all	O	334-337
the	O	338-341
homozygotes	O	342-353
have	O	354-358
a	O	359-360
137	O	361-364
-	O	364-365
bp	O	365-367
insertion	O	368-377
in	O	378-380
their	O	381-386
cDNA	O	387-391
caused	O	392-398
by	O	399-401
a	O	402-403
point	O	404-409
mutation	O	410-418
in	O	419-421
a	O	422-423
sequence	O	424-432
resembling	O	433-443
a	O	444-445
splice	O	446-452
-	O	452-453
donor	O	453-458
site	O	459-463
.	O	463-464

The	O	465-468
second	O	469-475
A	B	476-477
-	I	477-478
T	I	478-479
allele	O	480-486
has	O	487-490
a	O	491-492
different	O	493-502
mutation	O	503-511
in	O	512-514
each	O	515-519
patient	O	520-527
.	O	527-528

We	O	529-531
show	O	532-536
that	O	537-541
the	O	542-545
less	O	546-550
severe	O	551-557
phenotype	O	558-567
in	O	568-570
these	O	571-576
patients	O	577-585
is	O	586-588
caused	O	589-595
by	O	596-598
some	O	599-603
degree	O	604-610
of	O	611-613
normal	O	614-620
splicing	O	621-629
,	O	629-630
which	O	631-636
occurs	O	637-643
as	O	644-646
an	O	647-649
alternative	O	650-661
product	O	662-669
from	O	670-674
the	O	675-678
insertion	O	679-688
-	O	688-689
containing	O	689-699
allele	O	700-706
.	O	706-707

The	O	708-711
level	O	712-717
of	O	718-720
the	O	721-724
137	O	725-728
-	O	728-729
bp	O	729-731
PCR	O	732-735
product	O	736-743
containing	O	744-754
the	O	755-758
insertion	O	759-768
was	O	769-772
lowest	O	773-779
in	O	780-782
two	O	783-786
patients	O	787-795
who	O	796-799
showed	O	800-806
a	O	807-808
later	O	809-814
onset	O	815-820
of	O	821-823
cerebellar	B	824-834
ataxia	I	835-841
.	O	841-842

A	O	843-844
further	O	845-852
four	O	853-857
families	O	858-866
who	O	867-870
do	O	871-873
not	O	874-877
have	O	878-882
this	O	883-887
insertion	O	888-897
have	O	898-902
been	O	903-907
identified	O	908-918
.	O	918-919

Mutations	O	920-929
detected	O	930-938
in	O	939-941
two	O	942-945
of	O	946-948
four	O	949-953
of	O	954-956
these	O	957-962
are	O	963-966
missense	O	967-975
mutations	O	976-985
,	O	985-986
normally	O	987-995
rare	O	996-1000
in	O	1001-1003
A	B	1004-1005
-	I	1005-1006
T	I	1006-1007
patients	O	1008-1016
.	O	1016-1017

The	O	1018-1021
demonstration	O	1022-1035
of	O	1036-1038
mutations	O	1039-1048
giving	O	1049-1055
rise	O	1056-1060
to	O	1061-1063
a	O	1064-1065
slightly	O	1066-1074
milder	O	1075-1081
phenotype	O	1082-1091
in	O	1092-1094
A	B	1095-1096
-	I	1096-1097
T	I	1097-1098
raises	O	1099-1105
the	O	1106-1109
interesting	O	1110-1121
question	O	1122-1130
of	O	1131-1133
what	O	1134-1138
range	O	1139-1144
of	O	1145-1147
phenotypes	O	1148-1158
might	O	1159-1164
occur	O	1165-1170
in	O	1171-1173
individuals	O	1174-1185
in	O	1186-1188
whom	O	1189-1193
both	O	1194-1198
mutations	O	1199-1208
are	O	1209-1212
milder	O	1213-1219
.	O	1219-1220

One	O	1221-1224
possibility	O	1225-1236
might	O	1237-1242
be	O	1243-1245
that	O	1246-1250
individuals	O	1251-1262
who	O	1263-1266
are	O	1267-1270
compound	O	1271-1279
heterozygotes	O	1280-1293
for	O	1294-1297
ATM	O	1298-1301
mutations	O	1302-1311
are	O	1312-1315
more	O	1316-1320
common	O	1321-1327
than	O	1328-1332
we	O	1333-1335
realize	O	1336-1343
.	O	1343-1344
.	O	1343-1344

Cleavage	O	0-8
of	O	9-11
huntingtin	O	12-22
by	O	23-25
apopain	O	26-33
,	O	33-34
a	O	35-36
proapoptotic	O	37-49
cysteine	O	50-58
protease	O	59-67
,	O	67-68
is	O	69-71
modulated	O	72-81
by	O	82-84
the	O	85-88
polyglutamine	O	89-102
tract	O	103-108
.	O	108-109

Apoptosis	O	110-119
has	O	120-123
recently	O	124-132
been	O	133-137
recognized	O	138-148
as	O	149-151
a	O	152-153
mode	O	154-158
of	O	159-161
cell	O	162-166
death	O	167-172
in	O	173-175
Huntington	B	176-186
disease	I	187-194
(	O	195-196
HD	B	196-198
)	O	198-199
.	O	199-200

Apopain	O	201-208
,	O	208-209
a	O	210-211
human	O	212-217
counterpart	O	218-229
of	O	230-232
the	O	233-236
nematode	O	237-245
cysteine	O	246-254
protease	O	255-263
death	O	264-269
-	O	269-270
gene	O	270-274
product	O	275-282
,	O	282-283
CED	O	284-287
-	O	287-288
3	O	288-289
,	O	289-290
has	O	291-294
a	O	295-296
key	O	297-300
role	O	301-305
in	O	306-308
proteolytic	O	309-320
events	O	321-327
leading	O	328-335
to	O	336-338
apoptosis	O	339-348
.	O	348-349

Here	O	350-354
we	O	355-357
show	O	358-362
that	O	363-367
apoptotic	O	368-377
extracts	O	378-386
and	O	387-390
apopain	O	391-398
itself	O	399-405
specifically	O	406-418
cleave	O	419-425
the	O	426-429
HD	B	430-432
gene	O	433-437
product	O	438-445
,	O	445-446
huntingtin	O	447-457
.	O	457-458

The	O	459-462
rate	O	463-467
of	O	468-470
cleavage	O	471-479
increases	O	480-489
with	O	490-494
the	O	495-498
length	O	499-505
of	O	506-508
the	O	509-512
huntingtin	O	513-523
polyglutamine	O	524-537
tract	O	538-543
,	O	543-544
providing	O	545-554
an	O	555-557
explanation	O	558-569
for	O	570-573
the	O	574-577
gain	O	578-582
-	O	582-583
of	O	583-585
-	O	582-583
function	O	586-594
associated	O	595-605
with	O	606-610
CAG	O	611-614
expansion	O	615-624
.	O	624-625

Our	O	626-629
results	O	630-637
show	O	638-642
that	O	643-647
huntingtin	O	648-658
is	O	659-661
cleaved	O	662-669
by	O	670-672
cysteine	O	673-681
proteases	O	682-691
and	O	692-695
suggest	O	696-703
that	O	704-708
HD	B	709-711
might	O	712-717
be	O	718-720
a	O	721-722
disorder	B	723-731
of	I	732-734
inappropriate	I	735-748
apoptosis	I	749-758
.	O	758-759
.	O	758-759

